,pmid,start,end,tag,text,source,correct,error_type,annotator
0,58651,26,42,Group Characteristic,renal transplant,model,y,,ccurtis
1,58651,144,149,Drug Intervention,HAHTG,human,y,,ccurtis
2,58651,165,175,Non-Study Drug,prednisone,human,y,wrong label,ccurtis
3,58651,180,192,Non-Study Drug,azathioprine,human,y,wrong label,ccurtis
4,58651,194,200,Drug Intervention,lmuran,model,n,wrong label,ccurtis
5,58651,323,328,Drug Intervention,HAHTG,human,y,,ccurtis
6,58651,350,363,Intervention Administration,intravenously,model,y,,ccurtis
7,58651,404,408,Sample Size,four,human,n,wrong label,ccurtis
8,58651,428,460,Outcome (Study Endpoint),died of infectious complications,model,n,too much,ccurtis
9,58651,436,460,Outcome (Study Endpoint),infectious complications,human,y,,ccurtis
10,58651,492,497,Sample Size,three,human,n,wrong label,ccurtis
11,58651,517,549,Outcome (Study Endpoint),died of infectious complications,model,n,,ccurtis
12,58651,587,601,Outcome (Study Endpoint),graft survival,model,n,too little,ccurtis
13,58651,587,614,Outcome (Study Endpoint),graft survival at 18 months,human,y,,ccurtis
14,58651,619,622,Quantitative Measurement,ten,model,y,wrong label,ccurtis
15,58651,636,643,Group Name,control,model,n,too little,ccurtis
16,58651,636,649,Group Name,control group,human,y,,ccurtis
17,58651,654,657,Quantitative Measurement,ten,model,y,wrong label,ccurtis
18,58651,671,678,Group Name,treated,model,n,too little,ccurtis
19,58651,671,684,Group Name,treated group,human,y,,ccurtis
20,58651,686,692,Statistical Significance,chi2 =,model,n,too little,ccurtis
21,58651,686,697,Statistical Significance,chi2 = 1.26,human,y,,ccurtis
22,58651,693,697,Quantitative Measurement,1.26,model,n,wrong label,ccurtis
23,58651,763,770,Group Name,control,model,n,too little,ccurtis
24,58651,763,776,Group Name,control group,human,y,,ccurtis
25,58651,794,801,Group Name,treated,model,n,too little,ccurtis
26,58651,794,807,Group Name,treated group,human,y,,ccurtis
27,58651,994,1001,Group Name,control,model,n,too little,ccurtis
28,58651,994,1007,Group Name,control group,human,y,,ccurtis
29,58651,1025,1032,Group Name,treated,model,n,too little,ccurtis
30,58651,1025,1038,Group Name,treated group,human,y,,ccurtis
31,58651,1200,1205,Drug Intervention,HAHTG,human,y,,ccurtis
32,527347,127,150,Disease/Condition of Interest,exercise-induced asthma,human,y,,eduvaris
33,527347,423,434,Group Name,Clenbuterol,human,n,wrong label,eduvaris
34,527347,466,467,Quantitative Measurement,7,human,y,,eduvaris
35,527347,500,501,Quantitative Measurement,1,human,y,,eduvaris
36,527347,523,524,Quantitative Measurement,1,human,y,,eduvaris
37,527347,534,544,Drug Intervention,Salbutamol,model,y,wrong label,eduvaris
38,527347,553,572,Outcome (Study Endpoint),complete protection,human,y,,eduvaris
39,527347,576,577,Quantitative Measurement,5,human,y,,eduvaris
40,527347,588,606,Outcome (Study Endpoint),partial protection,human,y,,eduvaris
41,527347,610,611,Quantitative Measurement,1,human,y,,eduvaris
42,527347,616,629,Outcome (Study Endpoint),no protection,human,y,,eduvaris
43,527347,633,634,Quantitative Measurement,3,human,y,,eduvaris
44,527347,697,715,Outcome (Study Endpoint),protective effects,human,y,,eduvaris
45,527347,791,795,Outcome (Study Endpoint),FEV1,human,y,,eduvaris
46,527347,813,822,Outcome (Study Endpoint),FEF25-75%,human,y,,eduvaris
47,527347,825,832,Group Name,Placebo,human,y,,eduvaris
48,527347,869,875,Disease/Condition of Interest,asthma,human,n,,eduvaris
49,779588,61,73,Drug Intervention,Debrisoquine,model,y,,stan
50,779588,120,130,Drug Intervention,methyldopa,model,y,,stan
51,779588,354,363,Intervention Duration,two weeks,model,n,wrong label,stan
52,779588,470,475,Intervention Frequency,daily,human,y,,stan
53,779588,545,564,Drug Intervention,Hydrochlorothiazide,human,n,wrong label,stan
54,779588,733,745,Drug Intervention,debrisoquine,model,y,,stan
55,779588,789,799,Drug Intervention,methyldopa,model,y,,stan
56,779588,958,970,Drug Intervention,Debrisoquine,model,y,,stan
57,779588,985,993,Side Effects,sedation,model,y,,stan
58,779588,998,1007,Side Effects,dizziness,model,y,,stan
59,779588,1013,1023,Drug Intervention,methyldopa,model,y,,stan
60,1366257,47,73,Disease/Condition of Interest,mild-moderate hypertension,human,y,,cjackson
61,1366257,61,73,Disease/Condition of Interest,hypertension,model,n,too little,cjackson
62,1366257,505,514,Intervention Duration,four-week,model,y,,cjackson
63,1366257,570,579,Drug Intervention,enalapril,model,y,,cjackson
64,1366257,596,599,Drug Intervention,lis,model,n,too little,cjackson
65,1366257,632,633,Intervention Duration,4,human,n,too little,cjackson
66,1366257,632,638,Intervention Duration,4-week,model,y,,cjackson
67,1366257,669,676,Drug Intervention,placebo,model,n,wrong label,cjackson
68,1366257,678,689,Sample Size,Fifty-eight,model,n,not needed,cjackson
69,1366257,782,797,Outcome (Study Endpoint),Blood pressures,model,y,,cjackson
70,1366257,820,827,Quantitative Measurement,161/108,model,y,,cjackson
71,1366257,832,839,Quantitative Measurement,164/106,model,y,,cjackson
72,1366257,907,909,Outcome (Study Endpoint),LV,model,n,too little,cjackson
73,1366257,913,916,Quantitative Measurement,9.5,model,y,,cjackson
74,1366257,936,938,Units,mm,model,y,,cjackson
75,1366257,944,948,Outcome (Study Endpoint),IVSd,model,y,,cjackson
76,1366257,949,953,Quantitative Measurement,10.3,model,y,,cjackson
77,1366257,954,956,Units,mm,model,y,,cjackson
78,1366257,976,978,Units,mm,model,y,,cjackson
79,1366257,1148,1169,Outcome (Study Endpoint),blood pressure levels,model,y,,cjackson
80,1366257,1148,1200,Outcome (Study Endpoint),blood pressure levels during the early morning hours,human,n,too much,cjackson
81,1366257,1283,1295,Outcome (Study Endpoint),ACE activity,model,y,,cjackson
82,1366257,1283,1319,Outcome (Study Endpoint),ACE activity in serum 24 h post-dose,human,n,too much,cjackson
83,1366257,1379,1381,Type of Quant. Measure,SD,human,y,,cjackson
84,1366257,1382,1383,Quantitative Measurement,3,model,n,too little,cjackson
85,1366257,1382,1385,Quantitative Measurement,3.3,human,y,,cjackson
86,1366257,1425,1427,Type of Quant. Measure,SD,human,y,,cjackson
87,1366257,1463,1470,Drug Intervention,placebo,model,n,wrong label,cjackson
88,1366257,1482,1484,Type of Quant. Measure,SD,human,y,,cjackson
89,1366257,1500,1502,Type of Quant. Measure,SD,human,y,,cjackson
90,1703608,72,91,Drug Intervention,hydrochlorothiazide,model,n,wrong label,hcho
91,1703608,110,141,Disease/Condition of Interest,moderate to severe hypertension,model,n,too much,hcho
92,1703608,223,235,Disease/Condition of Interest,hypertension,human,y,,hcho
93,1703608,338,339,Group Name,D,model,n,,hcho
94,1703608,356,357,Group Name,C,model,n,,hcho
95,1703608,395,426,Outcome (Study Endpoint),supine diastolic blood pressure,model,y,,hcho
96,1703608,439,446,Quantitative Measurement,105-140,model,y,,hcho
97,1703608,447,452,Units,mm Hg,model,y,,hcho
98,1703608,456,475,Drug Intervention,hydrochlorothiazide,model,n,wrong label,hcho
99,1703608,504,511,Drug Intervention,placebo,model,n,wrong label,hcho
100,1703608,564,570,Sample Size,n = 29,human,n,too much,hcho
101,1703608,568,570,Sample Size,29,model,y,,hcho
102,1703608,585,591,Sample Size,n = 32,human,n,too much,hcho
103,1703608,589,591,Sample Size,32,model,y,,hcho
104,1703608,691,722,Group Characteristic,SuDBP was greater than 99 mm Hg,human,y,,hcho
105,1703608,724,735,Drug Intervention,hydralazine,model,y,,hcho
106,1703608,857,864,Intervention Duration,3-month,model,n,wrong label,hcho
107,1703608,983,987,Type of Quant. Measure,mean,human,n,too little,hcho
108,1703608,992,995,Type of Quant. Measure,SEM,human,n,too little,hcho
109,1703608,1028,1036,Group Name,D + HCTZ,human,n,wrong label,hcho
110,1703608,1038,1047,Quantitative Measurement,182 +/- 3,human,y,,hcho
111,1703608,1038,1057,Quantitative Measurement,182 +/- 3/112 +/- 1,model,n,not needed,hcho
112,1703608,1048,1057,Quantitative Measurement,112 +/- 1,human,y,,hcho
113,1703608,1059,1067,Group Name,C + HCTZ,human,n,wrong label,hcho
114,1703608,1069,1078,Quantitative Measurement,179 +/- 4,human,y,,hcho
115,1703608,1069,1088,Quantitative Measurement,179 +/- 4/113 +/- 1,model,n,not needed,hcho
116,1703608,1079,1088,Quantitative Measurement,113 +/- 1,human,y,,hcho
117,1703608,1126,1134,Group Name,D + HCTZ,human,n,wrong label,hcho
118,1703608,1136,1145,Quantitative Measurement,175 +/- 3,human,y,,hcho
119,1703608,1136,1155,Quantitative Measurement,175 +/- 3/114 +/- 2,model,n,not needed,hcho
120,1703608,1146,1155,Quantitative Measurement,114 +/- 2,human,y,,hcho
121,1703608,1169,1178,Quantitative Measurement,173 +/- 4,human,y,,hcho
122,1703608,1169,1188,Quantitative Measurement,173 +/- 4/113 +/- 1,model,n,not needed,hcho
123,1703608,1179,1188,Quantitative Measurement,113 +/- 1,human,y,,hcho
124,1777653,67,74,Group Characteristic,healthy,human,y,,ccurtis
125,1777653,79,109,Disease/Condition of Interest,non-insulin dependent diabetic,model,n,too much,ccurtis
126,1777653,101,109,Disease/Condition of Interest,diabetic,human,y,,ccurtis
127,1777653,375,396,Group Characteristic,non-insulin-dependent,human,y,,ccurtis
128,1777653,375,405,Group Characteristic,non-insulin-dependent diabetic,model,n,,ccurtis
129,1777653,397,405,Disease/Condition of Interest,diabetic,human,y,,ccurtis
130,1777653,629,636,Group Characteristic,healthy,human,y,,ccurtis
131,1777653,661,667,Units,mmol/l,model,y,,ccurtis
132,1777653,745,746,Dosage,5,model,y,,ccurtis
133,1777653,745,749,Dosage,5 mg,human,n,too much,ccurtis
134,1777653,747,749,Units,mg,model,y,,ccurtis
135,1777653,949,958,Drug Intervention,glipizide,human,y,,ccurtis
136,1777653,1051,1079,Outcome (Study Endpoint),plasma glucose concentration,human,y,,ccurtis
137,1777653,1086,1088,Quantitative Measurement,10,human,y,,ccurtis
138,1777653,1089,1095,Units,mmol/l,human,y,,ccurtis
139,1777653,1131,1140,Drug Intervention,Glipizide,human,y,,ccurtis
140,1777653,1402,1411,Drug Intervention,Glipizide,human,y,,ccurtis
141,1777653,1432,1455,Outcome (Study Endpoint),plasma insulin response,human,y,,ccurtis
142,1777653,1459,1462,Quantitative Measurement,180,human,y,,ccurtis
143,1777653,1463,1469,Units,pmol/l,human,y,,ccurtis
144,1777653,1527,1536,Drug Intervention,glipizide,human,y,,ccurtis
145,1777653,1595,1604,Drug Intervention,glipizide,human,y,,ccurtis
146,1777653,1790,1799,Drug Intervention,glipizide,human,y,,ccurtis
147,1886581,78,110,Disease/Condition of Interest,cadaveric kidney transplantation,model,y,wrong label,eduvaris
148,1886581,118,145,Study Years,November 1985 to March 1990,model,y,,eduvaris
149,1886581,150,178,Group Characteristic,cadaveric kidney transplants,model,n,wrong label,eduvaris
150,1886581,200,220,Non-Study Drug,cyclosporine therapy,model,n,too much,eduvaris
151,1886581,320,331,Non-Pharmaceutical Intervention,EC solution,human,n,wrong label,eduvaris
152,1886581,342,348,Sample Size,n = 27,human,n,too much,eduvaris
153,1886581,346,348,Sample Size,27,model,y,,eduvaris
154,1886581,353,364,Non-Pharmaceutical Intervention,UW solution,human,n,wrong label,eduvaris
155,1886581,376,382,Sample Size,n = 28,human,n,too much,eduvaris
156,1886581,380,382,Sample Size,28,model,y,,eduvaris
157,1886581,426,428,Group Name,II,model,n,too little,eduvaris
158,1886581,569,616,Outcome (Study Endpoint),Mean numbers of days for postoperative dialysis,model,n,multiple entities,eduvaris
159,1886581,594,616,Outcome (Study Endpoint),postoperative dialysis,human,n,too little,eduvaris
160,1886581,638,645,Group Name,group I,human,y,,eduvaris
161,1886581,665,673,Group Name,group II,human,y,,eduvaris
162,1886581,694,703,Intervention Duration,One-month,human,n,wrong label,eduvaris
163,1886581,694,714,Outcome (Study Endpoint),One-month creatinine,model,y,,eduvaris
164,1886581,742,749,Group Name,group I,human,y,,eduvaris
165,1886581,770,778,Group Name,group II,human,y,,eduvaris
166,1886581,785,810,Outcome (Study Endpoint),One-month graft survivals,model,y,,eduvaris
167,1886581,795,810,Outcome (Study Endpoint),graft survivals,human,n,too little,eduvaris
168,2047947,286,298,Sample Size,Twenty-three,model,y,,stan
169,2047947,305,315,Group Characteristic,asthmatics,model,y,,stan
170,2047947,952,956,Outcome (Study Endpoint),PEFR,model,y,,stan
171,2047947,958,961,Outcome (Study Endpoint),FVC,model,y,,stan
172,2047947,966,970,Outcome (Study Endpoint),FVC1,model,y,,stan
173,2047947,1097,1119,Outcome (Study Endpoint),decrease in protection,model,y,,stan
174,2047947,1145,1152,Intervention Duration,8 weeks,model,n,,stan
175,2047947,1173,1188,Group Name,high-dose group,human,y,,stan
176,2178384,11,20,Drug Intervention,captopril,model,y,,cjackson
177,2178384,28,37,Drug Intervention,milrinone,model,y,,cjackson
178,2178384,480,487,Drug Intervention,placebo,human,n,wrong label,cjackson
179,2178384,558,564,Group Characteristic,stable,model,n,not needed,cjackson
180,2178384,566,590,Group Characteristic,congestive heart failure,model,n,wrong label,cjackson
181,2178384,993,1000,Group Name,placebo,model,y,,cjackson
182,2252527,198,222,Disease/Condition of Interest,Type I diabetes mellitus,model,y,,hcho
183,2252527,198,229,Disease/Condition of Interest,Type I diabetes mellitus (IDDM),human,n,too much,hcho
184,2252527,224,228,Disease/Condition of Interest,IDDM,model,y,,hcho
185,2252527,263,282,Group Characteristic,aged 24 +/- 6 years,model,y,,hcho
186,2252527,268,282,Group Characteristic,24 +/- 6 years,human,n,too little,hcho
187,2252527,449,452,Group Name,(A),human,n,too much,hcho
188,2252527,450,451,Group Name,A,model,y,,hcho
189,2252527,468,470,Units,mg,model,y,,hcho
190,2252527,468,471,Units,mg/,human,n,too much,hcho
191,2252527,481,493,Drug Intervention,indomethacin,model,y,,hcho
192,2252527,499,501,Units,mg,model,y,,hcho
193,2252527,499,502,Units,mg/,human,n,too much,hcho
194,2252527,512,519,Group Name,placebo,model,y,,hcho
195,2252527,791,801,Drug Intervention,prednisone,human,y,,hcho
196,2252527,822,847,Outcome (Study Endpoint),lower insulin requirement,model,n,too much,hcho
197,2252527,828,847,Outcome (Study Endpoint),insulin requirement,human,y,,hcho
198,2252527,868,878,Drug Intervention,prednisone,human,y,,hcho
199,2252527,868,884,Group Name,prednisone group,model,y,,hcho
200,2252527,879,884,Group Name,group,human,n,too little,hcho
201,2252527,1187,1197,Drug Intervention,prednisone,human,y,,hcho
202,2252527,1187,1203,Group Name,prednisone group,model,y,,hcho
203,2252527,1198,1203,Group Name,group,human,n,too little,hcho
204,2252527,1280,1356,Side Effects,ANOVA confirmed differences among the three groups. Our study indicates that,human,n,wrong label,hcho
205,2252527,1357,1367,Drug Intervention,prednisone,human,y,,hcho
206,2252527,1368,1478,Side Effects,"administration, at low doses and for a long period of time, effectively restored endogenous insulin release in",human,n,wrong label,hcho
207,2252527,1479,1483,Disease/Condition of Interest,IDDM,human,y,,hcho
208,2252527,1484,1492,Side Effects,patients,human,n,wrong label,hcho
209,2308471,253,256,Drug Intervention,MPH,human,y,,ccurtis
210,2308471,296,322,Disease/Condition of Interest,Attention Deficit Disorder,human,y,,ccurtis
211,2308471,324,327,Disease/Condition of Interest,ADD,human,y,,ccurtis
212,2308471,375,378,Drug Intervention,MPH,human,y,,ccurtis
213,2308471,908,926,Outcome (Study Endpoint),Prolactin response,model,y,,ccurtis
214,2308471,918,926,Outcome (Study Endpoint),response,human,n,too little,ccurtis
215,2308471,942,948,Outcome (Study Endpoint),AUCPro,human,n,wrong label,ccurtis
216,2308471,1008,1009,Type of Quant. Measure,t,model,n,wrong label,ccurtis
217,2308471,1242,1261,Type of Quant. Measure,Fisher's exact test,model,n,,ccurtis
218,2308471,1353,1388,Outcome (Study Endpoint),improvement in reaction time on the,model,n,,ccurtis
219,2308471,1401,1412,Outcome (Study Endpoint),GH response,model,y,,ccurtis
220,2308471,1421,1422,Type of Quant. Measure,r,model,n,wrong label,ccurtis
221,2308471,1455,1473,Outcome (Study Endpoint),prolactin response,model,y,,ccurtis
222,2308471,1521,1545,Outcome (Study Endpoint),improvement in attention,model,n,too much,ccurtis
223,2376254,131,142,Drug Intervention,terbutaline,model,y,,eduvaris
224,2376254,148,158,Units,micrograms,model,n,too little,eduvaris
225,2376254,148,163,Units,micrograms.puff,human,y,,eduvaris
226,2376254,165,172,Intervention Administration,inhaled,human,y,,eduvaris
227,2376254,195,205,Drug Intervention,salbutamol,model,y,,eduvaris
228,2376254,211,221,Units,micrograms,model,n,too little,eduvaris
229,2376254,211,226,Units,micrograms.puff,human,y,,eduvaris
230,2376254,228,235,Intervention Administration,inhaled,human,y,,eduvaris
231,2376254,291,329,Disease/Condition of Interest,reversible obstructive airways disease,human,y,wrong label,eduvaris
232,2376254,367,387,Group Name,salbutamol/Volumatic,human,y,,eduvaris
233,2376254,454,475,Group Name,terbutaline/Nebuhaler,human,y,,eduvaris
234,2376254,477,480,Quantitative Measurement,one,human,y,,eduvaris
235,2376254,481,485,Units,puff,human,y,,eduvaris
236,2376254,506,511,Quantitative Measurement,eight,human,y,,eduvaris
237,2407872,17,26,Drug Intervention,diltiazem,model,y,,stan
238,2407872,31,50,Drug Intervention,hydrochlorothiazide,model,y,,stan
239,2407872,54,66,Disease/Condition of Interest,hypertension,model,y,,stan
240,2407872,267,323,Drug Intervention,slow-release (SR) formulation of diltiazem hydrochloride,human,n,too much,stan
241,2407872,300,323,Drug Intervention,diltiazem hydrochloride,model,y,,stan
242,2407872,359,378,Drug Intervention,hydrochlorothiazide,model,y,,stan
243,2407872,413,425,Disease/Condition of Interest,hypertension,model,y,,stan
244,2407872,471,474,Sample Size,297,model,y,,stan
245,2407872,547,556,Drug Intervention,diltiazem,model,y,,stan
246,2407872,547,559,Drug Intervention,diltiazem SR,human,n,too little or too much based on context,stan
247,2407872,589,608,Drug Intervention,hydrochlorothiazide,model,y,,stan
248,2407872,609,620,Group Name,monotherapy,model,n,wrong label,stan
249,2407872,658,667,Drug Intervention,diltiazem,model,y,,stan
250,2407872,658,670,Drug Intervention,diltiazem SR,human,n,too little or too much based on context,stan
251,2407872,675,694,Drug Intervention,hydrochlorothiazide,model,y,,stan
252,2407872,699,706,Intervention Duration,6 weeks,model,y,,stan
253,2407872,885,896,Group Name,combination,human,n,too little,stan
254,2407872,885,904,Group Name,combination therapy,model,y,,stan
255,2407872,948,957,Outcome (Study Endpoint),diastolic,model,y,,stan
256,2407872,972,980,Outcome (Study Endpoint),systolic,model,y,,stan
257,2407872,984,996,Group Name,diltiazem SR,human,n,wrong label,stan
258,2407872,1012,1015,Group Name,3.5,human,n,wrong label,stan
259,2407872,1022,1031,Outcome (Study Endpoint),diastolic,model,y,,stan
260,2407872,1046,1054,Outcome (Study Endpoint),systolic,model,y,,stan
261,2407872,1058,1077,Group Name,hydrochlorothiazide,human,n,wrong label,stan
262,2407872,1133,1161,Outcome (Study Endpoint),achieved goal blood pressure,human,n,too little or too much based on context,stan
263,2407872,1142,1161,Outcome (Study Endpoint),goal blood pressure,model,n,too little,stan
264,2407872,1175,1194,Group Name,hydrochlorothiazide,human,n,wrong label,stan
265,2407872,1213,1225,Drug Intervention,diltiazem SR,human,n,too little or too much based on context,stan
266,2407872,1248,1259,Group Name,combination,human,n,too little,stan
267,2449384,34,76,Disease/Condition of Interest,diffuse large cell non-Hodgkin's lymphomas,model,y,,cjackson
268,2449384,53,76,Disease/Condition of Interest,non-Hodgkin's lymphomas,human,n,too little,cjackson
269,2449384,157,180,Group Characteristic,non-Hodgkin's lymphomas,model,n,wrong label,cjackson
270,2449384,208,243,Group Characteristic,mostly diffuse large cell lymphomas,human,n,wrong label,cjackson
271,2449384,336,340,Drug Intervention,CHOP,human,y,,cjackson
272,2449384,343,344,Sample Size,n,model,n,not needed,cjackson
273,2449384,358,373,Drug Intervention,COPBLAM-regimen,human,n,too much,cjackson
274,2449384,375,376,Sample Size,n,model,n,not needed,cjackson
275,2449384,608,623,Group Name,COPBLAM treated,human,y,,cjackson
276,2449384,654,666,Group Name,CHOP treated,human,n,too little,cjackson
277,2449384,693,695,Quantitative Measurement,38,model,n,too little,cjackson
278,2449384,693,704,Quantitative Measurement,38 per cent,human,y,,cjackson
279,2449384,696,707,Units,per cent CR,model,n,wrong label,cjackson
280,2449384,850,861,Quantitative Measurement,85 per cent,model,y,,cjackson
281,2449384,915,921,Units,months,model,y,,cjackson
282,2449384,927,948,Outcome (Study Endpoint),mean observation time,model,n,too much,cjackson
283,2449384,1001,1003,Quantitative Measurement,37,model,y,,cjackson
284,2449384,1011,1013,Quantitative Measurement,30,model,y,,cjackson
285,2449384,1014,1020,Units,months,model,y,,cjackson
286,2607128,16,26,Drug Intervention,fluoxetine,model,y,,hcho
287,2607128,27,37,Drug Intervention,imipramine,model,y,,hcho
288,2607128,42,49,Drug Intervention,placebo,model,n,wrong label,hcho
289,2607128,142,152,Drug Intervention,fluoxetine,human,y,,hcho
290,2607128,154,164,Drug Intervention,imipramine,human,y,,hcho
291,2607128,170,177,Group Name,placebo,model,y,,hcho
292,2607128,240,304,Outcome (Study Endpoint),greater than or equal to 50% improvement in the HAMD-total score,human,y,,hcho
293,2607128,368,370,Quantitative Measurement,86,human,n,too little,hcho
294,2607128,368,371,Quantitative Measurement,86%,model,y,,hcho
295,2607128,370,371,Units,%,human,n,wrong label,hcho
296,2607128,407,415,Outcome (Study Endpoint),improved,model,n,too little,hcho
297,2607128,430,432,Quantitative Measurement,57,human,n,too little,hcho
298,2607128,430,433,Quantitative Measurement,57%,model,y,,hcho
299,2607128,432,433,Units,%,human,n,wrong label,hcho
300,2607128,441,459,Group Name,imipramine-treated,human,n,wrong label,hcho
301,2607128,464,466,Quantitative Measurement,38,human,n,too little,hcho
302,2607128,464,467,Quantitative Measurement,38%,model,y,,hcho
303,2607128,466,467,Units,%,human,n,wrong label,hcho
304,2607128,475,482,Group Name,placebo,model,y,,hcho
305,2607128,475,490,Group Name,placebo-treated,human,n,wrong label,hcho
306,2607128,521,539,Group Name,fluoxetine-treated,human,n,wrong label,hcho
307,2607128,622,623,Quantitative Measurement,7,human,n,too little,hcho
308,2607128,622,624,Quantitative Measurement,7%,model,y,,hcho
309,2607128,623,624,Units,%,human,n,wrong label,hcho
310,2679397,15,25,Disease/Condition of Interest,stomatitis,model,y,,ccurtis
311,2679397,144,154,Intervention Administration,mouth wash,human,n,wrong label,ccurtis
312,2679397,196,207,Group Characteristic,gynecologic,model,y,,ccurtis
313,2679397,196,216,Group Characteristic,gynecologic patients,human,n,too much,ccurtis
314,2679397,254,258,Drug Intervention,5-FU,model,y,,ccurtis
315,2679397,254,263,Non-Study Drug,5-FU+CDDP,human,n,too much,ccurtis
316,2679397,259,263,Drug Intervention,CDDP,model,y,,ccurtis
317,2679397,265,267,Drug Intervention,PF,model,y,,ccurtis
318,2679397,294,305,Non-Study Drug,vincristine,human,n,wrong label,ccurtis
319,2679397,310,323,Non-Study Drug,actinomycin-D,human,n,wrong label,ccurtis
320,2679397,324,340,Drug Intervention,cyclophosphamide,model,y,wrong label,ccurtis
321,2679397,342,345,Drug Intervention,VAC,model,y,,ccurtis
322,2679397,693,694,Quantitative Measurement,5,human,n,wrong label,ccurtis
323,2679397,755,756,Quantitative Measurement,2,human,y,,ccurtis
324,2679397,801,802,Quantitative Measurement,2,human,y,,ccurtis
325,2679397,823,842,Group Name,allopurinol-treated,model,n,too little,ccurtis
326,2679397,823,848,Group Name,allopurinol-treated group,human,y,,ccurtis
327,2719459,32,43,Intervention Frequency,single-dose,human,y,not necessary/wrong label,eduvaris
328,2719459,272,283,Intervention Frequency,single-dose,human,y,not necessary/wrong label,eduvaris
329,2719459,326,329,Group Characteristic,men,human,y,,eduvaris
330,2719459,334,337,Sample Size,100,human,y,,eduvaris
331,2719459,350,384,Group Characteristic,uncomplicated gonococcal infection,human,n,wrong label,eduvaris
332,2719459,897,906,Drug Intervention,ofloxacin,human,y,,eduvaris
333,2719459,1015,1024,Drug Intervention,ofloxacin,human,y,,eduvaris
334,2719459,1074,1077,Quantitative Measurement,0.3,human,y,wrong label,eduvaris
335,2719459,1104,1107,Outcome (Study Endpoint),MIC,human,y,,eduvaris
336,2719459,1111,1122,Drug Intervention,amoxicillin,human,y,,eduvaris
337,2719459,1154,1157,Quantitative Measurement,1.0,human,y,wrong label,eduvaris
338,2719459,1193,1202,Drug Intervention,ofloxacin,human,y,,eduvaris
339,2719459,1210,1221,Drug Intervention,amoxicillin,human,y,,eduvaris
340,2719459,1227,1237,Drug Intervention,probenecid,human,y,,eduvaris
341,2853406,44,69,Disease/Condition of Interest,cardiovascular reactivity,model,y,,stan
342,2853406,74,89,Disease/Condition of Interest,type A behavior,model,y,,stan
343,2853406,297,310,Disease/Condition of Interest,hypertensives,human,n,wrong label,stan
344,2853406,479,486,Group Name,placebo,model,y,,stan
345,2853406,678,686,Group Name,diuretic,human,n,wrong label,stan
346,2853406,691,698,Group Name,placebo,human,y,,stan
347,2853406,745,752,Group Name,control,model,n,wrong label,stan
348,2853406,745,758,Group Name,control group,human,y,,stan
349,2853406,789,802,Group Name,beta-blockers,human,n,wrong label,stan
350,2853406,803,855,Outcome (Study Endpoint),reduced heart rate but not blood pressure reactivity,human,n,wrong label,stan
351,2853406,811,821,Outcome (Study Endpoint),heart rate,model,y,,stan
352,2853406,830,872,Outcome (Study Endpoint),blood pressure reactivity to mental stress,model,n,wrong label,stan
353,2853406,1034,1047,Group Name,beta-blockers,human,n,wrong label,stan
354,2853406,1055,1063,Group Name,controls,human,y,,stan
355,2853406,1156,1167,Drug Intervention,propranolol,human,y,,stan
356,2853406,1197,1205,Drug Intervention,atenolol,human,y,,stan
357,2853406,1245,1263,Outcome (Study Endpoint),became less Type A,model,n,wrong label,stan
358,2853406,1252,1263,Outcome (Study Endpoint),less Type A,human,n,wrong label,stan
359,2853406,1351,1359,Drug Intervention,atenolol,human,y,,stan
360,2853406,1453,1464,Drug Intervention,propranolol,human,y,,stan
361,2915651,118,121,Sample Size,536,model,y,,cjackson
362,2915651,136,204,Group Characteristic,undergone either a modified radical mastectomy or a total mastectomy,human,y,,cjackson
363,2915651,426,470,Group Characteristic,estrogen-receptor-negative tumor of any size,model,y,,cjackson
364,2915651,477,599,Group Characteristic,estrogen-receptor-positive tumor at least 3 cm in diameter with no histopathological evidence of axillary-node involvement,model,y,,cjackson
365,2915651,635,639,Intervention Duration,four,model,n,not needed,cjackson
366,2915651,728,745,Intervention Duration,days 1 through 14,human,y,,cjackson
367,2915651,765,767,Units,mg,human,n,too little,cjackson
368,2915651,765,784,Units,mg per square meter,model,y,,cjackson
369,2915651,802,814,Intervention Duration,days 1 and 8,human,n,not needed,cjackson
370,2915651,835,837,Units,mg,human,n,too little,cjackson
371,2915651,835,854,Units,mg per square meter,model,y,,cjackson
372,2915651,872,884,Intervention Duration,days 1 and 8,human,n,not needed,cjackson
373,2915651,936,953,Intervention Duration,days 1 through 14,human,y,,cjackson
374,2915651,1365,1378,Group Characteristic,premenopausal,model,y,,cjackson
375,2915651,1435,1461,Group Characteristic,estrogen-receptor-positive,model,y,,cjackson
376,2915651,1470,1496,Group Characteristic,estrogen-receptor-negative,model,y,,cjackson
377,2915651,1505,1552,Side Effects,Severe or life-threatening hematologic toxicity,model,n,not needed,cjackson
378,2915651,1572,1574,Quantitative Measurement,33,human,n,too little,cjackson
379,2915651,1572,1582,Quantitative Measurement,33 percent,model,y,,cjackson
380,3178370,294,301,Group Characteristic,smokers,human,y,wrong label,hcho
381,3178370,344,355,Drug Intervention,propranolol,model,y,,hcho
382,3178370,344,365,Group Name,propranolol treatment,human,n,wrong label,hcho
383,3178370,377,388,Group Name,propranolol,model,n,wrong label,hcho
384,3178370,377,396,Group Name,propranolol-treated,human,n,wrong label,hcho
385,3178370,500,532,Outcome (Study Endpoint),initial blood pressure reduction,human,n,wrong label,hcho
386,3178370,508,522,Outcome (Study Endpoint),blood pressure,model,y,,hcho
387,3178370,647,661,Outcome (Study Endpoint),Blood pressure,human,y,,hcho
388,3178370,1233,1243,Outcome (Study Endpoint),terminated,human,n,too little,hcho
389,3178370,1359,1371,Disease/Condition of Interest,hypertension,human,y,,hcho
390,3178370,1435,1446,Drug Intervention,propranolol,human,y,,hcho
391,3247518,27,42,Disease/Condition of Interest,bronchodilation,human,y,,ccurtis
392,3247518,106,113,Intervention Administration,inhaled,human,y,,ccurtis
393,3247518,158,173,Intervention Duration,2 separate days,human,n,too much,ccurtis
394,3247518,235,236,Dosage,1,human,y,,ccurtis
395,3247518,235,237,Dosage,1-,model,n,too much,ccurtis
396,3247518,328,338,Intervention Administration,inhalation,human,y,,ccurtis
397,3247518,342,352,Drug Intervention,salbutamol,human,n,wrong label,ccurtis
398,3247518,376,397,Outcome (Study Endpoint),significantly greater,human,n,,ccurtis
399,3247518,448,457,Drug Intervention,ketotifen,human,y,,ccurtis
400,3247518,485,539,Outcome (Study Endpoint),difference between the effect of placebo and ketotifen,human,n,not needed,ccurtis
401,3247518,518,525,Group Name,placebo,model,y,,ccurtis
402,3294978,56,66,Drug Intervention,Nifedipine,model,y,,eduvaris
403,3294978,234,243,Group Characteristic,bronchial,model,n,wrong label,eduvaris
404,3294978,292,318,Outcome (Study Endpoint),peak expiratory flow rates,human,y,,eduvaris
405,3294978,445,490,Outcome (Study Endpoint),number of salbutamol rotacaps inhaled per day,human,y,,eduvaris
406,3307061,96,104,Disease/Condition of Interest,diabetes,human,y,,stan
407,3307061,108,123,Group Characteristic,renal allograft,model,n,wrong label,stan
408,3307061,153,185,Disease/Condition of Interest,posttransplant diabetes mellitus,human,y,wrong label,stan
409,3307061,307,311,Study Years,1980,model,y,,stan
410,3307061,307,320,Study Years,1980 and 1983,human,n,too little or too much based on context,stan
411,3307061,388,398,Drug Intervention,prednisone,model,y,,stan
412,3307061,388,402,Drug Intervention,prednisone (P),human,n,multiple entities,stan
413,3307061,400,401,Drug Intervention,P,model,y,,stan
414,3307061,628,650,Group Characteristic,previously nondiabetic,model,n,too little or too much based on context,stan
415,3307061,639,650,Group Characteristic,nondiabetic,human,y,,stan
416,3307061,685,687,Sample Size,47,human,y,,stan
417,3307061,707,714,Group Name,group 1,human,y,,stan
418,3307061,721,723,Sample Size,58,human,y,,stan
419,3307061,743,750,Group Name,group 2,human,y,,stan
420,3307061,762,764,Sample Size,68,human,y,,stan
421,3307061,793,807,Outcome (Study Endpoint),developed PTDM,human,n,too much,stan
422,3307061,997,1000,Drug Intervention,ALG,model,y,,stan
423,3307061,1127,1139,Drug Intervention,cyclosporine,human,y,,stan
424,3307061,1144,1154,Drug Intervention,prednisone,human,y,,stan
425,3307061,1538,1555,Outcome (Study Endpoint),incidence of PTDM,human,n,too much,stan
426,3307061,1579,1592,Group Characteristic,older than 45,model,y,,stan
427,3307061,1615,1633,Group Characteristic,heavier than 70 kg,model,y,,stan
428,3307061,1628,1633,Group Characteristic,70 kg,human,n,multiple entities,stan
429,3307061,1669,1689,Group Characteristic,cadaveric allografts,human,n,wrong label,stan
430,3307061,1733,1760,Group Characteristic,hospitalized for infections,model,n,too much,stan
431,3307061,1750,1760,Group Characteristic,infections,human,y,,stan
432,3307061,1949,1953,Outcome (Study Endpoint),PTDM,human,y,,stan
433,3307061,1997,2008,Outcome (Study Endpoint),nondiabetic,human,n,wrong label,stan
434,3307061,2013,2018,Outcome (Study Endpoint),graft,model,n,too little,stan
435,3307061,2013,2027,Outcome (Study Endpoint),graft survival,human,y,,stan
436,3307061,2088,2100,Drug Intervention,azathioprine,human,y,,stan
437,3307061,2102,2114,Drug Intervention,cyclosporine,human,y,,stan
438,3307061,2120,2130,Drug Intervention,prednisone,human,y,,stan
439,3320928,261,269,Group Characteristic,children,model,y,,hcho
440,3320928,275,307,Disease/Condition of Interest,acute otitis media with effusion,model,y,,hcho
441,3320928,514,516,Intervention Frequency,qd,model,y,,hcho
442,3320928,743,746,Quantitative Measurement,88%,human,n,wrong label,hcho
443,3320928,814,817,Quantitative Measurement,33%,human,n,wrong label,hcho
444,3320928,826,837,Outcome (Study Endpoint),Haemophilus,human,n,wrong label,hcho
445,3320928,843,846,Quantitative Measurement,41%,human,n,wrong label,hcho
446,3320928,847,871,Outcome (Study Endpoint),Streptococcus pneumoniae,human,n,wrong label,hcho
447,3320928,876,878,Quantitative Measurement,6%,human,n,wrong label,hcho
448,3320928,879,902,Outcome (Study Endpoint),Branhamella catarrhalis,human,n,wrong label,hcho
449,3320928,932,940,Drug Intervention,cefixime,human,y,,hcho
450,3320928,948,959,Drug Intervention,amoxicillin,human,y,,hcho
451,3320928,1079,1095,Group Name,cefixime-treated,model,n,wrong label,hcho
452,3320928,1119,1138,Group Name,amoxicillin-treated,model,n,wrong label,hcho
453,3320928,1239,1241,Quantitative Measurement,95,human,n,too little,hcho
454,3320928,1239,1242,Quantitative Measurement,95%,model,y,,hcho
455,3320928,1241,1242,Units,%,human,n,too little,hcho
456,3320928,1258,1274,Outcome (Study Endpoint),Clinical failure,human,n,too little,hcho
457,3320928,1258,1285,Outcome (Study Endpoint),Clinical failure or relapse,model,y,,hcho
458,3320928,1339,1347,Drug Intervention,cefixime,human,y,,hcho
459,3320928,1390,1401,Drug Intervention,amoxicillin,human,y,,hcho
460,3320928,1403,1431,Side Effects,Gastrointestinal disturbance,model,y,,hcho
461,3320928,1403,1440,Outcome (Study Endpoint),Gastrointestinal disturbance and rash,human,n,too much,hcho
462,3320928,1436,1440,Side Effects,rash,model,y,,hcho
463,3320928,1475,1483,Group Characteristic,children,human,y,,hcho
464,3320928,1497,1505,Drug Intervention,cefixime,human,y,,hcho
465,3320928,1514,1516,Quantitative Measurement,15,human,n,too little,hcho
466,3320928,1514,1517,Quantitative Measurement,15%,model,y,,hcho
467,3320928,1516,1517,Units,%,human,n,wrong label,hcho
468,3320928,1554,1565,Drug Intervention,amoxicillin,human,y,,hcho
469,3320928,1573,1574,Quantitative Measurement,2,human,n,wrong label,hcho
470,3320928,1573,1575,Quantitative Measurement,2%,model,y,,hcho
471,3320928,1574,1575,Units,%,human,n,wrong label,hcho
472,3320928,1690,1694,Side Effects,rash,model,y,,hcho
473,3320928,1736,1744,Drug Intervention,cefixime,model,y,,hcho
474,3320928,1751,1761,Intervention Frequency,once daily,model,y,,hcho
475,3320928,1790,1801,Drug Intervention,amoxicillin,model,y,,hcho
476,3352775,605,608,Sample Size,494,model,n,wrong label,ccurtis
477,3352775,698,717,Group Characteristic,intensive treatment,human,y,,ccurtis
478,3352775,926,930,Drug Intervention,MOPP,model,n,wrong label,ccurtis
479,3352775,948,966,Non-Pharmaceutical Intervention,mantle irradiation,human,y,,ccurtis
480,3352775,1006,1008,Group Name,3M,human,y,,ccurtis
481,3352775,1475,1513,Group Characteristic,men less than or equal to 40 years old,model,n,too much,ccurtis
482,3582605,83,92,Drug Intervention,melphalan,model,y,,eduvaris
483,3582605,380,396,Disease/Condition of Interest,multiple myeloma,model,y,,eduvaris
484,3582605,405,407,Group Name,MP,model,y,,eduvaris
485,3582605,416,438,Group Characteristic,refractory or relapsed,model,y,,eduvaris
486,3582605,485,490,Group Name,MOCCA,model,y,,eduvaris
487,3582605,553,555,Group Name,MP,model,y,,eduvaris
488,3582605,562,575,Outcome (Study Endpoint),response rate,model,y,,eduvaris
489,3899346,238,241,Disease/Condition of Interest,CLL,human,y,,stan
490,3899346,353,356,Group Name,CLR,model,n,wrong label,stan
491,3899346,377,382,Intervention Duration,day 6,model,n,wrong label,stan
492,3899346,401,404,Group Name,PDN,model,n,wrong label,stan
493,3899346,424,432,Intervention Duration,days 1-5,model,n,wrong label,stan
494,3899346,494,499,Intervention Duration,day 6,model,n,wrong label,stan
495,3899346,538,543,Intervention Duration,day 6,model,n,wrong label,stan
496,3899346,578,586,Intervention Duration,days 1-5,model,n,wrong label,stan
497,3899346,589,592,Group Name,COP,human,n,wrong label,stan
498,3899346,594,604,Intervention Frequency,each month,human,y,,stan
499,3899346,882,884,Outcome (Study Endpoint),CR,human,y,,stan
500,3899346,891,903,Group Name,CLR plus PDN,human,n,wrong label,stan
501,3899346,920,922,Outcome (Study Endpoint),CR,human,y,,stan
502,3899346,929,932,Group Name,COP,human,n,wrong label,stan
503,3899346,1041,1059,Group Characteristic,previously treated,human,y,,stan
504,3899346,1066,1091,Outcome (Study Endpoint),lower number of responses,model,y,,stan
505,3899346,1121,1142,Group Characteristic,no previous treatment,human,y,,stan
506,3899346,1200,1202,Group Characteristic,CR,human,n,wrong label,stan
507,3899346,1208,1215,Group Characteristic,good PR,human,n,wrong label,stan
508,3899346,1220,1236,Outcome (Study Endpoint),longer survivals,model,n,too little or too much based on context,stan
509,3899346,1227,1236,Outcome (Study Endpoint),survivals,human,y,,stan
510,3899346,1276,1283,Group Characteristic,poor PR,human,n,wrong label,stan
511,3899346,1285,1291,Type of Quant. Measure,median,human,y,,stan
512,3899346,1319,1334,Group Characteristic,did not respond,human,y,,stan
513,3899346,1349,1355,Type of Quant. Measure,median,human,y,,stan
514,6398628,23,31,Group Characteristic,children,model,y,,cjackson
515,6398628,53,88,Disease/Condition of Interest,idiopathic thrombocytopenic purpura,model,y,,cjackson
516,6398628,123,131,Outcome (Study Endpoint),efficacy,human,y,,cjackson
517,6398628,412,419,Drug Intervention,placebo,human,n,wrong label,cjackson
518,6398628,591,614,Outcome (Study Endpoint),clinical bleeding score,model,y,,cjackson
519,6398628,600,614,Outcome (Study Endpoint),bleeding score,human,n,too little,cjackson
520,6398628,948,958,Group Name,prednisone,human,n,wrong label,cjackson
521,6398628,996,1004,Outcome (Study Endpoint),bleeding,model,n,too little,cjackson
522,6398628,1215,1233,Outcome (Study Endpoint),effect on platelet,human,n,too little,cjackson
523,6398628,1267,1277,Drug Intervention,prednisone,human,y,,cjackson
524,6484553,15,27,Disease/Condition of Interest,endocarditis,human,y,,hcho
525,6484553,171,183,Disease/Condition of Interest,endocarditis,human,y,,hcho
526,6484553,197,208,Drug Intervention,amoxycillin,human,y,,hcho
527,6484553,214,226,Drug Intervention,erythromycin,human,y,,hcho
528,6484553,230,241,Drug Intervention,clindamycin,human,y,,hcho
529,6484553,384,388,Intervention Administration,oral,human,y,,hcho
530,6484553,518,521,Intervention Frequency,6 h,human,n,wrong label,hcho
531,6484553,518,527,Intervention Frequency,6 h apart,model,n,wrong label,hcho
532,6484553,582,592,Group Characteristic,volunteers,human,n,wrong label,hcho
533,6484553,645,656,Drug Intervention,amoxycillin,model,y,,hcho
534,6484553,661,672,Drug Intervention,clindamycin,model,y,,hcho
535,6484553,713,724,Drug Intervention,Amoxycillin,human,y,,hcho
536,6484553,771,776,Outcome (Study Endpoint),Serum,human,n,too little,hcho
537,6484553,855,859,Quantitative Measurement,0.03,human,y,,hcho
538,6484553,910,925,Outcome (Study Endpoint),mean peak serum,human,n,too little,hcho
539,6484553,910,940,Outcome (Study Endpoint),mean peak serum concentrations,model,y,,hcho
540,6484553,949,953,Units,mg/l,model,y,,hcho
541,6484553,1188,1200,Disease/Condition of Interest,endocarditis,human,y,,hcho
542,7297143,30,38,Drug Intervention,pindolol,model,y,,ccurtis
543,7297143,50,66,Disease/Condition of Interest,mild to moderate,model,n,too little,ccurtis
544,7297143,120,126,Disease/Condition of Interest,asthma,human,n,too little,ccurtis
545,7297143,131,163,Disease/Condition of Interest,chronic obstructive lung disease,model,y,,ccurtis
546,7297143,196,204,Drug Intervention,pindolol,human,y,,ccurtis
547,7297143,318,325,Drug Intervention,placebo,human,n,wrong label,ccurtis
548,7297143,332,358,Group Characteristic,mild to moderate asthmatic,model,n,wrong label,ccurtis
549,7297143,371,380,Group Characteristic,remission,model,y,,ccurtis
550,7297143,492,500,Group Name,pindolol,human,n,,ccurtis
551,7297143,505,512,Group Name,placebo,human,y,,ccurtis
552,7297143,749,756,Intervention Administration,inhaled,model,y,,ccurtis
553,7297143,757,770,Drug Intervention,isoproterenol,model,n,wrong label,ccurtis
554,7297143,785,789,Outcome (Study Endpoint),peak,model,n,too little,ccurtis
555,7297143,785,811,Outcome (Study Endpoint),peak expiratory flow rates,human,y,,ccurtis
556,7297143,931,939,Drug Intervention,pindolol,human,y,,ccurtis
557,7343379,417,427,Drug Intervention,metoprolol,human,n,too little,eduvaris
558,7343379,417,434,Drug Intervention,metoprolol RETARD,model,y,,eduvaris
559,7343379,435,438,Dosage,100,model,y,,eduvaris
560,7343379,435,441,Dosage,100 mg,human,n,multiple entities,eduvaris
561,7343379,439,441,Units,mg,model,y,,eduvaris
562,7343379,446,449,Dosage,200,model,y,,eduvaris
563,7343379,446,452,Dosage,200 mg,human,n,multiple entities,eduvaris
564,7343379,450,452,Units,mg,model,y,,eduvaris
565,7343379,599,616,Drug Intervention,metoprolol RETARD,model,y,,eduvaris
566,7343379,618,638,Outcome (Study Endpoint),Duration of exercise,model,y,,eduvaris
567,7343379,640,656,Outcome (Study Endpoint),maximal workload,model,y,,eduvaris
568,7343379,640,708,Outcome (Study Endpoint),maximal workload and total work performed did significantly increase,human,n,too much,eduvaris
569,7343379,661,681,Outcome (Study Endpoint),total work performed,model,y,,eduvaris
570,7343379,733,743,Drug Intervention,metoprolol,human,n,too little,eduvaris
571,7343379,751,757,Dosage,100 mg,human,n,multiple entities,eduvaris
572,7343379,781,787,Dosage,200 mg,human,n,multiple entities,eduvaris
573,7343379,785,787,Units,mg,model,y,,eduvaris
574,7343379,866,897,Outcome (Study Endpoint),Peak systolic arterial pressure,model,y,,eduvaris
575,7343379,866,912,Outcome (Study Endpoint),Peak systolic arterial pressure and heart rate,human,n,multiple entities,eduvaris
576,7343379,902,912,Outcome (Study Endpoint),heart rate,model,y,,eduvaris
577,7343379,929,946,Group Name,metoprolol RETARD,model,n,wrong label,eduvaris
578,7343379,947,950,Dosage,200,model,y,,eduvaris
579,7343379,947,953,Dosage,200 mg,human,n,multiple entities,eduvaris
580,7343379,951,953,Units,mg,model,y,,eduvaris
581,7343379,1093,1096,Group Name,100,model,n,wrong label,eduvaris
582,7343379,1093,1099,Dosage,100 mg,human,n,multiple entities,eduvaris
583,7343379,1097,1099,Units,mg,model,y,,eduvaris
584,7343379,1203,1206,Dosage,200,model,y,,eduvaris
585,7343379,1203,1209,Dosage,200 mg,human,n,multiple entities,eduvaris
586,7343379,1207,1209,Units,mg,model,y,,eduvaris
587,7343379,1402,1405,Dosage,200,model,y,,eduvaris
588,7343379,1402,1408,Dosage,200 mg,human,n,multiple entities,eduvaris
589,7343379,1406,1408,Units,mg,model,y,,eduvaris
590,7535080,0,3,Outcome (Study Endpoint),EFS,model,y,,cjackson
591,7535080,60,67,Group Characteristic,elderly,model,y,,stan
592,7535080,63,66,Quantitative Measurement,50%,human,y,,cjackson
593,7535080,70,73,Quantitative Measurement,18%,human,y,,cjackson
594,7535080,498,517,Group Characteristic,older than 65 years,model,y,,stan
595,7535080,523,535,Group Characteristic,intermediate,model,y,,stan
596,7535080,540,550,Group Characteristic,high-grade,model,y,,stan
597,7535080,592,599,Group Name,P-VEBEC,human,n,too little or too much based on context,stan
598,7535080,832,839,Intervention Duration,2 weeks,model,y,,stan
599,7535080,970,980,Intervention Frequency,every week,model,y,,stan
600,7535080,985,1003,Intervention Duration,4 consecutive days,model,y,,stan
601,7535080,1266,1269,Outcome (Study Endpoint),C.R,human,y,,stan
602,7535080,1287,1289,Quantitative Measurement,66,model,n,too little,stan
603,7535080,1287,1290,Quantitative Measurement,66%,human,y,,stan
604,7535080,1500,1509,Follow-up period,24 months,model,y,,stan
605,7535080,1510,1512,Outcome (Study Endpoint),OS,model,y,,stan
606,7535080,1514,1517,Outcome (Study Endpoint),DFS,model,y,,stan
607,7535080,1522,1525,Outcome (Study Endpoint),EFS,model,y,,stan
608,7535080,1531,1534,Quantitative Measurement,55%,model,y,,stan
609,7535080,1536,1539,Quantitative Measurement,52%,model,y,,stan
610,7535080,1545,1548,Quantitative Measurement,33%,model,y,,stan
611,7535080,1766,1776,Outcome (Study Endpoint),median RDI,model,y,,stan
612,7535080,1773,1776,Outcome (Study Endpoint),RDI,human,n,too little,stan
613,7535080,1778,1780,Quantitative Measurement,94,model,n,too little,stan
614,7535080,1778,1781,Quantitative Measurement,94%,human,y,,stan
615,7535080,1785,1787,Quantitative Measurement,79,model,n,too little,stan
616,7535080,1785,1788,Quantitative Measurement,79%,human,y,,stan
617,7535080,1838,1841,Quantitative Measurement,18%,human,y,,stan
618,7535080,1845,1847,Quantitative Measurement,56,model,n,too little,stan
619,7535080,1845,1848,Quantitative Measurement,56%,human,y,,stan
620,7535080,1855,1865,Outcome (Study Endpoint),rate of CR,model,y,,stan
621,7535080,1895,1897,Quantitative Measurement,89,model,y,,stan
622,7535080,1902,1904,Quantitative Measurement,56,model,y,,stan
623,7648234,9,20,Drug Intervention,bezafibrate,model,y,,hcho
624,7648234,25,36,Drug Intervention,simvastatin,model,y,,hcho
625,7648234,51,72,Disease/Condition of Interest,mixed hyperlipidaemia,model,y,,hcho
626,7648234,110,121,Drug Intervention,bezafibrate,model,y,,hcho
627,7648234,122,133,Drug Intervention,simvastatin,model,y,,hcho
628,7648234,159,161,Sample Size,49,model,y,,hcho
629,7648234,176,212,Group Characteristic,diet-resistant mixed hyperlipidaemia,model,n,wrong label,hcho
630,7648234,214,222,Disease/Condition of Interest,type IIb,model,y,,hcho
631,7648234,233,242,Disease/Condition of Interest,two-month,human,n,wrong label,hcho
632,7648234,243,250,Disease/Condition of Interest,placebo,human,n,wrong label,hcho
633,7648234,301,312,Drug Intervention,Bezafibrate,model,y,,hcho
634,7648234,338,342,Intervention Frequency,mane,model,y,,hcho
635,7648234,346,357,Drug Intervention,simvastatin,model,y,,hcho
636,7648234,364,369,Intervention Frequency,nocte,model,y,,hcho
637,7648234,382,394,Intervention Duration,three months,model,y,,hcho
638,7648234,650,661,Group Name,Simvastatin,model,n,wrong label,hcho
639,7648234,686,700,Group Name,Bezafibrate SR,model,n,wrong label,hcho
640,7648234,713,730,Outcome (Study Endpoint),total cholesterol,model,y,,hcho
641,7648234,732,735,Quantitative Measurement,2.0,model,y,,hcho
642,7648234,740,743,Quantitative Measurement,1.1,model,y,,hcho
643,7648234,744,750,Units,mmol/l,model,y,,hcho
644,7648234,752,761,Statistical Significance,p = 0.003,model,y,,hcho
645,7648234,793,796,Quantitative Measurement,1.7,model,y,,hcho
646,7648234,801,804,Quantitative Measurement,0.4,model,y,,hcho
647,7648234,805,811,Units,mmol/l,model,y,,hcho
648,7648234,813,823,Statistical Significance,p = 0.0001,model,y,,hcho
649,7648234,879,892,Outcome (Study Endpoint),triglycerides,model,y,,hcho
650,7648234,897,900,Quantitative Measurement,41%,model,y,,hcho
651,7648234,905,908,Quantitative Measurement,17%,model,y,,hcho
652,7648234,910,919,Statistical Significance,p = 0.001,model,y,,hcho
653,7648234,952,961,Statistical Significance,p = 0.004,model,y,,hcho
654,7648234,978,989,Drug Intervention,simvastatin,model,y,,hcho
655,7648234,1055,1068,Outcome (Study Endpoint),triglycerides,model,y,,hcho
656,7648234,1078,1088,Statistical Significance,p = 0.0003,model,y,,hcho
657,7648234,1103,1105,Quantitative Measurement,11,model,y,,hcho
658,7648234,1106,1111,Units,mg/dl,model,y,,hcho
659,7648234,1113,1121,Statistical Significance,p = 0.03,model,y,,hcho
660,7648234,1152,1154,Quantitative Measurement,21,model,y,,hcho
661,7648234,1155,1160,Units,mg/dl,model,y,,hcho
662,7648234,1162,1172,Statistical Significance,p = 0.0008,model,y,,hcho
663,7648234,1313,1324,Drug Intervention,bezafibrate,model,y,,hcho
664,7648234,1329,1340,Drug Intervention,simvastatin,model,y,,hcho
665,7662446,78,99,Disease/Condition of Interest,hypercholesterolaemia,model,y,,ccurtis
666,7662446,117,140,Group Characteristic,coronary artery disease,model,y,wrong label,ccurtis
667,7662446,412,456,Group Characteristic,total cholesterol concentration > 6.5 mmol/l,human,n,not needed,ccurtis
668,7662446,472,506,Group Characteristic,documented coronary artery disease,human,n,not needed,ccurtis
669,7662446,718,729,Sample Size,Fifty eight,model,n,wrong label,ccurtis
670,7662446,1139,1140,Intervention Duration,2,human,y,wrong label,ccurtis
671,7662446,1154,1155,Intervention Duration,3,human,y,wrong label,ccurtis
672,7662446,1165,1170,Units,years,human,y,,ccurtis
673,7662446,1368,1370,Type of Quant. Measure,SD,model,y,,ccurtis
674,7662446,1407,1410,Quantitative Measurement,5.2,model,y,,ccurtis
675,7662446,1412,1415,Quantitative Measurement,0.8,model,y,,ccurtis
676,7662446,1466,1467,Intervention Duration,1,model,n,too little,ccurtis
677,7662446,1644,1648,Quantitative Measurement,Four,human,n,wrong label,ccurtis
678,7662446,1658,1681,Group Name,simvastatin-bezafibrate,human,n,too little,ccurtis
679,7662446,1700,1711,Outcome (Study Endpoint),CK activity,model,y,,ccurtis
680,7664433,14,21,Group Name,placebo,human,n,not needed,eduvaris
681,7664433,96,124,Disease/Condition of Interest,severe chronic heart failure,human,n,too much,eduvaris
682,7664433,103,124,Disease/Condition of Interest,chronic heart failure,model,y,,eduvaris
683,7664433,239,243,Group Characteristic,mild,human,n,too little,eduvaris
684,7664433,247,255,Group Characteristic,moderate,human,n,too little,eduvaris
685,7664433,384,386,Sample Size,56,model,n,not needed,eduvaris
686,7664433,401,407,Group Characteristic,severe,human,y,,eduvaris
687,7664433,451,458,Group Name,placebo,human,n,not needed,eduvaris
688,7664433,509,519,Drug Intervention,carvedilol,human,y,,eduvaris
689,7664433,623,636,Quantitative Measurement,0.16 +/- 0.01,model,n,not needed,eduvaris
690,7664433,648,674,Group Characteristic,maximal oxygen consumption,model,n,not needed,eduvaris
691,7664433,678,690,Quantitative Measurement,13.6 +/- 0.6,model,n,not needed,eduvaris
692,7664433,691,704,Units,mL.kg-1.min-1,model,n,not needed,eduvaris
693,7664433,847,849,Sample Size,49,human,y,,eduvaris
694,7664433,998,1005,Group Name,placebo,human,n,too little,eduvaris
695,7664433,1177,1190,Group Name,placebo group,human,y,,eduvaris
696,7664433,1208,1218,Group Name,carvedilol,human,n,too little,eduvaris
697,7664433,1241,1260,Outcome (Study Endpoint),cardiac performance,model,n,not needed,eduvaris
698,7664433,1293,1297,Outcome (Study Endpoint),left,human,n,too little,eduvaris
699,7664433,1293,1327,Outcome (Study Endpoint),left ventricular ejection fraction,model,y,,eduvaris
700,7664433,1490,1494,Statistical Significance,0.002,human,n,too little,eduvaris
701,7664433,1500,1504,Statistical Significance,.017,human,n,too little,eduvaris
702,7664433,1548,1555,Group Name,placebo,human,n,wrong label,eduvaris
703,7664433,1579,1589,Drug Intervention,carvedilol,human,y,,eduvaris
704,7664433,1748,1770,Outcome (Study Endpoint),combined risk of death,human,n,too little,eduvaris
705,7664433,1892,1905,Group Name,placebo group,human,y,,eduvaris
706,7664433,1922,1932,Drug Intervention,carvedilol,human,y,,eduvaris
707,7664433,1995,2005,Drug Intervention,Carvedilol,human,y,,eduvaris
708,7722114,193,206,Group Characteristic,heart failure,model,n,too little or too much based on context,stan
709,7722114,217,254,Group Characteristic,idiopathic or ischemic cardiomyopathy,model,n,multiple entities,stan
710,7722114,485,498,Group Characteristic,heart failure,model,n,too little or too much based on context,stan
711,7722114,485,554,Group Characteristic,heart failure (New York Heart Association functional classes II to IV,human,y,,stan
712,7722114,673,683,Drug Intervention,carvedilol,model,y,,stan
713,7722114,685,690,Dosage,3.125,model,y,,stan
714,7722114,691,693,Units,mg,model,y,,stan
715,7722114,694,705,Intervention Frequency,twice a day,model,y,,stan
716,7722114,738,748,Drug Intervention,carvedilol,model,y,,stan
717,7722114,765,772,Group Name,placebo,model,n,wrong label,stan
718,7722114,818,825,Intervention Duration,1 month,model,y,,stan
719,7722114,831,835,Dosage,6.25,human,y,,stan
720,7722114,831,841,Dosage,6.25 to 25,model,n,multiple entities,stan
721,7722114,839,841,Dosage,25,human,y,,stan
722,7722114,1175,1181,Outcome (Study Endpoint),stroke,model,y,,stan
723,7722114,1268,1271,Quantitative Measurement,52%,model,y,,stan
724,7722114,1270,1271,Units,%,human,n,wrong label,stan
725,7722114,1403,1438,Outcome (Study Endpoint),lessening of heart failure symptoms,human,y,,stan
726,7722114,1416,1438,Outcome (Study Endpoint),heart failure symptoms,model,n,too little or too much based on context,stan
727,7722114,1558,1559,Units,s,human,y,,stan
728,7771914,76,84,Group Characteristic,children,model,y,,cjackson
729,7771914,90,102,Disease/Condition of Interest,tic disorder,model,y,,cjackson
730,7771914,275,315,Disease/Condition of Interest,attention-deficit hyperactivity disorder,human,y,,cjackson
731,7771914,359,370,Group Characteristic,prepubertal,human,y,,cjackson
732,7771914,359,379,Group Characteristic,prepubertal children,model,n,too much,cjackson
733,7771914,385,425,Group Characteristic,attention-deficit hyperactivity disorder,model,n,wrong label,cjackson
734,7771914,385,442,Group Characteristic,attention-deficit hyperactivity disorder and tic disorder,human,n,wrong label,cjackson
735,7771914,430,442,Group Characteristic,tic disorder,model,n,wrong label,cjackson
736,7771914,452,459,Group Name,placebo,human,y,,cjackson
737,7771914,828,839,Outcome (Study Endpoint),hyperactive,model,y,,cjackson
738,7912102,94,104,Drug Intervention,metoprolol,model,y,,hcho
739,7912102,106,114,Drug Intervention,pindolol,model,y,,hcho
740,7912102,120,131,Drug Intervention,propranolol,model,y,,hcho
741,7912102,184,194,Drug Intervention,metoprolol,model,y,,hcho
742,7912102,196,204,Drug Intervention,pindolol,model,y,,hcho
743,7912102,210,221,Drug Intervention,propranolol,model,y,,hcho
744,7912102,225,232,Group Characteristic,elderly,model,y,,hcho
745,7912102,225,256,Group Characteristic,elderly cardiovascular patients,human,n,too much,hcho
746,7912102,607,633,Group Characteristic,mean age of about 70 years,model,y,,hcho
747,7912102,625,633,Group Characteristic,70 years,human,n,too little,hcho
748,7912102,1071,1081,Drug Intervention,metoprolol,model,y,,hcho
749,7912102,1458,1466,Drug Intervention,pindolol,model,y,,hcho
750,7912102,1471,1482,Drug Intervention,propranolol,model,y,,hcho
751,7912102,1537,1567,Outcome (Study Endpoint),mean beta 1-receptor occupancy,model,n,multiple entities,hcho
752,7912102,1542,1567,Outcome (Study Endpoint),beta 1-receptor occupancy,human,y,,hcho
753,7912102,1575,1585,Drug Intervention,metoprolol,model,y,,hcho
754,7912102,1692,1711,Outcome (Study Endpoint),antagonist activity,model,n,wrong label,hcho
755,7912102,1719,1729,Drug Intervention,metoprolol,model,y,,hcho
756,7954041,0,10,Intervention Frequency,Once daily,model,y,,ccurtis
757,7954041,73,112,Disease/Condition of Interest,mild to moderate essential hypertension,model,y,,ccurtis
758,7954041,90,112,Disease/Condition of Interest,essential hypertension,human,y,,ccurtis
759,7954041,138,149,Drug Intervention,Perindopril,model,y,,ccurtis
760,7954041,235,246,Drug Intervention,perindopril,model,y,,ccurtis
761,7954041,341,350,Drug Intervention,diltiazem,model,n,wrong label,ccurtis
762,7954041,407,474,Group Characteristic,mean sitting diastolic blood pressure (DBP) between 95 and 110 mmHg,human,n,too little,ccurtis
763,7954041,407,484,Group Characteristic,mean sitting diastolic blood pressure (DBP) between 95 and 110 mmHg inclusive,model,n,too much,ccurtis
764,7954041,514,521,Group Characteristic,without,model,n,not needed,ccurtis
765,7954041,606,608,Sample Size,49,human,y,,ccurtis
766,7954041,658,668,Intervention Duration,four weeks,model,y,,ccurtis
767,7954041,672,679,Group Name,placebo,model,y,,ccurtis
768,7954041,705,716,Group Name,perindopril,model,n,too little,ccurtis
769,7954041,747,756,Group Name,diltiazem,model,n,too little,ccurtis
770,7954041,805,822,Group Name,perindopril group,model,y,,ccurtis
771,7954041,827,830,Dosage,120,model,y,,ccurtis
772,7954041,831,833,Units,mg,model,y,,ccurtis
773,7954041,853,868,Group Name,diltiazem group,model,y,,ccurtis
774,7954041,903,905,Units,mg,model,y,,ccurtis
775,7954041,906,908,Intervention Frequency,od,model,y,,ccurtis
776,7954041,916,927,Group Name,perindopril,model,n,too little,ccurtis
777,7954041,941,944,Dosage,360,model,y,,ccurtis
778,7954041,945,947,Units,mg,model,y,,ccurtis
779,7954041,953,955,Units,mg,model,y,,ccurtis
780,7954041,956,959,Intervention Frequency,bid,model,y,,ccurtis
781,7954041,968,977,Group Name,diltiazem,model,n,too little,ccurtis
782,7954041,987,1013,Group Characteristic,DBP remained above 90 mmHg,human,y,,ccurtis
783,7954041,1015,1034,Drug Intervention,Hydrochlorothiazide,model,n,wrong label,ccurtis
784,7954041,1203,1206,Outcome (Study Endpoint),DBP,model,y,,ccurtis
785,7954041,1236,1240,Units,mmHg,model,y,,ccurtis
786,7954041,1322,1329,Outcome (Study Endpoint),SBP/DBP,human,n,too much,ccurtis
787,7954041,1385,1389,Units,mmHg,model,y,,ccurtis
788,7954041,1425,1429,Units,mmHg,model,y,,ccurtis
789,8103646,233,251,Disease/Condition of Interest,asthmatic response,human,n,not needed,eduvaris
790,8103646,483,524,Group Characteristic,known dual reaction to allergen challenge,human,n,too much,eduvaris
791,8103646,489,524,Group Characteristic,dual reaction to allergen challenge,model,y,,eduvaris
792,8103646,571,578,Group Name,placebo,human,y,wrong label,eduvaris
793,8103646,613,619,Intervention Frequency,10 min,model,n,too little,eduvaris
794,8103646,840,850,Drug Intervention,Salmeterol,human,y,,eduvaris
795,8103646,920,939,Outcome (Study Endpoint),asthmatic reactions,human,y,,eduvaris
796,8103646,947,954,Drug Intervention,placebo,human,n,wrong label,eduvaris
797,8103646,1041,1043,Dosage,50,human,y,,eduvaris
798,8103646,1048,1051,Dosage,100,human,y,,eduvaris
799,8103646,1052,1062,Dosage,micrograms,human,n,wrong label,eduvaris
800,8103646,1063,1073,Drug Intervention,salmeterol,human,y,,eduvaris
801,8103646,1075,1077,Outcome (Study Endpoint),BH,human,y,,eduvaris
802,8103646,1155,1172,Outcome (Study Endpoint),Blood eosinophils,human,y,,eduvaris
803,8103646,1318,1325,Drug Intervention,placebo,human,n,wrong label,eduvaris
804,8103646,1362,1367,Outcome (Study Endpoint),s-ECP,human,y,,eduvaris
805,8103646,1373,1399,Outcome (Study Endpoint),serum eosinophil protein X,human,y,,eduvaris
806,8103646,1401,1406,Outcome (Study Endpoint),s-EPX,human,y,,eduvaris
807,8103646,1502,1512,Drug Intervention,salmeterol,human,y,,eduvaris
808,8103646,1513,1515,Dosage,50,human,y,,eduvaris
809,8103646,1516,1526,Units,micrograms,human,y,,eduvaris
810,8103646,1626,1636,Drug Intervention,salmeterol,human,y,,eduvaris
811,8103646,1637,1640,Dosage,100,human,y,,eduvaris
812,8103646,1641,1651,Units,micrograms,human,y,,eduvaris
813,8103646,1716,1726,Drug Intervention,salmeterol,human,y,,eduvaris
814,8151609,147,157,Drug Intervention,amlodipine,model,y,,stan
815,8151609,183,200,Drug Intervention,nifedipine retard,model,y,,stan
816,8151609,474,484,Drug Intervention,nifedipine,model,n,too little,stan
817,8151609,517,524,Quantitative Measurement,175/105,model,y,,stan
818,8151609,525,529,Units,mmHg,model,y,,stan
819,8151609,534,541,Quantitative Measurement,168/104,model,y,,stan
820,8151609,542,546,Units,mmHg,model,y,,stan
821,8151609,675,685,Drug Intervention,amlodipine,model,y,,stan
822,8151609,686,689,Dosage,7.3,model,y,,stan
823,8151609,690,692,Units,mg,model,y,,stan
824,8151609,697,714,Drug Intervention,nifedipine retard,model,y,,stan
825,8151609,715,719,Dosage,58.9,model,y,,stan
826,8151609,720,722,Units,mg,model,y,,stan
827,8151609,828,844,Group Name,amlodipine group,model,y,,stan
828,8151609,870,893,Group Name,nifedipine retard group,model,y,,stan
829,8151609,952,966,Outcome (Study Endpoint),adverse events,model,y,,stan
830,8151609,1022,1024,Quantitative Measurement,42,model,y,,stan
831,8151609,1029,1031,Quantitative Measurement,36,model,y,,stan
832,8151609,1094,1096,Quantitative Measurement,22,model,y,,stan
833,8151609,1101,1103,Quantitative Measurement,22,model,y,,stan
834,8151609,1220,1229,Side Effects,headaches,model,y,,stan
835,8151609,1270,1276,Side Effects,oedema,model,y,,stan
836,8161669,28,59,Disease/Condition of Interest,postprandial digestive function,human,y,,cjackson
837,8161669,264,266,Dosage,30,model,y,,cjackson
838,8161669,264,269,Dosage,30 mg,human,n,multiple entities,cjackson
839,8161669,267,269,Units,mg,model,y,,cjackson
840,8161669,363,370,Group Name,placebo,model,y,,cjackson
841,8161669,414,456,Outcome (Study Endpoint),mean +/- S.E.M. 3-h gastric acid secretion,human,n,multiple entities,cjackson
842,8161669,430,456,Outcome (Study Endpoint),3-h gastric acid secretion,model,y,,cjackson
843,8161669,893,905,Drug Intervention,lansoprazole,human,y,,cjackson
844,8161669,948,955,Group Name,placebo,model,y,,cjackson
845,8195451,0,10,Drug Intervention,Clonazepam,model,y,,hcho
846,8195451,185,195,Sample Size,Thirty-two,model,y,,hcho
847,8195451,196,207,Group Characteristic,outpatients,human,y,,hcho
848,8195451,254,284,Group Characteristic,agoraphobia with panic attacks,model,y,,hcho
849,8195451,337,347,Drug Intervention,clonazepam,human,y,,hcho
850,8195451,512,522,Group Name,Clonazepam,model,n,wrong label,hcho
851,8195451,512,530,Group Name,Clonazepam-treated,human,n,wrong label,hcho
852,8195451,749,783,Outcome (Study Endpoint),symptoms of anxiety and depression,model,y,,hcho
853,8195451,761,783,Outcome (Study Endpoint),anxiety and depression,human,n,too little,hcho
854,8195451,801,810,Outcome (Study Endpoint),mean dose,model,n,multiple entities,hcho
855,8195451,839,842,Dosage,2.2,model,y,,hcho
856,8195451,867,870,Quantitative Measurement,0.7,model,y,,hcho
857,8195451,871,873,Units,mg,model,y,,hcho
858,8195451,909,920,Outcome (Study Endpoint),correlation,model,n,too little,hcho
859,8195451,929,957,Outcome (Study Endpoint),drug concentration in plasma,human,y,,hcho
860,8195451,929,1011,Outcome (Study Endpoint),drug concentration in plasma and decrease in the global measure of the severity of,model,n,too much,hcho
861,8195451,962,970,Outcome (Study Endpoint),decrease,human,n,not needed,hcho
862,8195451,978,1026,Outcome (Study Endpoint),global measure of the severity of panic disorder,human,y,,hcho
863,8195451,1028,1029,Type of Quant. Measure,r,model,y,,hcho
864,8195451,1032,1033,Quantitative Measurement,0,model,n,too little,hcho
865,8195451,1096,1097,Type of Quant. Measure,r,model,y,,hcho
866,8195451,1120,1121,Type of Quant. Measure,r,model,y,,hcho
867,8195451,1133,1146,Outcome (Study Endpoint),panic attacks,model,y,,hcho
868,8195451,1288,1289,Quantitative Measurement,9,human,y,,hcho
869,8195451,1293,1295,Sample Size,13,human,n,wrong label,hcho
870,8202045,23,65,Disease/Condition of Interest,disseminated Langerhans cell histiocytosis,model,n,too much,ccurtis
871,8202045,36,65,Disease/Condition of Interest,Langerhans cell histiocytosis,human,y,,ccurtis
872,8202045,853,858,Intervention Frequency,eight,human,n,wrong label,ccurtis
873,8202045,928,935,Group Name,group B,model,y,,ccurtis
874,8202045,966,973,Group Name,group C,model,y,,ccurtis
875,8202045,1214,1237,Outcome (Study Endpoint),frequency of recurrence,human,y,,ccurtis
876,8202045,1214,1262,Outcome (Study Endpoint),frequency of recurrence after initial resolution,model,n,too much,ccurtis
877,8202045,1348,1375,Outcome (Study Endpoint),remained free of recurrence,human,n,too much,ccurtis
878,8202045,1357,1375,Outcome (Study Endpoint),free of recurrence,model,y,,ccurtis
879,8202045,1377,1399,Outcome (Study Endpoint),Permanent consequences,model,y,,ccurtis
880,8202045,1377,1409,Outcome (Study Endpoint),Permanent consequences developed,human,n,too much,ccurtis
881,8202045,1450,1468,Outcome (Study Endpoint),Diabetes insipidus,model,y,,ccurtis
882,8202045,1450,1498,Outcome (Study Endpoint),Diabetes insipidus after initiation of treatment,human,n,too much,ccurtis
883,8202045,1585,1588,Quantitative Measurement,two,human,y,,ccurtis
884,8202045,1589,1597,Units,patients,human,n,not needed,ccurtis
885,8202045,1606,1611,Quantitative Measurement,eight,human,y,,ccurtis
886,8202045,1612,1620,Units,patients,human,n,not needed,ccurtis
887,8202045,1727,1734,Follow-up period,6 years,model,y,,ccurtis
888,8202045,1727,1744,Follow-up period,"6 years, 9 months",human,n,too much,ccurtis
889,8202045,1736,1744,Follow-up period,9 months,model,y,,ccurtis
890,8227233,55,65,Drug Intervention,metoprolol,model,n,too little,eduvaris
891,8227233,70,80,Drug Intervention,metoprolol,model,n,too little,eduvaris
892,8227233,213,218,Intervention Frequency,daily,model,y,,eduvaris
893,8227233,241,264,Drug Intervention,conventional metoprolol,human,y,,eduvaris
894,8227233,254,264,Drug Intervention,metoprolol,model,n,too little,eduvaris
895,8227233,273,275,Dosage,50,model,y,,eduvaris
896,8227233,273,282,Dosage,50 or 100,human,n,multiple entities,eduvaris
897,8227233,279,282,Dosage,100,model,y,,eduvaris
898,8227233,286,312,Drug Intervention,slow-release metoprolol CR,human,n,too much,eduvaris
899,8227233,299,309,Drug Intervention,metoprolol,model,n,too little,eduvaris
900,8227233,331,338,Group Name,placebo,human,y,wrong label,eduvaris
901,8227233,391,398,Group Characteristic,healthy,model,y,,eduvaris
902,8227233,391,409,Group Characteristic,healthy volunteers,human,n,too much,eduvaris
903,8227233,550,606,Outcome (Study Endpoint),reduction in the exercise-induced increase in heart rate,human,n,too much,eduvaris
904,8227233,584,606,Outcome (Study Endpoint),increase in heart rate,model,n,too much,eduvaris
905,8227233,624,631,Group Name,placebo,human,y,,eduvaris
906,8227233,666,693,Outcome (Study Endpoint),increase in plasma glycerol,human,n,too little,eduvaris
907,8227233,678,693,Outcome (Study Endpoint),plasma glycerol,model,n,too little,eduvaris
908,8227233,726,767,Outcome (Study Endpoint),diminished by all metoprolol preparations,human,n,not needed,eduvaris
909,8227233,777,799,Outcome (Study Endpoint),greater extent by M100,human,n,not needed,eduvaris
910,8227233,975,1014,Outcome (Study Endpoint),significant elevation in plasma ammonia,human,n,too much,eduvaris
911,8227233,1000,1014,Outcome (Study Endpoint),plasma ammonia,model,y,,eduvaris
912,8227233,1071,1112,Outcome (Study Endpoint),perceived exertion at the end of exercise,human,n,too much,eduvaris
913,8270292,112,114,Dosage,20,human,y,,stan
914,8270292,112,117,Dosage,20 mg,model,n,multiple entities,stan
915,8270292,115,117,Units,mg,human,y,,stan
916,8270292,265,269,Intervention Administration,oral,model,y,,stan
917,8270292,278,280,Dosage,20,human,y,,stan
918,8270292,278,283,Dosage,20 mg,model,n,multiple entities,stan
919,8270292,281,283,Units,mg,human,y,,stan
920,8270292,354,400,Group Characteristic,duodenal ulcer patients and healthy volunteers,human,n,multiple entities,stan
921,8270292,445,447,Dosage,20,human,y,,stan
922,8270292,445,450,Dosage,20 mg,model,n,multiple entities,stan
923,8270292,448,450,Units,mg,human,y,,stan
924,8270292,451,456,Intervention Frequency,daily,human,y,,stan
925,8270292,464,466,Dosage,20,human,y,,stan
926,8270292,464,469,Dosage,20 mg,model,n,multiple entities,stan
927,8270292,467,469,Units,mg,human,y,,stan
928,8270292,473,487,Intervention Frequency,alternate days,human,y,,stan
929,8270292,508,522,Disease/Condition of Interest,duodenal ulcer,human,y,,stan
930,8270292,589,593,Sample Size,five,model,y,,stan
931,8270292,627,634,Group Characteristic,healthy,model,n,too little,stan
932,8270292,627,645,Group Characteristic,healthy volunteers,human,y,,stan
933,8270292,696,698,Dosage,20,human,y,,stan
934,8270292,696,701,Dosage,20 mg,model,n,multiple entities,stan
935,8270292,699,706,Units,mg oral,human,n,multiple entities,stan
936,8270292,702,706,Intervention Administration,oral,model,y,,stan
937,8270292,751,764,Group Characteristic,uncomplicated,model,n,too little,stan
938,8270292,751,788,Group Characteristic,uncomplicated duodenal ulcer patients,human,y,,stan
939,8270292,765,779,Group Characteristic,duodenal ulcer,model,n,too little,stan
940,8270292,827,829,Dosage,20,human,y,,stan
941,8270292,827,832,Dosage,20 mg,model,n,multiple entities,stan
942,8270292,830,832,Units,mg,human,y,,stan
943,8270292,840,845,Intervention Frequency,daily,model,y,wrong label,stan
944,8270292,847,853,Sample Size,n = 30,human,n,too much,stan
945,8270292,851,853,Sample Size,30,model,y,,stan
946,8270292,861,875,Intervention Frequency,alternate days,model,y,wrong label,stan
947,8270292,877,883,Sample Size,n = 28,human,n,too much,stan
948,8270292,881,883,Sample Size,28,model,y,,stan
949,8270292,1243,1245,Dosage,20,human,y,,stan
950,8270292,1246,1248,Units,mg,human,y,,stan
951,8270292,1249,1259,Drug Intervention,omeprazole,human,y,,stan
952,8270292,1347,1371,Outcome (Study Endpoint),Endoscopic healing rates,model,y,,stan
953,8270292,1446,1461,Group Name,daily treatment,model,y,,stan
954,8270292,1508,1531,Group Name,alternate-day treatment,model,y,,stan
955,8270292,1593,1595,Dosage,20,human,y,,stan
956,8270292,1593,1598,Dosage,20 mg,model,n,multiple entities,stan
957,8270292,1596,1598,Units,mg,human,y,,stan
958,8270292,1647,1649,Dosage,20,human,y,,stan
959,8270292,1647,1652,Dosage,20 mg,model,n,multiple entities,stan
960,8270292,1650,1652,Units,mg,human,y,,stan
961,8369320,19,29,Drug Intervention,prednisone,human,y,,hcho
962,8369320,30,37,Group Characteristic,therapy,human,n,wrong label,hcho
963,8369320,38,44,Outcome (Study Endpoint),gained,human,n,wrong label,hcho
964,8369320,106,118,Group Characteristic,tapered from,human,y,,hcho
965,8369320,119,129,Drug Intervention,prednisone,human,y,,hcho
966,8369320,119,133,Disease/Condition of Interest,Hyperlipidemia,model,y,,cjackson
967,8369320,130,137,Group Characteristic,therapy,human,n,wrong label,hcho
968,8369320,151,153,Units,kg,model,y,,hcho
969,8369320,177,202,Outcome (Study Endpoint),increase in actual weight,model,n,too much,hcho
970,8369320,189,202,Outcome (Study Endpoint),actual weight,human,y,,hcho
971,8369320,223,231,Outcome (Study Endpoint),increase,human,n,wrong label,hcho
972,8369320,223,260,Outcome (Study Endpoint),increase in percent ideal body weight,model,n,too much,hcho
973,8369320,235,260,Outcome (Study Endpoint),percent ideal body weight,human,y,,hcho
974,8369320,262,264,Quantitative Measurement,14,human,n,too little,hcho
975,8369320,262,273,Quantitative Measurement,14% +/- 11%,model,y,,hcho
976,8369320,264,265,Units,%,human,n,wrong label,hcho
977,8369320,266,272,Quantitative Measurement,+/- 11,human,n,too little,hcho
978,8369320,272,273,Units,%,human,n,wrong label,hcho
979,8369320,281,282,Quantitative Measurement,9,human,n,too little,hcho
980,8369320,281,291,Quantitative Measurement,9% +/- 13%,model,y,,hcho
981,8369320,282,283,Units,%,human,n,wrong label,hcho
982,8369320,284,290,Quantitative Measurement,+/- 13,human,y,,hcho
983,8369320,290,291,Units,%,human,n,wrong label,hcho
984,8369320,473,484,Drug Intervention,triple-drug,model,n,not needed,cjackson
985,8369320,769,794,Group Characteristic,history of hyperlipidemia,model,y,,cjackson
986,8369320,769,823,Group Characteristic,history of hyperlipidemia before heart transplantation,human,n,too little,cjackson
987,8369320,952,977,Outcome (Study Endpoint),rise in cholesterol level,human,n,too much,cjackson
988,8369320,960,977,Outcome (Study Endpoint),cholesterol level,model,y,,cjackson
989,8369320,1008,1036,Group Characteristic,no history of hyperlipidemia,human,y,,cjackson
990,8369320,1059,1065,Drug Intervention,triple,model,n,not needed,cjackson
991,8369320,1059,1088,Group Name,triple-drug immunosuppression,human,n,not needed,cjackson
992,8369320,1100,1102,Quantitative Measurement,64,human,n,too little,cjackson
993,8369320,1100,1103,Quantitative Measurement,64%,model,y,,cjackson
994,8369320,1102,1103,Units,%,human,n,wrong label,cjackson
995,8369320,1131,1133,Quantitative Measurement,24,human,n,too little,cjackson
996,8369320,1131,1134,Quantitative Measurement,24%,model,y,,cjackson
997,8369320,1133,1134,Units,%,human,n,wrong label,cjackson
998,8369320,1166,1178,Group Name,steroid-free,model,n,too little,cjackson
999,8369320,1166,1196,Group Name,steroid-free immunosuppression,human,y,,cjackson
1000,8369320,1256,1273,Outcome (Study Endpoint),cholesterol level,model,y,,cjackson
1001,8369320,1256,1283,Outcome (Study Endpoint),cholesterol level increased,human,n,too much,cjackson
1002,8369320,1287,1289,Quantitative Measurement,20,human,n,too little,cjackson
1003,8369320,1287,1290,Quantitative Measurement,20%,model,y,,cjackson
1004,8369320,1289,1290,Units,%,human,n,wrong label,cjackson
1005,8369320,1333,1335,Quantitative Measurement,14,human,n,too little,cjackson
1006,8369320,1333,1336,Quantitative Measurement,14%,model,y,,cjackson
1007,8369320,1335,1336,Units,%,human,n,wrong label,cjackson
1008,8369320,1395,1397,Quantitative Measurement,83,human,n,too little,cjackson
1009,8369320,1395,1398,Quantitative Measurement,83%,model,y,,cjackson
1010,8369320,1397,1398,Units,%,human,n,wrong label,cjackson
1011,8369320,1444,1446,Quantitative Measurement,92,human,n,too little,cjackson
1012,8369320,1444,1447,Quantitative Measurement,92%,model,y,,cjackson
1013,8369320,1446,1447,Units,%,human,n,wrong label,cjackson
1014,8369320,1455,1473,Group Name,steroid-free group,model,y,,cjackson
1015,8369320,1631,1666,Outcome (Study Endpoint),percent change in cholesterol level,human,n,too much,cjackson
1016,8369320,1639,1666,Outcome (Study Endpoint),change in cholesterol level,model,n,too much,cjackson
1017,8369320,1860,1937,Outcome (Study Endpoint),predictive of the percent change in low-density lipoprotein cholesterol level,human,n,too much,cjackson
1018,8369320,2001,2069,Outcome (Study Endpoint),predicted the percent change in high-density lipoprotein cholesterol,human,n,too much,cjackson
1019,8369320,2023,2069,Outcome (Study Endpoint),change in high-density lipoprotein cholesterol,model,n,too much,cjackson
1020,8446138,94,101,Group Name,placebo,human,y,,ccurtis
1021,8446138,1155,1170,Group Characteristic,59 +/- 10 years,human,y,,ccurtis
1022,8446138,1203,1225,Outcome (Study Endpoint),average blood pressure,human,n,too much,ccurtis
1023,8446138,1270,1279,Group Name,Diltiazem,human,n,wrong label,ccurtis
1024,8446138,1304,1319,Outcome (Study Endpoint),rate of success,model,y,,ccurtis
1025,8446138,1496,1504,Group Name,Atenolol,human,n,wrong label,ccurtis
1026,8446138,1570,1579,Group Name,clonidine,human,n,wrong label,ccurtis
1027,8446138,1595,1614,Group Name,hydrochlorothiazide,human,n,wrong label,ccurtis
1028,8446138,1630,1639,Group Name,captopril,human,n,wrong label,ccurtis
1029,8446138,1659,1667,Group Name,prazosin,human,n,wrong label,ccurtis
1030,8446138,1726,1738,Outcome (Study Endpoint),success rate,model,y,,ccurtis
1031,8446138,1859,1871,Outcome (Study Endpoint),success rate,model,y,,ccurtis
1032,8446138,1918,1930,Outcome (Study Endpoint),success rate,model,y,,ccurtis
1033,8470032,336,341,Drug Intervention,BACOP,human,y,,eduvaris
1034,8470032,351,355,Drug Intervention,COPP,human,y,,eduvaris
1035,8470032,365,369,Drug Intervention,CHOP,human,y,,eduvaris
1036,8470032,383,387,Drug Intervention,CNOP,human,y,,eduvaris
1037,8470032,718,727,Intervention Frequency,6 monthly,model,y,,eduvaris
1038,8470032,720,727,Intervention Frequency,monthly,human,n,too little,eduvaris
1039,8470032,781,790,Intervention Frequency,8 monthly,model,y,,eduvaris
1040,8470032,783,790,Intervention Frequency,monthly,human,n,too little,eduvaris
1041,8470032,804,827,Group Characteristic,median age was 55 years,human,n,not needed,eduvaris
1042,8470032,819,827,Group Characteristic,55 years,model,n,not needed,eduvaris
1043,8470032,844,847,Group Name,FGR,model,n,too little,eduvaris
1044,8470032,844,853,Group Name,FGR group,human,y,,eduvaris
1045,8470032,883,888,Group Name,CAVPE,model,n,too little,eduvaris
1046,8470032,883,894,Group Name,CAVPE group,human,y,,eduvaris
1047,8470032,1445,1488,Outcome (Study Endpoint),estimated probability of sustained first CR,model,n,too much,eduvaris
1048,8470032,1455,1501,Outcome (Study Endpoint),probability of sustained first CR at 72 months,human,y,,eduvaris
1049,8470032,1636,1688,Outcome (Study Endpoint),"alive and well, with no signs of disease progression",model,n,too much,eduvaris
1050,8470032,1657,1688,Outcome (Study Endpoint),no signs of disease progression,human,y,,eduvaris
1051,8803300,36,46,Drug Intervention,lisinopril,model,y,,cjackson
1052,8803300,50,60,Drug Intervention,nifedipine,model,y,,cjackson
1053,8803300,105,134,Disease/Condition of Interest,mild-to-moderate hypertension,human,y,,cjackson
1054,8803300,122,134,Disease/Condition of Interest,hypertension,model,n,too little,cjackson
1055,8803300,152,189,Group Characteristic,chronic obstructive pulmonary disease,model,n,wrong label,cjackson
1056,8803300,386,388,Sample Size,76,model,y,,cjackson
1057,8803300,415,444,Group Characteristic,mild-to-moderate hypertension,human,n,wrong label,cjackson
1058,8803300,432,444,Disease/Condition of Interest,hypertension,model,n,too little,cjackson
1059,8803300,488,492,Group Characteristic,COPD,model,n,wrong label,cjackson
1060,8803300,583,593,Drug Intervention,lisinopril,model,y,,cjackson
1061,8803300,595,605,Drug Intervention,nifedipine,model,y,,cjackson
1062,8803300,813,823,Drug Intervention,lisinopril,model,y,,cjackson
1063,8803300,855,865,Drug Intervention,nifedipine,model,y,,cjackson
1064,8803300,900,909,Drug Intervention,diuretics,human,y,,cjackson
1065,8803300,953,963,Drug Intervention,sorbitrate,human,y,wrong label,cjackson
1066,8803300,968,979,Drug Intervention,hydralazine,human,y,wrong label,cjackson
1067,8803300,984,1007,Drug Intervention,selective beta-blockers,human,y,,cjackson
1068,8803300,1151,1168,Intervention Duration,at least one year,model,y,,cjackson
1069,8803300,1160,1168,Intervention Duration,one year,human,n,too little,cjackson
1070,8803300,1245,1264,Outcome (Study Endpoint),high blood pressure,model,y,,cjackson
1071,8803300,1245,1290,Outcome (Study Endpoint),high blood pressure was significantly reduced,human,n,too much,cjackson
1072,8803300,1330,1332,Statistical Significance,no,model,n,not needed,cjackson
1073,8803300,1637,1638,Group Name,B,model,y,,cjackson
1074,8803300,1643,1644,Group Name,C,model,y,,cjackson
1075,8803300,1783,1784,Group Name,C,model,y,,cjackson
1076,8803300,1794,1795,Group Name,B,model,y,,cjackson
1077,8803300,2100,2101,Group Name,C,model,y,,cjackson
1078,8900907,76,95,Disease/Condition of Interest,Helicobacter pylori,human,y,,hcho
1079,8900907,105,125,Disease/Condition of Interest,functional dyspepsia,model,y,,hcho
1080,8900907,394,413,Group Characteristic,H. pylori infection,model,n,wrong label,hcho
1081,8900907,418,449,Group Characteristic,symptoms of non-ulcer dyspepsia,model,n,wrong label,hcho
1082,8900907,1322,1328,Follow-up period,week 8,model,y,,hcho
1083,8900907,1381,1411,Outcome (Study Endpoint),mean symptom score improvement,model,n,multiple entities,hcho
1084,8900907,1386,1411,Outcome (Study Endpoint),symptom score improvement,human,y,,hcho
1085,8900907,1449,1460,Group Characteristic,eradication,human,y,,hcho
1086,8900907,1476,1496,Group Characteristic,persistent infection,human,y,,hcho
1087,8900907,1524,1526,Sample Size,29,model,n,wrong label,hcho
1088,8900907,1566,1568,Sample Size,19,model,n,wrong label,hcho
1089,8900907,1588,1601,Outcome (Study Endpoint),symptom score,model,y,,hcho
1090,8900907,1660,1663,Quantitative Measurement,9.1,model,y,,hcho
1091,8900907,1707,1711,Quantitative Measurement,10.0,model,y,,hcho
1092,8964646,0,10,Study Duration,Four years,model,y,,ccurtis
1093,8964646,43,47,Group Characteristic,with,human,n,not needed,ccurtis
1094,8964646,48,69,Disease/Condition of Interest,severe hyperlipidemia,model,y,,ccurtis
1095,8964646,55,69,Disease/Condition of Interest,hyperlipidemia,human,n,too little,ccurtis
1096,8964646,71,91,Drug Intervention,Lipid lowering drugs,human,y,,ccurtis
1097,8964646,152,179,Disease/Condition of Interest,heterozygous hyperlipidemia,human,y,wrong label,ccurtis
1098,8964646,226,230,Group Characteristic,aged,human,n,too little,ccurtis
1099,8964646,226,250,Group Characteristic,aged 49.5 +/- 11.5 years,model,y,,ccurtis
1100,8964646,231,244,Quantitative Measurement,49.5 +/- 11.5,human,n,too little,ccurtis
1101,8964646,245,250,Units,years,human,n,wrong label,ccurtis
1102,8964646,253,257,Non-Pharmaceutical Intervention,diet,model,y,,ccurtis
1103,8964646,343,347,Group Characteristic,aged,human,n,too little,ccurtis
1104,8964646,343,367,Group Characteristic,aged 48.0 +/- 11.9 years,model,y,,ccurtis
1105,8964646,348,361,Quantitative Measurement,48.0 +/- 11.9,human,n,too little,ccurtis
1106,8964646,362,367,Units,years,human,n,wrong label,ccurtis
1107,8964646,397,410,Intervention Duration,44.4 +/- 14.3,model,y,,ccurtis
1108,8964646,433,446,Intervention Duration,33.5 +/- 15.9,model,y,,ccurtis
1109,8964646,460,466,Units,months,human,y,,ccurtis
1110,8964646,779,788,Group Name,apheresis,human,n,too little,ccurtis
1111,8964646,807,811,Side Effects,died,human,y,,ccurtis
1112,8964646,846,877,Side Effects,non-fatal myocardial infarction,human,y,,ccurtis
1113,8964646,903,925,Side Effects,coronary heart disease,model,y,,ccurtis
1114,8964646,948,952,Group Name,drug,human,n,too little,ccurtis
1115,8964646,1031,1040,Group Name,apheresis,human,n,too little,ccurtis
1116,8964646,1112,1135,Outcome (Study Endpoint),physological well-being,model,y,,ccurtis
1117,8964646,1181,1185,Group Name,drug,human,n,too little,ccurtis
1118,9050975,184,187,Dosage,180,model,y,,eduvaris
1119,9050975,184,190,Dosage,180 mg,human,n,multiple entities,eduvaris
1120,9050975,188,190,Units,mg,model,y,,eduvaris
1121,9050975,223,224,Dosage,2,model,y,,eduvaris
1122,9050975,223,227,Dosage,2 mg,human,n,multiple entities,eduvaris
1123,9050975,225,227,Units,mg,model,y,,eduvaris
1124,9050975,242,245,Dosage,100,model,y,,eduvaris
1125,9050975,242,251,Dosage,100/25 mg,human,n,multiple entities,eduvaris
1126,9050975,246,248,Dosage,25,model,y,,eduvaris
1127,9050975,249,251,Units,mg,model,y,,eduvaris
1128,9050975,277,279,Dosage,20,model,y,,eduvaris
1129,9050975,277,287,Dosage,20/12.5 mg,human,n,multiple entities,eduvaris
1130,9050975,280,284,Dosage,12.5,model,y,,eduvaris
1131,9050975,285,287,Units,mg,model,y,,eduvaris
1132,9050975,323,330,Drug Intervention,placebo,model,n,wrong label,eduvaris
1133,9050975,348,357,Disease/Condition of Interest,essential,model,n,too little,eduvaris
1134,9050975,358,370,Disease/Condition of Interest,hypertension,model,y,wrong label,eduvaris
1135,9050975,374,380,Intervention Duration,4-week,model,n,not needed,eduvaris
1136,9050975,533,555,Group Characteristic,essential hypertension,human,n,not needed,eduvaris
1137,9050975,600,644,Group Characteristic,supine diastolic blood pressure 101-114 mmHg,model,n,not needed,eduvaris
1138,9050975,850,867,Intervention Frequency,single daily dose,human,n,too much,eduvaris
1139,9050975,911,918,Group Name,placebo,model,y,,eduvaris
1140,9050975,935,940,Outcome (Study Endpoint),blood,model,n,too little,eduvaris
1141,9050975,1114,1116,Quantitative Measurement,13,model,y,,eduvaris
1142,9050975,1117,1121,Units,mmHg,model,y,,eduvaris
1143,9050975,1123,1146,Type of Quant. Measure,95% confidence interval,model,y,,eduvaris
1144,9050975,1152,1156,Quantitative Measurement,16-9,model,y,,eduvaris
1145,9050975,1181,1203,Group Name,verapamil/trandolapril,human,y,,eduvaris
1146,9050975,1205,1207,Quantitative Measurement,13,model,y,,eduvaris
1147,9050975,1208,1212,Units,mmHg,model,y,,eduvaris
1148,9050975,1214,1218,Quantitative Measurement,16-9,model,y,,eduvaris
1149,9050975,1225,1248,Group Name,atenolol/chlorthalidone,human,y,,eduvaris
1150,9050975,1253,1255,Quantitative Measurement,12,model,y,,eduvaris
1151,9050975,1256,1260,Units,mmHg,model,y,,eduvaris
1152,9050975,1262,1266,Quantitative Measurement,15-8,model,y,,eduvaris
1153,9050975,1273,1283,Drug Intervention,lisinopril,model,y,,eduvaris
1154,9050975,1273,1303,Group Name,lisinopril/hydrochlorothiazide,human,y,,eduvaris
1155,9050975,1305,1336,Outcome (Study Endpoint),Normalization of blood pressure,model,y,,eduvaris
1156,9050975,1369,1372,Quantitative Measurement,48%,model,y,,eduvaris
1157,9050975,1408,1430,Group Name,verapamil/trandolapril,human,y,,eduvaris
1158,9050975,1435,1438,Quantitative Measurement,46%,model,y,,eduvaris
1159,9050975,1444,1467,Group Name,atenolol/chlorthalidone,human,y,,eduvaris
1160,9050975,1475,1478,Quantitative Measurement,40%,model,y,,eduvaris
1161,9050975,1484,1514,Group Name,lisinopril/hydrochlorothiazide,human,y,,eduvaris
1162,9050975,1516,1530,Outcome (Study Endpoint),Response rates,model,y,,eduvaris
1163,9050975,1621,1624,Quantitative Measurement,72%,model,y,,eduvaris
1164,9050975,1647,1669,Group Name,verapamil/trandolapril,human,y,,eduvaris
1165,9050975,1671,1674,Quantitative Measurement,76%,model,y,,eduvaris
1166,9050975,1679,1702,Group Name,atenolol/chlorthalidone,human,y,,eduvaris
1167,9050975,1707,1710,Quantitative Measurement,69%,model,y,,eduvaris
1168,9050975,1715,1745,Group Name,lisinopril/hydrochlorothiazide,human,y,,eduvaris
1169,9050975,2017,2029,Group Characteristic,hypertensive,human,y,,eduvaris
1170,9156363,0,10,Drug Intervention,Felodipine,model,y,,stan
1171,9156363,15,25,Drug Intervention,amlodipine,model,y,,stan
1172,9156363,280,289,Sample Size,Fifty-two,model,y,,stan
1173,9156363,304,347,Group Characteristic,documented exercise-induced angina pectoris,human,n,too much,stan
1174,9156363,315,347,Group Characteristic,exercise-induced angina pectoris,model,y,,stan
1175,9156363,479,480,Intervention Duration,8,human,n,too little,stan
1176,9156363,479,485,Intervention Duration,8-week,model,y,,stan
1177,9156363,641,651,Drug Intervention,amlodipine,model,y,,stan
1178,9156363,670,680,Drug Intervention,felodipine,model,y,,stan
1179,9156363,742,745,Units,min,model,y,,stan
1180,9156363,956,958,Quantitative Measurement,38,human,n,too little,stan
1181,9156363,956,959,Quantitative Measurement,38%,model,y,,stan
1182,9156363,999,1001,Quantitative Measurement,40,human,n,too little,stan
1183,9156363,999,1002,Quantitative Measurement,40%,model,y,,stan
1184,9156363,1370,1375,Units,/week,model,n,too much,stan
1185,9156363,1562,1570,Units,capsules,model,y,,stan
1186,9193431,177,200,Disease/Condition of Interest,coronary artery disease,model,y,,cjackson
1187,9193431,1235,1293,Group Characteristic,normal to mildly elevated total and LDL cholesterol levels,human,y,,cjackson
1188,9193431,1311,1329,Group Characteristic,Ser447-Stop allele,model,y,,cjackson
1189,9193431,1380,1386,Outcome (Study Endpoint),higher,model,n,not needed,cjackson
1190,9193431,1727,1735,Statistical Significance,P = .881,model,y,,cjackson
1191,9305491,65,79,Disease/Condition of Interest,duodenal ulcer,human,y,,hcho
1192,9305491,522,540,Group Characteristic,H. pylori-positive,model,n,too little,hcho
1193,9305491,522,555,Group Characteristic,H. pylori-positive duodenal ulcer,human,y,,hcho
1194,9305491,541,555,Group Characteristic,duodenal ulcer,model,n,too little,hcho
1195,9305491,566,568,Group Characteristic,DU,model,n,wrong label,hcho
1196,9305491,882,909,Group Name,H. pylori-negative subjects,human,n,wrong label,hcho
1197,9305491,914,918,Outcome (Study Endpoint),IL-8,model,y,,hcho
1198,9305491,934,957,Outcome (Study Endpoint),neutrophil infiltration,model,y,,hcho
1199,9305491,1099,1126,Group Name,H. pylori-positive patients,human,n,wrong label,hcho
1200,9305491,1179,1197,Outcome (Study Endpoint),IL-8 concentration,model,y,,hcho
1201,9305491,1356,1379,Outcome (Study Endpoint),neutrophil infiltration,model,y,,hcho
1202,9305491,1672,1682,Drug Intervention,omeprazole,human,y,,hcho
1203,9305491,1724,1747,Outcome (Study Endpoint),neutrophil infiltration,model,y,,hcho
1204,9305491,1795,1805,Drug Intervention,omeprazole,human,y,,hcho
1205,9305491,1897,1933,Disease/Condition of Interest,H. pylori-positive chronic gastritis,model,n,wrong label,hcho
1206,9555617,23,48,Drug Intervention,anticholinergic treatment,human,n,not needed,ccurtis
1207,9555617,52,80,Drug Intervention,beta 2-adrenergic medication,human,n,not needed,ccurtis
1208,9555617,173,198,Drug Intervention,anticholinergic treatment,human,n,not needed,ccurtis
1209,9555617,206,234,Drug Intervention,beta 2-adrenergic medication,human,n,not needed,ccurtis
1210,9555617,400,410,Drug Intervention,salbutamol,human,y,,ccurtis
1211,9555617,415,426,Drug Intervention,ipratropium,human,y,,ccurtis
1212,9555617,477,485,Group Characteristic,children,model,y,,ccurtis
1213,9555617,477,510,Group Characteristic,children with acute asthma attack,human,n,too much,ccurtis
1214,9555617,491,510,Group Characteristic,acute asthma attack,model,n,wrong label,ccurtis
1215,9555617,529,540,Group Characteristic,outpatients,human,y,,ccurtis
1216,9555617,734,744,Units,micrograms,human,y,,ccurtis
1217,9555617,734,748,Units,micrograms/inh,model,n,too much,ccurtis
1218,9555617,745,748,Intervention Administration,inh,human,y,,ccurtis
1219,9555617,775,785,Units,micrograms,human,y,,ccurtis
1220,9555617,775,789,Units,micrograms/inh,model,n,too much,ccurtis
1221,9555617,786,789,Intervention Administration,inh,human,y,,ccurtis
1222,9555617,820,830,Units,micrograms,human,y,,ccurtis
1223,9555617,820,834,Units,micrograms/inh,model,n,too much,ccurtis
1224,9555617,831,834,Intervention Administration,inh,human,y,,ccurtis
1225,9555617,857,867,Units,micrograms,human,y,,ccurtis
1226,9555617,857,871,Units,micrograms/inh,model,n,too much,ccurtis
1227,9555617,868,871,Intervention Administration,inh,human,y,,ccurtis
1228,9555617,938,943,Quantitative Measurement,+/- 5,human,y,,ccurtis
1229,9555617,1020,1025,Follow-up period,0 min,human,n,wrong label,ccurtis
1230,9555617,1035,1037,Follow-up period,15,human,n,wrong label,ccurtis
1231,9555617,1039,1041,Follow-up period,30,human,n,wrong label,ccurtis
1232,9555617,1043,1045,Follow-up period,45,human,n,wrong label,ccurtis
1233,9555617,1047,1049,Follow-up period,60,human,n,wrong label,ccurtis
1234,9555617,1051,1053,Follow-up period,80,human,n,wrong label,ccurtis
1235,9555617,1055,1058,Follow-up period,100,human,n,wrong label,ccurtis
1236,9555617,1063,1066,Follow-up period,120,human,n,wrong label,ccurtis
1237,9555617,1067,1070,Units,min,human,y,,ccurtis
1238,9555617,1106,1116,Intervention Administration,inhalation,model,y,,ccurtis
1239,9555617,1198,1210,Group Characteristic,mean age was,human,n,too much,ccurtis
1240,9555617,1222,1231,Outcome (Study Endpoint),Tal score,model,y,,ccurtis
1241,9555617,1286,1295,Outcome (Study Endpoint),Tal score,human,y,,ccurtis
1242,9555617,1328,1338,Drug Intervention,salbutamol,human,y,,ccurtis
1243,9555617,1339,1350,Drug Intervention,ipratropium,human,y,,ccurtis
1244,9555617,1355,1381,Drug Intervention,salbutamol vs. ipratropium,human,n,too much,ccurtis
1245,9555617,1406,1416,Drug Intervention,salbutamol,human,y,,ccurtis
1246,9555617,1417,1428,Drug Intervention,ipratropium,human,y,,ccurtis
1247,9555617,1433,1443,Drug Intervention,salbutamol,human,y,,ccurtis
1248,9555617,1472,1482,Drug Intervention,salbutamol,human,y,,ccurtis
1249,9555617,1483,1494,Drug Intervention,ipratropium,human,y,,ccurtis
1250,9555617,1499,1509,Drug Intervention,salbutamol,human,y,,ccurtis
1251,9555617,1528,1533,Quantitative Measurement,70.9%,model,y,,ccurtis
1252,9555617,1528,1550,Quantitative Measurement,"70.9%, 71.3% and 68.6%",human,n,too much,ccurtis
1253,9555617,1535,1540,Quantitative Measurement,71.3%,model,y,,ccurtis
1254,9555617,1545,1550,Quantitative Measurement,68.6%,model,y,,ccurtis
1255,9555617,1610,1620,Drug Intervention,salbutamol,human,y,,ccurtis
1256,9555617,1621,1632,Drug Intervention,ipratropium,human,y,,ccurtis
1257,9555617,1637,1647,Drug Intervention,salbutamol,human,y,,ccurtis
1258,9555617,1666,1677,Drug Intervention,ipratropium,human,y,,ccurtis
1259,9555617,1702,1712,Drug Intervention,salbutamol,human,y,,ccurtis
1260,9555617,1713,1724,Drug Intervention,ipratropium,human,y,,ccurtis
1261,9555617,1729,1755,Drug Intervention,salbutamol and ipratropium,human,n,too much,ccurtis
1262,9555617,1765,1768,Quantitative Measurement,4.7,human,y,,ccurtis
1263,9555617,1778,1788,Drug Intervention,salbutamol,human,y,,ccurtis
1264,9555617,1804,1829,Outcome (Study Endpoint),improve the asthma attack,human,n,wrong label,ccurtis
1265,9555617,1831,1834,Quantitative Measurement,5.3,human,y,,ccurtis
1266,9555617,1854,1857,Quantitative Measurement,3.7,human,y,,ccurtis
1267,9555617,1903,1913,Drug Intervention,salbutamol,human,y,,ccurtis
1268,9555617,1914,1925,Drug Intervention,ipratropium,human,y,,ccurtis
1269,9555617,1930,1940,Drug Intervention,salbutamol,human,y,,ccurtis
1270,9555617,1945,1956,Drug Intervention,ipratropium,human,y,,ccurtis
1271,9616339,43,65,Disease/Condition of Interest,dilated cardiomyopathy,model,y,,stan
1272,9616339,422,436,Follow-up period,52 (32) months,model,y,,stan
1273,9616339,438,448,Drug Intervention,Metoprolol,model,y,,stan
1274,9616339,653,656,Sample Size,175,model,y,,stan
1275,9616339,657,675,Group Name,metoprolol treated,model,y,,stan
1276,9616339,932,951,Outcome (Study Endpoint),all cause mortality,human,y,,stan
1277,9616339,956,993,Outcome (Study Endpoint),combined mortality or transplantation,human,y,,stan
1278,9616339,978,993,Outcome (Study Endpoint),transplantation,model,n,too little or too much based on context,stan
1279,9616339,994,996,Quantitative Measurement,51,model,n,too little,stan
1280,9616339,994,997,Quantitative Measurement,51%,human,y,,stan
1281,9616339,996,997,Units,%,model,n,wrong label,stan
1282,9616339,1219,1238,Outcome (Study Endpoint),Seven year survival,model,y,,stan
1283,9616339,1240,1243,Quantitative Measurement,80%,model,y,,stan
1284,9616339,1246,1249,Quantitative Measurement,62%,model,y,,stan
1285,9616339,1251,1260,Statistical Significance,p = 0.004,model,y,,stan
1286,9616339,1266,1290,Outcome (Study Endpoint),transplant-free survival,model,y,,stan
1287,9616339,1292,1295,Quantitative Measurement,68%,model,y,,stan
1288,9616339,1298,1301,Quantitative Measurement,51%,model,y,,stan
1289,9616339,1303,1312,Statistical Significance,p = 0.005,model,y,,stan
1290,9616339,1343,1346,Sample Size,127,model,y,,stan
1291,9616339,1347,1357,Group Name,metoprolol,model,n,too little,stan
1292,9616339,1380,1383,Sample Size,127,model,y,,stan
1293,9616339,1384,1392,Group Name,controls,model,y,,stan
1294,9616339,1460,1470,Drug Intervention,Metoprolol,model,y,,stan
1295,9616339,1493,1496,Quantitative Measurement,30%,model,y,,stan
1296,9616339,1497,1506,Outcome (Study Endpoint),reduction,model,y,,stan
1297,9616339,1510,1529,Outcome (Study Endpoint),all cause mortality,model,y,,stan
1298,9616339,1542,1551,Statistical Significance,p = 0.015,model,y,,stan
1299,9616339,1559,1562,Quantitative Measurement,26%,model,y,,stan
1300,9616339,1563,1604,Outcome (Study Endpoint),reduction in mortality or transplantation,model,y,,stan
1301,9616339,1617,1626,Statistical Significance,p = 0.009,model,y,,stan
1302,9690573,12,39,Drug Intervention,salmeterol xinafoate powder,model,n,too much,cjackson
1303,9690573,111,121,Drug Intervention,salmeterol,model,y,,cjackson
1304,9690573,237,245,Drug Intervention,salmeter,model,n,too little,cjackson
1305,9690573,336,361,Group Characteristic,chronic persistent asthma,model,n,wrong label,cjackson
1306,9690573,562,569,Group Name,placebo,model,y,,cjackson
1307,9690573,575,584,Non-Study Drug,albuterol,human,n,wrong label,cjackson
1308,9690573,614,629,Intervention Administration,breath-actuated,human,y,,cjackson
1309,9690573,614,636,Intervention Administration,breath-actuated device,model,n,too much,cjackson
1310,9690573,781,801,Outcome (Study Endpoint),peak expiratory flow,model,y,,cjackson
1311,9690573,919,957,Outcome (Study Endpoint),weighted mean percent of predicted PEF,model,n,too much,cjackson
1312,9690573,933,957,Outcome (Study Endpoint),percent of predicted PEF,human,y,,cjackson
1313,9690573,987,991,Outcome (Study Endpoint),week,model,n,not needed,cjackson
1314,9690573,1014,1038,Outcome (Study Endpoint),forced expiratory volume,human,n,too little,cjackson
1315,9690573,1014,1052,Outcome (Study Endpoint),forced expiratory volume in one second,model,y,,cjackson
1316,9690573,1229,1236,Group Name,placebo,model,y,,cjackson
1317,9690573,1238,1286,Outcome (Study Endpoint),Overall reductions in supplemental albuterol use,model,n,too much,cjackson
1318,9690573,1260,1286,Outcome (Study Endpoint),supplemental albuterol use,human,y,,cjackson
1319,9690573,1291,1317,Outcome (Study Endpoint),mean asthma symptom scores,model,n,too much,cjackson
1320,9690573,1296,1317,Outcome (Study Endpoint),asthma symptom scores,human,y,,cjackson
1321,9690573,1682,1690,Intervention Duration,12 weeks,model,y,,cjackson
1322,9787684,127,149,Disease/Condition of Interest,acute pediatric asthma,human,n,too much,hcho
1323,9787684,234,242,Group Characteristic,children,human,y,,hcho
1324,9787684,265,271,Group Characteristic,asthma,human,n,wrong label,hcho
1325,9787684,434,439,Dosage,0.075,model,y,,hcho
1326,9787684,434,445,Dosage,0.075 mg/kg,human,n,multiple entities,hcho
1327,9787684,440,445,Units,mg/kg,model,y,,hcho
1328,9787684,505,508,Dosage,250,model,y,,hcho
1329,9787684,505,519,Dosage,250 micrograms,human,n,multiple entities,hcho
1330,9787684,509,519,Units,micrograms,model,y,,hcho
1331,9787684,555,561,Intervention Frequency,hourly,model,y,,hcho
1332,9787684,574,578,Dosage,0.15,model,y,,hcho
1333,9787684,574,584,Dosage,0.15 mg/kg,human,n,multiple entities,hcho
1334,9787684,579,584,Units,mg/kg,model,y,,hcho
1335,9787684,620,624,Group Characteristic,mild,model,n,wrong label,hcho
1336,9787684,620,649,Group Characteristic,mild or moderate acute asthma,human,n,wrong label,hcho
1337,9787684,696,718,Outcome (Study Endpoint),respiratory resistance,model,y,,hcho
1338,9787684,858,876,Group Characteristic,aged 3 to 17 years,human,y,,hcho
1339,9787684,863,876,Group Characteristic,3 to 17 years,model,n,too little,hcho
1340,9787684,897,898,Units,%,human,n,wrong label,hcho
1341,9787684,932,933,Units,%,human,n,wrong label,hcho
1342,9787684,967,992,Outcome (Study Endpoint),increased bronchodilation,model,n,too much,hcho
1343,9787684,977,992,Outcome (Study Endpoint),bronchodilation,human,y,,hcho
1344,9787684,1060,1070,Drug Intervention,salbutamol,human,y,,hcho
1345,9787684,1072,1074,Type of Quant. Measure,RR,model,y,,hcho
1346,9787684,1077,1080,Quantitative Measurement,0.9,model,y,,hcho
1347,9787684,1106,1109,Quantitative Measurement,0.7,human,n,too little,hcho
1348,9787684,1106,1114,Quantitative Measurement,"0.7, 1.3",model,y,,hcho
1349,9787684,1111,1114,Quantitative Measurement,1.3,human,n,too little,hcho
1350,9787684,1120,1135,Outcome (Study Endpoint),the addition of,human,n,wrong label,hcho
1351,9787684,1156,1170,Outcome (Study Endpoint),versus placebo,human,n,wrong label,hcho
1352,9787684,1163,1170,Drug Intervention,placebo,model,n,wrong label,hcho
1353,9787684,1172,1174,Type of Quant. Measure,RR,model,y,,hcho
1354,9787684,1177,1180,Quantitative Measurement,1.0,model,y,,hcho
1355,9787684,1182,1185,Quantitative Measurement,0.8,human,n,too little,hcho
1356,9787684,1182,1190,Quantitative Measurement,"0.8, 1.3",model,y,,hcho
1357,9787684,1187,1190,Quantitative Measurement,1.3,human,n,too little,hcho
1358,9787684,1254,1264,Drug Intervention,Salbutamol,human,y,,hcho
1359,9787684,1307,1325,Outcome (Study Endpoint),increased vomiting,human,n,too much,hcho
1360,9787684,1327,1329,Type of Quant. Measure,RR,model,y,,hcho
1361,9787684,1332,1335,Quantitative Measurement,2.5,model,y,,hcho
1362,9787684,1337,1340,Quantitative Measurement,1.1,human,n,too little,hcho
1363,9787684,1337,1345,Quantitative Measurement,"1.1, 6.0",model,y,,hcho
1364,9787684,1342,1345,Quantitative Measurement,6.0,human,n,too little,hcho
1365,9787684,1419,1429,Drug Intervention,salbutamol,human,y,,hcho
1366,9787684,1449,1468,Drug Intervention,ipratropium bromide,human,y,,hcho
1367,9787684,1504,1514,Drug Intervention,salbutamol,human,y,,hcho
1368,9819288,61,69,Disease/Condition of Interest,allergic,human,n,wrong label,ccurtis
1369,9819288,161,167,Disease/Condition of Interest,asthma,model,y,,ccurtis
1370,9819288,447,460,Drug Intervention,beta2-agonist,human,y,,ccurtis
1371,9819288,516,523,Drug Intervention,Placebo,model,n,wrong label,ccurtis
1372,9819288,708,731,Study Years,April through September,model,n,wrong label,ccurtis
1373,9819288,999,1013,Type of Quant. Measure,geometric mean,model,y,,ccurtis
1374,9819288,999,1033,Outcome (Study Endpoint),geometric mean of serum IgE levels,human,n,too much,ccurtis
1375,9819288,1017,1033,Outcome (Study Endpoint),serum IgE levels,model,y,,ccurtis
1376,9819288,1087,1092,Units,IU/mL,model,y,,ccurtis
1377,9819288,1115,1117,Quantitative Measurement,12,model,n,too little,ccurtis
1378,9819288,1121,1124,Quantitative Measurement,878,model,n,too little,ccurtis
1379,9819288,1227,1255,Outcome (Study Endpoint),magnitude of the rise in IgE,human,n,not needed,ccurtis
1380,9819288,1282,1287,Type of Quant. Measure,ratio,model,y,,ccurtis
1381,9819288,1410,1415,Outcome (Study Endpoint),Total,model,n,too little,ccurtis
1382,9819288,1420,1446,Outcome (Study Endpoint),nonvascular symptom scores,model,y,,ccurtis
1383,9819288,1432,1446,Outcome (Study Endpoint),symptom scores,human,y,,ccurtis
1384,9819288,1557,1561,Intervention Administration,oral,model,y,,ccurtis
1385,9863121,200,203,Disease/Condition of Interest,NHL,model,y,,eduvaris
1386,9863121,234,242,Group Characteristic,patients,human,n,not needed,eduvaris
1387,9863121,366,373,Drug Intervention,Chinese,model,n,too little,eduvaris
1388,9863121,394,406,Drug Intervention,chemotherapy,model,y,,eduvaris
1389,9863121,453,465,Non-Study Drug,chemotherapy,model,n,wrong label,eduvaris
1390,9863121,476,490,Outcome (Study Endpoint),effective rate,model,y,,eduvaris
1391,9863121,492,499,Outcome (Study Endpoint),CR + PR,model,y,,eduvaris
1392,9863121,508,516,Group Name,combined,model,n,too little,eduvaris
1393,9863121,538,552,Outcome (Study Endpoint),survival rates,model,y,not capturable,eduvaris
1394,9863121,556,557,Outcome (Study Endpoint),1,model,y,,eduvaris
1395,9863121,560,561,Outcome (Study Endpoint),3,model,y,,eduvaris
1396,9863121,620,640,Outcome (Study Endpoint),median survival time,model,n,too much,eduvaris
1397,9863121,645,648,Quantitative Measurement,554,model,y,,eduvaris
1398,9863121,649,653,Units,days,model,y,,eduvaris
1399,9863121,658,665,Group Name,control,model,n,too little,eduvaris
1400,9863121,676,685,Outcome (Study Endpoint),effective,model,n,too little,eduvaris
1401,9863121,789,809,Outcome (Study Endpoint),median survival time,model,n,too much,eduvaris
1402,9863121,814,817,Quantitative Measurement,465,model,y,,eduvaris
1403,9863121,818,822,Units,days,model,y,,eduvaris
1404,9863121,937,945,Group Name,combined,model,n,too little,eduvaris
1405,9863121,956,975,Outcome (Study Endpoint),activity of NK cell,model,y,,eduvaris
1406,9863121,977,981,Outcome (Study Endpoint),OKT3,model,y,,eduvaris
1407,9863121,983,987,Outcome (Study Endpoint),OKT4,model,y,,eduvaris
1408,9863121,992,1010,Outcome (Study Endpoint),ratio of OKT4/OKT8,model,y,,eduvaris
1409,9863121,1069,1100,Outcome (Study Endpoint),level of platelet adhesion rate,model,y,,eduvaris
1410,9863121,1109,1124,Outcome (Study Endpoint),blood viscosity,model,y,,eduvaris
1411,9863121,1354,1418,Side Effects,side effect in the combination therapy group was less and milder,human,n,too much,eduvaris
1412,9863121,1373,1392,Group Name,combination therapy,model,n,not needed,eduvaris
1413,9863121,1436,1448,Group Name,chemotherapy,model,n,wrong label,eduvaris
1414,10101629,17,30,Drug Intervention,Harpagophytum,model,n,too little,stan
1415,10101629,17,46,Drug Intervention,Harpagophytum extract WS 1531,human,y,,stan
1416,10101629,152,161,Intervention Frequency,Two daily,human,y,,stan
1417,10101629,156,161,Intervention Frequency,daily,model,n,too little,stan
1418,10101629,176,189,Drug Intervention,Harpagophytum,model,n,too little,stan
1419,10101629,176,205,Drug Intervention,Harpagophytum extract WS 1531,human,y,,stan
1420,10101629,246,248,Dosage,50,model,y,,stan
1421,10101629,253,256,Dosage,100,model,y,,stan
1422,10101629,306,313,Drug Intervention,placebo,human,n,wrong label,stan
1423,10101629,424,445,Group Characteristic,current exacerbations,model,n,wrong label,stan
1424,10101629,466,483,Group Characteristic,pain worse than 5,human,y,,stan
1425,10101629,1000,1009,Outcome (Study Endpoint),pain-free,model,y,,stan
1426,10101629,1000,1018,Outcome (Study Endpoint),pain-free patients,human,n,too much,stan
1427,10101629,1049,1062,Group Name,placebo group,model,y,,stan
1428,10101629,1072,1085,Drug Intervention,Harpagophytum,human,n,too little,stan
1429,10101629,1072,1095,Group Name,Harpagophytum 600 group,model,y,,stan
1430,10101629,1111,1135,Group Name,Harpagophytum 1200 group,model,y,,stan
1431,10101629,1169,1202,Type of Quant. Measure,one-tailed Cochrane-Armitage test,human,y,,stan
1432,10101629,1631,1635,Group Name,H600,human,y,,stan
1433,10101629,2015,2040,Side Effects,gastrointestinal symptoms,human,y,,stan
1434,10418756,185,196,Drug Intervention,ceftriaxone,model,y,,cjackson
1435,10418756,213,216,Group Name,CTX,model,y,,cjackson
1436,10418756,272,275,Group Name,STD,model,y,,cjackson
1437,10418756,281,315,Disease/Condition of Interest,lower respiratory tract infections,model,y,,cjackson
1438,10418756,317,321,Disease/Condition of Interest,LRTI,model,y,,cjackson
1439,10418756,423,433,Drug Intervention,cefuroxime,model,y,wrong label,cjackson
1440,10418756,461,464,Intervention Frequency,q8h,model,y,,cjackson
1441,10418756,467,478,Drug Intervention,amoxicillin,model,y,,cjackson
1442,10418756,467,494,Non-Study Drug,amoxicillin/clavulanic acid,human,n,wrong label,cjackson
1443,10418756,479,494,Drug Intervention,clavulanic acid,model,y,,cjackson
1444,10418756,510,521,Drug Intervention,ceftriaxone,model,y,wrong label,cjackson
1445,10418756,561,570,Non-Study Drug,macrolide,human,n,wrong label,cjackson
1446,10418756,591,597,Intervention Duration,5 days,human,y,,cjackson
1447,10418756,737,740,Group Name,STD,model,y,,cjackson
1448,10418756,1265,1294,Outcome (Study Endpoint),Mean duration of i.v. therapy,human,n,too much,cjackson
1449,10418756,1299,1302,Quantitative Measurement,7.4,human,y,,cjackson
1450,10418756,1299,1307,Intervention Duration,7.4 days,model,n,wrong label,cjackson
1451,10418756,1303,1307,Units,days,human,y,,cjackson
1452,10418756,1324,1359,Outcome (Study Endpoint),Average duration of hospitalisation,human,n,too much,cjackson
1453,10418756,1364,1368,Quantitative Measurement,15.0,human,y,wrong label,cjackson
1454,10418756,1395,1399,Quantitative Measurement,15.9,human,y,wrong label,cjackson
1455,10418756,1709,1739,Outcome (Study Endpoint),Mean total costs per treatment,human,n,too much,cjackson
1456,10418756,1714,1725,Outcome (Study Endpoint),total costs,model,n,too little,cjackson
1457,10418756,1833,1844,Drug Intervention,ceftriaxone,model,y,,cjackson
1458,10418756,1845,1846,Dosage,1,model,y,,cjackson
1459,10418756,1847,1848,Units,g,model,y,,cjackson
1460,10418756,1849,1859,Intervention Frequency,once daily,model,y,,cjackson
1461,10423597,27,37,Drug Intervention,lovastatin,model,y,,ccurtis
1462,10423597,42,53,Drug Intervention,gemfibrozil,model,y,,ccurtis
1463,10423597,53,63,Drug Intervention,lovastatin,model,y,,hcho
1464,10423597,68,79,Drug Intervention,gemfibrozil,model,y,,hcho
1465,10423597,115,131,Group Characteristic,organ transplant,model,n,too little,hcho
1466,10423597,215,225,Group Characteristic,transplant,model,n,too little,hcho
1467,10423597,719,801,Group Characteristic,National Cholesterol Education Program Adult Treatment Guidelines diet for 8 weeks,human,y,,hcho
1468,10423597,810,864,Group Characteristic,persistent elevations of total cholesterol (>240 mg/dL,model,n,too little,hcho
1469,10423597,810,865,Group Characteristic,persistent elevations of total cholesterol (>240 mg/dL),human,y,,hcho
1470,10423597,919,920,Intervention Duration,8,human,n,too little,hcho
1471,10423597,919,926,Intervention Duration,8 weeks,model,y,,hcho
1472,10423597,987,993,Group Characteristic,stable,model,n,wrong label,hcho
1473,10423597,1127,1137,Group Name,Lovastatin,human,n,wrong label,hcho
1474,10423597,1127,1145,Group Name,Lovastatin therapy,model,n,wrong label,hcho
1475,10423597,1184,1188,Quantitative Measurement,15.5,human,n,too little,hcho
1476,10423597,1184,1189,Quantitative Measurement,15.5%,model,y,,hcho
1477,10423597,1188,1189,Units,%,human,n,wrong label,hcho
1478,10423597,1287,1291,Quantitative Measurement,22.7,human,n,too little,hcho
1479,10423597,1287,1292,Quantitative Measurement,22.7%,model,y,,hcho
1480,10423597,1291,1292,Units,%,human,n,wrong label,hcho
1481,10423597,1539,1542,Quantitative Measurement,7.9,human,n,too little,hcho
1482,10423597,1539,1543,Quantitative Measurement,7.9%,model,y,,hcho
1483,10423597,1542,1543,Units,%,human,n,wrong label,hcho
1484,10423597,1618,1621,Quantitative Measurement,5.1,human,n,too little,hcho
1485,10423597,1618,1622,Quantitative Measurement,5.1%,model,y,,hcho
1486,10423597,1621,1622,Units,%,human,n,wrong label,hcho
1487,10423597,1741,1742,Units,%,human,n,wrong label,hcho
1488,10423597,1826,1827,Units,%,human,n,wrong label,hcho
1489,10424515,40,55,Disease/Condition of Interest,acute rejection,model,n,wrong label,eduvaris
1490,10424515,281,310,Drug Intervention,rabbit antithymocyte globulin,model,y,,eduvaris
1491,10424515,281,317,Drug Intervention,rabbit antithymocyte globulin (RATG),human,n,multiple entities,eduvaris
1492,10424515,312,316,Drug Intervention,RATG,model,y,,eduvaris
1493,10424515,497,516,Group Characteristic,single or bilateral,model,n,too little,eduvaris
1494,10424515,497,549,Group Characteristic,single or bilateral adult lung transplant recipients,human,y,,eduvaris
1495,10424515,517,538,Group Characteristic,adult lung transplant,model,n,too little,eduvaris
1496,10424515,591,595,Drug Intervention,RATG,human,y,,eduvaris
1497,10424515,627,632,Units,mg/kg,model,y,,eduvaris
1498,10424515,627,634,Units,mg/kg/d,human,n,multiple entities,eduvaris
1499,10424515,633,634,Intervention Frequency,d,model,y,,eduvaris
1500,10424515,722,734,Non-Study Drug,cyclosporine,model,y,,eduvaris
1501,10424515,722,753,Non-Study Drug,"cyclosporine, azathioprine, and",human,n,multiple entities,eduvaris
1502,10424515,736,748,Non-Study Drug,azathioprine,model,y,,eduvaris
1503,10424515,754,764,Drug Intervention,prednisone,human,n,wrong label,eduvaris
1504,10424515,906,987,Outcome (Study Endpoint),number of patients experiencing biopsy-proven grade II or greater acute rejection,human,n,too much,eduvaris
1505,10424515,952,987,Outcome (Study Endpoint),grade II or greater acute rejection,model,y,,eduvaris
1506,10424515,1061,1064,Quantitative Measurement,23%,model,y,,eduvaris
1507,10424515,1156,1159,Quantitative Measurement,55%,model,y,,eduvaris
1508,10424515,1239,1285,Outcome (Study Endpoint),incidence of bronchiolitis obliterans syndrome,model,y,,eduvaris
1509,10424515,1342,1346,Group Name,RATG,human,n,wrong label,eduvaris
1510,10519734,23,34,Drug Intervention,simvastatin,model,y,,stan
1511,10519734,39,53,Drug Intervention,cholestyramine,model,y,,stan
1512,10519734,705,707,Sample Size,24,model,y,,stan
1513,10519734,708,712,Group Characteristic,male,model,y,,stan
1514,10519734,717,719,Sample Size,19,model,y,,stan
1515,10519734,720,726,Group Characteristic,female,model,y,,stan
1516,10519734,741,769,Group Characteristic,primary hypercholesterolemia,model,y,,stan
1517,10519734,797,806,Intervention Duration,four-week,model,y,,stan
1518,10519734,888,895,Drug Intervention,cholest,model,n,too little,stan
1519,10519734,957,959,Dosage,10,model,y,,stan
1520,10519734,963,965,Dosage,40,model,y,,stan
1521,10519734,966,968,Units,mg,model,y,,stan
1522,10519734,994,995,Dosage,8,model,y,,stan
1523,10519734,999,1001,Dosage,24,model,y,,stan
1524,10519734,1002,1003,Units,g,model,y,,stan
1525,10519734,1158,1165,Study Duration,18-week,model,y,,stan
1526,10519734,1404,1421,Outcome (Study Endpoint),Plasma CETP level,model,y,,stan
1527,10519734,1411,1421,Outcome (Study Endpoint),CETP level,human,n,too little,stan
1528,10574419,465,472,Drug Intervention,placebo,model,n,wrong label,cjackson
1529,10574419,742,782,Outcome (Study Endpoint),Mean reductions in 24-hour ambulatory BP,model,n,too much,cjackson
1530,10574419,742,803,Outcome (Study Endpoint),Mean reductions in 24-hour ambulatory BP and office seated BP,human,n,too much,cjackson
1531,10574419,787,803,Outcome (Study Endpoint),office seated BP,model,y,,cjackson
1532,10574419,808,823,Group Name,irbesartan/HCTZ,human,n,wrong label,cjackson
1533,10574419,953,955,Quantitative Measurement,65,human,n,too little,cjackson
1534,10574419,953,960,Quantitative Measurement,65%-69%,model,y,,cjackson
1535,10574419,976,978,Quantitative Measurement,24,human,n,too little,cjackson
1536,10574419,976,979,Quantitative Measurement,24%,model,y,,cjackson
1537,10621763,274,284,Drug Intervention,fluoxetine,human,y,,hcho
1538,10621763,308,315,Drug Intervention,placebo,model,n,wrong label,hcho
1539,10621763,349,353,Group Characteristic,PTSD,human,n,wrong label,hcho
1540,10621763,355,361,Sample Size,n = 53,human,n,,hcho
1541,10621763,359,361,Sample Size,53,model,y,,hcho
1542,10621763,417,421,Intervention Frequency,/day,human,n,,hcho
1543,10621763,418,421,Intervention Frequency,day,model,y,,hcho
1544,10621763,426,433,Drug Intervention,placebo,model,n,wrong label,hcho
1545,10621763,644,670,Outcome (Study Endpoint),much or very much improved,human,n,wrong label,hcho
1546,10621763,785,795,Type of Quant. Measure,difference,model,y,,hcho
1547,10621763,959,967,Outcome (Study Endpoint),severity,human,y,,hcho
1548,10621763,969,979,Outcome (Study Endpoint),disability,human,y,,hcho
1549,10621763,981,1001,Outcome (Study Endpoint),stress vulnerability,human,y,,hcho
1550,10621763,1036,1049,Group Name,placebo-group,human,y,,hcho
1551,10715302,25,28,Drug Intervention,ACV,model,n,,ccurtis
1552,10715302,35,42,Drug Intervention,m-BACOD,model,y,,ccurtis
1553,10715302,77,105,Disease/Condition of Interest,low-risk aggressive lymphoma,model,n,too much,ccurtis
1554,10715302,323,328,Drug Intervention,ACVBP,model,y,,ccurtis
1555,10715302,416,423,Drug Intervention,m-BACOD,model,y,,ccurtis
1556,10715302,462,470,Disease/Condition of Interest,lymphoma,model,y,,ccurtis
1557,10715302,483,486,Sample Size,752,model,n,wrong label,ccurtis
1558,10715302,501,537,Group Characteristic,intermediate- or high-grade lymphoma,model,n,wrong label,ccurtis
1559,10715302,542,571,Group Characteristic,no adverse prognostic factors,model,y,,ccurtis
1560,10715302,845,850,Drug Intervention,ACVBP,model,y,,ccurtis
1561,10715302,868,875,Drug Intervention,m-BACOD,model,y,,ccurtis
1562,10715302,881,904,Outcome (Study Endpoint),complete remission rate,model,y,,ccurtis
1563,10715302,890,904,Outcome (Study Endpoint),remission rate,human,y,,ccurtis
1564,10715302,920,922,Quantitative Measurement,86,human,n,too little,ccurtis
1565,10715302,920,923,Quantitative Measurement,86%,model,y,,ccurtis
1566,10715302,922,923,Units,%,human,n,wrong label,ccurtis
1567,10715302,993,1021,Outcome (Study Endpoint),5-year failure-free survival,model,y,,ccurtis
1568,10715302,993,1032,Outcome (Study Endpoint),5-year failure-free survival (FFS) rate,human,n,too much,ccurtis
1569,10715302,1037,1039,Quantitative Measurement,65,human,n,too little,ccurtis
1570,10715302,1037,1040,Quantitative Measurement,65%,model,y,,ccurtis
1571,10715302,1039,1040,Units,%,human,n,wrong label,ccurtis
1572,10715302,1048,1053,Group Name,ACVBP,model,n,too little,ccurtis
1573,10715302,1064,1066,Quantitative Measurement,61,human,n,too little,ccurtis
1574,10715302,1064,1067,Quantitative Measurement,61%,model,y,,ccurtis
1575,10715302,1066,1067,Units,%,human,n,wrong label,ccurtis
1576,10715302,1075,1088,Group Name,m-BACOD group,model,y,,ccurtis
1577,10715302,1136,1138,Quantitative Measurement,75,human,n,too little,ccurtis
1578,10715302,1136,1139,Quantitative Measurement,75%,model,y,,ccurtis
1579,10715302,1138,1139,Units,%,human,n,wrong label,ccurtis
1580,10715302,1147,1158,Group Name,ACVBP group,model,y,,ccurtis
1581,10715302,1163,1165,Quantitative Measurement,73,human,n,too little,ccurtis
1582,10715302,1163,1166,Quantitative Measurement,73%,model,y,,ccurtis
1583,10715302,1165,1166,Units,%,human,n,wrong label,ccurtis
1584,10715302,1174,1181,Group Name,m-BACOD,model,n,too little,ccurtis
1585,10715302,1229,1267,Outcome (Study Endpoint),severe and life-threatening infections,human,n,wrong label,ccurtis
1586,10715302,1302,1320,Outcome (Study Endpoint),pulmonary toxicity,human,n,wrong label,ccurtis
1587,10751747,0,11,Drug Intervention,Pravastatin,model,y,,eduvaris
1588,10751747,24,35,Drug Intervention,bezafibrate,model,y,,eduvaris
1589,10751747,72,87,Group Characteristic,insulin-treated,human,y,,eduvaris
1590,10751747,218,230,Disease/Condition of Interest,dyslipidemia,model,y,,eduvaris
1591,10751747,489,491,Sample Size,22,human,n,not needed,eduvaris
1592,10751747,500,502,Sample Size,23,human,n,not needed,eduvaris
1593,10751747,524,539,Group Characteristic,insulin-treated,model,y,,eduvaris
1594,10751747,524,564,Group Characteristic,insulin-treated Type 2 diabetes patients,human,n,too much,eduvaris
1595,10751747,540,555,Group Characteristic,Type 2 diabetes,model,y,,eduvaris
1596,10751747,616,627,Group Name,Pravastatin,model,n,wrong label,eduvaris
1597,10751747,660,668,Outcome (Study Endpoint),reducing,human,n,not needed,eduvaris
1598,10751747,669,686,Outcome (Study Endpoint),total cholesterol,model,y,,eduvaris
1599,10751747,669,762,Outcome (Study Endpoint),"total cholesterol, LDL-cholesterol, LDL-triglycerides, LDL-ApoB and LDL/HDL-cholesterol ratio",human,n,too much,eduvaris
1600,10751747,688,703,Outcome (Study Endpoint),LDL-cholesterol,model,y,,eduvaris
1601,10751747,705,722,Outcome (Study Endpoint),LDL-triglycerides,model,y,,eduvaris
1602,10751747,724,732,Outcome (Study Endpoint),LDL-ApoB,model,y,,eduvaris
1603,10751747,737,762,Outcome (Study Endpoint),LDL/HDL-cholesterol ratio,model,y,,eduvaris
1604,10751747,796,817,Outcome (Study Endpoint),total/HDL-cholesterol,model,y,,eduvaris
1605,10751747,796,843,Outcome (Study Endpoint),total/HDL-cholesterol and ApoA1/LDL-ApoB ratios,human,n,too much,eduvaris
1606,10751747,822,843,Outcome (Study Endpoint),ApoA1/LDL-ApoB ratios,model,y,,eduvaris
1607,10751747,1039,1049,Outcome (Study Endpoint),increasing,human,n,not needed,eduvaris
1608,10751747,1113,1137,Outcome (Study Endpoint),decreasing triglycerides,human,n,too much,eduvaris
1609,10751747,1124,1137,Outcome (Study Endpoint),triglycerides,model,y,,eduvaris
1610,10751747,1345,1375,Outcome (Study Endpoint),LDL-cholesterol/LDL-ApoB ratio,human,y,,eduvaris
1611,10751747,1675,1686,Drug Intervention,Pravastatin,model,y,,eduvaris
1612,10751747,1812,1823,Drug Intervention,Bezafibrate,model,y,,eduvaris
1613,10795647,42,61,Intervention Administration,aqueous nasal spray,human,n,too much,stan
1614,10795647,50,61,Intervention Administration,nasal spray,model,y,,stan
1615,10795647,299,318,Intervention Administration,aqueous nasal spray,human,n,too much,stan
1616,10795647,719,726,Group Name,placebo,human,y,,stan
1617,10795647,758,768,Drug Intervention,Budesonide,model,y,,stan
1618,10795647,807,818,Drug Intervention,fluticasone,model,y,,stan
1619,10795647,965,975,Drug Intervention,budesonide,model,y,,stan
1620,10795647,1173,1183,Group Name,budesonide,human,n,too little,stan
1621,10795647,1173,1189,Group Name,budesonide group,model,y,,stan
1622,10795647,1194,1197,Units,CAD,human,y,wrong label,stan
1623,10795647,1215,1220,Quantitative Measurement,23.3%,human,y,,stan
1624,10795647,1239,1250,Group Name,fluticasone,human,n,too little,stan
1625,10795647,1239,1256,Group Name,fluticasone group,model,y,,stan
1626,10795647,1268,1271,Quantitative Measurement,CAD,model,n,wrong label,stan
1627,10795647,1337,1347,Drug Intervention,Budesonide,human,y,,stan
1628,10795647,1356,1367,Intervention Administration,nasal spray,human,y,,stan
1629,10795647,1409,1431,Drug Intervention,fluticasone propionate,human,y,,stan
1630,10795647,1432,1443,Intervention Administration,nasal spray,human,y,,stan
1631,10795647,1464,1491,Disease/Condition of Interest,perennial allergic rhinitis,human,y,,stan
1632,10809999,85,93,Group Characteristic,patients,human,n,not needed,cjackson
1633,10809999,305,318,Disease/Condition of Interest,heart failure,human,n,too little,cjackson
1634,10809999,328,335,Group Name,control,model,n,too little,cjackson
1635,10809999,328,341,Group Name,control group,human,y,,cjackson
1636,10809999,430,438,Group Characteristic,patients,human,n,not needed,cjackson
1637,10809999,464,477,Disease/Condition of Interest,heart failure,human,n,too little,cjackson
1638,10809999,493,507,Group Characteristic,living at home,model,n,not needed,cjackson
1639,10809999,567,574,Group Characteristic,healthy,model,y,,cjackson
1640,10809999,575,583,Group Name,controls,model,n,not needed,cjackson
1641,10809999,585,603,Group Name,furosemide-treated,model,y,,cjackson
1642,10809999,631,650,Outcome (Study Endpoint),reduced whole blood,human,n,not needed,cjackson
1643,10809999,639,669,Outcome (Study Endpoint),whole blood thiamine phosphate,model,y,,cjackson
1644,10809999,651,669,Outcome (Study Endpoint),thiamine phosphate,human,y,,cjackson
1645,10809999,717,737,Outcome (Study Endpoint),thiamine diphosphate,model,y,,cjackson
1646,10809999,835,876,Outcome (Study Endpoint),related to the haemoglobin concentrations,human,n,wrong label,cjackson
1647,10809999,942,944,Outcome (Study Endpoint),TP,model,y,,cjackson
1648,10809999,1017,1020,Outcome (Study Endpoint),TPP,model,y,,cjackson
1649,10809999,1099,1100,Outcome (Study Endpoint),T,human,y,,cjackson
1650,10809999,1105,1122,Outcome (Study Endpoint),TP concentrations,human,y,,cjackson
1651,10809999,1210,1220,Drug Intervention,furosemide,human,y,,cjackson
1652,10852758,43,55,Group Characteristic,acute asthma,human,n,wrong label,hcho
1653,10852758,199,204,Statistical Significance,0.005,model,n,too little,ccurtis
1654,10852758,266,271,Group Characteristic,acute,human,n,wrong label,hcho
1655,10852758,272,278,Disease/Condition of Interest,asthma,human,n,too little,hcho
1656,10852758,557,598,Group Characteristic,presented to an emergency department (ED),model,y,,hcho
1657,10852758,643,677,Group Characteristic,baseline FEV(1) < 50% of predicted,human,y,,hcho
1658,10852758,670,672,Drug Intervention,IB,model,y,,ccurtis
1659,10852758,676,685,Drug Intervention,albuterol,model,n,wrong label,ccurtis
1660,10852758,756,763,Drug Intervention,placebo,model,n,wrong label,hcho
1661,10852758,842,862,Intervention Administration,metered-dose inhaler,human,y,,hcho
1662,10852758,877,883,Intervention Frequency,10-min,human,y,,hcho
1663,10852758,931,940,Drug Intervention,albuterol,human,y,,hcho
1664,10852758,959,961,Drug Intervention,IB,human,y,,hcho
1665,10852758,967,971,Intervention Frequency,hour,human,y,,hcho
1666,10852758,1221,1223,Drug Intervention,IB,human,y,,hcho
1667,10852758,1287,1298,Outcome (Study Endpoint),improvement,model,n,too little,hcho
1668,10852758,1287,1305,Outcome (Study Endpoint),improvement in PEF,human,n,too much,hcho
1669,10852758,1362,1383,Outcome (Study Endpoint),improvement in FEV(1),human,n,too much,hcho
1670,10852758,1377,1383,Outcome (Study Endpoint),FEV(1),model,n,too little,hcho
1671,10852758,1393,1406,Group Name,control group,human,y,,hcho
1672,10852758,1432,1435,Intervention Duration,3 h,human,y,,hcho
1673,10852758,1470,1477,Group Name,control,model,n,too little,hcho
1674,10852758,1470,1483,Group Name,control group,human,y,,hcho
1675,10852758,1508,1510,Group Name,IB,model,n,too little,hcho
1676,10852758,1508,1516,Group Name,IB group,human,y,,hcho
1677,10852758,1522,1530,Outcome (Study Endpoint),admitted,model,y,,hcho
1678,10852758,1660,1664,Quantitative Measurement,Five,human,n,wrong label,hcho
1679,10938493,7,30,Follow-up period,follow-up (6-12 months),human,n,not needed,cjackson
1680,10938493,18,29,Follow-up period,6-12 months,model,y,,cjackson
1681,10938493,145,180,Disease/Condition of Interest,refractory congestive heart failure,human,y,,eduvaris
1682,10938493,156,180,Disease/Condition of Interest,congestive heart failure,model,n,too little,eduvaris
1683,10938493,175,177,Quantitative Measurement,12,model,y,,cjackson
1684,10938493,239,263,Disease/Condition of Interest,refractory heart failure,human,n,too little,eduvaris
1685,10938493,249,252,Quantitative Measurement,Six,model,n,wrong label,stan
1686,10938493,253,261,Units,patients,model,n,wrong label,stan
1687,10938493,281,293,Outcome (Study Endpoint),hyponatremia,model,y,,stan
1688,10938493,289,299,Drug Intervention,furosemide,model,y,,cjackson
1689,10938493,311,314,Units,mEq,model,y,,stan
1690,10938493,404,413,Quantitative Measurement,390+/-155,model,y,,stan
1691,10938493,417,427,Quantitative Measurement,2100+/-626,model,y,,stan
1692,10938493,438,447,Quantitative Measurement,433+/-141,model,y,,stan
1693,10938493,439,465,Drug Intervention,hypertonic saline solution,model,y,,eduvaris
1694,10938493,451,461,Quantitative Measurement,1650+/-537,model,y,,stan
1695,10938493,467,470,Drug Intervention,HSS,model,y,,eduvaris
1696,10938493,498,505,Quantitative Measurement,49+/-15,model,y,,stan
1697,10938493,509,517,Quantitative Measurement,198+/-28,model,y,,stan
1698,10938493,518,521,Units,mEq,model,y,,stan
1699,10938493,518,527,Units,mEq./24 h,human,n,wrong label,stan
1700,10938493,526,550,Disease/Condition of Interest,congestive heart failure,model,n,too little,eduvaris
1701,10938493,545,555,Drug Intervention,furosemide,model,y,,cjackson
1702,10938493,569,579,Quantitative Measurement,53.83+/-12,model,y,,stan
1703,10938493,583,591,Quantitative Measurement,129+/-39,model,y,,stan
1704,10938493,590,644,Group Characteristic,refractory CHF (NYHA class IV) of different etiologies,human,n,too much,eduvaris
1705,10938493,592,595,Units,mEq,model,y,,stan
1706,10938493,592,601,Units,mEq./24 h,human,n,wrong label,stan
1707,10938493,624,644,Group Characteristic,different etiologies,model,n,not needed,eduvaris
1708,10938493,627,638,Quantitative Measurement,135.9+/-6.8,model,y,,stan
1709,10938493,642,654,Quantitative Measurement,142.2+/-3. 8,model,y,,stan
1710,10938493,731,742,Quantitative Measurement,134.7+/-7.9,model,y,,stan
1711,10938493,746,757,Quantitative Measurement,130.1+/-4.3,model,y,,stan
1712,10938493,795,804,Quantitative Measurement,4.4+/-0.6,model,y,,stan
1713,10938493,808,817,Quantitative Measurement,3.9+/-0.6,model,y,,stan
1714,10938493,823,830,Quantitative Measurement,4.6+/-9,model,y,,stan
1715,10938493,834,843,Quantitative Measurement,3.6+/-0.5,model,y,,stan
1716,10938493,899,909,Quantitative Measurement,73.8+/-9.1,model,y,,stan
1717,10938493,913,924,Quantitative Measurement,63. 8+/-8.8,model,y,,stan
1718,10938493,935,946,Quantitative Measurement,72.9+/-10.2,model,y,,stan
1719,10938493,950,960,Quantitative Measurement,64.5+/-7.5,model,y,,stan
1720,10938493,1010,1036,Outcome (Study Endpoint),patients in NYHA class III,human,n,too much,stan
1721,10938493,1022,1036,Outcome (Study Endpoint),NYHA class III,model,y,,stan
1722,10938493,1051,1053,Quantitative Measurement,18,model,y,,stan
1723,10938493,1058,1059,Quantitative Measurement,2,model,y,,stan
1724,10938493,1061,1068,Dosage,1.4-4.6,model,n,not needed,eduvaris
1725,10938493,1070,1074,Drug Intervention,NaCl,model,n,not needed,eduvaris
1726,10938493,1086,1092,Intervention Duration,30 min,model,y,,eduvaris
1727,10938493,1242,1245,Drug Intervention,KCl,model,n,wrong label,eduvaris
1728,10938493,1244,1251,Group Name,Group 2,human,y,,stan
1729,10938493,1275,1286,Disease/Condition of Interest,hypokalemia,model,n,not needed,eduvaris
1730,10938493,1807,1811,Units,mmol,model,y,,eduvaris
1731,10938493,1846,1848,Units,ml,model,y,,eduvaris
1732,10938493,2005,2008,Intervention Administration,i.v,human,y,,eduvaris
1733,10938493,2068,2070,Units,mg,model,y,,eduvaris
1734,10938493,2071,2074,Intervention Frequency,day,model,y,,eduvaris
1735,11030277,31,40,Group Characteristic,asthmatic,human,n,wrong label,hcho
1736,11030277,31,49,Group Characteristic,asthmatic children,model,n,too much,hcho
1737,11030277,41,49,Group Characteristic,children,human,y,,hcho
1738,11030277,106,113,Intervention Administration,inhaled,human,y,,hcho
1739,11030277,299,300,Intervention Duration,6,model,n,too little,hcho
1740,11030277,299,307,Intervention Duration,6 months,human,y,,hcho
1741,11030277,323,330,Intervention Administration,inhaled,human,y,,hcho
1742,11030277,562,580,Group Characteristic,asthmatic children,model,n,too much,hcho
1743,11030277,608,615,Intervention Administration,inhaled,model,y,,hcho
1744,11030277,653,657,Intervention Frequency,/day,human,n,too much,hcho
1745,11030277,654,657,Intervention Frequency,day,model,y,,hcho
1746,11030277,710,714,Intervention Frequency,/day,human,n,too much,hcho
1747,11030277,711,714,Intervention Frequency,day,model,y,,hcho
1748,11030277,794,807,Group Name,control group,human,y,,hcho
1749,11030277,814,823,Group Characteristic,asthmatic,human,n,wrong label,hcho
1750,11030277,824,832,Group Characteristic,children,human,y,,hcho
1751,11030277,902,907,Outcome (Study Endpoint),total,human,n,too little,hcho
1752,11030277,902,929,Outcome (Study Endpoint),total and regional fat mass,model,y,,hcho
1753,11030277,912,920,Outcome (Study Endpoint),regional,human,n,too little,hcho
1754,11030277,921,929,Outcome (Study Endpoint),fat mass,human,y,,hcho
1755,11030277,975,990,Outcome (Study Endpoint),growth velocity,human,y,,hcho
1756,11030277,1074,1087,Type of Quant. Measure,% mean change,human,n,too little,hcho
1757,11030277,1094,1096,Type of Quant. Measure,SD,human,n,too little,hcho
1758,11030277,1100,1108,Outcome (Study Endpoint),fat mass,model,y,,hcho
1759,11030277,1235,1238,Quantitative Measurement,two,human,y,,hcho
1760,11030277,1242,1249,Group Name,group 1,human,y,,hcho
1761,11030277,1253,1262,Group Characteristic,preschool,model,n,too little,hcho
1762,11030277,1271,1276,Quantitative Measurement,three,human,y,,hcho
1763,11030277,1280,1287,Group Name,group 2,human,y,,hcho
1764,11030277,1291,1309,Group Characteristic,preschool children,model,y,,hcho
1765,11030277,1315,1318,Quantitative Measurement,two,human,y,,hcho
1766,11030277,1326,1339,Group Name,control group,human,y,,hcho
1767,11030277,1345,1383,Group Characteristic,prepubertal boys aged 8.5 and 9.5 year,model,y,,hcho
1768,11030277,1413,1428,Outcome (Study Endpoint),growth velocity,human,y,,hcho
1769,11030277,1454,1480,Outcome (Study Endpoint),below the third percentile,human,n,too little,hcho
1770,11030277,1507,1514,Intervention Administration,inhaled,human,y,,hcho
1771,11030277,1750,1759,Group Characteristic,asthmatic,human,n,wrong label,hcho
1772,11030277,1760,1768,Group Characteristic,children,human,y,,hcho
1773,11030277,1855,1862,Intervention Administration,inhaled,human,y,,hcho
1774,11061985,301,308,Group Characteristic,smokers,human,y,,ccurtis
1775,11061985,314,318,Disease/Condition of Interest,COPD,model,y,,ccurtis
1776,11061985,476,487,Group Characteristic,stable COPD,model,n,wrong label,ccurtis
1777,11061985,524,531,Group Name,placebo,human,y,wrong label,ccurtis
1778,11061985,702,712,Non-Study Drug,salbutamol,human,y,wrong label,ccurtis
1779,11061985,765,776,Group Name,Zafirlukast,human,n,wrong label,ccurtis
1780,11061985,786,793,Group Name,placebo,human,y,wrong label,ccurtis
1781,11061985,827,842,Outcome (Study Endpoint),bronchodilation,human,y,,ccurtis
1782,11061985,975,985,Quantitative Measurement,Nine of 16,human,y,,ccurtis
1783,11061985,1060,1071,Drug Intervention,zafirlukast,model,y,,ccurtis
1784,11061985,1085,1108,Outcome (Study Endpoint),mean increase in FEV(1),human,n,too much,ccurtis
1785,11061985,1090,1108,Outcome (Study Endpoint),increase in FEV(1),model,n,too much,ccurtis
1786,11061985,1201,1206,Quantitative Measurement,0.221,model,y,,ccurtis
1787,11061985,1220,1224,Outcome (Study Endpoint),mean,model,n,,ccurtis
1788,11061985,1220,1267,Outcome (Study Endpoint),mean difference of post-salbutamol FEV(1)values,human,n,too much,ccurtis
1789,11061985,1239,1267,Outcome (Study Endpoint),post-salbutamol FEV(1)values,model,n,too much,ccurtis
1790,11061985,1358,1412,Outcome (Study Endpoint),mean of differences in pre- and post-salbutamol FEV(1),human,n,too much,ccurtis
1791,11061985,1447,1448,Units,l,human,y,,ccurtis
1792,11061985,1573,1581,Outcome (Study Endpoint),mean AUC,model,n,too much,ccurtis
1793,11061985,1578,1581,Outcome (Study Endpoint),AUC,human,y,,ccurtis
1794,11061985,1615,1616,Units,l,human,y,,ccurtis
1795,11061985,1639,1640,Units,l,human,y,,ccurtis
1796,11061985,1709,1712,Outcome (Study Endpoint),AUC,human,y,,ccurtis
1797,11115306,26,34,Drug Intervention,ventolin,model,y,,stan
1798,11115306,85,103,Drug Intervention,chlorofluorocarbon,model,n,,stan
1799,11115306,119,127,Group Characteristic,children,human,y,,stan
1800,11115306,153,159,Disease/Condition of Interest,asthma,model,y,,stan
1801,11115306,177,183,Drug Intervention,chloro,model,n,too little,stan
1802,11115306,197,200,Drug Intervention,CFC,model,n,wrong label,stan
1803,11115306,407,424,Drug Intervention,albuterol sulfate,model,n,wrong label,stan
1804,11115306,486,498,Drug Intervention,Ventolin HFA,model,y,,stan
1805,11115306,552,561,Drug Intervention,albuterol,model,n,wrong label,stan
1806,11115306,563,571,Drug Intervention,Ventolin,model,y,,stan
1807,11115306,662,668,Study Duration,2-week,model,y,,stan
1808,11115306,752,764,Drug Intervention,Ventolin CFC,model,y,,stan
1809,11115306,819,825,Group Characteristic,asthma,model,y,,stan
1810,11115306,903,910,Drug Intervention,placebo,human,n,wrong label,stan
1811,11115306,942,962,Intervention Administration,metered-dose inhaler,model,y,,stan
1812,11115306,1009,1018,Non-Study Drug,albuterol,model,y,,stan
1813,11115306,1155,1175,Outcome (Study Endpoint),peak expiratory flow,model,y,,stan
1814,11115306,1321,1348,Outcome (Study Endpoint),percentage of predicted PEF,human,n,too much,stan
1815,11115306,1321,1367,Outcome (Study Endpoint),percentage of predicted PEF increased postdose,model,n,too much,stan
1816,11115306,1515,1521,Outcome (Study Endpoint),week 2,human,n,wrong label,stan
1817,11115306,1523,1536,Outcome (Study Endpoint),mean postdose,human,n,wrong label,stan
1818,11115306,1523,1546,Outcome (Study Endpoint),mean postdose increases,model,n,wrong label,stan
1819,11115306,1633,1640,Group Name,placebo,model,n,too little,stan
1820,11117379,0,30,Disease/Condition of Interest,Coronary vasomotor dysfunction,model,y,,hcho
1821,11117379,748,751,Drug Intervention,TKL,human,y,wrong label,hcho
1822,11117379,823,826,Drug Intervention,TKL,human,y,,hcho
1823,11117379,1529,1539,Drug Intervention,prednisone,human,n,wrong label,hcho
1824,11199945,16,26,Drug Intervention,fluoxetine,model,n,wrong label,ccurtis
1825,11199945,16,28,Drug Intervention,fluoxetine's,human,n,wrong label,ccurtis
1826,11199945,226,234,Drug Intervention,pindolol,human,y,,ccurtis
1827,11199945,418,422,Units,days,model,y,,ccurtis
1828,11199945,468,472,Units,days,model,y,,ccurtis
1829,11199945,477,487,Drug Intervention,fluoxetine,human,n,wrong label,ccurtis
1830,11199945,477,500,Group Name,fluoxetine plus placebo,model,n,multiple entities,ccurtis
1831,11199945,493,500,Drug Intervention,placebo,human,n,wrong label,ccurtis
1832,11199945,614,646,Outcome (Study Endpoint),plasma concentration of pindolol,model,y,,ccurtis
1833,11199945,638,646,Drug Intervention,pindolol,human,y,,ccurtis
1834,11199945,793,801,Drug Intervention,pindolol,human,y,,ccurtis
1835,11199945,834,836,Quantitative Measurement,11,human,y,,ccurtis
1836,11199945,837,839,Units,nM,human,y,,ccurtis
1837,11199945,864,877,Drug Intervention,norfluoxetine,model,n,not needed,ccurtis
1838,11199945,948,973,Outcome (Study Endpoint),Fluoxetine concentrations,model,y,,ccurtis
1839,11199945,1581,1589,Statistical Significance,p = 0.01,model,y,,ccurtis
1840,11199945,1819,1830,Group Name,fluoxetine-,model,n,too little,ccurtis
1841,11199945,1819,1843,Group Name,fluoxetine-plus-pindolol,human,n,too little,ccurtis
1842,11199945,2035,2059,Group Name,fluoxetine-plus-pindolol,human,n,too little,ccurtis
1843,11200381,19,30,Drug Intervention,amoxicillin,model,n,too little,eduvaris
1844,11200381,19,42,Drug Intervention,amoxicillin-clavulanate,human,y,,eduvaris
1845,11200381,31,42,Drug Intervention,clavulanate,model,n,too little,eduvaris
1846,11200381,47,62,Drug Intervention,corticosteroids,model,n,not needed,eduvaris
1847,11200381,238,249,Drug Intervention,amoxicillin,model,n,too little,eduvaris
1848,11200381,356,362,Group Characteristic,adults,model,y,,eduvaris
1849,11200381,482,485,Sample Size,433,model,n,not needed,eduvaris
1850,11243947,119,126,Intervention Administration,inhaled,human,y,,stan
1851,11243947,127,137,Drug Intervention,salmeterol,model,y,,stan
1852,11243947,345,352,Group Characteristic,417 men,human,n,multiple entities,stan
1853,11243947,354,363,Group Characteristic,494 women,human,n,multiple entities,stan
1854,11243947,369,414,Group Characteristic,met American Thoracic Society asthma criteria,human,y,,stan
1855,11243947,481,491,Drug Intervention,salmeterol,model,y,,stan
1856,11243947,533,540,Group Name,placebo,human,n,wrong label,stan
1857,11243947,813,819,Disease/Condition of Interest,asthma,human,y,,stan
1858,11243947,1138,1145,Group Name,placebo,human,n,too little,stan
1859,11243947,1307,1314,Group Name,placebo,human,n,too little,stan
1860,11243947,1327,1333,Outcome (Study Endpoint),Median,model,n,wrong label,stan
1861,11243947,1327,1357,Outcome (Study Endpoint),Median daily use of salbutamol,human,n,multiple entities,stan
1862,11243947,1334,1357,Outcome (Study Endpoint),daily use of salbutamol,model,y,,stan
1863,11243947,1413,1424,Units,inhalations,human,y,,stan
1864,11243947,1429,1436,Group Name,placebo,human,n,wrong label,stan
1865,11243947,1574,1581,Group Name,placebo,human,n,wrong label,stan
1866,11286949,80,108,Disease/Condition of Interest,primary hypercholesterolemia,human,y,,cjackson
1867,11286949,88,108,Disease/Condition of Interest,hypercholesterolemia,model,n,too little,cjackson
1868,11286949,148,173,Drug Intervention,colesevelam hydrochloride,model,y,,cjackson
1869,11286949,262,273,Drug Intervention,simvastatin,model,y,,cjackson
1870,11286949,380,486,Group Characteristic,plasma low density lipoprotein [LDL] cholesterol level > 160 mg/dL and triglyceride level < or = 300 mg/dL,human,y,,cjackson
1871,11286949,522,527,Intervention Frequency,daily,model,y,,cjackson
1872,11286949,546,552,Sample Size,n = 33,human,n,too much,cjackson
1873,11286949,550,552,Sample Size,33,model,y,,cjackson
1874,11286949,555,566,Drug Intervention,colesevelam,model,y,,cjackson
1875,11286949,592,598,Sample Size,n = 37,human,n,too much,cjackson
1876,11286949,596,598,Sample Size,37,model,y,,cjackson
1877,11286949,601,612,Drug Intervention,simvastatin,model,y,,cjackson
1878,11286949,620,626,Sample Size,n = 35,human,n,too much,cjackson
1879,11286949,624,626,Sample Size,35,model,y,,cjackson
1880,11286949,629,640,Drug Intervention,colesevelam,model,y,,cjackson
1881,11286949,652,663,Drug Intervention,simvastatin,model,y,,cjackson
1882,11286949,671,677,Sample Size,n = 34,human,n,too much,cjackson
1883,11286949,675,677,Sample Size,34,model,y,,cjackson
1884,11286949,680,691,Drug Intervention,colesevelam,model,y,,cjackson
1885,11286949,709,715,Sample Size,n = 36,human,n,too much,cjackson
1886,11286949,713,715,Sample Size,36,model,y,,cjackson
1887,11286949,718,729,Drug Intervention,simvastatin,model,y,,cjackson
1888,11286949,737,743,Sample Size,n = 39,human,n,too much,cjackson
1889,11286949,741,743,Sample Size,39,model,y,,cjackson
1890,11286949,749,760,Drug Intervention,colesevelam,model,y,,cjackson
1891,11286949,772,783,Drug Intervention,simvastatin,model,y,,cjackson
1892,11286949,791,797,Sample Size,n = 37,human,n,too much,cjackson
1893,11286949,795,797,Sample Size,37,model,y,,cjackson
1894,11286949,879,892,Group Name,placebo group,human,y,,cjackson
1895,11286949,977,996,Group Name,combination therapy,human,n,wrong label,cjackson
1896,11286949,1051,1054,Quantitative Measurement,-80,model,y,,cjackson
1897,11286949,1055,1060,Units,mg/dL,model,y,,cjackson
1898,11286949,1132,1143,Drug Intervention,simvastatin,model,y,wrong label,cjackson
1899,11286949,1144,1146,Dosage,10,model,y,,cjackson
1900,11286949,1147,1149,Units,mg,model,y,,cjackson
1901,11286949,1151,1155,Quantitative Measurement,-26%,human,y,,cjackson
1902,11286949,1151,1156,Quantitative Measurement,"-26%,",model,n,too much,cjackson
1903,11286949,1157,1160,Quantitative Measurement,-48,model,y,,cjackson
1904,11286949,1161,1166,Units,mg/dL,model,y,,cjackson
1905,11286949,1171,1173,Dosage,20,model,y,,cjackson
1906,11286949,1174,1176,Units,mg,model,y,,cjackson
1907,11286949,1184,1187,Quantitative Measurement,-61,model,y,,cjackson
1908,11286949,1188,1193,Units,mg/dL,model,y,,cjackson
1909,11286949,1209,1220,Group Name,colesevelam,human,n,wrong label,cjackson
1910,11286949,1221,1222,Dosage,2,model,n,too little,cjackson
1911,11286949,1233,1236,Quantitative Measurement,-17,model,y,,cjackson
1912,11286949,1237,1242,Units,mg/dL,model,y,,cjackson
1913,11286949,1247,1249,Dosage,3.,model,n,too little,cjackson
1914,11286949,1260,1263,Quantitative Measurement,-31,model,y,,cjackson
1915,11286949,1264,1269,Units,mg/dL,model,y,,cjackson
1916,11286949,1562,1566,Drug Intervention,cole,model,n,too little,cjackson
1917,11286949,1578,1589,Drug Intervention,simvastatin,model,y,,cjackson
1918,11386263,166,179,Disease/Condition of Interest,heart failure,model,y,,hcho
1919,11386263,277,337,Group Characteristic,had symptoms of heart failure at rest or on minimal exertion,human,n,,hcho
1920,11386263,281,337,Group Characteristic,symptoms of heart failure at rest or on minimal exertion,model,y,,hcho
1921,11386263,812,818,Outcome (Study Endpoint),deaths,model,y,,hcho
1922,11386263,908,918,Quantitative Measurement,35 percent,model,y,,hcho
1923,11386263,1007,1014,Units,percent,model,n,wrong label,hcho
1924,11386263,1092,1095,Quantitative Measurement,507,model,y,,hcho
1925,11386263,1105,1130,Outcome (Study Endpoint),died or were hospitalized,model,y,,hcho
1926,11386263,1170,1173,Quantitative Measurement,425,model,y,,hcho
1927,11386263,1227,1237,Quantitative Measurement,24 percent,model,y,,hcho
1928,11386263,1254,1295,Outcome (Study Endpoint),combined risk of death or hospitalization,human,y,,hcho
1929,11386263,1263,1295,Outcome (Study Endpoint),risk of death or hospitalization,model,n,too little,hcho
1930,11386263,1354,1361,Units,percent,model,n,wrong label,hcho
1931,11386263,1675,1681,Statistical Significance,P=0.02,model,y,,hcho
1932,11386927,27,43,Group Name,amlodipine group,model,y,,eduvaris
1933,11386927,90,98,Group Name,ramipril,model,n,too little,eduvaris
1934,11386927,115,122,Outcome (Study Endpoint),reduced,model,n,not needed,eduvaris
1935,11386927,123,150,Outcome (Study Endpoint),risk of clinical end points,model,y,,eduvaris
1936,11386927,260,268,Drug Intervention,Ramipril,model,y,,eduvaris
1937,11386927,284,294,Drug Intervention,amlodipine,model,y,,eduvaris
1938,11386927,409,417,Drug Intervention,ramipril,model,y,,ccurtis
1939,11386927,463,473,Drug Intervention,amlodipine,model,y,,ccurtis
1940,11386927,511,537,Disease/Condition of Interest,hypertensive renal disease,model,y,,ccurtis
1941,11386927,710,772,Group Characteristic,glomerular filtration rate [GFR] of 20-65 mL/min per 1.73 m(2),human,n,not needed,ccurtis
1942,11386927,850,858,Group Name,ramipril,model,y,,ccurtis
1943,11386927,863,873,Group Name,amlodipine,model,y,,ccurtis
1944,11386927,1004,1014,Drug Intervention,amlodipine,model,y,,ccurtis
1945,11386927,1024,1026,Units,mg,model,y,,ccurtis
1946,11386927,1024,1027,Units,mg/,human,y,,ccurtis
1947,11386927,1040,1048,Drug Intervention,ramipril,model,y,,ccurtis
1948,11386927,1060,1062,Units,mg,model,y,,ccurtis
1949,11386927,1060,1063,Units,mg/,human,y,,ccurtis
1950,11386927,1079,1089,Drug Intervention,metoprolol,model,y,,ccurtis
1951,11386927,1101,1103,Units,mg,model,y,,ccurtis
1952,11386927,1101,1104,Units,mg/,human,y,,ccurtis
1953,11386927,1217,1238,Outcome (Study Endpoint),rate of change in GFR,model,y,,ccurtis
1954,11386927,1296,1315,Outcome (Study Endpoint),clinical end points,human,n,not needed,ccurtis
1955,11386927,1319,1335,Outcome (Study Endpoint),reduction in GFR,human,n,too little,ccurtis
1956,11386927,1381,1404,Outcome (Study Endpoint),end-stage renal disease,human,y,,ccurtis
1957,11386927,1409,1414,Outcome (Study Endpoint),death,human,y,,ccurtis
1958,11386927,1435,1553,Group Characteristic,with a urinary protein to creatinine ratio of >0.22 (corresponding approximately to proteinuria of more than 300 mg/d),human,n,too much,ccurtis
1959,11386927,1442,1486,Group Characteristic,urinary protein to creatinine ratio of >0.22,model,y,,ccurtis
1960,11386927,1585,1589,Quantitative Measurement,2.02,model,y,,ccurtis
1961,11386927,1625,1651,Outcome (Study Endpoint),slower mean decline in GFR,model,n,multiple entities,ccurtis
1962,11386927,1625,1664,Outcome (Study Endpoint),slower mean decline in GFR over 3 years,human,n,multiple entities,ccurtis
1963,11386927,1685,1697,Outcome (Study Endpoint),reduced risk,human,n,not needed,ccurtis
1964,11386927,1685,1724,Outcome (Study Endpoint),reduced risk of the clinical end points,model,n,too much,ccurtis
1965,11386927,1837,1892,Outcome (Study Endpoint),difference in mean GFR decline from baseline to 3 years,human,n,multiple entities,ccurtis
1966,11386927,1851,1867,Outcome (Study Endpoint),mean GFR decline,model,n,multiple entities,ccurtis
1967,11401110,92,104,Intervention Administration,subcutaneous,model,y,,stan
1968,11401110,105,119,Drug Intervention,erythropoietin,model,y,,stan
1969,11401110,136,140,Drug Intervention,iron,model,y,,stan
1970,11401110,214,220,Group Characteristic,anemic,model,y,,stan
1971,11401110,506,520,Drug Intervention,erythropoietin,model,y,,stan
1972,11401110,574,592,Group Characteristic,moderate to severe,model,n,multiple entities,stan
1973,11401110,574,596,Group Characteristic,moderate to severe CHF,human,y,,stan
1974,11401110,920,923,Drug Intervention,EPO,model,y,,stan
1975,11401110,928,930,Intervention Administration,IV,model,y,,stan
1976,11401110,1136,1140,Intervention Administration,oral,model,y,,stan
1977,11401110,1145,1156,Intervention Administration,intravenous,model,y,,stan
1978,11401110,1162,1172,Drug Intervention,furosemide,model,n,wrong label,stan
1979,11401110,1261,1270,Follow-up period,8.2+/-2.6,model,y,,stan
1980,11401110,1279,1283,Quantitative Measurement,four,human,n,wrong label,stan
1981,11401110,1296,1303,Group Name,Group B,model,y,,stan
1982,11401110,1316,1323,Group Name,Group A,model,y,,stan
1983,11401110,1324,1328,Outcome (Study Endpoint),died,model,n,wrong label,stan
1984,11401110,1359,1363,Outcome (Study Endpoint),mean,model,n,wrong label,stan
1985,11401110,1375,1383,Outcome (Study Endpoint),improved,model,n,wrong label,stan
1986,11401110,1396,1397,Group Name,A,model,y,,stan
1987,11401110,1402,1410,Outcome (Study Endpoint),worsened,model,n,wrong label,stan
1988,11401110,1423,1424,Group Name,B,model,y,,stan
1989,11401110,1456,1457,Group Name,A,model,y,,stan
1990,11401110,1483,1484,Group Name,B,model,y,,stan
1991,11401110,1525,1526,Group Name,A,model,y,,stan
1992,11401110,1560,1573,Outcome (Study Endpoint),need for oral,human,n,too little,stan
1993,11401110,1560,1591,Outcome (Study Endpoint),need for oral and IV furosemide,model,y,,stan
1994,11401110,1578,1591,Outcome (Study Endpoint),IV furosemide,human,n,too much,stan
1995,11401110,1637,1638,Group Name,A,model,y,,stan
1996,11401110,1688,1689,Group Name,B,model,y,,stan
1997,11401110,1814,1815,Group Name,A,model,y,,stan
1998,11401110,1842,1843,Group Name,B,model,y,,stan
1999,11403727,356,373,Disease/Condition of Interest,smoking cessation,model,n,wrong label,cjackson
2000,11403727,401,408,Group Characteristic,chronic,model,n,too little,cjackson
2001,11403727,401,426,Group Characteristic,chronic cigarette smokers,human,y,,cjackson
2002,11403727,459,462,Drug Intervention,bup,model,n,too little,cjackson
2003,11403727,459,468,Drug Intervention,bupropion,human,y,,cjackson
2004,11403727,506,513,Drug Intervention,placebo,human,n,wrong label,cjackson
2005,11403727,1534,1539,Units,times,human,n,not needed,cjackson
2006,11403727,1574,1577,Group Name,100,human,n,wrong label,cjackson
2007,11403727,1579,1582,Group Name,150,human,n,wrong label,cjackson
2008,11403727,1588,1591,Group Name,300,human,n,wrong label,cjackson
2009,11403727,1948,1955,Side Effects,Anxiety,human,n,not needed,cjackson
2010,11403751,13,22,Drug Intervention,diuretics,human,y,,hcho
2011,11403751,132,140,Drug Intervention,Diuretic,model,y,,hcho
2012,11403751,402,432,Group Characteristic,transudative pleural effusions,model,y,,hcho
2013,11403751,402,464,Group Characteristic,transudative pleural effusions due to congestive heart failure,human,n,too much,hcho
2014,11403751,440,464,Group Characteristic,congestive heart failure,model,n,,hcho
2015,11403751,674,698,Group Characteristic,congestive heart failure,model,n,wrong label,hcho
2016,11403751,674,763,Group Characteristic,congestive heart failure who underwent only a single thoracentesis after diuretic therapy,human,n,too much,hcho
2017,11403751,747,763,Group Characteristic,diuretic therapy,model,n,wrong label,hcho
2018,11403751,1077,1099,Outcome (Study Endpoint),pleural concentrations,model,y,,hcho
2019,11403751,1223,1225,Quantitative Measurement,23,model,n,too little,hcho
2020,11403751,1223,1231,Quantitative Measurement,23 +/- 7,human,y,,hcho
2021,11403751,1531,1560,Outcome (Study Endpoint),serum-pleural fluid gradients,model,y,,hcho
2022,11403751,1565,1572,Outcome (Study Endpoint),albumin,model,y,,hcho
2023,11403751,1574,1581,Quantitative Measurement,12% +/-,model,n,too little,hcho
2024,11403751,1582,1585,Quantitative Measurement,22%,model,n,too little,hcho
2025,11403751,1591,1604,Outcome (Study Endpoint),total protein,model,y,,hcho
2026,11403751,1606,1617,Quantitative Measurement,11% +/- 12%,model,y,,hcho
2027,11403751,1713,1724,Quantitative Measurement,47% +/- 49%,model,y,,hcho
2028,11403751,1741,1752,Quantitative Measurement,48% +/- 40%,model,y,,hcho
2029,11403751,1803,1814,Quantitative Measurement,27% +/- 29%,model,y,,hcho
2030,11403751,1831,1842,Quantitative Measurement,38% +/- 34%,model,y,,hcho
2031,11497193,226,238,Disease/Condition of Interest,Hypertension,human,y,,ccurtis
2032,11497193,656,668,Group Characteristic,hypertensive,model,y,,ccurtis
2033,11497193,1057,1075,Group Characteristic,persistent ECG LVH,human,y,,ccurtis
2034,11497193,1131,1146,Group Characteristic,without ECG LVH,human,y,,ccurtis
2035,11497193,1356,1377,Outcome (Study Endpoint),echocardiographic LVH,model,y,,ccurtis
2036,11497193,1374,1377,Outcome (Study Endpoint),LVH,human,n,too little,ccurtis
2037,11497193,1415,1438,Group Characteristic,ECG LVH on the baseline,human,y,,ccurtis
2038,11497193,1611,1632,Outcome (Study Endpoint),echocardiographic LVH,model,y,,ccurtis
2039,11497193,1629,1632,Outcome (Study Endpoint),LVH,human,n,too little,ccurtis
2040,11497193,2160,2189,Outcome (Study Endpoint),risk of echocardiographic LVH,model,n,too much,ccurtis
2041,11544429,47,64,Group Characteristic,renal transplants,model,y,,stan
2042,11544429,293,299,Group Characteristic,stable,model,n,too little,stan
2043,11544429,293,314,Group Characteristic,stable renal function,human,y,,stan
2044,11544429,319,331,Disease/Condition of Interest,hypertension,model,n,too little or too much based on context,stan
2045,11544429,460,466,Intervention Duration,2-week,model,y,,stan
2046,11544429,589,622,Outcome (Study Endpoint),fractional excretion of uric acid,human,y,,stan
2047,11544429,624,637,Outcome (Study Endpoint),FE(uric acid),human,y,,stan
2048,11544429,754,768,Group Name,control period,human,y,,stan
2049,11544429,808,814,Quantitative Measurement,-1.15%,model,y,,stan
2050,11544429,818,824,Quantitative Measurement,+2.77%,model,y,,stan
2051,11544429,833,841,Group Name,losartan,model,n,too little,stan
2052,11544429,833,848,Group Name,losartan period,human,y,,stan
2053,11544429,912,919,Group Name,control,human,n,too little,stan
2054,11544429,954,959,Quantitative Measurement,-0.10,model,y,,stan
2055,11544429,963,967,Quantitative Measurement,0.06,model,y,,stan
2056,11544429,979,987,Group Name,losartan,human,n,too little,stan
2057,11544429,1050,1054,Units,mmHg,human,y,,stan
2058,11544429,1063,1070,Group Name,control,human,n,too little,stan
2059,11544429,1104,1107,Quantitative Measurement,-13,model,y,,stan
2060,11544429,1111,1113,Quantitative Measurement,+6,model,y,,stan
2061,11544429,1127,1135,Group Name,losartan,human,n,too little,stan
2062,11544429,1293,1300,Group Name,control,human,n,too little,stan
2063,11544429,1362,1370,Group Name,losartan,human,n,too little,stan
2064,11544429,1436,1443,Group Name,control,human,n,too little,stan
2065,11544429,1502,1510,Group Name,losartan,human,n,too little,stan
2066,11544429,1559,1561,Dosage,50,model,y,,stan
2067,11544429,1562,1564,Units,mg,model,y,,stan
2068,11544429,1568,1576,Drug Intervention,losartan,model,n,too little or too much based on context,stan
2069,11544429,1580,1592,Group Characteristic,hypertensive,model,y,,stan
2070,11544429,1593,1604,Group Characteristic,CsA-treated,model,y,,stan
2071,11544429,1646,1649,Quantitative Measurement,17%,human,y,,stan
2072,11544429,1662,1675,Outcome (Study Endpoint),FE(uric acid),human,y,,stan
2073,11544429,1683,1684,Quantitative Measurement,8,model,n,too little,stan
2074,11544429,1683,1685,Quantitative Measurement,8%,human,y,,stan
2075,11544429,1694,1710,Outcome (Study Endpoint),plasma uric acid,human,y,,stan
2076,11809183,12,26,Drug Intervention,immunoglobulin,model,y,,cjackson
2077,11809183,40,58,Drug Intervention,methylprednisolone,human,y,,cjackson
2078,11809183,76,80,Intervention Administration,oral,human,y,,cjackson
2079,11809183,221,256,Disease/Condition of Interest,autoimmune thrombocytopenic purpura,model,y,,cjackson
2080,11809183,428,434,Group Characteristic,adults,model,y,,cjackson
2081,11809183,697,703,Group Characteristic,adults,model,y,,cjackson
2082,11809183,865,868,Intervention Duration,1-3,human,n,too little,cjackson
2083,11809183,968,972,Intervention Duration,4-21,human,n,too little,cjackson
2084,11809183,1060,1123,Outcome (Study Endpoint),number of days on which platelet counts were above 50 x 10(9)/L,model,y,,cjackson
2085,11809183,1084,1123,Outcome (Study Endpoint),platelet counts were above 50 x 10(9)/L,human,n,too little,cjackson
2086,11809183,1134,1136,Sample Size,56,model,n,wrong label,cjackson
2087,11809183,1137,1145,Units,patients,human,n,not needed,cjackson
2088,11809183,1193,1195,Sample Size,60,model,n,wrong label,cjackson
2089,11809183,1276,1291,Outcome (Study Endpoint),platelet counts,human,n,too little,cjackson
2090,11809183,1276,1309,Outcome (Study Endpoint),platelet counts over 50 x 10(9)/L,model,y,,cjackson
2091,11809183,1330,1331,Quantitative Measurement,7,human,n,too little,cjackson
2092,11809183,1330,1332,Quantitative Measurement,7%,model,y,,cjackson
2093,11809183,1337,1339,Quantitative Measurement,79,human,n,too little,cjackson
2094,11809183,1337,1340,Quantitative Measurement,79%,model,y,,cjackson
2095,11809183,1363,1389,Group Name,intravenous immunoglobulin,model,n,too little,cjackson
2096,11809183,1363,1395,Group Name,intravenous immunoglobulin group,human,y,,cjackson
2097,11809183,1410,1411,Quantitative Measurement,2,human,n,too little,cjackson
2098,11809183,1410,1412,Quantitative Measurement,2%,model,y,,cjackson
2099,11809183,1417,1419,Quantitative Measurement,60,human,n,too little,cjackson
2100,11809183,1417,1420,Quantitative Measurement,60%,model,y,,cjackson
2101,11809183,1453,1477,Group Name,methylprednisolone group,human,y,,cjackson
2102,11809183,1524,1534,Drug Intervention,prednisone,model,y,,cjackson
2103,11809183,1559,1566,Group Name,placebo,model,y,,cjackson
2104,11809183,1650,1660,Drug Intervention,prednisone,model,y,,cjackson
2105,11809183,1822,1826,Units,days,human,y,,cjackson
2106,11809183,1864,1874,Drug Intervention,prednisone,model,y,,cjackson
2107,11809183,1945,1955,Drug Intervention,prednisone,model,y,,cjackson
2108,11809987,40,47,Group Characteristic,elderly,human,y,,hcho
2109,11809987,60,86,Disease/Condition of Interest,chronic airflow limitation,model,y,,hcho
2110,11809987,569,572,Group Name,CAL,model,n,wrong label,hcho
2111,11809987,581,589,Group Name,controls,model,y,,hcho
2112,11809987,829,839,Sample Size,Forty four,human,y,,hcho
2113,11809987,868,870,Sample Size,29,human,y,,hcho
2114,11809987,1281,1296,Outcome (Study Endpoint),distance walked,model,y,,hcho
2115,12055585,52,58,Drug Intervention,lectin,human,n,wrong label,ccurtis
2116,12055585,59,68,Drug Intervention,galactose,human,n,wrong label,ccurtis
2117,12055585,458,475,Group Characteristic,Colorectal cancer,model,n,wrong label,ccurtis
2118,12055585,458,481,Group Name,Colorectal cancer cases,human,n,wrong label,ccurtis
2119,12055585,476,481,Group Name,cases,model,n,wrong label,ccurtis
2120,12055585,727,739,Drug Intervention,cereal fiber,model,n,wrong label,ccurtis
2121,12055585,744,749,Drug Intervention,fruit,model,n,wrong label,ccurtis
2122,12055585,832,845,Outcome (Study Endpoint),dietary fiber,model,n,too little,ccurtis
2123,12055585,832,863,Outcome (Study Endpoint),dietary fiber galactose content,human,y,,ccurtis
2124,12055585,846,863,Outcome (Study Endpoint),galactose content,model,n,too little,ccurtis
2125,12055585,917,919,Type of Quant. Measure,OR,model,y,,ccurtis
2126,12055585,982,984,Type of Quant. Measure,CI,model,y,,ccurtis
2127,12055585,1138,1174,Outcome (Study Endpoint),Intake of nonlegume green vegetables,human,n,not needed,ccurtis
2128,12055585,1148,1174,Drug Intervention,nonlegume green vegetables,model,n,wrong label,ccurtis
2129,12055585,1643,1655,Disease/Condition of Interest,colon cancer,model,y,,ccurtis
2130,12185556,201,212,Drug Intervention,venlafaxine,model,y,,eduvaris
2131,12185556,430,433,Dosage,300,human,y,,eduvaris
2132,12185556,430,434,Dosage,300-,model,n,too much,eduvaris
2133,12185556,635,654,Outcome (Study Endpoint),racemic venlafaxine,human,y,,eduvaris
2134,12185556,643,654,Drug Intervention,venlafaxine,model,y,,eduvaris
2135,12185556,656,657,Outcome (Study Endpoint),V,human,n,wrong label,eduvaris
2136,12185556,663,685,Outcome (Study Endpoint),O-desmethylvenlafaxine,human,n,wrong label,eduvaris
2137,12185556,876,903,Outcome (Study Endpoint),Interindividual variability,model,y,,eduvaris
2138,12185556,975,1002,Outcome (Study Endpoint),Intraindividual variability,model,y,,eduvaris
2139,12185556,1037,1056,Outcome (Study Endpoint),Enantiomeric ratios,human,y,,eduvaris
2140,12185556,1103,1124,Outcome (Study Endpoint),median (+)/(-) ratios,model,n,wrong label,eduvaris
2141,12185556,1157,1190,Outcome (Study Endpoint),ODV/V metabolite formation ratios,model,y,,eduvaris
2142,12185556,1163,1190,Outcome (Study Endpoint),metabolite formation ratios,human,n,too little,eduvaris
2143,12185556,1269,1275,Type of Quant. Measure,median,model,y,,eduvaris
2144,12185556,1322,1341,Outcome (Study Endpoint),reduced ODV/V ratio,human,n,not needed,eduvaris
2145,12185556,1404,1423,Outcome (Study Endpoint),(+)/(-) ratio for V,model,n,not needed,eduvaris
2146,12185556,1425,1429,Type of Quant. Measure,r(S),model,y,,eduvaris
2147,12185556,1430,1434,Quantitative Measurement,0.71,model,y,,eduvaris
2148,12185556,1449,1480,Outcome (Study Endpoint),increased (+)/(-) ratio for ODV,model,n,not needed,eduvaris
2149,12185556,1482,1486,Type of Quant. Measure,r(S),model,y,,eduvaris
2150,12185556,1487,1492,Quantitative Measurement,-0.79,model,y,,eduvaris
2151,12185556,1517,1528,Outcome (Study Endpoint),ODV/V ratio,model,y,,eduvaris
2152,12185556,1682,1687,Quantitative Measurement,-0.38,model,y,,eduvaris
2153,12185556,1689,1695,Statistical Significance,P<0.05,model,y,,eduvaris
2154,12185556,1717,1722,Group Characteristic,males,model,y,,eduvaris
2155,12185556,1724,1731,Group Characteristic,females,model,y,,eduvaris
2156,12185556,1764,1775,Outcome (Study Endpoint),ODV/V ratio,model,y,,eduvaris
2157,12185556,1764,1798,Outcome (Study Endpoint),ODV/V ratio for the (-) enantiomer,human,n,too much,eduvaris
2158,12185556,1800,1806,Type of Quant. Measure,median,human,y,,eduvaris
2159,12185556,1878,1884,Type of Quant. Measure,median,human,y,,eduvaris
2160,12213517,35,48,Drug Intervention,D-amphetamine,human,y,,cjackson
2161,12213517,488,499,Drug Intervention,amphetamine,model,y,,cjackson
2162,12213517,513,515,Group Name,PL,human,n,not needed,cjackson
2163,12213517,947,968,Outcome (Study Endpoint),positively associated,model,n,not needed,cjackson
2164,12213517,1013,1014,Type of Quant. Measure,r,model,y,,cjackson
2165,12213517,1015,1023,Quantitative Measurement,+.55-.78,model,y,,cjackson
2166,12213517,1091,1139,Outcome (Study Endpoint),negatively associated with salivary progesterone,model,n,not needed,cjackson
2167,12213517,1118,1139,Outcome (Study Endpoint),salivary progesterone,human,y,,cjackson
2168,12213517,1141,1142,Type of Quant. Measure,r,model,y,,cjackson
2169,12213517,1143,1151,Quantitative Measurement,-.66-.68,model,y,,cjackson
2170,12796759,11,21,Drug Intervention,amlodipine,human,y,,hcho
2171,12796759,40,86,Non-Pharmaceutical Intervention,percutaneous transluminal coronary angioplasty,model,y,,hcho
2172,12796759,214,218,Non-Pharmaceutical Intervention,PTCA,model,y,,hcho
2173,12796759,565,572,Group Name,placebo,human,y,wrong label,hcho
2174,12796759,1155,1157,Statistical Significance,03,human,y,,hcho
2175,12801622,304,307,Units,cal,model,y,,ccurtis
2176,12801622,387,397,Drug Intervention,xuezhikang,human,y,,ccurtis
2177,12801622,417,421,Dosage,1200,model,y,,ccurtis
2178,12801622,422,424,Units,mg,model,y,,ccurtis
2179,12801622,425,428,Intervention Frequency,day,model,y,,ccurtis
2180,12801622,519,526,Non-Study Drug,aspirin,model,y,,ccurtis
2181,12801622,528,538,Non-Study Drug,metoprolol,model,y,,ccurtis
2182,12801622,543,553,Drug Intervention,fosinopril,model,n,wrong label,ccurtis
2183,12801622,558,566,Non-Study Drug,nitrates,model,y,,ccurtis
2184,12801622,584,591,Study Duration,6 weeks,model,n,wrong label,ccurtis
2185,12801622,912,913,Outcome (Study Endpoint),4,model,n,wrong label,ccurtis
2186,12801622,918,921,Outcome (Study Endpoint),6 h,model,n,wrong label,ccurtis
2187,12801622,943,945,Quantitative Measurement,43,human,n,too little,ccurtis
2188,12801622,943,946,Quantitative Measurement,43%,model,y,,ccurtis
2189,12801622,945,946,Units,%,human,n,wrong label,ccurtis
2190,12801622,997,1020,Outcome (Study Endpoint),TG area under the curve,model,n,wrong label,ccurtis
2191,12801622,1143,1149,Units,mmol/l,model,y,,ccurtis
2192,12801622,1178,1184,Units,mmol/l,model,y,,ccurtis
2193,12801622,1186,1203,Outcome (Study Endpoint),fasting TG levels,model,y,,ccurtis
2194,12801622,1214,1216,Quantitative Measurement,50,human,n,too little,ccurtis
2195,12801622,1214,1217,Quantitative Measurement,50%,model,y,,ccurtis
2196,12801622,1216,1217,Units,%,human,n,wrong label,ccurtis
2197,12803732,222,225,Disease/Condition of Interest,CAD,model,y,,eduvaris
2198,12803732,325,328,Disease/Condition of Interest,CAD,model,y,,eduvaris
2199,12803732,428,436,Group Characteristic,patients,human,n,not needed,eduvaris
2200,12803732,479,485,Sample Size,n = 46,human,n,too much,eduvaris
2201,12803732,483,485,Sample Size,46,model,y,,eduvaris
2202,12803732,502,504,Dosage,20,model,y,,eduvaris
2203,12803732,502,507,Dosage,20 mg,human,n,multiple entities,eduvaris
2204,12803732,505,507,Units,mg,model,y,,eduvaris
2205,12803732,507,508,Dosage,/,model,n,too much,eduvaris
2206,12803732,508,511,Intervention Frequency,day,model,y,,eduvaris
2207,12803732,576,588,Non-Study Drug,beta-blocker,model,y,,eduvaris
2208,12803732,590,597,Non-Study Drug,nitrate,model,y,,eduvaris
2209,12803732,602,609,Non-Study Drug,aspirin,model,y,wrong label,eduvaris
2210,12803732,624,630,Sample Size,n = 32,human,n,too much,eduvaris
2211,12803732,628,630,Sample Size,32,model,y,,eduvaris
2212,12803732,690,697,Follow-up period,4 weeks,model,n,wrong label,eduvaris
2213,12803732,779,783,Quantitative Measurement,20.3,model,y,,eduvaris
2214,12803732,784,789,Units,mg/dl,model,y,,eduvaris
2215,12803732,791,797,Type of Quant. Measure,95% CI,model,y,wrong label,eduvaris
2216,12803732,799,805,Quantitative Measurement,9-31.8,model,y,,eduvaris
2217,12803732,810,814,Quantitative Measurement,10.8,model,y,,eduvaris
2218,12803732,815,820,Units,mg/dl,model,y,,eduvaris
2219,12803732,822,828,Statistical Significance,95% CI,human,n,wrong label,eduvaris
2220,12803732,830,838,Quantitative Measurement,2.7-18.9,model,y,,eduvaris
2221,12803732,884,886,Quantitative Measurement,17,model,y,,eduvaris
2222,12803732,887,892,Units,mg/dl,model,y,,eduvaris
2223,12803732,894,900,Statistical Significance,95% CI,human,n,wrong label,eduvaris
2224,12803732,902,909,Quantitative Measurement,13.1-21,model,y,,eduvaris
2225,12803732,914,918,Quantitative Measurement,12.8,model,y,,eduvaris
2226,12803732,919,924,Units,mg/dl,model,y,,eduvaris
2227,12803732,926,932,Type of Quant. Measure,95% CI,model,y,wrong label,eduvaris
2228,12803732,934,942,Quantitative Measurement,9.7-15.9,model,y,,eduvaris
2229,12803732,960,1004,Outcome (Study Endpoint),decrease in group A was more than in group B,human,n,not needed,eduvaris
2230,12803732,972,979,Group Name,group A,model,y,,eduvaris
2231,12803732,997,1004,Group Name,group B,model,y,,eduvaris
2232,12838216,36,50,Drug Intervention,corticosteroid,human,y,,stan
2233,12838216,153,165,Disease/Condition of Interest,Pancreatitis,human,y,,stan
2234,12838216,628,634,Intervention Administration,orally,human,y,,stan
2235,12838216,648,662,Drug Intervention,corticosteroid,human,y,,stan
2236,12838216,704,726,Disease/Condition of Interest,post-ERCP pancreatitis,human,y,,stan
2237,12838216,811,818,Drug Intervention,placebo,human,n,wrong label,stan
2238,12838216,819,825,Intervention Administration,orally,human,y,,stan
2239,12838216,826,834,Intervention Frequency,15 hours,human,y,,stan
2240,12838216,839,846,Intervention Frequency,3 hours,human,y,,stan
2241,12838216,956,997,Group Characteristic,undergoing diagnostic or therapeutic ERCP,model,n,multiple entities,stan
2242,12838216,1216,1225,Quantitative Measurement,92 of 555,human,n,wrong label,stan
2243,12838216,1222,1225,Sample Size,555,model,y,,stan
2244,12838216,1226,1234,Units,patients,human,n,wrong label,stan
2245,12838216,1242,1256,Group Name,corticosteroid,human,n,,stan
2246,12838216,1242,1262,Group Name,corticosteroid group,model,y,,stan
2247,12838216,1279,1288,Quantitative Measurement,76 of 560,human,n,wrong label,stan
2248,12838216,1285,1288,Sample Size,560,model,y,,stan
2249,12838216,1289,1297,Units,patients,human,n,wrong label,stan
2250,12838216,1305,1312,Group Name,control,human,n,,stan
2251,12838216,1305,1318,Group Name,control group,model,y,,stan
2252,12838216,1359,1363,Outcome (Study Endpoint),mild,model,y,,stan
2253,12838216,1375,1383,Outcome (Study Endpoint),moderate,model,y,,stan
2254,12838216,1398,1404,Outcome (Study Endpoint),severe,model,y,,stan
2255,12838216,1946,1952,Intervention Administration,orally,human,y,,stan
2256,12838216,2000,2009,Outcome (Study Endpoint),frequency,human,y,,stan
2257,12838216,2013,2021,Outcome (Study Endpoint),severity,human,y,,stan
2258,12838216,2025,2047,Disease/Condition of Interest,post-ERCP pancreatitis,human,y,,stan
2259,12911678,172,187,Drug Intervention,Belzer solution,model,y,,cjackson
2260,12911678,189,196,Drug Intervention,Viaspan,human,y,,cjackson
2261,12911678,269,280,Drug Intervention,Eurocollins,human,y,,cjackson
2262,12911678,316,338,Disease/Condition of Interest,delayed graft function,human,n,wrong label,cjackson
2263,12911678,641,673,Study Years,1 January 1993 and 31 March 1998,model,n,not needed,cjackson
2264,12911678,651,655,Study Years,1993,human,n,not needed,cjackson
2265,12911678,669,673,Study Years,1998,human,n,not needed,cjackson
2266,12911678,945,958,Group Characteristic,kidney grafts,model,n,not needed,cjackson
2267,12911678,998,1009,Group Name,strategy S1,model,n,not needed,cjackson
2268,12911678,1007,1009,Group Name,S1,human,n,not needed,cjackson
2269,12911678,1011,1013,Group Name,n1,model,n,not needed,cjackson
2270,12911678,1024,1034,Outcome (Study Endpoint),cost/graft,model,y,,cjackson
2271,12911678,1067,1074,Drug Intervention,Viaspan,model,y,,cjackson
2272,12911678,1076,1087,Group Name,strategy S2,model,n,not needed,cjackson
2273,12911678,1085,1087,Group Name,S2,human,n,not needed,cjackson
2274,12911678,1116,1120,Outcome (Study Endpoint),cost,model,n,too little,cjackson
2275,12911678,1229,1234,Type of Quant. Measure,ebeta,model,y,,cjackson
2276,12911678,1237,1242,Quantitative Measurement,0.437,model,y,,cjackson
2277,12911678,1257,1271,Outcome (Study Endpoint),preventing DGF,human,y,,cjackson
2278,12911678,1382,1385,Quantitative Measurement,278,model,y,,cjackson
2279,12911678,1422,1423,Quantitative Measurement,2,model,n,too little,cjackson
2280,12932588,445,455,Intervention Duration,six months,model,y,,hcho
2281,12932588,593,596,Disease/Condition of Interest,CAD,human,y,,hcho
2282,12932588,801,803,Sample Size,25,model,y,,hcho
2283,12932588,801,812,Sample Size,25 patients,human,n,too much,hcho
2284,12932588,814,823,Group Characteristic,36% women,human,y,,hcho
2285,12932588,818,823,Group Characteristic,women,model,n,too little,hcho
2286,12932588,830,833,Group Characteristic,CAD,human,n,wrong label,hcho
2287,12932588,1069,1097,Outcome (Study Endpoint),Mean stress perfusion defect,model,n,multiple entities,hcho
2288,12932588,1074,1097,Outcome (Study Endpoint),stress perfusion defect,human,y,,hcho
2289,12932588,1303,1306,Quantitative Measurement,48%,model,y,,hcho
2290,12932588,1339,1342,Quantitative Measurement,43%,model,y,,hcho
2291,12932588,1373,1375,Quantitative Measurement,9%,model,y,,hcho
2292,12932588,1636,1647,Drug Intervention,pravastatin,human,y,,hcho
2293,12932588,1701,1712,Drug Intervention,pravastatin,human,y,,hcho
2294,14530474,12,22,Drug Intervention,carvedilol,model,y,,ccurtis
2295,14530474,65,75,Outcome (Study Endpoint),NYHA class,model,y,,eduvaris
2296,14530474,141,149,Statistical Significance,P < 0.05,model,y,,eduvaris
2297,14530474,149,159,Drug Intervention,metoprolol,model,y,,ccurtis
2298,14530474,152,162,Drug Intervention,Carvedilol,model,y,,eduvaris
2299,14530474,169,179,Drug Intervention,Carvedilol,model,y,,ccurtis
2300,14530474,184,194,Drug Intervention,metoprolol,model,y,,ccurtis
2301,14530474,296,306,Drug Intervention,metoprolol,model,y,,eduvaris
2302,14530474,474,496,Group Characteristic,dilated cardiomyopathy,model,n,wrong label,ccurtis
2303,14530474,498,501,Group Characteristic,DCM,model,n,wrong label,ccurtis
2304,14530474,728,746,Outcome (Study Endpoint),total defect score,human,n,wrong label,ccurtis
2305,14530474,761,781,Outcome (Study Endpoint),heart-to-mediastinum,human,n,too little,ccurtis
2306,14530474,832,858,Outcome (Study Endpoint),New York Heart Association,human,n,too little,ccurtis
2307,14530474,894,928,Outcome (Study Endpoint),left ventricular ejection fraction,human,y,,ccurtis
2308,14530474,976,979,Outcome (Study Endpoint),TDS,model,n,wrong label,ccurtis
2309,14530474,1235,1239,Outcome (Study Endpoint),LVEF,model,y,,ccurtis
2310,14530474,1369,1373,Outcome (Study Endpoint),NYHA,human,n,too little,ccurtis
2311,14530474,1369,1390,Outcome (Study Endpoint),NYHA functional class,model,y,,ccurtis
2312,14530474,1592,1593,Type of Quant. Measure,r,human,y,,ccurtis
2313,14530474,1596,1600,Quantitative Measurement,0.41,human,y,,ccurtis
2314,14530474,1629,1633,Quantitative Measurement,0.53,human,y,,ccurtis
2315,14758137,0,19,Disease/Condition of Interest,Second malignancies,human,n,wrong label,stan
2316,14758137,205,211,Group Characteristic,adults,model,y,,stan
2317,14758137,335,358,Group Characteristic,age from 16 to 88 years,model,n,too much,stan
2318,14758137,335,494,Group Characteristic,age from 16 to 88 years with stage I or II Hodgkin disease who were treated between 1980 and 1995 with chemotherapy followed 3 to 4 weeks later by radiotherapy,human,n,multiple entities,stan
2319,14758137,364,393,Group Characteristic,stage I or II Hodgkin disease,model,n,multiple entities,stan
2320,14758137,419,423,Study Years,1980,model,y,,stan
2321,14758137,428,432,Study Years,1995,model,y,,stan
2322,14758137,482,494,Non-Pharmaceutical Intervention,radiotherapy,model,y,,stan
2323,14758137,704,708,Drug Intervention,MOPP,model,y,,stan
2324,14758137,830,840,Drug Intervention,prednisone,model,y,,stan
2325,14758137,830,852,Drug Intervention,prednisone/doxorubicin,human,n,multiple entities,stan
2326,14758137,841,852,Drug Intervention,doxorubicin,model,y,,stan
2327,14758137,895,897,Sample Size,18,human,y,,stan
2328,14758137,915,940,Drug Intervention,chemotherapeutic regimens,human,n,wrong label,stan
2329,14758137,979,991,Non-Pharmaceutical Intervention,radiotherapy,model,y,,stan
2330,14758137,1001,1003,Dosage,40,model,y,,stan
2331,14758137,1004,1006,Units,Gy,model,y,,stan
2332,14758137,1019,1024,Intervention Frequency,daily,model,y,,stan
2333,14758137,1025,1029,Dosage,2-Gy,human,n,multiple entities,stan
2334,14758137,1106,1111,Follow-up period,"2,230",model,n,wrong label,stan
2335,14758137,1165,1179,Outcome (Study Endpoint),relative risks,model,y,,stan
2336,14758137,1227,1229,Type of Quant. Measure,RR,model,y,,stan
2337,14758137,1231,1235,Quantitative Measurement,69.3,model,y,,stan
2338,14758137,1237,1243,Type of Quant. Measure,95% CI,model,y,,stan
2339,14758137,1241,1243,Type of Quant. Measure,CI,human,y,,stan
2340,14758137,1243,1255,Quantitative Measurement,", 14.3-202.6",human,n,too much,stan
2341,14758137,1245,1255,Quantitative Measurement,14.3-202.6,model,y,,stan
2342,14758137,1271,1273,Type of Quant. Measure,RR,model,y,,stan
2343,14758137,1275,1278,Quantitative Measurement,7.3,model,y,,stan
2344,14758137,1280,1286,Type of Quant. Measure,95% CI,model,y,,stan
2345,14758137,1284,1286,Type of Quant. Measure,CI,human,n,too little,stan
2346,14758137,1286,1296,Quantitative Measurement,", 1.5-21.3",human,n,too much,stan
2347,14758137,1288,1296,Quantitative Measurement,1.5-21.3,model,y,,stan
2348,14758137,1303,1304,Outcome (Study Endpoint),5,model,n,wrong label,stan
2349,14758137,1303,1365,Outcome (Study Endpoint),"5-, 10-, and 15-year actuarial risks of acute myeloid leukemia",human,n,multiple entities,stan
2350,14758137,1307,1309,Outcome (Study Endpoint),10,model,n,not needed,stan
2351,14758137,1316,1318,Outcome (Study Endpoint),15,model,n,not needed,stan
2352,14758137,1324,1365,Outcome (Study Endpoint),actuarial risks of acute myeloid leukemia,model,y,,stan
2353,14758137,1371,1375,Quantitative Measurement,0.8%,model,y,,stan
2354,14758137,1371,1391,Quantitative Measurement,"0.8%, 1.3%, and 1.3%",human,n,multiple entities,stan
2355,14758137,1377,1381,Quantitative Measurement,1.3%,model,y,,stan
2356,14758137,1387,1391,Quantitative Measurement,1.3%,model,y,,stan
2357,14758137,1429,1433,Group Name,MOPP,model,n,wrong label,stan
2358,14758137,1442,1484,Outcome (Study Endpoint),highest 15-year actuarial risk of leukemia,human,n,too much,stan
2359,14758137,1450,1484,Outcome (Study Endpoint),15-year actuarial risk of leukemia,model,n,too little or too much based on context,stan
2360,14758137,1497,1498,Outcome (Study Endpoint),5,model,n,not needed,stan
2361,14758137,1497,1549,Outcome (Study Endpoint),"5-, 10-, and 15-year actuarial risks of solid tumors",human,n,multiple entities,stan
2362,14758137,1501,1503,Outcome (Study Endpoint),10,model,n,not needed,stan
2363,14758137,1510,1512,Outcome (Study Endpoint),15,model,n,not needed,stan
2364,14758137,1518,1549,Outcome (Study Endpoint),actuarial risks of solid tumors,model,y,,stan
2365,14758137,1555,1559,Quantitative Measurement,1.9%,model,y,,stan
2366,14758137,1555,1576,Quantitative Measurement,"1.9%, 9.3%, and 16.8%",human,n,multiple entities,stan
2367,14758137,1561,1565,Quantitative Measurement,9.3%,model,y,,stan
2368,14758137,1571,1576,Quantitative Measurement,16.8%,model,y,,stan
2369,14758137,1680,1769,Outcome (Study Endpoint),increased risk of solid tumors relative to radiotherapy to only one side of the diaphragm,human,n,too much,stan
2370,14998380,36,46,Drug Intervention,formoterol,model,y,,cjackson
2371,14998380,54,64,Intervention Administration,Turbuhaler,model,y,,cjackson
2372,14998380,79,89,Drug Intervention,salmeterol,model,y,,cjackson
2373,14998380,197,207,Drug Intervention,formoterol,human,y,,cjackson
2374,14998380,231,241,Drug Intervention,salmeterol,human,y,,cjackson
2375,14998380,267,275,Group Characteristic,children,human,y,,cjackson
2376,14998380,281,287,Disease/Condition of Interest,asthma,human,y,,cjackson
2377,14998380,391,416,Group Characteristic,moderate-to-severe asthma,model,n,wrong label,cjackson
2378,14998380,559,572,Intervention Administration,metered doses,model,y,,cjackson
2379,14998380,597,609,Intervention Administration,metered dose,model,y,,cjackson
2380,14998380,614,621,Drug Intervention,placebo,human,n,wrong label,cjackson
2381,14998380,957,961,Outcome (Study Endpoint),FEV1,human,y,,cjackson
2382,14998380,976,983,Group Name,placebo,model,y,,cjackson
2383,14998380,1074,1091,Outcome (Study Endpoint),average 12-h FEV1,model,n,too much,cjackson
2384,14998380,1082,1091,Outcome (Study Endpoint),12-h FEV1,human,n,too much,cjackson
2385,14998946,0,9,Intervention Duration,Six-month,model,y,,hcho
2386,14998946,88,93,Group Characteristic,women,human,y,,hcho
2387,14998946,217,230,Drug Intervention,dexamethasone,human,y,,hcho
2388,14998946,234,249,Outcome (Study Endpoint),androgen levels,human,y,,hcho
2389,14998946,291,295,Disease/Condition of Interest,PCOS,human,n,,hcho
2390,14998946,310,340,Non-Pharmaceutical Intervention,diet and lifestyle counselling,human,y,,hcho
2391,14998946,453,458,Group Characteristic,women,human,y,,hcho
2392,14998946,526,533,Group Name,placebo,human,y,wrong label,hcho
2393,14998946,561,565,Non-Pharmaceutical Intervention,diet,model,n,too little,hcho
2394,14998946,570,591,Non-Pharmaceutical Intervention,lifestyle counselling,model,n,too little,hcho
2395,14998946,609,618,Drug Intervention,metformin,model,n,wrong label,hcho
2396,14998946,696,711,Outcome (Study Endpoint),androgen levels,human,y,,hcho
2397,14998946,713,734,Outcome (Study Endpoint),body mass index (BMI),human,y,,hcho
2398,14998946,736,753,Outcome (Study Endpoint),insulin c-peptide,human,y,,hcho
2399,14998946,755,770,Outcome (Study Endpoint),fasting glucose,human,y,,hcho
2400,14998946,775,787,Outcome (Study Endpoint),serum lipids,human,y,,hcho
2401,14998946,871,884,Drug Intervention,dexamethasone,human,y,,hcho
2402,14998946,1015,1020,Group Characteristic,women,human,y,,hcho
2403,14998946,1186,1199,Drug Intervention,dexamethasone,human,y,,hcho
2404,14998946,1245,1262,Group Characteristic,metformin-treated,human,y,,hcho
2405,14998946,1268,1273,Group Characteristic,women,human,y,,hcho
2406,14999200,378,381,Disease/Condition of Interest,AMI,human,y,,ccurtis
2407,14999200,647,650,Disease/Condition of Interest,AMI,model,y,,ccurtis
2408,14999200,810,818,Drug Intervention,losartan,model,y,,ccurtis
2409,14999200,832,841,Drug Intervention,captopril,model,y,,ccurtis
2410,14999200,1132,1136,Outcome (Study Endpoint),WMSI,model,y,,ccurtis
2411,14999200,1132,1146,Outcome (Study Endpoint),WMSI decreased,human,n,too much,ccurtis
2412,14999200,1172,1185,Quantitative Measurement,1.58 +/- 0.23,model,y,,ccurtis
2413,14999200,1189,1202,Quantitative Measurement,1.52 +/- 0.26,model,y,,ccurtis
2414,14999200,1204,1211,Statistical Significance,P =.009,model,y,,ccurtis
2415,14999200,1223,1236,Quantitative Measurement,1.60 +/- 0.24,model,y,,ccurtis
2416,14999200,1240,1253,Quantitative Measurement,1.48 +/- 0.22,model,y,,ccurtis
2417,14999200,1255,1262,Statistical Significance,P <.001,model,y,,ccurtis
2418,14999200,1413,1417,Outcome (Study Endpoint),E-DT,model,y,,ccurtis
2419,14999200,1507,1517,Quantitative Measurement,193 +/- 61,model,y,,ccurtis
2420,14999200,1518,1520,Units,ms,model,y,,ccurtis
2421,14999200,1524,1534,Quantitative Measurement,208 +/- 70,model,y,,ccurtis
2422,14999200,1535,1537,Units,ms,model,y,,ccurtis
2423,14999200,1539,1545,Statistical Significance,P =.05,model,y,,ccurtis
2424,14999200,1552,1566,Outcome (Study Endpoint),change in E-DT,human,n,too much,ccurtis
2425,14999200,1562,1566,Outcome (Study Endpoint),E-DT,model,y,,ccurtis
2426,14999200,1668,1677,Outcome (Study Endpoint),Tei index,model,y,,ccurtis
2427,14999200,1668,1687,Outcome (Study Endpoint),Tei index decreased,human,n,too much,ccurtis
2428,14999200,1713,1726,Quantitative Measurement,0.59 +/- 0.13,model,y,,ccurtis
2429,14999200,1730,1743,Quantitative Measurement,0.55 +/- 0.15,model,y,,ccurtis
2430,14999200,1745,1751,Statistical Significance,P =.04,model,y,,ccurtis
2431,14999200,1763,1776,Quantitative Measurement,0.62 +/- 0.15,model,y,,ccurtis
2432,14999200,1780,1793,Quantitative Measurement,0.55 +/- 0.13,model,y,,ccurtis
2433,14999200,1795,1802,Statistical Significance,P <.001,model,y,,ccurtis
2434,15066135,0,35,Drug Intervention,Nonsteroidal anti-inflammatory drug,model,y,,stan
2435,15066135,36,43,Disease/Condition of Interest,induced,model,n,too little,stan
2436,15066135,44,56,Disease/Condition of Interest,liver injury,model,n,too little,stan
2437,15066135,104,140,Drug Intervention,nonsteroidal anti-inflammatory drugs,model,y,,stan
2438,15066135,142,148,Drug Intervention,NSAIDs,model,y,,stan
2439,15066135,1030,1041,Quantitative Measurement,2.9 +/- 2.2,human,y,,stan
2440,15066135,1046,1057,Quantitative Measurement,1.8 +/- 1.8,human,y,,stan
2441,15066135,1084,1094,Statistical Significance,P < 10(-4),human,y,,stan
2442,15066135,1248,1251,Group Characteristic,men,human,y,,stan
2443,15066135,1253,1255,Type of Quant. Measure,OR,model,y,,stan
2444,15066135,1288,1290,Sample Size,22,model,y,,stan
2445,15066135,1313,1319,Drug Intervention,NSAIDs,model,y,,stan
2446,15066135,1330,1335,Sample Size,seven,model,y,,stan
2447,15066135,1361,1372,Drug Intervention,salicylates,model,n,wrong label,stan
2448,15066135,1374,1378,Sample Size,five,model,y,,stan
2449,15066135,1382,1392,Drug Intervention,diclofenac,model,n,wrong label,stan
2450,15066135,1394,1398,Sample Size,four,model,y,,stan
2451,15066135,1402,1411,Drug Intervention,ibuprofen,model,n,wrong label,stan
2452,15066135,1413,1417,Sample Size,four,model,y,,stan
2453,15066135,1421,1431,Drug Intervention,ketoprofen,model,n,wrong label,stan
2454,15066135,1433,1436,Sample Size,two,model,y,,stan
2455,15066135,1440,1453,Drug Intervention,niflumic acid,model,n,wrong label,stan
2456,15066135,1455,1458,Sample Size,one,model,y,,stan
2457,15066135,1462,1474,Drug Intervention,flurbiprofen,model,n,wrong label,stan
2458,15066135,1479,1482,Sample Size,one,model,y,,stan
2459,15066135,1486,1495,Drug Intervention,meloxicam,model,n,wrong label,stan
2460,15066135,1497,1500,Sample Size,two,model,y,,stan
2461,15066135,1649,1663,Side Effects,hepatocellular,human,y,,stan
2462,15066135,1673,1684,Side Effects,cholestatic,human,y,,stan
2463,15066135,1694,1699,Side Effects,mixed,human,y,,stan
2464,15070633,41,52,Drug Intervention,amoxicillin,model,y,,cjackson
2465,15070633,57,77,Disease/Condition of Interest,non-severe pneumonia,model,y,,cjackson
2466,15070633,81,95,Group Characteristic,young children,model,y,,cjackson
2467,15070633,212,216,Intervention Administration,oral,model,y,,cjackson
2468,15070633,399,403,Sample Size,2188,model,y,,cjackson
2469,15070633,404,412,Group Characteristic,children,model,y,,cjackson
2470,15070633,413,429,Group Characteristic,aged 2-59 months,model,y,,cjackson
2471,15070633,431,435,Sample Size,1095,model,y,,cjackson
2472,15070633,470,474,Sample Size,1093,model,y,,cjackson
2473,15070633,481,490,Intervention Duration,five days,model,y,,cjackson
2474,15070633,492,496,Intervention Administration,Oral,model,y,,cjackson
2475,15070633,497,508,Drug Intervention,amoxicillin,model,y,,cjackson
2476,15070633,509,514,Dosage,31-54,model,y,,cjackson
2477,15070633,515,520,Units,mg/kg,model,y,,cjackson
2478,15070633,521,524,Intervention Frequency,day,model,y,,cjackson
2479,15070633,796,815,Outcome (Study Endpoint),clinical cure rates,model,y,,cjackson
2480,15070633,821,831,Disease/Condition of Interest,three days,human,n,wrong label,cjackson
2481,15070633,836,845,Disease/Condition of Interest,five days,human,n,wrong label,cjackson
2482,15070633,864,869,Quantitative Measurement,89.5%,model,y,,cjackson
2483,15070633,874,879,Quantitative Measurement,89.9%,model,y,,cjackson
2484,15070633,895,914,Type of Quant. Measure,absolute difference,model,y,,cjackson
2485,15070633,920,943,Type of Quant. Measure,95% confidence interval,model,y,,cjackson
2486,15070633,959,989,Outcome (Study Endpoint),Adherence to treatment regimen,model,y,,cjackson
2487,15070633,994,997,Quantitative Measurement,94%,model,y,,cjackson
2488,15070633,1002,1005,Quantitative Measurement,85%,model,y,,cjackson
2489,15070633,1010,1019,Intervention Duration,three day,human,y,,cjackson
2490,15070633,1024,1032,Intervention Duration,five day,human,y,,cjackson
2491,15070633,1182,1185,Quantitative Measurement,225,human,y,,cjackson
2492,15070633,1187,1192,Quantitative Measurement,10.3%,model,y,,cjackson
2493,15070633,1194,1211,Outcome (Study Endpoint),clinical failures,model,y,,cjackson
2494,15070633,1216,1219,Quantitative Measurement,106,human,y,,cjackson
2495,15070633,1221,1225,Quantitative Measurement,5.3%,model,y,,cjackson
2496,15070633,1227,1235,Outcome (Study Endpoint),relapses,model,y,,cjackson
2497,15070633,1323,1363,Outcome (Study Endpoint),positive for respiratory syncytial virus,human,y,,cjackson
2498,15070633,1590,1609,Type of Quant. Measure,adjusted odds ratio,model,y,,cjackson
2499,15070633,1599,1609,Type of Quant. Measure,odds ratio,human,n,too little,cjackson
2500,15070633,1610,1614,Quantitative Measurement,1.95,model,y,,cjackson
2501,15070633,1616,1639,Type of Quant. Measure,95% confidence interval,model,y,,cjackson
2502,15070633,1654,1700,Outcome (Study Endpoint),excess respiratory rate of > 10 breaths/minute,model,y,,cjackson
2503,15070633,1728,1741,Outcome (Study Endpoint),non-adherence,model,y,,cjackson
2504,15070633,1887,1907,Disease/Condition of Interest,non-severe pneumonia,human,y,,cjackson
2505,15222407,227,256,Disease/Condition of Interest,familial hypercholesterolemia,human,y,,hcho
2506,15222407,236,256,Disease/Condition of Interest,hypercholesterolemia,model,n,too little,hcho
2507,15222407,537,549,Drug Intervention,atorvastatin,model,y,,hcho
2508,15222407,556,557,Dosage,),human,n,wrong label,hcho
2509,15222407,603,626,Outcome (Study Endpoint),LDL subfraction profile,human,y,,hcho
2510,15222407,638,655,Outcome (Study Endpoint),LDL oxidizability,human,y,,hcho
2511,15222407,671,713,Outcome (Study Endpoint),circulating autoantibodies to oxidized LDL,human,y,,hcho
2512,15222407,1008,1019,Type of Quant. Measure,correlation,human,y,,hcho
2513,15222407,1038,1058,Outcome (Study Endpoint),plasma triglycerides,model,n,not needed,hcho
2514,15222407,1092,1093,Type of Quant. Measure,r,model,y,,hcho
2515,15222407,1118,1131,Outcome (Study Endpoint),plasma levels,model,n,too little,hcho
2516,15222407,1153,1169,Outcome (Study Endpoint),small dense LDL3,model,y,,hcho
2517,15222407,1207,1208,Type of Quant. Measure,r,model,y,,hcho
2518,15222407,1211,1214,Quantitative Measurement,.11,human,y,,hcho
2519,15222407,1228,1235,Type of Quant. Measure,r = .15,model,n,too much,hcho
2520,15222407,1232,1235,Quantitative Measurement,.15,human,y,,hcho
2521,15222407,1491,1502,Drug Intervention,simvastatin,human,y,,hcho
2522,15222407,1962,1973,Drug Intervention,simvastatin,human,y,,hcho
2523,15222407,1975,1988,Outcome (Study Endpoint),Change of IMT,human,y,,hcho
2524,15222407,2050,2053,Quantitative Measurement,.41,human,y,,hcho
2525,15222407,2077,2081,Quantitative Measurement,-.20,human,y,,hcho
2526,15222407,2154,2157,Quantitative Measurement,.28,human,y,,hcho
2527,15255464,175,198,Disease/Condition of Interest,coronary artery disease,model,y,,ccurtis
2528,15255464,412,418,Group Characteristic,normal,model,y,,ccurtis
2529,15255464,475,487,Drug Intervention,atorvastatin,human,y,,ccurtis
2530,15255464,849,854,Outcome (Study Endpoint),LDL-C,model,y,,ccurtis
2531,15255464,969,971,Outcome (Study Endpoint),TC,model,y,,ccurtis
2532,15255464,976,981,Outcome (Study Endpoint),LDL-C,model,y,,ccurtis
2533,15262828,365,369,Dosage,600-,model,n,too much,eduvaris
2534,15262828,751,765,Group Characteristic,never received,model,y,,eduvaris
2535,15262828,751,777,Group Characteristic,never received clopidogrel,human,n,too much,eduvaris
2536,15262828,766,777,Drug Intervention,clopidogrel,model,y,,eduvaris
2537,15262828,779,788,Group Name,first-use,human,n,too little,eduvaris
2538,15262828,779,794,Group Name,first-use group,model,y,,eduvaris
2539,15262828,836,851,Group Characteristic,chronic therapy,model,y,,eduvaris
2540,15262828,859,864,Intervention Frequency,daily,human,y,,eduvaris
2541,15262828,859,869,Intervention Frequency,daily dose,model,n,too much,eduvaris
2542,15262828,895,908,Intervention Duration,> or =1 month,model,y,,eduvaris
2543,15262828,901,908,Intervention Duration,1 month,human,n,too little,eduvaris
2544,15262828,1007,1010,Dosage,600,human,y,,eduvaris
2545,15262828,1011,1013,Units,mg,human,y,,eduvaris
2546,15262828,1014,1025,Drug Intervention,clopidogrel,human,y,,eduvaris
2547,15262828,1078,1087,Group Name,first-use,model,n,too little,eduvaris
2548,15262828,1078,1093,Group Name,first-use group,human,y,,eduvaris
2549,15262828,1108,1111,Dosage,600,human,y,,eduvaris
2550,15262828,1112,1114,Units,mg,human,y,,eduvaris
2551,15262828,1115,1126,Drug Intervention,clopidogrel,human,y,,eduvaris
2552,15262828,1262,1265,Dosage,600,human,y,,eduvaris
2553,15262828,1266,1268,Units,mg,human,y,,eduvaris
2554,15262828,1269,1280,Drug Intervention,clopidogrel,human,y,,eduvaris
2555,15262828,1416,1418,Units,mg,human,y,,eduvaris
2556,15262828,1475,1478,Dosage,600,human,y,,eduvaris
2557,15262828,1479,1481,Units,mg,human,y,,eduvaris
2558,15262828,1482,1493,Drug Intervention,clopidogrel,human,y,,eduvaris
2559,15362794,72,116,Disease/Condition of Interest,gastric antral epithelial hyperproliferation,human,y,,stan
2560,15362794,132,141,Follow-up period,six-month,model,y,,stan
2561,15362794,159,168,Disease/Condition of Interest,H. pylori,model,n,wrong label,stan
2562,15362794,617,623,Disease/Condition of Interest,Triple,model,n,too little,stan
2563,15362794,617,643,Drug Intervention,Triple eradication therapy,human,y,,stan
2564,15362794,748,751,Follow-up period,six,model,n,too little,stan
2565,15362794,963,967,Quantitative Measurement,40.2,human,n,too little,stan
2566,15362794,963,968,Quantitative Measurement,40.2%,model,y,,stan
2567,15362794,967,968,Units,%,human,n,wrong label,stan
2568,15362794,1063,1082,Outcome (Study Endpoint),proliferative index,model,y,,stan
2569,15362794,1145,1149,Quantitative Measurement,25.5,human,n,too little,stan
2570,15362794,1145,1150,Quantitative Measurement,25.5%,model,y,,stan
2571,15362794,1149,1150,Units,%,human,n,wrong label,stan
2572,15389231,12,27,Outcome (Study Endpoint),levels of LDL-C,human,y,,hcho
2573,15389231,173,185,Drug Intervention,atorvastatin,model,y,,hcho
2574,15389231,276,303,Group Characteristic,high risk for heart disease,human,y,,cjackson
2575,15389231,304,316,Drug Intervention,atorvastatin,model,y,,hcho
2576,15389231,427,439,Drug Intervention,atorvastatin,model,y,,hcho
2577,15389231,626,628,Units,mg,human,y,,hcho
2578,15389231,626,632,Units,mg/day,model,n,multiple entities,hcho
2579,15389231,629,632,Intervention Frequency,day,human,y,,hcho
2580,15389231,679,691,Drug Intervention,atorvastatin,human,y,,cjackson
2581,15389231,815,838,Group Characteristic,not at their LDL-C goal,model,y,,cjackson
2582,15389231,1038,1044,Group Characteristic,adults,model,y,,cjackson
2583,15389231,1109,1155,Group Characteristic,multiple (> or =2) cardiovascular risk factors,model,y,,cjackson
2584,15389231,1128,1155,Group Characteristic,cardiovascular risk factors,human,n,too little,cjackson
2585,15389231,1258,1262,Dosage,/day,model,n,too much,cjackson
2586,15389231,1259,1262,Intervention Frequency,day,human,y,,cjackson
2587,15389231,1329,1341,Drug Intervention,atorvastatin,model,y,,cjackson
2588,15389231,1420,1421,Dosage,/,model,n,not needed,cjackson
2589,15389231,1493,1505,Drug Intervention,atorvastatin,model,y,,cjackson
2590,15389231,1544,1545,Intervention Duration,4,model,n,too little,cjackson
2591,15389231,1689,1691,Units,mg,human,y,,cjackson
2592,15389231,1689,1695,Units,mg/day,model,n,too much,cjackson
2593,15389231,1692,1695,Intervention Frequency,day,human,y,,cjackson
2594,15389231,1753,1755,Units,mg,human,y,,cjackson
2595,15389231,1753,1759,Units,mg/day,model,n,too much,cjackson
2596,15389231,1756,1759,Intervention Frequency,day,human,y,,cjackson
2597,15389231,1988,1990,Dosage,10,model,y,,cjackson
2598,15389231,1991,1993,Units,mg,model,y,,cjackson
2599,15389231,1994,1997,Intervention Frequency,day,model,y,,cjackson
2600,15389231,2001,2013,Drug Intervention,atorvastatin,model,y,,cjackson
2601,15389231,2024,2026,Units,mg,model,y,,cjackson
2602,15389231,2027,2030,Intervention Frequency,day,model,y,,cjackson
2603,15389231,2087,2125,Outcome (Study Endpoint),reaching their target LDL-C level goal,model,y,,cjackson
2604,15389231,2102,2125,Outcome (Study Endpoint),target LDL-C level goal,human,n,too little,cjackson
2605,15389231,2177,2194,Group Name,co-administration,human,n,too little,cjackson
2606,15488877,132,143,Drug Intervention,simvastatin,human,y,,ccurtis
2607,15488877,428,451,Group Characteristic,coronary artery disease,human,n,wrong label,ccurtis
2608,15488877,491,498,Group Name,placebo,human,y,wrong label,ccurtis
2609,15488877,567,587,Group Characteristic,hypercholesterolemic,model,y,,ccurtis
2610,15488877,709,726,Group Name,Simvastatin alone,model,y,,ccurtis
2611,15488877,730,738,Group Name,combined,model,y,,ccurtis
2612,15488877,965,978,Outcome (Study Endpoint),plasma levels,human,n,too little,ccurtis
2613,15488877,965,989,Outcome (Study Endpoint),plasma levels of nitrate,model,y,,ccurtis
2614,15488877,982,989,Outcome (Study Endpoint),nitrate,human,n,,ccurtis
2615,15488877,1744,1755,Drug Intervention,Simvastatin,model,y,,ccurtis
2616,15488877,1779,1787,Drug Intervention,ramipril,model,y,,ccurtis
2617,15488877,1888,1911,Disease/Condition of Interest,coronary artery disease,model,y,,ccurtis
2618,15531766,29,38,Drug Intervention,abciximab,model,y,,eduvaris
2619,15531766,80,115,Disease/Condition of Interest,percutaneous coronary interventions,human,n,not needed,eduvaris
2620,15531766,160,171,Drug Intervention,clopidogrel,model,n,wrong label,eduvaris
2621,15531766,173,181,Group Characteristic,Diabetic,model,y,,eduvaris
2622,15531766,355,364,Drug Intervention,abciximab,model,y,,eduvaris
2623,15531766,765,773,Group Characteristic,diabetic,model,y,,eduvaris
2624,15531766,816,872,Group Characteristic,underwent an elective percutaneous coronary intervention,human,n,too much,eduvaris
2625,15531766,829,872,Group Characteristic,elective percutaneous coronary intervention,model,y,,eduvaris
2626,15531766,899,902,Dosage,600,human,y,,eduvaris
2627,15531766,903,905,Units,mg,human,y,,eduvaris
2628,15531766,914,925,Non-Study Drug,clopidogrel,human,y,wrong label,eduvaris
2629,15531766,1026,1033,Drug Intervention,placebo,model,n,not needed,eduvaris
2630,15531766,1475,1490,Group Name,abciximab group,model,y,,eduvaris
2631,15531766,1508,1521,Group Name,placebo group,model,y,,eduvaris
2632,15531766,1539,1552,Type of Quant. Measure,relative risk,model,y,,eduvaris
2633,15531766,1562,1568,Type of Quant. Measure,95% CI,model,y,,eduvaris
2634,15531766,1589,1633,Outcome (Study Endpoint),incidence of target lesion revascularization,model,y,,eduvaris
2635,15531766,1638,1643,Quantitative Measurement,23.2%,model,y,,eduvaris
2636,15531766,1651,1666,Group Name,abciximab group,model,y,,eduvaris
2637,15531766,1671,1676,Quantitative Measurement,30.4%,model,y,,eduvaris
2638,15531766,1684,1697,Group Name,placebo group,model,y,,eduvaris
2639,15531766,1699,1705,Statistical Significance,P=0.03,model,y,,eduvaris
2640,15531766,1774,1783,Drug Intervention,abciximab,model,y,,eduvaris
2641,15531766,2043,2052,Drug Intervention,abciximab,model,y,,eduvaris
2642,15750445,220,223,Disease/Condition of Interest,ALL,human,y,,stan
2643,15750445,264,265,Intervention Duration,4,model,n,too little,stan
2644,15750445,264,270,Intervention Duration,4-week,human,y,,stan
2645,15750445,590,598,Group Characteristic,children,model,y,,stan
2646,15750445,629,639,Drug Intervention,prednisone,model,y,,stan
2647,15750445,643,656,Drug Intervention,dexamethasone,model,y,,stan
2648,15750445,737,739,Sample Size,28,human,y,,stan
2649,15750445,758,771,Drug Intervention,dexamethasone,model,y,,stan
2650,15750445,785,787,Sample Size,35,human,y,,stan
2651,15750445,799,809,Drug Intervention,prednisone,model,y,,stan
2652,15750445,831,870,Outcome (Study Endpoint),at least one steroid withdrawal symptom,human,y,,stan
2653,15750445,957,976,Group Name,dexamethasone group,model,y,,stan
2654,15750445,1000,1016,Group Name,prednisone group,model,y,,stan
2655,15750445,1228,1246,Outcome (Study Endpoint),performance status,model,y,,stan
2656,15750445,1259,1267,Statistical Significance,P < 0.05,model,y,,stan
2657,15857327,11,21,Drug Intervention,amlodipine,model,y,,cjackson
2658,15857327,26,36,Drug Intervention,fosinopril,model,y,,cjackson
2659,15857327,109,131,Disease/Condition of Interest,essential hypertension,model,n,too little,cjackson
2660,15857327,356,395,Disease/Condition of Interest,mild-to-moderate essential hypertension,human,y,,cjackson
2661,15857327,647,657,Drug Intervention,amlodipine,model,y,,cjackson
2662,15857327,661,671,Drug Intervention,fosinopril,model,y,,cjackson
2663,15857327,986,996,Group Name,amlodipine,human,n,wrong label,cjackson
2664,15857327,986,1002,Group Name,amlodipine group,model,y,,cjackson
2665,15857327,1107,1118,Outcome (Study Endpoint),third month,human,n,not needed,cjackson
2666,15857327,1163,1174,Outcome (Study Endpoint),sixth month,human,n,not needed,cjackson
2667,15857327,1192,1202,Group Name,fosinopril,human,n,wrong label,cjackson
2668,15857327,1192,1208,Group Name,fosinopril group,model,y,,cjackson
2669,15857327,1369,1375,Units,g/m(2),human,y,,cjackson
2670,15857327,1473,1479,Quantitative Measurement,101 +/,model,n,too little,cjackson
2671,15864242,0,11,Drug Intervention,Simvastatin,model,y,,hcho
2672,15864242,403,422,Disease/Condition of Interest,in-stent restenosis,model,y,,hcho
2673,15864242,424,427,Disease/Condition of Interest,ISR,model,y,,hcho
2674,15864242,826,854,Group Name,simvastatin-treated patients,model,n,wrong label,hcho
2675,15864242,883,889,Statistical Significance,P = NS,model,y,,hcho
2676,15864242,1054,1060,Statistical Significance,P = NS,model,y,,hcho
2677,15864242,1173,1179,Units,mm3/mm,model,y,,hcho
2678,15864242,1251,1291,Outcome (Study Endpoint),intermediate plaques at nonstented sites,human,y,,hcho
2679,15864242,1275,1291,Outcome (Study Endpoint),nonstented sites,model,n,too little,hcho
2680,15864242,1322,1328,Units,mm3/mm,model,y,,hcho
2681,15917383,43,50,Drug Intervention,Statins,human,y,,ccurtis
2682,15917383,154,161,Drug Intervention,Statins,human,y,,ccurtis
2683,15917383,448,478,Group Characteristic,diagnosis of colorectal cancer,model,n,too much,ccurtis
2684,15917383,461,497,Group Characteristic,colorectal cancer in northern Israel,human,n,too much,ccurtis
2685,15917383,482,497,Group Characteristic,northern Israel,model,n,not needed,ccurtis
2686,15917383,506,510,Study Years,1998,model,n,not needed,ccurtis
2687,15917383,506,519,Study Years,1998 and 2004,human,n,not needed,ccurtis
2688,15917383,897,903,Outcome (Study Endpoint),use of,model,n,not needed,ccurtis
2689,15917383,925,935,Intervention Duration,five years,human,y,,ccurtis
2690,15917383,986,1042,Outcome (Study Endpoint),significantly reduced relative risk of colorectal cancer,human,n,too much,ccurtis
2691,15917383,1008,1042,Outcome (Study Endpoint),relative risk of colorectal cancer,model,y,,ccurtis
2692,15917383,1062,1092,Statistical Significance,95 percent confidence interval,human,n,wrong label,ccurtis
2693,15917383,1404,1414,Type of Quant. Measure,odds ratio,model,y,,ccurtis
2694,15917383,1422,1452,Statistical Significance,95 percent confidence interval,human,n,wrong label,ccurtis
2695,15917383,1480,1577,Outcome (Study Endpoint),fibric-acid derivatives was not associated with a significantly reduced risk of colorectal cancer,human,n,too much,ccurtis
2696,15917383,1552,1577,Outcome (Study Endpoint),risk of colorectal cancer,model,y,,ccurtis
2697,15917383,1597,1627,Type of Quant. Measure,95 percent confidence interval,model,y,wrong label,ccurtis
2698,15917383,1716,1728,Quantitative Measurement,96.5 percent,model,y,,ccurtis
2699,15917383,1843,1940,Outcome (Study Endpoint),relative reduction in the risk of colorectal cancer after adjustment for other known risk factors,human,n,too much,ccurtis
2700,15960573,69,81,Drug Intervention,escitalopram,model,y,,eduvaris
2701,15960573,184,196,Drug Intervention,escitalopram,human,y,,eduvaris
2702,15960573,261,292,Disease/Condition of Interest,premenstrual dysphoric disorder,human,y,,eduvaris
2703,15960573,320,352,Group Characteristic,meeting DSM-IV criteria for PMDD,human,y,,eduvaris
2704,15960573,418,421,Sample Size,N =,model,n,too much,eduvaris
2705,15960573,444,450,Sample Size,N = 14,model,n,too much,eduvaris
2706,15960573,448,450,Sample Size,14,human,y,,eduvaris
2707,15960573,494,524,Intervention Duration,3 consecutive menstrual cycles,human,y,,eduvaris
2708,15960573,558,566,Disease/Condition of Interest,November,human,n,wrong label,eduvaris
2709,15960573,558,584,Study Years,November 2002 to July 2003,model,y,,eduvaris
2710,15960573,567,571,Disease/Condition of Interest,2002,human,n,wrong label,eduvaris
2711,15960573,572,584,Study Duration,to July 2003,human,n,wrong label,eduvaris
2712,15960573,925,937,Group Name,Luteal phase,human,n,too little,eduvaris
2713,15960573,942,955,Group Name,symptom-onset,human,n,too little,eduvaris
2714,15960573,972,984,Drug Intervention,escitalopram,human,y,,eduvaris
2715,15960573,991,1016,Intervention Duration,mean of 13.5 and 6.0 days,human,n,multiple entities,eduvaris
2716,15960573,999,1003,Quantitative Measurement,13.5,model,n,wrong label,eduvaris
2717,15960573,1008,1011,Quantitative Measurement,6.0,model,n,wrong label,eduvaris
2718,15960573,1012,1016,Units,days,model,n,wrong label,eduvaris
2719,15960573,1051,1063,Quantitative Measurement,15.2 +/- 5.1,human,n,not needed,eduvaris
2720,15960573,1064,1066,Units,mg,model,n,not needed,eduvaris
2721,15960573,1064,1070,Units,mg/day,human,n,not needed,eduvaris
2722,15960573,1102,1131,Outcome (Study Endpoint),Total premenstrual DSR scores,model,y,,eduvaris
2723,15960573,1102,1168,Outcome (Study Endpoint),Total premenstrual DSR scores significantly improved from baseline,human,n,too much,eduvaris
2724,15960573,1208,1226,Group Name,luteal phase group,human,y,,eduvaris
2725,15960573,1253,1272,Group Name,symptom-onset group,human,y,,eduvaris
2726,15960573,1296,1339,Outcome (Study Endpoint),DSR score decrease > or = 50% from baseline,human,y,,eduvaris
2727,15960573,1363,1365,Sample Size,13,human,y,,eduvaris
2728,15960573,1366,1374,Units,patients,human,n,not needed,eduvaris
2729,15960573,1382,1400,Group Name,luteal phase group,human,y,,eduvaris
2730,15960573,1410,1412,Sample Size,14,human,y,,eduvaris
2731,15960573,1429,1448,Group Name,symptom-onset group,human,y,,eduvaris
2732,15960573,1502,1521,Group Name,symptom-onset group,human,y,,eduvaris
2733,15960573,1668,1680,Drug Intervention,Escitalopram,human,y,,eduvaris
2734,15960573,1751,1752,Sample Size,2,human,n,not needed,eduvaris
2735,15960573,1825,1856,Disease/Condition of Interest,Premenstrual dysphoric disorder,human,y,,eduvaris
2736,15960573,1932,1944,Drug Intervention,escitalopram,human,y,,eduvaris
2737,15960573,1969,1973,Disease/Condition of Interest,PMDD,human,y,,eduvaris
2738,15962651,70,79,Group Characteristic,diabetics,model,y,,stan
2739,15962651,360,377,Group Characteristic,Type II diabetics,model,y,,stan
2740,15962651,384,414,Group Characteristic,no prior cardiovascular events,model,y,,stan
2741,15962651,419,469,Group Characteristic,total cholesterol at admission of < or = 200 mg/dl,human,y,,stan
2742,15962651,419,493,Group Characteristic,total cholesterol at admission of < or = 200 mg/dl or LDL < or = 140 mg/dl,model,n,too much,stan
2743,15962651,473,493,Group Characteristic,LDL < or = 140 mg/dl,human,y,,stan
2744,15962651,634,658,Outcome (Study Endpoint),flow-mediated dilatation,human,y,,stan
2745,15962651,786,798,Follow-up period,thirty weeks,model,n,,stan
2746,15962651,895,907,Intervention Duration,thirty weeks,model,y,,stan
2747,15962651,926,929,Outcome (Study Endpoint),FMD,model,y,,stan
2748,15962651,1278,1293,Disease/Condition of Interest,type 2 diabetes,model,y,,stan
2749,15968928,36,47,Intervention Administration,intravenous,human,y,,cjackson
2750,15968928,36,62,Non-Pharmaceutical Intervention,intravenous immunoglobulin,model,n,too much,cjackson
2751,15968928,48,62,Non-Pharmaceutical Intervention,immunoglobulin,human,y,,cjackson
2752,15968928,435,461,Non-Pharmaceutical Intervention,intravenous immunoglobulin,model,n,too much,cjackson
2753,15968928,465,480,Non-Pharmaceutical Intervention,plasma exchange,model,y,,cjackson
2754,15968928,887,897,Drug Intervention,prednisone,human,y,wrong label,cjackson
2755,15968928,933,942,Outcome (Study Endpoint),decreased,human,n,not needed,cjackson
2756,15968928,957,983,Group Name,intravenous immunoglobulin,model,n,wrong label,cjackson
2757,15968928,957,989,Group Name,intravenous immunoglobulin group,human,y,,cjackson
2758,15968928,1002,1008,Group Name,plasma,model,n,too little,cjackson
2759,15968928,1002,1023,Group Name,plasma exchange group,human,y,,cjackson
2760,15968928,1040,1050,Group Name,prednisone,model,n,too little,cjackson
2761,15968928,1040,1056,Group Name,prednisone group,human,y,,cjackson
2762,15975312,32,44,Drug Intervention,Shengxueling,human,y,,hcho
2763,15975312,119,131,Drug Intervention,Shengxueling,human,y,,hcho
2764,15975312,133,136,Drug Intervention,SXL,human,y,,hcho
2765,15975312,141,176,Disease/Condition of Interest,idiopathic thrombocytopenic purpura,model,y,,hcho
2766,15975312,238,241,Group Characteristic,ITP,human,n,wrong label,hcho
2767,15975312,595,596,Intervention Duration,3,model,n,too little,hcho
2768,15975312,689,702,Group Name,control group,human,y,,hcho
2769,15975312,727,728,Intervention Duration,6,model,n,wrong label,hcho
2770,16003231,104,117,Drug Intervention,thymoglobulin,model,y,,ccurtis
2771,16003231,121,137,Group Characteristic,renal transplant,model,n,wrong label,ccurtis
2772,16003231,182,192,Drug Intervention,tacrolimus,model,y,,ccurtis
2773,16003231,194,197,Drug Intervention,TAC,model,y,,ccurtis
2774,16003231,206,218,Drug Intervention,cyclosporine,model,y,,ccurtis
2775,16003231,229,232,Drug Intervention,CsA,model,y,,ccurtis
2776,16003231,926,929,Group Name,TAC,human,n,too little,ccurtis
2777,16003231,926,935,Group Name,TAC group,model,y,,ccurtis
2778,16003231,954,957,Group Name,CsA,human,n,too little,ccurtis
2779,16003231,954,963,Group Name,CsA group,model,y,,ccurtis
2780,16003231,1009,1035,Outcome (Study Endpoint),incidence of CMV infection,human,n,too much,ccurtis
2781,16003231,1188,1233,Outcome (Study Endpoint),incidence of posttransplant diabetes mellitus,human,n,too much,ccurtis
2782,16003231,1201,1233,Outcome (Study Endpoint),posttransplant diabetes mellitus,model,y,,ccurtis
2783,16003231,1311,1333,Outcome (Study Endpoint),dyslipidemia treatment,model,y,,ccurtis
2784,16003231,1335,1338,Quantitative Measurement,40%,model,y,,ccurtis
2785,16003231,1347,1350,Quantitative Measurement,67%,model,y,,ccurtis
2786,16003231,1356,1364,Statistical Significance,P=0.0005,model,y,,ccurtis
2787,16003231,1404,1433,Outcome (Study Endpoint),discontinue these medications,model,n,not needed,ccurtis
2788,16003231,1466,1469,Quantitative Measurement,25%,model,y,,ccurtis
2789,16003231,1478,1481,Quantitative Measurement,47%,model,y,,ccurtis
2790,16003231,1488,1519,Outcome (Study Endpoint),Total 12-month medication costs,model,n,too much,ccurtis
2791,16003231,1494,1519,Outcome (Study Endpoint),12-month medication costs,human,y,,ccurtis
2792,16138566,107,136,Disease/Condition of Interest,cardiovascular organ injuries,model,y,,eduvaris
2793,16138566,460,482,Disease/Condition of Interest,essential hypertension,human,n,wrong label,eduvaris
2794,16138566,643,646,Drug Intervention,ARB,model,n,not needed,eduvaris
2795,16138566,689,691,Sample Size,22,human,y,,eduvaris
2796,16138566,754,756,Sample Size,21,human,y,,eduvaris
2797,16138566,1134,1165,Outcome (Study Endpoint),average systolic blood pressure,human,y,,eduvaris
2798,16138566,1134,1178,Outcome (Study Endpoint),average systolic blood pressure of 24-h ABPM,model,n,too much,eduvaris
2799,16138566,1483,1487,Units,g/m2,human,y,,eduvaris
2800,16138566,1882,1886,Units,mg/g,model,y,,eduvaris
2801,16138566,1882,1897,Units,mg/g creatinine,human,n,too much,eduvaris
2802,16224054,0,27,Disease/Condition of Interest,Severe hypercholesterolemia,model,y,,cjackson
2803,16224054,7,27,Disease/Condition of Interest,hypercholesterolemia,human,n,too little,cjackson
2804,16224054,36,43,Group Characteristic,British,model,y,,cjackson
2805,16224054,163,171,Follow-up period,30 years,model,n,wrong label,cjackson
2806,16224054,298,303,Group Characteristic,white,human,y,,cjackson
2807,16224054,338,343,Group Characteristic,white,human,y,,cjackson
2808,16224054,344,351,Group Characteristic,British,human,y,,cjackson
2809,16224054,366,408,Group Characteristic,heterozygous familial hypercholesterolemia,human,n,wrong label,cjackson
2810,16224054,425,496,Group Characteristic,3 specific mutations in the low-density lipoprotein (LDL) receptor gene,human,y,,cjackson
2811,16224054,541,545,Group Name,PCSK,model,n,not needed,cjackson
2812,16224054,600,607,Outcome (Study Endpoint),younger,human,n,wrong label,cjackson
2813,16224054,611,623,Outcome (Study Endpoint),presentation,human,n,not needed,cjackson
2814,16224054,684,721,Outcome (Study Endpoint),pretreatment serum cholesterol levels,human,y,,cjackson
2815,16224054,974,987,Non-Pharmaceutical Intervention,LDL apheresis,model,y,,cjackson
2816,16224054,992,1012,Non-Pharmaceutical Intervention,partial ileal bypass,model,y,,cjackson
2817,16224054,1088,1151,Outcome (Study Endpoint),affected >10 years earlier by premature coronary artery disease,human,n,not needed,cjackson
2818,16224054,1118,1151,Outcome (Study Endpoint),premature coronary artery disease,model,n,too little,cjackson
2819,16224054,1171,1177,Quantitative Measurement,46.8+/,model,n,too little,cjackson
2820,16224054,1171,1181,Quantitative Measurement,46.8+/-8.9,human,y,,cjackson
2821,16521637,48,60,Drug Intervention,atorvastatin,model,y,,hcho
2822,16521637,118,122,Quantitative Measurement,9.7%,model,y,,ccurtis
2823,16521637,231,236,Quantitative Measurement,13.9%,model,y,,ccurtis
2824,16521637,251,256,Group Name,study,model,n,too little,ccurtis
2825,16521637,358,363,Quantitative Measurement,4.05%,model,y,,ccurtis
2826,16521637,471,476,Quantitative Measurement,3.57%,model,y,,ccurtis
2827,16521637,487,500,Group Name,placebo group,model,y,,ccurtis
2828,16521637,521,525,Statistical Significance,p=NS,model,y,,ccurtis
2829,16521637,587,634,Group Characteristic,angiographically proven coronary artery disease,human,n,,hcho
2830,16521637,611,634,Disease/Condition of Interest,coronary artery disease,model,y,,hcho
2831,16521637,650,665,Disease/Condition of Interest,atherosclerosis,model,y,,ccurtis
2832,16521637,795,802,Drug Intervention,placebo,model,n,wrong label,hcho
2833,16521637,1182,1185,Follow-up period,one,human,n,too little,hcho
2834,16521637,1182,1190,Follow-up period,one year,model,y,,hcho
2835,16521637,1186,1190,Units,year,human,n,wrong label,hcho
2836,16521637,1206,1210,Outcome (Study Endpoint),mean,model,n,wrong label,hcho
2837,16521637,1364,1385,Outcome (Study Endpoint),common carotid artery,human,n,wrong label,hcho
2838,16521637,1408,1434,Outcome (Study Endpoint),common carotid bifurcation,human,n,wrong label,hcho
2839,16521637,1457,1480,Outcome (Study Endpoint),internal carotid artery,human,n,wrong label,hcho
2840,16521637,1555,1576,Outcome (Study Endpoint),common carotid artery,human,n,wrong label,hcho
2841,16521637,1597,1623,Outcome (Study Endpoint),common carotid bifurcation,human,n,wrong label,hcho
2842,16521637,1642,1665,Outcome (Study Endpoint),internal carotid artery,human,n,wrong label,hcho
2843,16521637,1820,1830,Type of Quant. Measure,difference,human,y,,hcho
2844,16521637,1831,1837,Quantitative Measurement,-0.013,human,y,,hcho
2845,16521637,1919,1929,Type of Quant. Measure,difference,human,y,,hcho
2846,16709310,165,182,Disease/Condition of Interest,myasthenia gravis,model,y,,eduvaris
2847,16709310,184,186,Disease/Condition of Interest,MG,model,y,,eduvaris
2848,16709310,474,484,Drug Intervention,tacrolimus,model,y,,eduvaris
2849,16709310,706,711,Units,mg/kg,model,y,,eduvaris
2850,16709310,706,719,Units,mg/kg per day,human,n,multiple entities,eduvaris
2851,16709310,778,783,Units,mg/kg,model,y,,eduvaris
2852,16709310,778,784,Units,mg/kg/,human,n,too much,eduvaris
2853,16709310,905,906,Intervention Duration,1,model,n,too little,eduvaris
2854,16709310,1054,1057,Dosage,4.9,model,n,not needed,eduvaris
2855,16709310,1058,1060,Units,mg,model,n,not needed,eduvaris
2856,16709310,1061,1064,Intervention Frequency,day,model,n,not needed,eduvaris
2857,16709310,1125,1128,Dosage,7.6,model,n,not needed,eduvaris
2858,16709310,1129,1134,Units,ng/mL,model,n,not needed,eduvaris
2859,16709310,1208,1213,Quantitative Measurement,93.7%,model,n,not needed,eduvaris
2860,16709310,1244,1248,Quantitative Measurement,100%,model,n,not needed,eduvaris
2861,16709310,1273,1284,Follow-up period,24.4 months,model,y,,eduvaris
2862,16709310,1417,1426,Statistical Significance,p < 0.001,model,y,,eduvaris
2863,16709310,1473,1477,Quantitative Measurement,33.4,human,n,too little,eduvaris
2864,16709310,1473,1478,Quantitative Measurement,33.4%,model,y,,eduvaris
2865,16709310,1477,1478,Units,%,human,n,wrong label,eduvaris
2866,16709310,1492,1517,Outcome (Study Endpoint),pharmacological remission,model,y,,eduvaris
2867,16709310,1521,1526,Quantitative Measurement,62.6%,model,y,,eduvaris
2868,16709310,1525,1526,Units,%,human,n,wrong label,eduvaris
2869,16709310,1528,1530,Quantitative Measurement,4%,model,y,,eduvaris
2870,16709310,1664,1675,Follow-up period,37.9 months,model,n,wrong label,eduvaris
2871,16709310,1706,1715,Quantitative Measurement,26.4-49.5,model,y,,eduvaris
2872,16709310,1729,1751,Outcome (Study Endpoint),overall crude CSR rate,human,y,,eduvaris
2873,16709310,1768,1771,Quantitative Measurement,47%,model,y,,eduvaris
2874,16709310,1844,1847,Quantitative Measurement,67%,model,y,,eduvaris
2875,16709310,1856,1859,Group Name,non,model,n,too little,eduvaris
2876,16799799,11,26,Drug Intervention,corticosteroids,human,y,,stan
2877,16799799,155,170,Drug Intervention,corticosteroids,human,y,,stan
2878,16799799,172,175,Drug Intervention,ICS,human,y,,stan
2879,16799799,250,253,Drug Intervention,ICS,human,y,,stan
2880,16799799,318,329,Group Characteristic,prepubertal,model,y,,stan
2881,16799799,318,332,Group Characteristic,prepubertal CF,human,y,,stan
2882,16799799,468,475,Drug Intervention,placebo,model,n,wrong label,stan
2883,16799799,528,532,Type of Quant. Measure,mean,human,y,,stan
2884,16799799,583,584,Quantitative Measurement,8,model,n,too little,stan
2885,16799799,583,586,Quantitative Measurement,8.2,human,y,,stan
2886,16799799,588,591,Quantitative Measurement,0.6,human,y,,stan
2887,16799799,593,598,Units,years,human,n,wrong label,stan
2888,16799799,624,625,Quantitative Measurement,9,model,n,too little,stan
2889,16799799,624,627,Quantitative Measurement,9.0,human,y,,stan
2890,16799799,629,632,Quantitative Measurement,0.5,human,y,,stan
2891,16799799,634,639,Units,years,human,n,,stan
2892,16799799,670,705,Outcome (Study Endpoint),mean (SEM) forced expiratory volume,human,n,too much,stan
2893,16799799,681,712,Outcome (Study Endpoint),forced expiratory volume in 1 s,model,y,,stan
2894,16799799,726,728,Quantitative Measurement,91,model,n,too little,stan
2895,16799799,726,729,Quantitative Measurement,91%,human,y,,stan
2896,16799799,731,733,Quantitative Measurement,4%,human,y,,stan
2897,16799799,742,755,Group Name,placebo group,human,y,,stan
2898,16799799,760,762,Quantitative Measurement,86,model,n,too little,stan
2899,16799799,760,763,Quantitative Measurement,86%,human,y,,stan
2900,16799799,765,767,Quantitative Measurement,4%,human,y,,stan
2901,16799799,776,779,Group Name,flu,model,n,too little,stan
2902,16799799,776,793,Group Name,fluticasone group,human,y,,stan
2903,16799799,948,967,Outcome (Study Endpoint),longitudinal growth,human,y,,stan
2904,16799799,971,991,Group Name,fluticasone patients,human,y,,stan
2905,16799799,1025,1041,Group Name,placebo patients,human,y,,stan
2906,16799799,1049,1050,Quantitative Measurement,0,model,y,,stan
2907,16799799,1049,1053,Quantitative Measurement,0.29,human,y,,stan
2908,16799799,1071,1075,Quantitative Measurement,0.38,human,y,,stan
2909,16799799,1077,1079,Units,cm,human,y,,stan
2910,16799799,1129,1137,Study Duration,12-month,human,y,,stan
2911,16799799,1185,1194,Outcome (Study Endpoint),change in,model,n,too little,stan
2912,16799799,1243,1247,Quantitative Measurement,0.09,human,y,,stan
2913,16799799,1256,1273,Group Name,fluticasone group,human,y,,stan
2914,16799799,1288,1292,Quantitative Measurement,0.07,human,y,,stan
2915,16799799,1301,1314,Group Name,placebo group,human,y,,stan
2916,16799799,1443,1445,Disease/Condition of Interest,CF,human,y,,stan
2917,16946176,93,103,Disease/Condition of Interest,depression,model,y,,cjackson
2918,16946176,318,325,Drug Intervention,lithium,human,y,,cjackson
2919,16946176,333,349,Drug Intervention,triiodothyronine,human,y,,cjackson
2920,16946176,414,439,Disease/Condition of Interest,major depressive disorder,model,y,,cjackson
2921,16946176,522,548,Group Characteristic,had not achieved remission,human,n,too much,cjackson
2922,16946176,526,548,Group Characteristic,not achieved remission,model,y,,cjackson
2923,16946176,561,623,Group Characteristic,intolerant to an initial prospective treatment with citalopram,model,y,,cjackson
2924,16946176,710,717,Drug Intervention,lithium,model,y,,cjackson
2925,16946176,719,728,Dosage,up to 900,human,y,,cjackson
2926,16946176,725,728,Dosage,900,model,n,too little,cjackson
2927,16946176,751,755,Drug Intervention,T(3),model,y,,cjackson
2928,16946176,757,765,Dosage,up to 50,human,y,,cjackson
2929,16946176,763,765,Dosage,50,model,n,too little,cjackson
2930,16946176,791,793,Intervention Duration,14,human,n,too little,cjackson
2931,16946176,791,799,Intervention Duration,14 weeks,model,y,,cjackson
2932,16946176,1325,1329,Quantitative Measurement,23.2,human,n,too little,cjackson
2933,16946176,1325,1330,Quantitative Measurement,23.2%,model,y,,cjackson
2934,16946176,1338,1341,Quantitative Measurement,9.6,human,n,too little,cjackson
2935,16946176,1338,1342,Quantitative Measurement,9.6%,model,y,,cjackson
2936,17387391,48,50,Study Duration,33,model,n,too little,hcho
2937,17387391,145,161,Disease/Condition of Interest,malignant tumors,human,y,,hcho
2938,17387391,183,214,Group Characteristic,underwent renal transplantation,human,y,,hcho
2939,17387391,338,341,Sample Size,188,human,n,wrong label,hcho
2940,17387391,718,756,Outcome (Study Endpoint),mean time of diagnosis of malignancies,human,n,too much,hcho
2941,17387391,794,805,Quantitative Measurement,58.5+/-44.8,human,y,,hcho
2942,17387391,806,812,Units,months,human,y,,hcho
2943,17387391,1204,1212,Group Characteristic,mean age,human,y,,hcho
2944,17387391,1229,1233,Group Characteristic,47.3,human,y,,hcho
2945,17387391,1235,1239,Group Characteristic,53.5,human,y,,hcho
2946,17387391,1241,1245,Group Characteristic,55.5,human,y,,hcho
2947,17387391,1250,1254,Group Characteristic,58.1,human,y,,hcho
2948,17696962,26,38,Drug Intervention,esomeprazole,human,y,,ccurtis
2949,17696962,406,409,Dosage,b.d,human,n,wrong label,ccurtis
2950,17696962,431,434,Dosage,o.d,human,n,wrong label,ccurtis
2951,17696962,487,490,Dosage,b.d,human,n,wrong label,ccurtis
2952,17696962,514,517,Intervention Frequency,b.d,model,y,,ccurtis
2953,17696962,571,576,Follow-up period,eight,human,n,too little,ccurtis
2954,17696962,571,582,Follow-up period,eight weeks,model,y,,ccurtis
2955,17696962,801,822,Outcome (Study Endpoint),Per-protocol analysis,human,n,wrong label,ccurtis
2956,17696962,1016,1031,Outcome (Study Endpoint),good compliance,human,n,wrong label,ccurtis
2957,17696962,1051,1057,Type of Quant. Measure,95% CI,model,y,,ccurtis
2958,17696962,1051,1067,Statistical Significance,"95% CI, 3.0-35.7",human,n,wrong label,ccurtis
2959,17696962,1059,1067,Quantitative Measurement,3.0-35.7,model,y,,ccurtis
2960,17905442,34,44,Drug Intervention,duloxetine,model,y,,eduvaris
2961,17905442,55,65,Drug Intervention,duloxetine,model,y,,eduvaris
2962,17905442,116,126,Disease/Condition of Interest,depression,human,y,,eduvaris
2963,17905442,454,464,Drug Intervention,duloxetine,human,y,,eduvaris
2964,17905442,472,507,Non-Pharmaceutical Intervention,standardized telephone intervention,human,y,,eduvaris
2965,17905442,1254,1258,Quantitative Measurement,10.7,human,n,too little,eduvaris
2966,17905442,1254,1259,Quantitative Measurement,10.7%,model,y,,eduvaris
2967,17905442,1264,1268,Quantitative Measurement,13.0,human,n,too little,eduvaris
2968,17905442,1264,1269,Quantitative Measurement,13.0%,model,y,,eduvaris
2969,17905442,1271,1278,Statistical Significance,P=0.318,model,y,,eduvaris
2970,17905442,1364,1367,Quantitative Measurement,3.5,human,n,too little,eduvaris
2971,17905442,1364,1368,Quantitative Measurement,3.5%,model,y,,eduvaris
2972,17905442,1373,1377,Quantitative Measurement,10.1,human,n,too little,eduvaris
2973,17905442,1373,1378,Quantitative Measurement,10.1%,model,y,,eduvaris
2974,17905442,1404,1407,Quantitative Measurement,0.2,human,n,too little,eduvaris
2975,17905442,1404,1408,Quantitative Measurement,0.2%,model,y,,eduvaris
2976,17905442,1413,1416,Quantitative Measurement,1.7,human,n,too little,eduvaris
2977,17905442,1413,1417,Quantitative Measurement,1.7%,model,y,,eduvaris
2978,18054750,213,235,Drug Intervention,acid-suppressing drugs,model,y,,stan
2979,18054750,261,276,Outcome (Study Endpoint),gastroenteritis,model,y,,stan
2980,18054750,292,308,Group Characteristic,aged 20-74 years,model,y,,stan
2981,18054750,317,346,Group Characteristic,episode of acute bacterial GE,model,n,too little,stan
2982,18054750,328,346,Group Characteristic,acute bacterial GE,human,y,,stan
2983,18054750,377,384,Group Name,control,model,n,too little,stan
2984,18054750,377,390,Group Name,control group,human,y,,stan
2985,18054750,422,447,Group Characteristic,without a diagnosis of GE,human,y,,stan
2986,18054750,645,667,Drug Intervention,proton pump inhibitors,model,y,,stan
2987,18054750,678,710,Drug Intervention,histamine-2 receptor antagonists,model,y,,stan
2988,18054750,712,717,Drug Intervention,H2RAs,model,y,,stan
2989,18054750,773,777,Outcome (Study Endpoint),risk,model,n,too little,stan
2990,18054750,773,793,Outcome (Study Endpoint),risk of bacterial GE,human,y,,stan
2991,18054750,854,856,Type of Quant. Measure,RR,model,y,,stan
2992,18054750,944,948,Drug Intervention,H2RA,model,y,,stan
2993,18054750,954,956,Type of Quant. Measure,RR,model,y,,stan
2994,18054750,963,969,Type of Quant. Measure,95% CI,model,y,,stan
2995,18054750,1067,1073,Type of Quant. Measure,95% CI,model,y,,stan
2996,18054750,1185,1189,Outcome (Study Endpoint),risk,model,n,too little,stan
2997,18054750,1247,1249,Type of Quant. Measure,RR,model,y,,stan
2998,18054750,1256,1262,Type of Quant. Measure,95% CI,model,y,,stan
2999,18054750,1291,1293,Type of Quant. Measure,RR,model,y,,stan
3000,18054750,1300,1306,Type of Quant. Measure,95% CI,model,y,,stan
3001,18054750,1406,1410,Sample Size,4124,model,y,,stan
3002,18054750,1432,1436,Sample Size,1885,model,y,,stan
3003,18309682,101,122,Drug Intervention,benzalkonium chloride,model,y,,cjackson
3004,18309682,124,127,Drug Intervention,BAC,model,y,,cjackson
3005,18309682,373,376,Drug Intervention,BAC,model,y,,cjackson
3006,18309682,399,415,Group Characteristic,bronchial asthma,model,n,wrong label,cjackson
3007,18309682,423,429,Group Characteristic,normal,model,y,,cjackson
3008,18309682,430,438,Group Name,controls,human,y,,cjackson
3009,18309682,470,479,Intervention Administration,nebulized,model,y,,cjackson
3010,18309682,489,492,Drug Intervention,BAC,human,y,,cjackson
3011,18309682,516,520,Outcome (Study Endpoint),FEV1,human,y,,cjackson
3012,18309682,629,645,Intervention Frequency,every 20 minutes,model,n,too much,cjackson
3013,18309682,635,645,Intervention Frequency,20 minutes,human,y,,cjackson
3014,18309682,734,735,Intervention Frequency,3,human,n,not needed,cjackson
3015,18625886,39,59,Disease/Condition of Interest,mantle cell lymphoma,model,y,,hcho
3016,18625886,216,236,Disease/Condition of Interest,Mantle cell lymphoma,model,y,,hcho
3017,18625886,238,241,Disease/Condition of Interest,MCL,model,y,,hcho
3018,18625886,446,453,Group Characteristic,younger,human,n,too little,hcho
3019,18625886,446,467,Group Characteristic,younger than 66 years,model,y,,hcho
3020,18625886,729,733,Drug Intervention,BEAC,model,n,wrong label,hcho
3021,18625886,735,745,Drug Intervention,carmustine,model,y,,hcho
3022,18625886,747,756,Drug Intervention,etoposide,model,y,,hcho
3023,18625886,758,768,Drug Intervention,cytarabine,model,y,,hcho
3024,18625886,774,783,Drug Intervention,melphalan,model,y,,hcho
3025,18625886,784,800,Drug Intervention,cyclophosphamide,model,y,,hcho
3026,18625886,824,852,Non-Pharmaceutical Intervention,autologous stem cell support,model,y,,hcho
3027,18625886,854,861,Outcome (Study Endpoint),Overall,model,y,,hcho
3028,18625886,866,883,Outcome (Study Endpoint),complete response,model,n,,hcho
3029,18625886,931,945,Outcome (Study Endpoint),6-year overall,model,y,,hcho
3030,18625886,947,957,Outcome (Study Endpoint),event-free,model,y,,hcho
3031,18625886,963,988,Outcome (Study Endpoint),progression-free survival,model,y,,hcho
3032,18625886,1169,1189,Outcome (Study Endpoint),nonrelapse mortality,model,y,,hcho
3033,18625886,1568,1576,Statistical Significance,P < .001,model,y,,hcho
3034,18759650,22,43,Disease/Condition of Interest,adolescent depression,human,n,too much,ccurtis
3035,18759650,33,43,Disease/Condition of Interest,depression,model,y,,ccurtis
3036,18759650,407,418,Group Characteristic,adolescents,human,n,too little,ccurtis
3037,18759650,419,435,Group Characteristic,aged 13-19 years,model,n,too little,ccurtis
3038,18759650,424,435,Group Characteristic,13-19 years,human,n,too little,ccurtis
3039,18759650,741,748,Group Name,placebo,human,y,wrong label,ccurtis
3040,18759650,777,787,Group Name,sertraline,human,n,too little,ccurtis
3041,18759650,792,794,Intervention Duration,52,human,y,,ccurtis
3042,18759650,792,800,Intervention Duration,52 weeks,model,n,too much,ccurtis
3043,18759650,795,800,Units,weeks,human,y,,ccurtis
3044,18759650,868,878,Drug Intervention,sertraline,model,y,,ccurtis
3045,18759650,895,902,Drug Intervention,placebo,human,n,wrong label,ccurtis
3046,18759650,904,909,Sample Size,n = 9,human,n,too much,ccurtis
3047,18759650,908,909,Sample Size,9,model,y,,ccurtis
3048,18759650,1012,1019,Drug Intervention,placebo,human,n,wrong label,ccurtis
3049,18759650,1050,1095,Outcome (Study Endpoint),no significant differences between the groups,human,n,wrong label,ccurtis
3050,18799953,83,95,Group Characteristic,hypertensive,model,y,,eduvaris
3051,18799953,202,210,Outcome (Study Endpoint),systolic,model,n,too little,eduvaris
3052,18799953,322,334,Group Characteristic,hypertensive,model,y,,eduvaris
3053,18799953,335,349,Group Characteristic,postmenopausal,human,n,too little,eduvaris
3054,18799953,350,355,Group Characteristic,women,human,n,too little,eduvaris
3055,18799953,387,399,Group Characteristic,hypertensive,model,y,,eduvaris
3056,18799953,400,420,Group Characteristic,postmenopausal women,model,y,,eduvaris
3057,18799953,452,492,Group Characteristic,under treatment with enalapril maleate (,human,n,wrong label,eduvaris
3058,18799953,473,490,Drug Intervention,enalapril maleate,model,y,wrong label,eduvaris
3059,18799953,500,548,Group Characteristic,/day) combined or not with hydrochlorothiazide (,human,n,wrong label,eduvaris
3060,18799953,501,504,Intervention Frequency,day,model,y,,eduvaris
3061,18799953,527,546,Drug Intervention,hydrochlorothiazide,model,n,wrong label,eduvaris
3062,18799953,553,558,Group Characteristic,/day),human,n,too much,eduvaris
3063,18799953,554,557,Intervention Frequency,day,model,y,,eduvaris
3064,18799953,582,593,Intervention Administration,transdermal,model,y,,eduvaris
3065,18799953,800,801,Follow-up period,6,model,n,too little,eduvaris
3066,18799953,838,839,Follow-up period,6,model,n,too little,eduvaris
3067,19019667,338,363,Disease/Condition of Interest,aspirin-intolerant asthma,model,y,,stan
3068,19019667,365,368,Disease/Condition of Interest,AIA,model,y,,stan
3069,19019667,983,986,Group Name,ATA,model,n,wrong label,stan
3070,19019667,997,1003,Group Characteristic,normal,human,y,wrong label,stan
3071,19019667,1058,1064,Group Name,normal,human,n,wrong label,stan
3072,19019667,1083,1086,Group Name,AIA,human,n,wrong label,stan
3073,19019667,1244,1253,Outcome (Study Endpoint),haplotype,model,n,wrong label,stan
3074,19019667,1264,1273,Outcome (Study Endpoint),ht[C-T-G],model,y,,stan
3075,19019667,1288,1297,Outcome (Study Endpoint),ht[A-C-G],model,y,,stan
3076,19019667,1322,1329,Outcome (Study Endpoint),ht[A-T],model,y,,stan
3077,19129205,113,116,Group Characteristic,men,human,y,,cjackson
3078,19129205,126,137,Disease/Condition of Interest,Hot flashes,human,y,,cjackson
3079,19129205,173,176,Group Characteristic,men,human,y,,cjackson
3080,19129205,295,306,Disease/Condition of Interest,hot flashes,human,y,,cjackson
3081,19129205,308,356,Group Characteristic,on a stable androgen deprivation therapy program,human,y,,cjackson
3082,19129205,400,410,Drug Intervention,gabapentin,human,y,,cjackson
3083,19129205,447,449,Units,mg,human,y,,cjackson
3084,19129205,447,450,Units,mg/,model,n,too much,cjackson
3085,19129205,543,544,Follow-up period,4,model,n,too little,cjackson
3086,19129205,543,550,Intervention Duration,4 weeks,human,y,,cjackson
3087,19129205,763,770,Group Name,placebo,model,n,too little,cjackson
3088,19129205,763,776,Group Name,placebo group,human,y,,cjackson
3089,19129205,823,833,Group Name,gabapentin,model,n,too little,cjackson
3090,19129205,823,840,Group Name,gabapentin groups,human,y,,cjackson
3091,19129205,1018,1024,Outcome (Study Endpoint),change,model,n,not needed,cjackson
3092,19129205,1049,1060,Outcome (Study Endpoint),frequencies,model,y,,cjackson
3093,19129205,1093,1097,Quantitative Measurement,0.10,model,n,wrong label,cjackson
3094,19129205,1102,1106,Statistical Significance,0.02,human,y,wrong label,cjackson
3095,19129205,1188,1198,Drug Intervention,gabapentin,human,y,,cjackson
3096,19129205,1260,1270,Drug Intervention,gabapentin,human,y,,cjackson
3097,19129205,1281,1292,Disease/Condition of Interest,hot flashes,human,y,,cjackson
3098,19522426,0,9,Drug Intervention,Metformin,model,y,,hcho
3099,19522426,21,30,Drug Intervention,clomifene,model,n,wrong label,hcho
3100,19522426,83,108,Disease/Condition of Interest,Polycystic ovary syndrome,model,y,,hcho
3101,19522426,110,114,Disease/Condition of Interest,PCOS,model,y,,hcho
3102,19522426,640,657,Drug Intervention,clomifene citrate,model,n,wrong label,hcho
3103,19522426,663,672,Drug Intervention,metformin,model,y,,hcho
3104,19522426,677,694,Drug Intervention,clomifene citrate,model,n,wrong label,hcho
3105,19522426,700,707,Group Name,placebo,human,y,,hcho
3106,19522426,722,763,Group Characteristic,newly diagnosed polycystic ovary syndrome,human,n,not needed,hcho
3107,19522426,738,763,Disease/Condition of Interest,polycystic ovary syndrome,model,y,,hcho
3108,19522426,1076,1083,Drug Intervention,placebo,model,n,,hcho
3109,19522426,1469,1484,Group Name,metformin group,model,y,,hcho
3110,19522426,1489,1496,Group Name,placebo,model,y,,hcho
3111,19522426,1722,1737,Group Name,metformin group,model,y,,hcho
3112,19522426,1775,1788,Group Name,placebo group,model,y,,hcho
3113,19522426,1873,1877,Quantitative Measurement,1.66,model,y,,hcho
3114,19522426,1878,1883,Units,times,model,y,,hcho
3115,19522426,1991,1998,Group Name,placebo,model,y,,hcho
3116,19593886,375,391,Group Characteristic,aged 16-70 years,model,n,too much,ccurtis
3117,19593886,380,391,Group Characteristic,16-70 years,human,y,,ccurtis
3118,19593886,659,664,Intervention Frequency,6-8 h,model,y,,ccurtis
3119,19593886,795,809,Group Characteristic,supratentorial,model,n,too little,ccurtis
3120,19593886,814,828,Group Characteristic,infratentorial,model,n,too little,ccurtis
3121,19593886,1048,1055,Group Name,Group 1,model,y,,ccurtis
3122,19593886,1130,1137,Group Name,group 2,model,y,,ccurtis
3123,19593886,1172,1197,Group Characteristic,infratentorial craniotomy,human,y,,ccurtis
3124,19593886,1229,1254,Group Characteristic,supratentorial craniotomy,human,y,,ccurtis
3125,19593886,1479,1487,Statistical Significance,P > 0.05,human,y,,ccurtis
3126,19996621,38,71,Disease/Condition of Interest,postoperative nausea and vomiting,model,y,,eduvaris
3127,19996621,83,98,Non-Pharmaceutical Intervention,cholecystectomy,model,y,,eduvaris
3128,19996621,190,200,Drug Intervention,gabapentin,human,y,,eduvaris
3129,19996621,269,273,Disease/Condition of Interest,PONV,model,y,,eduvaris
3130,19996621,286,301,Non-Pharmaceutical Intervention,cholecystectomy,model,y,,eduvaris
3131,19996621,317,325,Group Characteristic,patients,human,n,not needed,eduvaris
3132,19996621,405,415,Group Name,gabapentin,human,n,too little,eduvaris
3133,19996621,405,421,Group Name,gabapentin group,model,y,,eduvaris
3134,19996621,423,426,Dosage,600,model,y,,eduvaris
3135,19996621,423,429,Dosage,600 mg,human,n,multiple entities,eduvaris
3136,19996621,427,429,Units,mg,model,y,,eduvaris
3137,19996621,489,490,Sample Size,1,human,n,not needed,eduvaris
3138,19996621,521,531,Group Name,gabapentin,human,n,too little,eduvaris
3139,19996621,542,543,Sample Size,2,human,n,not needed,eduvaris
3140,19996621,544,552,Group Characteristic,patients,human,n,not needed,eduvaris
3141,19996621,562,575,Group Name,placebo group,human,y,,eduvaris
3142,19996621,623,632,Non-Study Drug,Pethidine,model,y,wrong label,eduvaris
3143,19996621,637,651,Non-Study Drug,metoclopramide,model,y,wrong label,eduvaris
3144,19996621,996,1006,Drug Intervention,gabapentin,human,y,,eduvaris
3145,19996621,1040,1047,Group Name,placebo,human,n,too little,eduvaris
3146,19996621,1048,1056,Group Characteristic,patients,human,n,not needed,eduvaris
3147,19996621,1149,1198,Outcome (Study Endpoint),no difference in the severity of PONV between the,human,n,too much,eduvaris
3148,19996621,1170,1186,Outcome (Study Endpoint),severity of PONV,model,y,,eduvaris
3149,19996621,1199,1209,Group Name,gabapentin,human,n,too little,eduvaris
3150,19996621,1210,1213,Outcome (Study Endpoint),and,human,n,not needed,eduvaris
3151,19996621,1214,1221,Group Name,placebo,human,n,too little,eduvaris
3152,19996621,1222,1228,Outcome (Study Endpoint),groups,human,n,not needed,eduvaris
3153,19996621,1271,1280,Outcome (Study Endpoint),pethidine,model,n,wrong label,eduvaris
3154,19996621,1282,1295,Quantitative Measurement,28.33 +/- 129,model,y,,eduvaris
3155,19996621,1296,1298,Units,mg,model,y,,eduvaris
3156,19996621,1304,1318,Outcome (Study Endpoint),metoclopramide,model,n,wrong label,eduvaris
3157,19996621,1320,1330,Quantitative Measurement,6.0 +/-6.3,model,y,,eduvaris
3158,19996621,1331,1333,Units,mg,model,y,,eduvaris
3159,19996621,1359,1372,Quantitative Measurement,35.1 +/- 15.1,model,y,,eduvaris
3160,19996621,1377,1389,Quantitative Measurement,9.33 +/- 7.1,model,y,,eduvaris
3161,19996621,1390,1392,Units,mg,model,y,,eduvaris
3162,19996621,1542,1560,Outcome (Study Endpoint),postoperative pain,model,y,,eduvaris
3163,20046687,37,64,Disease/Condition of Interest,panretinal photocoagulation,human,n,wrong label,stan
3164,20046687,137,164,Disease/Condition of Interest,panretinal photocoagulation,human,n,wrong label,stan
3165,20046687,166,169,Disease/Condition of Interest,PRP,human,n,wrong label,stan
3166,20046687,231,242,Sample Size,Fifty-eight,model,y,,stan
3167,20046687,453,461,Drug Intervention,tramadol,human,y,,stan
3168,20046687,671,675,Type of Quant. Measure,mean,model,n,too little or too much based on context,stan
3169,20046687,671,687,Outcome (Study Endpoint),mean pain scores,human,n,multiple entities,stan
3170,20046687,676,687,Outcome (Study Endpoint),pain scores,model,y,,stan
3171,20046687,699,700,Group Name,A,model,n,too little or too much based on context,stan
3172,20046687,705,706,Group Name,B,model,n,too little or too much based on context,stan
3173,20046687,853,860,Group Name,group A,human,y,,stan
3174,20046687,990,997,Group Name,group A,human,y,,stan
3175,20046687,1219,1227,Drug Intervention,tramadol,human,y,,stan
3176,20046687,1300,1308,Drug Intervention,tramadol,human,y,,stan
3177,20046687,1449,1452,Disease/Condition of Interest,PRP,human,n,wrong label,stan
3178,20179166,174,180,Disease/Condition of Interest,cancer,model,n,wrong label,cjackson
3179,20179166,351,417,Group Characteristic,received at least three prescriptions covering parts of each month,model,y,,cjackson
3180,20179166,360,388,Group Characteristic,at least three prescriptions,human,n,too little,cjackson
3181,20179166,435,449,Intervention Duration,6-month period,model,n,not needed,cjackson
3182,20179166,732,759,Outcome (Study Endpoint),medication possession ratio,model,y,,cjackson
3183,20179166,1015,1018,Group Characteristic,69%,model,n,wrong label,cjackson
3184,20179166,1027,1030,Group Characteristic,71%,model,n,wrong label,cjackson
3185,20179166,1044,1061,Group Characteristic,mean age of 52.94,model,y,,cjackson
3186,20179166,1166,1169,Quantitative Measurement,78%,model,y,,cjackson
3187,20179166,1198,1201,Outcome (Study Endpoint),MPR,model,n,too little,cjackson
3188,20179166,1215,1218,Quantitative Measurement,22%,model,y,,cjackson
3189,20179166,1236,1249,Outcome (Study Endpoint),less than 80%,model,n,too little,cjackson
3190,20179166,1451,1454,Outcome (Study Endpoint),MPR,human,y,,cjackson
3191,20179166,1528,1531,Outcome (Study Endpoint),MPR,human,y,,cjackson
3192,20179166,1589,1592,Outcome (Study Endpoint),MPR,human,y,,cjackson
3193,20179166,1619,1633,Group Characteristic,non-Caucasians,human,y,,cjackson
3194,20571180,59,93,Disease/Condition of Interest,comorbid major depressive disorder,human,n,too much,hcho
3195,20571180,68,93,Disease/Condition of Interest,major depressive disorder,model,y,,hcho
3196,20571180,95,106,Drug Intervention,Eszopiclone,human,y,,hcho
3197,20571180,167,175,Group Characteristic,insomnia,human,n,wrong label,hcho
3198,20571180,189,214,Group Characteristic,major depressive disorder,human,n,wrong label,hcho
3199,20571180,256,267,Drug Intervention,eszopiclone,human,y,,ccurtis
3200,20571180,328,331,Drug Intervention,ESZ,model,y,,ccurtis
3201,20571180,332,335,Drug Intervention,FLX,model,n,wrong label,ccurtis
3202,20571180,455,465,Drug Intervention,fluoxetine,model,n,wrong label,hcho
3203,20571180,488,495,Drug Intervention,placebo,model,n,wrong label,hcho
3204,20571180,517,527,Non-Study Drug,fluoxetine,human,y,,hcho
3205,20571180,580,588,Group Characteristic,insomnia,human,n,wrong label,hcho
3206,20571180,593,596,Group Characteristic,MDD,human,n,wrong label,hcho
3207,20571180,1291,1309,Outcome (Study Endpoint),increases in QALYs,model,n,too much,hcho
3208,20571180,1304,1309,Outcome (Study Endpoint),QALYs,human,y,,hcho
3209,20571180,1355,1362,Group Name,ESZ+FLX,human,n,wrong label,hcho
3210,20571180,1367,1374,Group Name,PBO+FLX,human,n,wrong label,hcho
3211,20571180,1397,1419,Outcome (Study Endpoint),Mean per-patient costs,model,y,,hcho
3212,20571180,1425,1428,Type of Quant. Measure,USD,model,n,wrong label,hcho
3213,20571180,1429,1434,Quantitative Measurement,"1,279",model,y,,hcho
3214,20571180,1439,1442,Type of Quant. Measure,USD,model,n,wrong label,hcho
3215,20571180,1443,1448,Quantitative Measurement,"1,198",model,y,,hcho
3216,20571180,1507,1520,Outcome (Study Endpoint),net increases,model,n,wrong label,hcho
3217,20571180,1524,1530,Quantitative Measurement,0.0058,model,y,,hcho
3218,20571180,1545,1547,Quantitative Measurement,81,model,y,,hcho
3219,20571180,1646,1657,Drug Intervention,eszopiclone,human,y,,hcho
3220,20571180,2337,2345,Disease/Condition of Interest,insomnia,human,y,,hcho
3221,20659023,34,42,Drug Intervention,Monafram,model,y,,eduvaris
3222,20659023,175,183,Drug Intervention,monafram,human,y,,eduvaris
3223,20659023,287,295,Drug Intervention,monafram,model,y,,eduvaris
3224,20659023,345,368,Disease/Condition of Interest,acute coronary syndrome,model,y,,eduvaris
3225,20659023,560,570,Intervention Administration,i.v. bolus,model,y,,eduvaris
3226,20659023,631,638,Non-Study Drug,aspirin,human,y,wrong label,eduvaris
3227,20659023,702,713,Non-Study Drug,clopidogrel,human,y,wrong label,eduvaris
3228,20659023,797,805,Outcome (Study Endpoint),monafram,model,n,wrong label,eduvaris
3229,20659023,1354,1369,Group Name,monafram groups,human,y,,eduvaris
3230,20659023,1407,1411,Quantitative Measurement,8.9%,model,y,,eduvaris
3231,20659023,1610,1614,Quantitative Measurement,0.5%,human,y,,eduvaris
3232,20929910,33,73,Disease/Condition of Interest,attention-deficit/hyperactivity disorder,human,y,,stan
3233,20929910,113,153,Disease/Condition of Interest,attention-deficit/hyperactivity disorder,model,y,,stan
3234,20929910,155,159,Disease/Condition of Interest,ADHD,model,y,,stan
3235,20929910,316,324,Group Characteristic,children,model,y,,stan
3236,20929910,330,334,Group Characteristic,ADHD,model,y,,stan
3237,20929910,550,557,Group Name,control,model,n,too little,stan
3238,20929910,566,590,Outcome (Study Endpoint),Prevalence of overweight,model,n,too little,stan
3239,20929910,580,590,Outcome (Study Endpoint),overweight,human,y,,stan
3240,20929910,620,624,Group Name,ADHD,model,n,too little,stan
3241,20929910,620,630,Group Name,ADHD group,human,y,,stan
3242,20929910,743,752,Follow-up period,17 months,model,y,,stan
3243,21048320,0,10,Drug Intervention,Clonazepam,human,y,,cjackson
3244,21048320,253,279,Disease/Condition of Interest,cisplatin-induced vomiting,model,y,,cjackson
3245,21048320,365,378,Drug Intervention,dexamethasone,human,y,,cjackson
3246,21048320,424,428,Drug Intervention,clon,model,n,too little,cjackson
3247,21048320,424,434,Drug Intervention,clonazepam,human,y,,cjackson
3248,21048320,531,536,Sample Size,seven,model,y,,cjackson
3249,21048320,537,545,Group Characteristic,patients,human,n,not needed,cjackson
3250,21048320,575,578,Dosage,0.5,model,y,,cjackson
3251,21048320,575,585,Dosage,0.5 or 1.0,human,n,too much,cjackson
3252,21048320,582,585,Dosage,1.0,model,y,,cjackson
3253,21048320,659,684,Outcome (Study Endpoint),grade of delayed vomiting,model,y,,cjackson
3254,21048320,676,684,Outcome (Study Endpoint),vomiting,human,y,,cjackson
3255,21048320,889,960,Group Characteristic,serum clonazepam concentrations were below the lower limit of detection,model,y,,cjackson
3256,21048320,985,993,Outcome (Study Endpoint),vomiting,model,y,,cjackson
3257,21048320,1048,1106,Group Characteristic,serum clonazepam concentrations were higher than 4.3 ng/ml,model,y,,cjackson
3258,21048320,1097,1100,Quantitative Measurement,4.3,human,n,not needed,cjackson
3259,21048320,1119,1130,Outcome (Study Endpoint),no vomiting,model,y,,cjackson
3260,21048320,1134,1146,Quantitative Measurement,six of seven,human,n,too much,cjackson
3261,21122542,15,26,Drug Intervention,thiopurines,human,y,,hcho
3262,21122542,83,86,Disease/Condition of Interest,IBD,human,y,,hcho
3263,21122542,88,99,Drug Intervention,Allopurinol,model,y,,hcho
3264,21122542,176,202,Disease/Condition of Interest,inflammatory bowel disease,model,y,,hcho
3265,21122542,583,609,Group Characteristic,inflammatory bowel disease,model,n,wrong label,hcho
3266,21122542,634,645,Drug Intervention,allopurinol,model,y,,hcho
3267,21122542,816,818,Sample Size,20,model,y,,hcho
3268,21122542,845,846,Sample Size,7,model,y,,hcho
3269,21122542,896,904,Sample Size,Thirteen,human,n,wrong label,hcho
3270,21122542,926,952,Outcome (Study Endpoint),major clinical improvement,model,y,,hcho
3271,21122542,957,958,Sample Size,7,human,n,wrong label,hcho
3272,21122542,1075,1078,Side Effects,PCP,human,y,,hcho
3273,21122542,1080,1083,Side Effects,EBV,human,y,,hcho
3274,21122542,1089,1105,Side Effects,viral meningitis,human,y,,hcho
3275,21122542,1438,1444,Type of Quant. Measure,median,model,y,,hcho
3276,21122542,1453,1456,Units,mm³,human,y,,hcho
3277,21122542,1468,1471,Units,mm³,human,y,,hcho
3278,21122542,1558,1584,Outcome (Study Endpoint),major clinical improvement,model,y,,hcho
3279,21122542,1588,1591,Quantitative Measurement,48%,model,y,,hcho
3280,21122660,193,213,Disease/Condition of Interest,hypercholesterolemia,model,y,,ccurtis
3281,21122660,218,240,Disease/Condition of Interest,coronary heart disease,model,y,,ccurtis
3282,21122660,242,245,Disease/Condition of Interest,CHD,human,y,,ccurtis
3283,21122660,369,384,Group Characteristic,established CHD,model,n,too much,ccurtis
3284,21122660,389,441,Group Characteristic,were taking a stable daily dose of simvastatin 20 mg,human,n,too much,ccurtis
3285,21122660,394,438,Group Characteristic,taking a stable daily dose of simvastatin 20,model,n,too much,ccurtis
3286,21122660,439,441,Units,mg,model,y,,ccurtis
3287,21122660,580,609,Outcome (Study Endpoint),change from baseline in LDL-C,human,n,too much,ccurtis
3288,21122660,1083,1088,Outcome (Study Endpoint),LDL-C,model,y,,ccurtis
3289,21122660,1090,1107,Outcome (Study Endpoint),total cholesterol,model,y,,ccurtis
3290,21122660,1113,1126,Outcome (Study Endpoint),triglycerides,model,y,,ccurtis
3291,21122660,1164,1166,Dosage,40,model,y,,ccurtis
3292,21122660,1167,1169,Units,mg,model,y,,ccurtis
3293,21122660,1222,1227,Outcome (Study Endpoint),LDL-C,model,y,,ccurtis
3294,21122660,1222,1298,Outcome (Study Endpoint),LDL-C less than 100 mg/dL (<2.6 mmol/L) and less than 80 mg/dL (<2.0 mmol/L),human,n,too much,ccurtis
3295,21122660,1242,1244,Units,mg,model,y,,ccurtis
3296,21122660,1279,1284,Units,mg/dL,model,y,,ccurtis
3297,21122660,1363,1365,Dosage,40,model,y,,ccurtis
3298,21122660,1366,1368,Units,mg,model,y,,ccurtis
3299,21122660,1370,1374,Quantitative Measurement,73.2,human,n,too little,ccurtis
3300,21122660,1370,1375,Quantitative Measurement,73.2%,model,y,,ccurtis
3301,21122660,1374,1375,Units,%,human,n,too little,ccurtis
3302,21122660,1379,1383,Quantitative Measurement,25.0,human,n,too little,ccurtis
3303,21122660,1379,1384,Quantitative Measurement,25.0%,model,y,,ccurtis
3304,21122660,1383,1384,Units,%,human,n,too little,ccurtis
3305,21122660,1513,1522,Group Characteristic,high-risk,model,y,,ccurtis
3306,21122660,1803,1805,Units,mg,model,y,,ccurtis
3307,21317621,134,147,Drug Intervention,Beta-blockers,human,y,,eduvaris
3308,21317621,418,434,Units,beats per minute,model,n,not needed,eduvaris
3309,21317621,436,439,Units,bpm,model,n,not needed,eduvaris
3310,21317621,896,904,Study Years,May 2007,model,y,,eduvaris
3311,21317621,973,980,Study Duration,6-month,human,n,not needed,eduvaris
3312,21317621,1074,1082,Group Name,protocol,human,n,too little,eduvaris
3313,21317621,1074,1088,Group Name,protocol group,model,y,,eduvaris
3314,21317621,1497,1511,Group Name,protocol group,model,y,,eduvaris
3315,21317621,1540,1557,Group Name,preprotocol group,model,y,,eduvaris
3316,21317621,1575,1589,Group Name,protocol group,model,y,,eduvaris
3317,21317621,1643,1660,Group Name,preprotocol group,model,y,,eduvaris
3318,21317621,1693,1712,Outcome (Study Endpoint),mean discharge dose,human,n,multiple entities,eduvaris
3319,21317621,1693,1726,Outcome (Study Endpoint),mean discharge dose of metoprolol,model,n,multiple entities,eduvaris
3320,21317621,1716,1726,Drug Intervention,metoprolol,human,n,too little,eduvaris
3321,21317621,1734,1742,Group Name,protocol,model,n,too little,eduvaris
3322,21372302,19,25,Drug Intervention,statin,human,y,,stan
3323,21372302,181,183,Disease/Condition of Interest,MI,model,y,,stan
3324,21372302,322,328,Drug Intervention,statin,human,y,,stan
3325,21372302,387,402,Group Characteristic,ST-elevation MI,model,n,too little,stan
3326,21372302,400,411,Group Characteristic,MI patients,human,n,too little,stan
3327,21372302,450,459,Group Name,no statin,human,y,,stan
3328,21372302,574,575,Intervention Duration,7,model,y,,stan
3329,21372302,623,625,Dosage,20,model,y,,stan
3330,21372302,626,628,Units,mg,model,y,,stan
3331,21372302,629,632,Intervention Frequency,day,model,n,too little or too much based on context,stan
3332,21372302,633,644,Drug Intervention,simvastatin,model,y,,stan
3333,21372302,663,670,Intervention Duration,3 weeks,model,y,,stan
3334,21372302,759,777,Outcome (Study Endpoint),C-reactive protein,model,y,,stan
3335,21372302,759,783,Outcome (Study Endpoint),C-reactive protein (CRP),human,n,too much,stan
3336,21372302,801,811,Group Name,non-statin,human,n,too little,stan
3337,21372302,801,817,Group Name,non-statin users,model,y,,stan
3338,21372302,985,996,Follow-up period,seventh day,model,y,,stan
3339,21372302,1013,1035,Outcome (Study Endpoint),higher the statin dose,human,n,not needed,stan
3340,21372302,1041,1105,Outcome (Study Endpoint),lower the elevation of interleukin-2 and tumor necrosis factor-α,human,n,multiple entities,stan
3341,21372302,1111,1180,Outcome (Study Endpoint),greater the reduction of 8-isoprostane and low-density lipoprotein(-),human,n,multiple entities,stan
3342,21372302,1190,1236,Outcome (Study Endpoint),greater the increase in nitrate/nitrite levels,human,n,too much,stan
3343,21372302,1214,1236,Outcome (Study Endpoint),nitrate/nitrite levels,model,y,,stan
3344,21372302,1376,1379,Outcome (Study Endpoint),CRP,human,y,,stan
3345,21456039,85,95,Drug Intervention,fluoxetine,model,y,,cjackson
3346,21456039,101,110,Drug Intervention,modafinil,model,y,,cjackson
3347,21456039,118,128,Drug Intervention,fluoxetine,model,y,,cjackson
3348,21456039,134,141,Drug Intervention,placebo,model,n,wrong label,cjackson
3349,21456039,162,178,Disease/Condition of Interest,major depression,model,y,,cjackson
3350,21456039,168,178,Disease/Condition of Interest,depression,human,n,too little,cjackson
3351,21456039,433,443,Drug Intervention,fluoxetine,model,y,,cjackson
3352,21456039,449,452,Drug Intervention,mod,model,n,too little,cjackson
3353,21456039,538,544,Intervention Duration,6-week,human,n,wrong label,cjackson
3354,21456039,588,597,Sample Size,Forty-six,model,y,,cjackson
3355,21456039,710,776,Group Characteristic,baseline Hamilton Rating Scale for depression score of at least 18,model,y,,cjackson
3356,21456039,845,849,Intervention Frequency,/day,model,n,too much,cjackson
3357,21456039,846,849,Intervention Frequency,day,human,y,,cjackson
3358,21456039,869,871,Units,mg,model,y,,cjackson
3359,21456039,871,875,Intervention Frequency,/day,model,n,too much,cjackson
3360,21456039,872,875,Intervention Frequency,day,human,y,,cjackson
3361,21456039,877,880,Dosage,200,human,y,,cjackson
3362,21456039,877,883,Dosage,200 mg,model,n,too much,cjackson
3363,21456039,881,883,Units,mg,human,y,,cjackson
3364,21456039,947,954,Drug Intervention,placebo,model,n,wrong label,cjackson
3365,21456039,1162,1189,Outcome (Study Endpoint),Hamilton Rating Scale score,human,n,too little,cjackson
3366,21456039,1162,1204,Outcome (Study Endpoint),Hamilton Rating Scale score for Depression,model,y,,cjackson
3367,21456039,1504,1510,Statistical Significance,df = 1,model,n,not needed,cjackson
3368,21456039,1516,1520,Quantitative Measurement,4.42,model,y,,cjackson
3369,21456039,1522,1531,Statistical Significance,P = 0.046,model,y,,cjackson
3370,21568147,555,556,Group Name,A,model,n,too little,hcho
3371,21568147,915,922,Intervention Duration,10 days,model,y,,hcho
3372,21568147,1519,1526,Group Name,Group C,human,y,,hcho
3373,21568147,1644,1659,Outcome (Study Endpoint),highest success,human,n,wrong label,hcho
3374,21623231,0,11,Drug Intervention,Clevidipine,human,y,,eduvaris
3375,21623231,27,38,Disease/Condition of Interest,hypotension,model,y,,ccurtis
3376,21623231,66,82,Side Effects,Mild tachycardia,human,y,,eduvaris
3377,21623231,304,326,Disease/Condition of Interest,controlled hypotension,human,n,too much,ccurtis
3378,21623231,328,330,Disease/Condition of Interest,CH,human,n,wrong label,ccurtis
3379,21623231,347,358,Group Characteristic,adolescents,human,y,,ccurtis
3380,21623231,440,451,Drug Intervention,clevidipine,human,y,,ccurtis
3381,21623231,961,972,Drug Intervention,clevidipine,human,y,,ccurtis
3382,21623231,1235,1249,Group Characteristic,14 to 18 years,human,y,,ccurtis
3383,21623231,1257,1280,Group Characteristic,weight from 46 to 96 kg,model,n,too much,ccurtis
3384,21623231,1269,1280,Group Characteristic,46 to 96 kg,human,y,,ccurtis
3385,21623231,1324,1332,Non-Study Drug,propofol,human,y,,ccurtis
3386,21623231,1334,1346,Non-Study Drug,remifentanil,human,y,,ccurtis
3387,21623231,1352,1367,Non-Study Drug,dexmedetomidine,human,y,,ccurtis
3388,21623231,1400,1405,Units,mm Hg,human,y,,ccurtis
3389,21623231,1461,1466,Units,mm Hg,human,y,,ccurtis
3390,21623231,1472,1483,Drug Intervention,clevidipine,human,y,,ccurtis
3391,21623231,1559,1567,Dosage,0.5 to 1,model,y,,ccurtis
3392,21623231,1568,1573,Units,μg/kg,model,y,,ccurtis
3393,21623231,1584,1598,Intervention Duration,2 to 3 minutes,model,y,,ccurtis
3394,21623231,1748,1773,Outcome (Study Endpoint),maintenance infusion rate,model,n,not needed,ccurtis
3395,21623231,1777,1788,Drug Intervention,clevidipine,human,y,,ccurtis
3396,21623231,1801,1807,Dosage,1 to 5,model,y,,ccurtis
3397,21623231,1808,1817,Units,μg/kg/min,model,y,,ccurtis
3398,21623231,1819,1826,Quantitative Measurement,2.9±0.7,model,n,wrong label,ccurtis
3399,21623231,1827,1836,Units,μg/kg/min,model,y,,ccurtis
3400,21623231,1866,1877,Drug Intervention,clevidipine,human,y,,ccurtis
3401,21623231,2049,2050,Sample Size,3,human,n,wrong label,ccurtis
3402,21623231,2145,2169,Outcome (Study Endpoint),MAP returned to baseline,human,n,wrong label,ccurtis
3403,21784392,65,87,Drug Intervention,antiplatelet treatment,human,y,,stan
3404,21784392,533,582,Group Characteristic,uninterrupted single or dual antiplatelet therapy,human,n,multiple entities,stan
3405,21784392,664,667,Sample Size,111,model,y,,stan
3406,21784392,669,674,Quantitative Measurement,17.3%,human,y,,stan
3407,21784392,824,829,Quantitative Measurement,82.7%,human,y,,stan
3408,21784392,949,953,Outcome (Study Endpoint),risk,model,n,too little,stan
3409,21784392,949,985,Outcome (Study Endpoint),risk of prolonged immediate bleeding,human,n,too much,stan
3410,21784392,957,985,Outcome (Study Endpoint),prolonged immediate bleeding,model,y,,stan
3411,21784392,1039,1052,Type of Quant. Measure,relative risk,model,y,,stan
3412,21784392,1054,1056,Type of Quant. Measure,RR,model,y,,stan
3413,21784392,1065,1088,Type of Quant. Measure,95% confidence interval,model,y,,stan
3414,21784392,1165,1171,Statistical Significance,95% CI,model,n,wrong label,stan
3415,21784392,1197,1208,Drug Intervention,clopidogrel,human,y,,stan
3416,21784392,1216,1218,Type of Quant. Measure,RR,model,y,,stan
3417,21784392,1226,1232,Statistical Significance,95% CI,model,y,,stan
3418,21784392,1427,1668,Outcome (Study Endpoint),"In conclusion, dental extractions may be safely performed in patients receiving single or dual antiplatelet therapy when appropriate local hemostatic measures are taken, thus averting thrombotic risk of temporary antiplatelet discontinuation",human,n,multiple entities,stan
3419,21802739,459,466,Intervention Duration,12-week,human,n,wrong label,cjackson
3420,21802739,603,606,Drug Intervention,MRI,model,n,wrong label,cjackson
3421,21802739,1025,1029,Group Characteristic,high,human,n,too little,cjackson
3422,21802739,1025,1033,Group Name,high DWM,model,n,wrong label,cjackson
3423,21802739,1030,1034,Group Characteristic,DWMH,human,n,too little,cjackson
3424,21802739,1045,1050,Units,times,human,n,not needed,cjackson
3425,21802739,1070,1110,Outcome (Study Endpoint),remit following antidepressant treatment,human,y,,cjackson
3426,21802739,1153,1156,Group Name,low,model,n,wrong label,cjackson
3427,21802739,1180,1191,Outcome (Study Endpoint),odds ratios,model,n,wrong label,cjackson
3428,21802739,1210,1213,Outcome (Study Endpoint),PVH,human,y,,cjackson
3429,21802739,1236,1249,Outcome (Study Endpoint),total volumes,human,y,,cjackson
3430,22235508,23,32,Drug Intervention,biguanide,model,n,wrong label,hcho
3431,22235508,37,43,Drug Intervention,statin,model,n,wrong label,hcho
3432,22235508,368,372,Disease/Condition of Interest,PCOS,human,y,,hcho
3433,22235508,526,535,Group Name,biguanide,human,n,too little,hcho
3434,22235508,578,584,Group Name,statin,human,n,,hcho
3435,22235508,1039,1057,Outcome (Study Endpoint),C-Reactive Protein,human,y,,hcho
3436,22235508,1059,1062,Outcome (Study Endpoint),CRP,human,y,,hcho
3437,22235508,1065,1101,Outcome (Study Endpoint),serum dehydroepiandrosterone sulfate,human,y,,hcho
3438,22235508,1103,1119,Outcome (Study Endpoint),hyperinsulinemia,human,y,,hcho
3439,22235508,1121,1137,Outcome (Study Endpoint),severity of acne,human,y,,hcho
3440,22235508,1142,1165,Outcome (Study Endpoint),menstrual abnormalities,human,y,,hcho
3441,22235508,1341,1356,Group Name,biguanide group,human,y,,hcho
3442,22235508,1569,1575,Group Name,statin,human,n,too little,hcho
3443,22257172,372,396,Group Characteristic,acute coronary syndromes,human,n,wrong label,ccurtis
3444,22257172,398,401,Disease/Condition of Interest,ACS,model,y,,ccurtis
3445,22257172,583,586,Group Name,NAP,model,y,,ccurtis
3446,22257172,745,754,Group Name,PAP users,model,y,,ccurtis
3447,22257172,793,817,Drug Intervention,dual antiplatelet agents,human,y,,ccurtis
3448,22257172,1103,1121,Outcome (Study Endpoint),recurrent ischemia,model,y,,ccurtis
3449,22257172,1103,1140,Outcome (Study Endpoint),recurrent ischemia in unstable angina,human,n,too much,ccurtis
3450,22257172,1125,1140,Outcome (Study Endpoint),unstable angina,model,n,not needed,ccurtis
3451,22257172,1142,1152,Type of Quant. Measure,odds ratio,model,y,,ccurtis
3452,22257172,1287,1293,Outcome (Study Endpoint),NSTEMI,human,n,not needed,ccurtis
3453,22257172,1505,1539,Non-Pharmaceutical Intervention,percutaneous coronary intervention,model,y,,ccurtis
3454,22257172,1566,1582,Outcome (Study Endpoint),risk of hospital,model,y,,ccurtis
3455,22257172,1574,1582,Outcome (Study Endpoint),hospital,human,n,too little,ccurtis
3456,22257172,1664,1672,Outcome (Study Endpoint),12-month,human,n,too little,ccurtis
3457,22257172,1664,1682,Outcome (Study Endpoint),12-month mortality,model,y,,ccurtis
3458,22257172,1673,1682,Outcome (Study Endpoint),mortality,human,n,too little,ccurtis
3459,22547422,59,87,Group Characteristic,first trimester of pregnancy,human,y,,eduvaris
3460,22547422,110,133,Disease/Condition of Interest,congenital malformation,model,n,not needed,eduvaris
3461,22547422,243,257,Disease/Condition of Interest,thyrotoxicosis,human,y,,eduvaris
3462,22547422,283,307,Disease/Condition of Interest,congenital malformations,model,n,not needed,eduvaris
3463,22547422,512,525,Group Name,control group,human,y,,eduvaris
3464,22547422,529,543,Group Characteristic,pregnant women,model,y,,eduvaris
3465,22547422,601,616,Group Characteristic,became pregnant,model,n,not needed,eduvaris
3466,22547422,608,616,Group Characteristic,pregnant,human,n,not needed,eduvaris
3467,22547422,682,686,Sample Size,5967,human,n,not needed,eduvaris
3468,22547422,700,703,Drug Intervention,MMI,model,y,wrong label,eduvaris
3469,22547422,789,792,Group Name,PTU,human,n,wrong label,eduvaris
3470,22547422,924,937,Group Name,control group,model,y,,eduvaris
3471,22547422,981,997,Drug Intervention,potassium iodide,model,n,wrong label,eduvaris
3472,22547422,999,1012,Drug Intervention,levothyroxine,model,n,wrong label,eduvaris
3473,22547422,1291,1304,Group Name,control group,model,y,,eduvaris
3474,22547422,1423,1436,Group Name,control group,model,y,,eduvaris
3475,22547422,1481,1485,Sample Size,1231,human,n,not needed,eduvaris
3476,22547422,1516,1539,Outcome (Study Endpoint),aplasia cutis congenita,model,y,,eduvaris
3477,22547422,1541,1544,Quantitative Measurement,six,model,y,,eduvaris
3478,22547422,1552,1563,Outcome (Study Endpoint),omphalocele,model,y,,eduvaris
3479,22547422,1565,1570,Quantitative Measurement,seven,model,y,,eduvaris
3480,22547422,1577,1619,Outcome (Study Endpoint),symptomatic omphalomesenteric duct anomaly,model,y,,eduvaris
3481,22547422,1625,1628,Quantitative Measurement,one,model,y,,eduvaris
3482,22547422,1633,1651,Outcome (Study Endpoint),esophageal atresia,model,y,,eduvaris
3483,22595898,52,75,Non-Pharmaceutical Intervention,carotid artery stenting,model,y,,stan
3484,22595898,157,160,Non-Pharmaceutical Intervention,CAS,model,y,,stan
3485,22595898,441,444,Drug Intervention,CLZ,model,y,,stan
3486,22595898,476,479,Non-Pharmaceutical Intervention,CAS,model,y,,stan
3487,22595898,604,607,Group Characteristic,CAS,human,n,wrong label,stan
3488,22595898,618,621,Group Characteristic,CWS,human,n,wrong label,stan
3489,22595898,745,759,Follow-up period,3 and 6 months,model,y,,stan
3490,22595898,955,958,Group Name,CLZ,human,n,too little,stan
3491,22595898,955,964,Group Name,CLZ group,model,y,,stan
3492,22595898,1016,1023,Group Name,non-CLZ,human,n,too little,stan
3493,22595898,1016,1029,Group Name,non-CLZ group,model,y,,stan
3494,22595898,1031,1032,Sample Size,n,model,n,not needed,stan
3495,22595898,1080,1083,Sample Size,n =,model,n,not needed,stan
3496,22595898,1113,1114,Sample Size,n,model,n,not needed,stan
3497,22595898,1255,1263,Intervention Duration,3 months,human,n,wrong label,stan
3498,22595898,1434,1447,Group Name,non-CLZ group,model,y,,stan
3499,22595898,1484,1493,Group Name,CLZ group,model,y,,stan
3500,22661187,245,265,Drug Intervention,acetylsalicylic acid,model,n,wrong label,cjackson
3501,22661187,289,292,Drug Intervention,CLO,model,n,wrong label,cjackson
3502,22661187,341,375,Non-Pharmaceutical Intervention,percutaneous coronary intervention,model,n,not needed,cjackson
3503,22661187,428,438,Group Characteristic,successful,model,n,too little,cjackson
3504,22661187,428,466,Group Characteristic,successful PCI with stent implantation,human,y,,cjackson
3505,22661187,558,561,Group Name,PPI,human,y,,cjackson
3506,22661187,602,612,Group Characteristic,F/M = 9/14,human,n,not needed,cjackson
3507,22661187,690,697,Group Name,group C,model,y,,cjackson
3508,22661187,696,697,Group Name,C,human,y,,cjackson
3509,22661187,713,723,Group Characteristic,F/M = 6/15,human,n,not needed,cjackson
3510,22661187,725,737,Group Characteristic,age = 64 ± 8,human,y,,cjackson
3511,22661187,930,933,Drug Intervention,CLO,model,n,wrong label,cjackson
3512,22661187,1133,1154,Outcome (Study Endpoint),platelets (PTL) tests,human,y,,cjackson
3513,22661187,1213,1216,Group Name,PPI,human,y,,cjackson
3514,22661187,1221,1222,Group Name,C,human,y,,cjackson
3515,22661187,1224,1228,Outcome (Study Endpoint),ASPI,model,y,,cjackson
3516,22661187,1258,1259,Units,U,model,y,,cjackson
3517,22661187,1261,1264,Outcome (Study Endpoint),COL,model,y,,cjackson
3518,22661187,1292,1293,Units,U,model,y,,cjackson
3519,22661187,1295,1298,Outcome (Study Endpoint),ADP,model,y,,cjackson
3520,22661187,1327,1328,Units,U,model,y,,cjackson
3521,22661187,1330,1334,Outcome (Study Endpoint),TRAP,model,y,,cjackson
3522,22661187,1364,1365,Units,U,model,y,,cjackson
3523,22717420,0,7,Group Name,T80/H25,human,n,wrong label,ccurtis
3524,22717420,16,19,Group Name,T80,human,n,wrong label,ccurtis
3525,22717420,55,58,Outcome (Study Endpoint),AEs,human,n,wrong label,ccurtis
3526,22717420,60,65,Quantitative Measurement,16.0%,model,y,,ccurtis
3527,22717420,69,74,Quantitative Measurement,17.0%,model,y,,ccurtis
3528,22717420,74,85,Drug Intervention,telmisartan,model,y,,hcho
3529,22717420,86,105,Drug Intervention,hydrochlorothiazide,model,y,,hcho
3530,22717420,96,117,Outcome (Study Endpoint),treatment-related AEs,model,n,wrong label,ccurtis
3531,22717420,106,108,Dosage,80,model,y,,hcho
3532,22717420,109,111,Disease/Condition of Interest,25,human,n,wrong label,hcho
3533,22717420,123,134,Group Name,T80/H25 SPC,human,n,wrong label,ccurtis
3534,22717420,139,142,Group Name,T80,human,n,wrong label,ccurtis
3535,22717420,145,157,Disease/Condition of Interest,hypertension,model,y,,hcho
3536,22717420,153,157,Quantitative Measurement,4.6%,model,y,,ccurtis
3537,22717420,162,166,Quantitative Measurement,2.8%,model,y,,ccurtis
3538,22717420,223,227,Quantitative Measurement,1.0%,model,y,,ccurtis
3539,22717420,232,236,Quantitative Measurement,2.8%,model,y,,ccurtis
3540,22717420,417,420,Group Name,T80,human,n,wrong label,ccurtis
3541,22717420,453,456,Group Name,SPC,human,n,wrong label,hcho
3542,22717420,461,472,Drug Intervention,telmisartan,model,y,,hcho
3543,22717420,473,492,Drug Intervention,hydrochlorothiazide,model,y,,hcho
3544,22717420,493,495,Dosage,80,model,y,,hcho
3545,22717420,496,498,Dosage,25,model,y,wrong label,hcho
3546,22717420,517,518,Drug Intervention,T,human,n,too little,hcho
3547,22717420,518,520,Disease/Condition of Interest,80,human,n,wrong label,hcho
3548,22717420,521,532,Group Name,monotherapy,human,n,wrong label,hcho
3549,22717420,645,648,Sample Size,894,model,y,,hcho
3550,22717420,799,802,Dosage,T40,human,n,too much or multiple entities based on context,hcho
3551,22717420,803,808,Dosage,H12.5,human,n,wrong label,hcho
3552,22717420,809,812,Group Name,SPC,human,n,wrong label,hcho
3553,22717420,816,827,Drug Intervention,telmisartan,model,y,,hcho
3554,22717420,834,845,Group Name,monotherapy,human,n,wrong label,hcho
3555,22717420,850,856,Intervention Duration,1 week,model,y,,hcho
3556,22717420,891,892,Drug Intervention,T,human,n,too little,hcho
3557,22717420,892,895,Group Name,80/,human,n,wrong label,hcho
3558,22717420,895,898,Group Name,H25,human,n,wrong label,hcho
3559,22717420,899,902,Group Name,SPC,human,n,wrong label,hcho
3560,22717420,906,907,Drug Intervention,T,human,n,too little,hcho
3561,22717420,907,909,Group Name,80,human,n,wrong label,hcho
3562,22717420,942,949,Intervention Duration,6 weeks,model,y,,hcho
3563,22717420,1088,1091,Sample Size,888,model,y,,hcho
3564,22717420,1121,1124,Sample Size,294,model,y,,hcho
3565,22717420,1129,1132,Sample Size,594,model,y,,hcho
3566,22717420,1188,1208,Group Characteristic,"mean age, 57.0 years",model,y,,hcho
3567,22717420,1210,1230,Group Characteristic,"age ≥65 years, 25.7%",model,y,,hcho
3568,22717420,1232,1237,Group Characteristic,"male,",model,n,too much,hcho
3569,22717420,1298,1315,Outcome (Study Endpoint),Mean baseline SBP,model,n,multiple entities,hcho
3570,22717420,1312,1319,Outcome (Study Endpoint),SBP/DBP,human,y,,hcho
3571,22717420,1351,1358,Group Name,T80/H25,human,n,wrong label,hcho
3572,22717420,1383,1386,Group Name,T80,human,n,wrong label,hcho
3573,22717420,1404,1407,Outcome (Study Endpoint),SBP,model,y,,hcho
3574,22717420,1423,1428,Quantitative Measurement,-37.0,model,y,,hcho
3575,22717420,1476,1486,Statistical Significance,P < 0.0001,model,y,,hcho
3576,22717420,1489,1492,Outcome (Study Endpoint),DBP,model,y,,hcho
3577,22717420,1508,1513,Quantitative Measurement,-18.6,model,y,,hcho
3578,22717420,1544,1554,Statistical Significance,P < 0.0001,model,y,,hcho
3579,22717420,1628,1638,Statistical Significance,P < 0.0001,model,y,,hcho
3580,22717420,1692,1697,Quantitative Measurement,55.5%,model,y,,hcho
3581,22717420,1702,1707,Quantitative Measurement,34.7%,model,y,,hcho
3582,22717420,1751,1761,Statistical Significance,P < 0.0001,model,y,,hcho
3583,22936125,0,7,Disease/Condition of Interest,Fatigue,human,n,wrong label,eduvaris
3584,22936125,25,53,Disease/Condition of Interest,systemic lupus erythematosus,model,y,wrong label,eduvaris
3585,22936125,100,107,Disease/Condition of Interest,Fatigue,human,n,wrong label,eduvaris
3586,22936125,334,341,Disease/Condition of Interest,fatigue,human,n,wrong label,eduvaris
3587,22936125,376,383,Disease/Condition of Interest,fatigue,human,n,wrong label,eduvaris
3588,22936125,395,401,Group Characteristic,female,model,y,,eduvaris
3589,22936125,395,419,Group Characteristic,female patients with SLE,human,n,too much,eduvaris
3590,22936125,416,419,Group Characteristic,SLE,model,n,wrong label,eduvaris
3591,22936125,447,449,Sample Size,31,human,y,,eduvaris
3592,22936125,457,459,Sample Size,29,human,y,,eduvaris
3593,22936125,470,480,Drug Intervention,prednisone,human,y,,eduvaris
3594,22936125,489,514,Group Characteristic,age-matched healthy women,human,n,too much,eduvaris
3595,22936125,501,508,Group Characteristic,healthy,model,y,,eduvaris
3596,22936125,509,514,Group Characteristic,women,model,y,,eduvaris
3597,22936125,562,565,Group Characteristic,low,human,n,too little,eduvaris
3598,22936125,570,576,Group Characteristic,normal,human,n,too little,eduvaris
3599,22936125,869,874,Group Characteristic,using,human,n,not needed,eduvaris
3600,22936125,875,885,Drug Intervention,prednisone,human,y,,eduvaris
3601,22936125,891,894,Group Characteristic,low,human,n,too little,eduvaris
3602,22936125,899,905,Group Characteristic,normal,human,n,too little,eduvaris
3603,22936125,930,954,Outcome (Study Endpoint),similar level of fatigue,human,n,not needed,eduvaris
3604,22936125,981,1018,Group Characteristic,low DHEAS levels not using prednisone,human,n,too much,eduvaris
3605,22936125,1028,1040,Outcome (Study Endpoint),less fatigue,human,n,too much,eduvaris
3606,22936125,1033,1040,Outcome (Study Endpoint),fatigue,model,y,,eduvaris
3607,22936125,1057,1076,Group Characteristic,normal DHEAS levels,human,y,,eduvaris
3608,22936125,1263,1270,Disease/Condition of Interest,fatigue,human,n,wrong label,eduvaris
3609,22936125,1374,1381,Disease/Condition of Interest,fatigue,human,n,wrong label,eduvaris
3610,23088590,0,6,Drug Intervention,Statin,human,y,,stan
3611,23088590,132,149,Disease/Condition of Interest,colorectal cancer,model,y,,stan
3612,23088590,744,755,Outcome (Study Endpoint),association,human,n,not needed,stan
3613,23088590,874,883,Outcome (Study Endpoint),all-cause,human,n,,stan
3614,23111138,109,138,Disease/Condition of Interest,permanent atrial fibrillation,human,n,too much,cjackson
3615,23111138,119,138,Disease/Condition of Interest,atrial fibrillation,model,y,,cjackson
3616,23111138,156,175,Disease/Condition of Interest,atrial fibrillation,model,y,,cjackson
3617,23111138,177,179,Disease/Condition of Interest,AF,model,y,,cjackson
3618,23111138,419,429,Intervention Frequency,once-daily,model,y,,cjackson
3619,23111138,670,672,Units,mg,model,y,,cjackson
3620,23111138,670,676,Units,mg/day,human,n,too much,cjackson
3621,23111138,672,676,Intervention Frequency,/day,model,n,too much,cjackson
3622,23111138,694,698,Intervention Frequency,/day,model,n,too much,cjackson
3623,23111138,695,698,Intervention Frequency,day,human,y,,cjackson
3624,23111138,717,721,Intervention Frequency,/day,model,n,too much,cjackson
3625,23111138,718,721,Intervention Frequency,day,human,y,,cjackson
3626,23111138,743,747,Intervention Frequency,/day,model,n,too much,cjackson
3627,23111138,744,747,Intervention Frequency,day,human,y,,cjackson
3628,23111138,1121,1130,Drug Intervention,diltiazem,model,y,wrong label,cjackson
3629,23111138,1155,1164,Group Name,verapamil,human,n,wrong label,cjackson
3630,23111138,1189,1199,Group Name,metoprolol,human,n,wrong label,cjackson
3631,23111138,1228,1238,Group Name,carvedilol,human,n,wrong label,cjackson
3632,23111138,1250,1272,Outcome (Study Endpoint),reduced the heart rate,model,n,too much,cjackson
3633,23111138,1318,1354,Outcome (Study Endpoint),24-hour heart rate was significantly,model,n,too much,cjackson
3634,23111138,1544,1552,Outcome (Study Endpoint),symptoms,model,y,,cjackson
3635,23111138,1652,1656,Outcome (Study Endpoint),/day,model,n,not needed,cjackson
3636,23113833,807,819,Drug Intervention,atorvastatin,model,y,,hcho
3637,23113833,831,840,Drug Intervention,SAR236553,human,y,,hcho
3638,23113833,883,888,Intervention Frequency,daily,human,y,,hcho
3639,23113833,894,903,Drug Intervention,SAR236553,human,y,,hcho
3640,23113833,936,948,Drug Intervention,atorvastatin,model,y,,hcho
3641,23113833,1052,1070,Type of Quant. Measure,least-squares mean,human,n,too little,hcho
3642,23113833,1072,1075,Type of Quant. Measure,±SE,human,n,too little,hcho
3643,23113833,1077,1094,Outcome (Study Endpoint),percent reduction,model,n,wrong label,hcho
3644,23113833,1146,1182,Group Name,80 mg of atorvastatin plus SAR236553,human,n,wrong label,hcho
3645,23113833,1224,1249,Group Name,atorvastatin plus placebo,human,n,wrong label,hcho
3646,23113833,1278,1314,Group Name,10 mg of atorvastatin plus SAR236553,human,n,wrong label,hcho
3647,23113833,1374,1376,Quantitative Measurement,52,human,n,too little,hcho
3648,23113833,1374,1377,Quantitative Measurement,52%,model,y,,hcho
3649,23113833,1448,1472,Outcome (Study Endpoint),LDL cholesterol level of,model,n,too much,hcho
3650,23113833,1518,1520,Quantitative Measurement,90,human,n,too little,hcho
3651,23113833,1518,1521,Quantitative Measurement,90%,model,y,,hcho
3652,23113833,1579,1581,Quantitative Measurement,17,human,n,too little,hcho
3653,23113833,1579,1582,Quantitative Measurement,17%,model,y,,hcho
3654,23113833,1641,1696,Outcome (Study Endpoint),LDL cholesterol levels of less than 70 mg per deciliter,model,y,,hcho
3655,23113833,1702,1716,Units,mmol per liter,model,y,,hcho
3656,23695545,316,325,Disease/Condition of Interest,H. pylori,model,y,,ccurtis
3657,23695545,517,524,Group Characteristic,Morocco,model,y,,ccurtis
3658,23695545,819,821,Dosage,20,human,y,,ccurtis
3659,23695545,819,824,Dosage,20 mg,model,n,too much,ccurtis
3660,23695545,822,824,Units,mg,human,y,,ccurtis
3661,23695545,845,846,Dosage,1,human,y,,ccurtis
3662,23695545,845,848,Dosage,1 g,model,n,too much,ccurtis
3663,23695545,847,848,Units,g,human,y,,ccurtis
3664,23695545,890,892,Dosage,20,human,y,,ccurtis
3665,23695545,890,895,Dosage,20 mg,model,n,too much,ccurtis
3666,23695545,893,895,Units,mg,human,y,,ccurtis
3667,23695545,915,918,Dosage,500,human,y,,ccurtis
3668,23695545,915,921,Dosage,500 mg,model,n,too much,ccurtis
3669,23695545,919,921,Units,mg,human,y,,ccurtis
3670,23695545,1018,1021,Follow-up period,4-6,model,n,too little,ccurtis
3671,23695545,1018,1027,Follow-up period,4-6 weeks,human,y,,ccurtis
3672,23695545,1397,1401,Quantitative Measurement,89.9,human,n,too little,ccurtis
3673,23695545,1397,1403,Quantitative Measurement,89.9 %,model,y,,ccurtis
3674,23695545,1658,1662,Quantitative Measurement,96.3,human,n,too little,ccurtis
3675,23695545,1658,1664,Quantitative Measurement,96.3 %,model,y,,ccurtis
3676,23695545,1663,1664,Units,%,human,n,wrong label,ccurtis
3677,23695545,1706,1710,Quantitative Measurement,27.9,human,n,too little,ccurtis
3678,23695545,1706,1712,Quantitative Measurement,27.9 %,model,y,,ccurtis
3679,23695545,1711,1712,Units,%,human,n,wrong label,ccurtis
3680,23695545,1796,1805,Disease/Condition of Interest,H. pylori,model,y,,ccurtis
3681,23698198,26,31,Group Characteristic,adult,model,y,,eduvaris
3682,23698198,196,198,Dosage,≥1,human,n,not needed,eduvaris
3683,23698198,199,205,Units,g/m(2),human,y,,eduvaris
3684,23698198,273,282,Non-Study Drug,acyclovir,human,n,not needed,eduvaris
3685,23698198,284,295,Non-Study Drug,allopurinol,human,n,wrong label,eduvaris
3686,23698198,297,319,Non-Study Drug,proton pump inhibitors,human,n,wrong label,eduvaris
3687,23698198,329,340,Non-Study Drug,antibiotics,human,n,not needed,eduvaris
3688,23698198,685,697,Drug Intervention,methotrexate,human,y,,eduvaris
3689,23698198,742,747,Group Characteristic,adult,model,y,,eduvaris
3690,23698198,742,756,Group Characteristic,adult oncology,human,n,multiple entities,eduvaris
3691,23698198,785,799,Group Characteristic,first cycle of,model,n,not needed,eduvaris
3692,23698198,791,822,Group Characteristic,cycle of high-dose methotrexate,human,n,not needed,eduvaris
3693,23698198,871,901,Outcome (Study Endpoint),delayed methotrexate clearance,model,y,wrong label,eduvaris
3694,23698198,919,964,Group Characteristic,serum methotrexate level ≥ 0.1 umol/L at 72 h,human,n,too much,eduvaris
3695,23698198,1046,1051,Group Name,cases,model,y,,eduvaris
3696,23698198,1056,1064,Group Name,controls,model,y,,eduvaris
3697,23698198,1193,1205,Drug Intervention,methotrexate,human,y,,eduvaris
3698,23698198,1458,1460,Sample Size,73,human,y,,eduvaris
3699,23698198,1518,1523,Group Name,cases,human,y,,eduvaris
3700,23698198,1563,1575,Drug Intervention,methotrexate,human,y,,eduvaris
3701,23698198,1563,1589,Outcome (Study Endpoint),methotrexate dose received,model,n,not needed,eduvaris
3702,23698198,1591,1595,Dosage,9116,human,y,wrong label,eduvaris
3703,23698198,1596,1605,Units,mg ± 4339,model,n,multiple entities,eduvaris
3704,23698198,1613,1617,Dosage,6054,human,y,wrong label,eduvaris
3705,23698198,1618,1627,Units,mg ± 2874,model,n,multiple entities,eduvaris
3706,23698198,1750,1772,Outcome (Study Endpoint),methotrexate clearance,human,n,too little,eduvaris
3707,23698198,1783,1789,Type of Quant. Measure,95% CI,model,y,wrong label,eduvaris
3708,23698198,1833,1845,Drug Intervention,methotrexate,human,y,,eduvaris
3709,23698198,1884,1895,Drug Intervention,allopurinol,model,y,,eduvaris
3710,23698198,1897,1919,Drug Intervention,proton pump inhibitors,model,y,,eduvaris
3711,23698198,1924,1953,Drug Intervention,sulfamethoxazole/trimethoprim,model,y,,eduvaris
3712,23698198,2136,2154,Outcome (Study Endpoint),rates of mucositis,human,y,,eduvaris
3713,23698198,2145,2154,Outcome (Study Endpoint),mucositis,model,n,too little,eduvaris
3714,23773352,180,183,Drug Intervention,PPI,human,y,,stan
3715,23773352,263,284,Disease/Condition of Interest,cardiovascular events,human,y,,stan
3716,23773352,351,362,Drug Intervention,clopidogrel,model,y,,stan
3717,23773352,543,557,Group Name,upon discharge,human,y,,stan
3718,23773352,561,577,Group Name,during follow-up,human,y,,stan
3719,23773352,594,626,Group Name,not taken the two drugs together,human,y,,stan
3720,23773352,823,825,Sample Size,26,model,y,,stan
3721,23773352,836,841,Quantitative Measurement,"19,6%",model,y,,stan
3722,23773352,891,935,Outcome (Study Endpoint),readmitted because of a cardiovascular event,human,y,,stan
3723,23773352,937,939,Quantitative Measurement,13,model,y,,stan
3724,23773352,952,963,Drug Intervention,clopidogrel,model,y,,stan
3725,24002795,55,60,Outcome (Study Endpoint),HDL-P,model,y,,hcho
3726,24002795,83,87,Quantitative Measurement,0.72,model,y,,hcho
3727,24002795,83,98,Quantitative Measurement,"0.72, 0.53-0.97",human,n,too much,hcho
3728,24002795,89,98,Quantitative Measurement,0.53-0.97,model,y,,hcho
3729,24002795,101,107,Drug Intervention,statin,human,y,,cjackson
3730,24002795,141,146,Outcome (Study Endpoint),HDL-C,human,n,wrong label,hcho
3731,24002795,228,231,Disease/Condition of Interest,CVD,human,y,,hcho
3732,24002795,364,370,Drug Intervention,statin,human,y,,cjackson
3733,24002795,638,644,Sample Size,10 886,model,y,,cjackson
3734,24002795,638,657,Sample Size,10 886 participants,human,n,too much,cjackson
3735,24002795,658,688,Group Characteristic,without cardiovascular disease,model,y,,cjackson
3736,24002795,658,694,Group Characteristic,without cardiovascular disease (CVD),human,n,too much,cjackson
3737,24002795,746,748,Dosage,20,model,y,,cjackson
3738,24002795,746,753,Dosage,20 mg/d,human,n,too much,cjackson
3739,24002795,749,751,Units,mg,model,y,,cjackson
3740,24002795,752,753,Intervention Frequency,d,model,y,,cjackson
3741,24002795,757,764,Group Name,placebo,human,y,wrong label,cjackson
3742,24002795,857,863,Statistical Significance,r=0.69,human,n,wrong label,cjackson
3743,24002795,892,898,Statistical Significance,r=0.55,human,n,wrong label,cjackson
3744,24002795,911,923,Drug Intervention,Rosuvastatin,human,y,,cjackson
3745,24002795,1100,1118,Outcome (Study Endpoint),on-treatment HDL-C,human,n,too much,cjackson
3746,24002795,1120,1126,Outcome (Study Endpoint),apoA-I,human,y,,cjackson
3747,24002795,1132,1137,Outcome (Study Endpoint),HDL-P,human,y,,cjackson
3748,24002795,1142,1179,Outcome (Study Endpoint),similar inverse associations with CVD,human,n,not needed,cjackson
3749,24002795,1181,1214,Type of Quant. Measure,risk factor-adjusted hazard ratio,human,y,,cjackson
3750,24002795,1202,1214,Type of Quant. Measure,hazard ratio,model,y,,cjackson
3751,24002795,1219,1242,Type of Quant. Measure,95% confidence interval,model,n,too little,cjackson
3752,24002795,1219,1267,Type of Quant. Measure,95% confidence interval per 1 standard deviation,human,y,,cjackson
3753,24002795,1384,1402,Outcome (Study Endpoint),on-treatment HDL-P,human,n,too much,cjackson
3754,24002795,1409,1477,Outcome (Study Endpoint),statistically significant and somewhat stronger association with CVD,human,n,not needed,cjackson
3755,24002795,1479,1483,Quantitative Measurement,0.73,human,y,,cjackson
3756,24002795,1479,1494,Quantitative Measurement,"0.73, 0.57-0.93",model,n,too much,cjackson
3757,24002795,1485,1494,Quantitative Measurement,0.57-0.93,human,y,,cjackson
3758,24002795,1509,1514,Outcome (Study Endpoint),HDL-C,human,y,,cjackson
3759,24002795,1516,1520,Quantitative Measurement,0.82,human,y,,cjackson
3760,24002795,1516,1531,Quantitative Measurement,"0.82, 0.63-1.08",model,n,too much,cjackson
3761,24002795,1522,1531,Quantitative Measurement,0.63-1.08,human,y,,cjackson
3762,24002795,1544,1550,Outcome (Study Endpoint),apoA-I,human,y,,cjackson
3763,24002795,1552,1556,Quantitative Measurement,0.86,human,y,,cjackson
3764,24002795,1552,1567,Quantitative Measurement,"0.86, 0.67-1.10",model,n,too much,cjackson
3765,24002795,1558,1567,Quantitative Measurement,0.67-1.10,human,y,,cjackson
3766,24420365,64,74,Drug Intervention,ticagrelor,model,y,,ccurtis
3767,24420365,217,222,Disease/Condition of Interest,acute,model,n,too little,ccurtis
3768,24420365,217,240,Disease/Condition of Interest,acute coronary syndrome,human,y,,ccurtis
3769,24420365,309,320,Drug Intervention,clopidogrel,human,n,wrong label,ccurtis
3770,24420365,332,342,Drug Intervention,ticagrelor,human,y,,ccurtis
3771,24420365,689,699,Drug Intervention,ticagrelor,model,y,,ccurtis
3772,24420365,739,755,Group Characteristic,cardiac surgical,human,n,too little,ccurtis
3773,24420365,1171,1177,Follow-up period,3 days,model,n,wrong label,ccurtis
3774,24420365,1371,1379,Quantitative Measurement,780-1600,human,y,,ccurtis
3775,24420365,1391,1401,Group Name,ticagrelor,human,n,wrong label,ccurtis
3776,24420365,1391,1407,Group Name,ticagrelor group,model,y,,ccurtis
3777,24420365,1436,1447,Group Name,clopidogrel,human,n,wrong label,ccurtis
3778,24420365,1436,1453,Group Name,clopidogrel group,model,y,,ccurtis
3779,24420365,1590,1628,Outcome (Study Endpoint),median prothrombin complex concentrate,human,n,too much,ccurtis
3780,24420365,1590,1632,Outcome (Study Endpoint),median prothrombin complex concentrate use,model,n,too much,ccurtis
3781,24420365,1654,1671,Outcome (Study Endpoint),median fibrinogen,human,n,too much,ccurtis
3782,24420365,1654,1675,Outcome (Study Endpoint),median fibrinogen use,model,n,too much,ccurtis
3783,24420365,1722,1732,Group Name,ticagrelor,human,n,wrong label,ccurtis
3784,24420365,1722,1738,Group Name,ticagrelor group,model,y,,ccurtis
3785,24420365,1757,1768,Group Name,clopidogrel,human,n,wrong label,ccurtis
3786,24420365,1757,1774,Group Name,clopidogrel group,model,y,,ccurtis
3787,24420365,2003,2018,Outcome (Study Endpoint),rethoracotomies,model,n,wrong label,ccurtis
3788,24420365,2026,2034,Outcome (Study Endpoint),bleeding,human,n,wrong label,ccurtis
3789,24420365,2136,2146,Drug Intervention,ticagrelor,human,y,,ccurtis
3790,24420365,2149,2152,Drug Intervention,ASA,human,n,wrong label,ccurtis
3791,24420365,2168,2178,Drug Intervention,ticagrelor,human,y,,ccurtis
3792,24420365,2399,2416,Drug Intervention,clopidogrel + ASA,human,n,wrong label,ccurtis
3793,24435325,295,301,Group Characteristic,stable,model,y,,eduvaris
3794,24435325,430,438,Group Name,controls,model,y,,eduvaris
3795,24435325,479,487,Outcome (Study Endpoint),elevated,human,n,not needed,eduvaris
3796,24435325,496,498,Quantitative Measurement,11,human,y,,eduvaris
3797,24435325,547,549,Quantitative Measurement,26,human,y,,eduvaris
3798,24435325,643,651,Outcome (Study Endpoint),elevated,human,n,not needed,eduvaris
3799,24435325,676,684,Group Name,controls,human,y,,eduvaris
3800,24671610,70,73,Group Characteristic,men,model,y,,stan
3801,24671610,158,164,Drug Intervention,statin,model,y,,stan
3802,24671610,238,244,Drug Intervention,statin,model,y,,stan
3803,24671610,298,301,Group Characteristic,men,model,y,,stan
3804,24671610,364,367,Group Characteristic,men,model,y,,stan
3805,24671610,373,388,Group Characteristic,prostate cancer,model,y,,stan
3806,24671610,445,475,Study Years,January 1999 and February 2009,model,y,,stan
3807,24671610,718,721,Group Characteristic,men,model,y,,stan
3808,24671610,970,1002,Outcome (Study Endpoint),Overall biochemical failure rate,model,n,too much,stan
3809,24671610,978,1002,Outcome (Study Endpoint),biochemical failure rate,human,y,,stan
3810,24671610,1052,1058,Drug Intervention,statin,model,y,,stan
3811,24671610,1154,1156,Type of Quant. Measure,HR,model,y,,stan
3812,24671610,1408,1440,Outcome (Study Endpoint),freedom from biochemical failure,human,n,too much,stan
3813,24671610,1486,1492,Drug Intervention,Statin,model,y,,stan
3814,24671610,1700,1706,Drug Intervention,statin,model,y,,stan
3815,24705623,36,46,Drug Intervention,cilostazol,model,y,,cjackson
3816,24705623,51,59,Drug Intervention,probucol,model,y,,cjackson
3817,24705623,84,94,Drug Intervention,cilostazol,model,y,,cjackson
3818,24705623,259,269,Drug Intervention,cilostazol,model,y,,cjackson
3819,24705623,274,282,Drug Intervention,probucol,model,y,,cjackson
3820,24705623,306,321,Disease/Condition of Interest,coronary plaque,model,y,,cjackson
3821,24705623,357,360,Sample Size,119,model,n,not needed,cjackson
3822,24705623,361,369,Group Characteristic,patients,model,n,not needed,cjackson
3823,24705623,859,870,Non-Study Drug,simvastatin,human,y,wrong label,cjackson
3824,24705623,1030,1037,Group Name,group Ⅰ,model,y,,cjackson
3825,24705623,1082,1132,Outcome (Study Endpoint),nominal change in normalized total atheroma volume,model,n,too much,cjackson
3826,24705623,1111,1180,Outcome (Study Endpoint),total atheroma volume (TAV) of the index intermediate coronary lesion,human,y,,cjackson
3827,24705623,1134,1137,Outcome (Study Endpoint),TAV,model,y,,cjackson
3828,24705623,1182,1183,Type of Quant. Measure,Δ,model,n,not needed,cjackson
3829,24705623,1300,1308,Units,patients,model,n,not needed,cjackson
3830,24705623,1397,1400,Outcome (Study Endpoint),TAV,model,y,,cjackson
3831,24705623,1471,1472,Type of Quant. Measure,Δ,model,n,not needed,cjackson
3832,24705623,1523,1524,Type of Quant. Measure,Δ,model,n,not needed,cjackson
3833,24705623,1592,1597,Group Name,group,model,n,too little,cjackson
3834,24705623,1627,1628,Type of Quant. Measure,Δ,model,n,not needed,cjackson
3835,24705623,1677,1678,Type of Quant. Measure,Δ,model,n,not needed,cjackson
3836,24743718,7,17,Drug Intervention,fluoxetine,model,y,,hcho
3837,24743718,92,96,Group Characteristic,with,human,n,wrong label,hcho
3838,24743718,97,122,Disease/Condition of Interest,major depressive disorder,model,y,,hcho
3839,24743718,158,186,Disease/Condition of Interest,generalized anxiety disorder,model,y,,hcho
3840,24743718,170,177,Disease/Condition of Interest,anxiety,human,n,too little,hcho
3841,24743718,200,203,Drug Intervention,FLX,model,y,,hcho
3842,24743718,498,502,Outcome (Study Endpoint),dose,human,n,wrong label,hcho
3843,24743718,556,557,Group Name,a,human,n,wrong label,hcho
3844,24743718,590,594,Group Characteristic,with,human,n,wrong label,hcho
3845,24743718,622,651,Group Characteristic,obsessive-compulsive disorder,model,n,wrong label,hcho
3846,24743718,656,684,Group Characteristic,generalized anxiety disorder,model,n,wrong label,hcho
3847,24743718,798,802,Group Characteristic,with,human,n,wrong label,hcho
3848,24743718,967,977,Drug Intervention,Fluoxetine,model,y,,hcho
3849,24743718,1045,1048,Drug Intervention,FLX,model,y,,hcho
3850,24743718,1050,1056,Drug Intervention,NORFLX,model,n,wrong label,hcho
3851,24743718,1058,1071,Drug Intervention,norfluoxetine,model,n,wrong label,hcho
3852,24743718,1074,1086,Drug Intervention,FLX + NORFLX,model,n,wrong label,hcho
3853,24743718,1092,1095,Drug Intervention,FLX,model,y,,hcho
3854,24743718,1096,1102,Drug Intervention,NORFLX,model,n,wrong label,hcho
3855,24743718,1258,1268,Group Name,responders,human,n,wrong label,hcho
3856,24743718,1273,1286,Group Name,nonresponders,human,n,wrong label,hcho
3857,24743718,1564,1574,Drug Intervention,Fluoxetine,model,y,,hcho
3858,24898695,108,133,Disease/Condition of Interest,peripheral artery disease,model,y,,ccurtis
3859,24898695,196,218,Drug Intervention,antithrombotic therapy,model,n,wrong label,ccurtis
3860,24898695,516,530,Drug Intervention,antithrombotic,model,n,wrong label,ccurtis
3861,24898695,738,773,Group Characteristic,requiring percutaneous intervention,model,n,too much,ccurtis
3862,24898695,808,863,Non-Pharmaceutical Intervention,peripheral artery percutaneous transluminal angioplasty,human,y,,ccurtis
3863,24898695,1188,1193,Quantitative Measurement,70.2%,model,y,,ccurtis
3864,24898695,1214,1221,Group Characteristic,optimal,human,n,not needed,ccurtis
3865,24898695,1270,1272,Sample Size,30,human,n,wrong label,ccurtis
3866,24898695,1274,1278,Quantitative Measurement,8.9%,model,y,,ccurtis
3867,24898695,1297,1308,Outcome (Study Endpoint),overtreated,model,n,wrong label,ccurtis
3868,24898695,1318,1323,Quantitative Measurement,20.8%,model,y,,ccurtis
3869,24898695,1330,1342,Group Characteristic,undertreated,human,y,wrong label,ccurtis
3870,24898695,1384,1397,Group Characteristic,heart failure,model,y,,ccurtis
3871,24898695,1435,1437,Type of Quant. Measure,OR,model,y,,ccurtis
3872,24898695,1444,1450,Type of Quant. Measure,95% CI,model,y,,ccurtis
3873,24898695,1452,1461,Quantitative Measurement,1.15-5.00,human,y,wrong label,ccurtis
3874,24898695,1539,1546,Outcome (Study Endpoint),overtre,model,n,too little,ccurtis
3875,24898695,1539,1550,Outcome (Study Endpoint),overtreated,human,n,wrong label,ccurtis
3876,24898695,1552,1554,Type of Quant. Measure,OR,model,y,,ccurtis
3877,24898695,1561,1567,Type of Quant. Measure,95% CI,model,y,,ccurtis
3878,24898695,1569,1579,Statistical Significance,1.61-10.00,model,n,wrong label,ccurtis
3879,24898695,1640,1659,Outcome (Study Endpoint),all-cause mortality,model,y,,ccurtis
3880,24898695,1650,1659,Outcome (Study Endpoint),mortality,human,n,too little,ccurtis
3881,24898695,1661,1673,Type of Quant. Measure,hazard ratio,model,y,,ccurtis
3882,24898695,1675,1677,Type of Quant. Measure,HR,model,y,,ccurtis
3883,24898695,1685,1691,Type of Quant. Measure,95% CI,model,y,,ccurtis
3884,24898695,1746,1748,Type of Quant. Measure,HR,model,y,,ccurtis
3885,24898695,1755,1761,Type of Quant. Measure,95% CI,model,y,,ccurtis
3886,24918960,0,23,Disease/Condition of Interest,Delayed ischemic stroke,model,n,wrong label,eduvaris
3887,24918960,193,216,Disease/Condition of Interest,delayed ischemic stroke,model,n,wrong label,eduvaris
3888,24918960,505,509,Sample Size,1579,model,n,not needed,eduvaris
3889,24918960,566,568,Sample Size,40,model,n,not needed,eduvaris
3890,24918960,601,630,Non-Pharmaceutical Intervention,stent-assisted coil placement,human,y,,eduvaris
3891,24918960,682,687,Group Name,early,human,y,,eduvaris
3892,24918960,711,719,Intervention Duration,3 months,human,y,,eduvaris
3893,24918960,813,823,Intervention Duration,≥ 9 months,model,y,,eduvaris
3894,24918960,1230,1238,Outcome (Study Endpoint),embolism,model,y,,eduvaris
3895,24918960,1240,1244,Quantitative Measurement,3.0%,model,y,,eduvaris
3896,24918960,1246,1266,Outcome (Study Endpoint),thrombotic occlusion,model,y,,eduvaris
3897,24918960,1268,1272,Quantitative Measurement,0.5%,model,y,,eduvaris
3898,24918960,1335,1358,Outcome (Study Endpoint),delayed ischemic stroke,model,y,,eduvaris
3899,24918960,1474,1494,Outcome (Study Endpoint),Incomplete occlusion,model,y,,eduvaris
3900,24918960,1548,1554,Quantitative Measurement,29.9,human,n,too little,eduvaris
3901,24936092,224,245,Disease/Condition of Interest,myocardial infarction,model,y,,stan
3902,24936092,371,392,Group Characteristic,myocardial infarction,model,y,,stan
3903,24936092,402,427,Group Characteristic,without revascularization,model,y,,stan
3904,24936092,452,484,Group Characteristic,first-time myocardial infarction,model,y,,stan
3905,24936092,488,497,Study Years,2002-2010,model,y,,stan
3906,24936092,499,531,Group Characteristic,not undergoing revascularization,model,y,,stan
3907,24936092,941,946,Group Name,users,model,y,,stan
3908,24936092,956,965,Group Name,non-users,model,y,,stan
3909,24936092,1052,1057,Group Characteristic,males,model,y,,stan
3910,24936092,1121,1130,Group Characteristic,<60 years,model,y,,stan
3911,24936092,1138,1149,Group Characteristic,60-69 years,model,y,,stan
3912,24936092,1157,1168,Group Characteristic,70-79 years,model,y,,stan
3913,24936092,1179,1188,Group Characteristic,>79 years,model,y,,stan
3914,24936092,1302,1311,Group Characteristic,<60 years,human,y,,stan
3915,24936092,1401,1407,Type of Quant. Measure,95% CI,model,y,,stan
3916,24936092,1442,1448,Type of Quant. Measure,95% CI,model,y,,stan
3917,24936092,1484,1490,Type of Quant. Measure,95% CI,model,y,,stan
3918,24936092,1609,1615,Type of Quant. Measure,95% CI,model,y,,stan
3919,24936092,1650,1656,Type of Quant. Measure,95% CI,model,y,,stan
3920,24936092,1695,1701,Type of Quant. Measure,95% CI,model,y,,stan
3921,24936092,1737,1743,Type of Quant. Measure,95% CI,model,y,,stan
3922,24990816,152,162,Drug Intervention,furosemide,model,n,wrong label,hcho
3923,24990816,409,422,Disease/Condition of Interest,heart failure,model,y,,hcho
3924,24990816,558,570,Group Characteristic,hospitalized,model,y,,hcho
3925,24990816,597,635,Study Years,"September 1, 2009, and August 31, 2011",model,n,wrong label,hcho
3926,24990816,667,678,Intervention Administration,intravenous,human,y,,hcho
3927,24990816,679,689,Drug Intervention,furosemide,model,n,wrong label,hcho
3928,24990816,718,721,Dosage,160,human,y,,hcho
3929,24990816,843,845,Units,mg,model,y,,hcho
3930,24990816,955,957,Units,mg,model,y,,hcho
3931,24990816,1003,1015,Outcome (Study Endpoint),urine output,human,n,too little,hcho
3932,24990816,1113,1117,Intervention Administration,oral,model,y,,hcho
3933,24990816,1118,1137,Drug Intervention,hydrochlorothiazide,model,y,,hcho
3934,24990816,1141,1152,Intervention Administration,intravenous,model,y,,hcho
3935,24990816,1153,1167,Drug Intervention,chlorothiazide,model,y,,hcho
3936,24990816,1229,1235,Statistical Significance,p=0.01,model,y,,hcho
3937,24990816,1266,1272,Statistical Significance,p=0.03,model,y,,hcho
3938,24990816,1446,1466,Outcome (Study Endpoint),24-hour urine output,model,y,,hcho
3939,24990816,1554,1573,Drug Intervention,hydrochlorothiazide,human,y,,hcho
3940,24990816,1644,1658,Drug Intervention,chlorothiazide,human,y,,hcho
3941,24990816,1709,1720,Outcome (Study Endpoint),Hypokalemia,model,y,,hcho
3942,24990816,1980,1999,Drug Intervention,hydrochlorothiazide,model,y,,hcho
3943,24990816,2003,2014,Intervention Administration,intravenous,model,y,,hcho
3944,24990816,2015,2029,Drug Intervention,chlorothiazide,model,y,,hcho
3945,24990816,2110,2124,Drug Intervention,chlorothiazide,model,y,,hcho
3946,24990816,2144,2163,Drug Intervention,hydrochlorothiazide,model,y,,hcho
3947,24990816,2262,2281,Drug Intervention,hydrochlorothiazide,model,y,,hcho
3948,25098924,273,283,Non-Pharmaceutical Intervention,Endoscopic,model,n,too little,ccurtis
3949,25098924,307,310,Non-Pharmaceutical Intervention,ESD,model,y,,ccurtis
3950,25098924,335,355,Disease/Condition of Interest,early gastric cancer,model,y,,ccurtis
3951,25098924,357,360,Disease/Condition of Interest,EGC,model,y,,ccurtis
3952,25098924,1132,1146,Outcome (Study Endpoint),scarring ratio,model,y,,ccurtis
3953,25098924,1169,1176,Group Name,group A,model,y,,ccurtis
3954,25098924,1215,1222,Group Name,group B,model,y,,ccurtis
3955,25098924,1275,1288,Outcome (Study Endpoint),scarring rate,model,y,,ccurtis
3956,25098924,1275,1324,Outcome (Study Endpoint),scarring rate of ulcers with an area ≥565.5 mm(2),human,n,too much,ccurtis
3957,25098924,1328,1335,Group Name,group A,model,y,,ccurtis
3958,25098924,1374,1381,Group Name,group B,model,y,,ccurtis
3959,25253582,14,24,Drug Intervention,olmesartan,model,y,,eduvaris
3960,25253582,82,89,Group Characteristic,elderly,model,y,,eduvaris
3961,25253582,90,102,Disease/Condition of Interest,hypertensive,model,n,wrong label,eduvaris
3962,25253582,255,294,Drug Intervention,dihydropyridine calcium channel blocker,human,y,,eduvaris
3963,25253582,306,314,Drug Intervention,diuretic,human,y,,eduvaris
3964,25253582,332,336,Group Characteristic,high,model,n,too little,eduvaris
3965,25253582,332,341,Group Characteristic,high-risk,human,y,,eduvaris
3966,25253582,342,349,Group Characteristic,elderly,human,y,,eduvaris
3967,25253582,359,371,Disease/Condition of Interest,hypertensive,human,n,wrong label,eduvaris
3968,25253582,566,575,Group Characteristic,High-risk,model,y,,eduvaris
3969,25253582,576,588,Group Characteristic,hypertensive,model,y,,eduvaris
3970,25253582,598,614,Group Characteristic,aged 65-84 years,model,y,,eduvaris
3971,25253582,603,614,Group Characteristic,65-84 years,human,n,too little,eduvaris
3972,25253582,754,756,Intervention Duration,at,model,n,too little,eduvaris
3973,25253582,1095,1119,Outcome (Study Endpoint),cardiovascular morbidity,human,y,,eduvaris
3974,25253582,1124,1133,Outcome (Study Endpoint),mortality,human,y,,eduvaris
3975,25253582,1158,1169,Outcome (Study Endpoint),serious AEs,human,y,,eduvaris
3976,25253582,1171,1195,Outcome (Study Endpoint),drug-related serious AEs,human,y,,eduvaris
3977,25253582,1200,1234,Outcome (Study Endpoint),discontinuation due to serious AEs,human,y,,eduvaris
3978,25253582,1253,1272,Group Name,olmesartan plus CCB,human,n,too little,eduvaris
3979,25253582,1253,1278,Group Name,olmesartan plus CCB group,model,y,,eduvaris
3980,25253582,1323,1363,Outcome (Study Endpoint),Serum levels of uric acid and creatinine,human,y,,eduvaris
3981,25253582,1397,1427,Group Name,olmesartan plus diuretic group,model,y,,eduvaris
3982,25253582,1440,1465,Group Name,olmesartan plus CCB group,model,y,,eduvaris
3983,25253582,1467,1477,Drug Intervention,Olmesartan,model,y,,eduvaris
3984,25253582,1528,1538,Drug Intervention,olmesartan,model,y,,eduvaris
3985,25364906,40,43,Group Characteristic,men,model,y,,stan
3986,25364906,177,187,Drug Intervention,zofenopril,human,y,,stan
3987,25364906,192,223,Group Name,placebo or other ACE-inhibitors,human,n,multiple entities,stan
3988,25364906,235,267,Disease/Condition of Interest,post-acute myocardial infarction,model,y,,stan
3989,25364906,269,272,Disease/Condition of Interest,AMI,model,y,,stan
3990,25364906,354,364,Drug Intervention,zofenopril,human,y,,stan
3991,25364906,537,539,Units,mg,model,y,,stan
3992,25364906,537,543,Units,mg/day,human,n,multiple entities,stan
3993,25364906,540,543,Intervention Frequency,day,model,y,,stan
3994,25364906,557,564,Drug Intervention,placebo,model,n,wrong label,stan
3995,25364906,580,582,Units,mg,model,y,,stan
3996,25364906,580,586,Units,mg/day,human,n,multiple entities,stan
3997,25364906,583,586,Intervention Frequency,day,model,y,,stan
3998,25364906,602,604,Units,mg,model,y,,stan
3999,25364906,602,608,Units,mg/day,human,n,multiple entities,stan
4000,25364906,605,608,Intervention Frequency,day,model,y,,stan
4001,25364906,617,620,Group Characteristic,AMI,model,n,wrong label,stan
4002,25364906,1037,1045,Group Characteristic,Southern,model,y,,stan
4003,25364906,1047,1051,Quantitative Measurement,+54%,model,n,too much,stan
4004,25364906,1061,1076,Group Characteristic,Northern Europe,model,y,,stan
4005,25364906,1078,1082,Quantitative Measurement,+12%,model,n,too much,stan
4006,25364906,1101,1111,Drug Intervention,zofenopril,human,y,,stan
4007,25364906,1180,1187,Group Name,placebo,human,y,,stan
4008,25364906,1239,1253,Outcome (Study Endpoint),risk reduction,human,n,too little or too much based on context,stan
4009,25440796,840,846,Intervention Frequency,biweek,model,n,too little,cjackson
4010,25440796,840,848,Intervention Frequency,biweekly,human,y,,cjackson
4011,25440796,849,859,Intervention Administration,injections,human,y,,cjackson
4012,25440796,863,869,Drug Intervention,aliroc,model,n,too little,cjackson
4013,25440796,863,873,Drug Intervention,alirocumab,human,y,,cjackson
4014,25440796,898,905,Group Name,placebo,model,y,,cjackson
4015,25440796,966,993,Group Characteristic,acute myocardial infarction,model,n,wrong label,cjackson
4016,25440796,997,1012,Group Characteristic,unstable angina,model,n,wrong label,cjackson
4017,25440796,1070,1072,Dosage,80,human,y,,cjackson
4018,25440796,1224,1234,Group Characteristic,LDL-C ≥ 70,model,n,not needed,cjackson
4019,25440796,1235,1240,Units,mg/dL,model,y,,cjackson
4020,25440796,1242,1294,Group Characteristic,non-high-density lipoprotein cholesterol ≥ 100 mg/dL,model,n,not needed,cjackson
4021,25440796,1299,1326,Group Characteristic,apolipoprotein B ≥ 80 mg/dL,model,n,not needed,cjackson
4022,25440796,1360,1416,Outcome (Study Endpoint),time to first occurrence of coronary heart disease death,model,y,,cjackson
4023,25440796,1388,1416,Outcome (Study Endpoint),coronary heart disease death,human,n,too little,cjackson
4024,25440796,1447,1482,Outcome (Study Endpoint),hospitalization for unstable angina,human,y,,cjackson
4025,25440796,1614,1616,Follow-up period,at,model,n,not needed,cjackson
4026,25440796,1729,1744,Side Effects,allergic events,model,n,not needed,cjackson
4027,25440796,1749,1773,Side Effects,injection site reactions,model,n,not needed,cjackson
4028,25448925,68,81,Disease/Condition of Interest,regurgitation,human,y,,hcho
4029,25448925,116,156,Non-Pharmaceutical Intervention,Transoral esophagogastric fundoplication,model,y,,hcho
4030,25448925,116,161,Drug Intervention,Transoral esophagogastric fundoplication (TF),human,n,wrong label,hcho
4031,25448925,200,231,Disease/Condition of Interest,gastroesophageal reflux disease,model,y,,hcho
4032,25448925,200,238,Disease/Condition of Interest,gastroesophageal reflux disease (GERD),human,n,too much,hcho
4033,25448925,262,322,Group Characteristic,symptoms persist despite proton pump inhibitor (PPI) therapy,human,y,,hcho
4034,25448925,401,426,Disease/Condition of Interest,troublesome regurgitation,human,n,wrong label,hcho
4035,25448925,452,456,Drug Intervention,PPIs,human,y,,hcho
4036,25448925,469,478,Group Characteristic,with GERD,human,n,wrong label,hcho
4037,25448925,492,495,Sample Size,696,model,y,,hcho
4038,25448925,492,504,Sample Size,696 patients,human,n,too much,hcho
4039,25448925,510,535,Group Characteristic,troublesome regurgitation,model,n,wrong label,hcho
4040,25448925,510,615,Group Characteristic,"troublesome regurgitation despite daily PPI use with 3 validated GERD-specific symptom scales, on and off",human,n,too much,hcho
4041,25448925,616,620,Drug Intervention,PPIs,human,n,wrong label,hcho
4042,25448925,633,667,Group Characteristic,at least troublesome regurgitation,human,n,wrong label,hcho
4043,25448925,682,701,Type of Quant. Measure,Montreal definition,human,n,wrong label,hcho
4044,25448925,706,710,Drug Intervention,PPIs,human,n,wrong label,hcho
4045,25448925,721,859,Non-Pharmaceutical Intervention,"barium swallow, esophagogastroduodenoscopy, 48-hour esophageal pH monitoring (off PPIs), and high-resolution esophageal manometry analyses",human,n,too much,hcho
4046,25448925,861,904,Group Characteristic,Patients with GERD and hiatal hernias ≤2 cm,human,n,too much,hcho
4047,25448925,884,904,Group Characteristic,hiatal hernias ≤2 cm,model,y,,hcho
4048,25448925,953,985,Group Name,TF and then received 6 months of,human,n,wrong label,hcho
4049,25448925,974,982,Intervention Duration,6 months,model,y,,hcho
4050,25448925,995,1001,Sample Size,n = 87,human,n,too much,hcho
4051,25448925,999,1001,Sample Size,87,model,y,,hcho
4052,25448925,1036,1044,Intervention Frequency,once- or,model,n,too little,hcho
4053,25448925,1079,1085,Sample Size,n = 42,human,n,too much,hcho
4054,25448925,1083,1085,Sample Size,42,model,y,,hcho
4055,25448925,1102,1109,Group Characteristic,blinded,human,n,wrong label,hcho
4056,25448925,1163,1182,Follow-up period,"2, 12, and 26 weeks",human,n,too much or multiple entities based on context,hcho
4057,25448925,1187,1195,Type of Quant. Measure,6 months,human,n,wrong label,hcho
4058,25448925,1216,1223,Intervention Duration,48-hour,human,n,wrong label,hcho
4059,25448925,1224,1248,Non-Pharmaceutical Intervention,esophageal pH monitoring,human,n,wrong label,hcho
4060,25448925,1253,1279,Non-Pharmaceutical Intervention,esophagogastroduodenoscopy,human,n,wrong label,hcho
4061,25448925,1313,1409,Outcome (Study Endpoint),TF eliminated troublesome regurgitation in a larger proportion of patients (67%) than PPIs (45%),human,n,too much,hcho
4062,25448925,1316,1352,Outcome (Study Endpoint),eliminated troublesome regurgitation,model,y,,hcho
4063,25448925,1389,1392,Quantitative Measurement,67%,model,y,,hcho
4064,25448925,1405,1408,Quantitative Measurement,45%,model,y,,hcho
4065,25448925,1410,1420,Statistical Significance,(P = .023),human,n,too much,hcho
4066,25448925,1411,1419,Statistical Significance,P = .023,model,y,,hcho
4067,25448925,1422,1518,Outcome (Study Endpoint),A larger proportion of controls had no response at 3 months (36%) than subjects that received TF,human,n,too much,hcho
4068,25448925,1458,1469,Outcome (Study Endpoint),no response,model,y,,hcho
4069,25448925,1483,1486,Quantitative Measurement,36%,model,y,,hcho
4070,25448925,1519,1520,Statistical Significance,(,human,n,too little,hcho
4071,25448925,1523,1534,Statistical Significance,; P = .004),human,n,too much,hcho
4072,25448925,1525,1533,Statistical Significance,P = .004,model,y,,hcho
4073,25448925,1536,1560,Outcome (Study Endpoint),Control of esophageal pH,model,y,,hcho
4074,25448925,1536,1580,Outcome (Study Endpoint),Control of esophageal pH improved after TF (,human,n,too much,hcho
4075,25448925,1580,1584,Type of Quant. Measure,mean,model,y,,hcho
4076,25448925,1585,1589,Quantitative Measurement,9.3%,model,y,,hcho
4077,25448925,1601,1605,Quantitative Measurement,6.3%,model,y,,hcho
4078,25448925,1613,1621,Statistical Significance,P < .001,model,y,,hcho
4079,25448925,1613,1622,Statistical Significance,P < .001),human,n,too much,hcho
4080,25448925,1624,1650,Outcome (Study Endpoint),but not after sham surgery,human,n,wrong label,hcho
4081,25448925,1652,1656,Type of Quant. Measure,mean,model,y,,hcho
4082,25448925,1657,1661,Quantitative Measurement,8.6%,model,y,,hcho
4083,25448925,1673,1677,Quantitative Measurement,8.9%,model,y,,hcho
4084,25448925,1716,1738,Group Characteristic,completed the protocol,human,n,wrong label,hcho
4085,25448925,1739,1785,Outcome (Study Endpoint),had similar reductions in GERD symptom scores.,human,n,too much,hcho
4086,25448925,1786,1816,Outcome (Study Endpoint),Severe complications were rare,human,n,wrong label,hcho
4087,25448925,1818,1819,Sample Size,3,human,n,wrong label,hcho
4088,25448925,1839,1841,Group Name,TF,human,n,wrong label,hcho
4089,25448925,1846,1847,Sample Size,1,human,n,wrong label,hcho
4090,25448925,1862,1874,Disease/Condition of Interest,sham surgery,human,n,wrong label,hcho
4091,25448925,1877,2011,Outcome (Study Endpoint),"TF was an effective treatment for patients with GERD symptoms, particularly in those with persistent regurgitation despite PPI therapy",human,n,wrong label,hcho
4092,25448925,2033,2061,Follow-up period,6 months after the procedure,human,n,too much,hcho
4093,26177937,89,90,Dosage,5,model,n,not needed,eduvaris
4094,26177937,91,93,Units,μg,model,n,not needed,eduvaris
4095,26177937,94,104,Drug Intervention,olodaterol,model,y,,eduvaris
4096,26177937,105,110,Intervention Frequency,daily,model,n,not needed,eduvaris
4097,26177937,112,113,Dosage,5,model,y,,eduvaris
4098,26177937,114,116,Units,μg,model,y,,eduvaris
4099,26177937,117,119,Intervention Frequency,QD,model,y,,eduvaris
4100,26177937,123,126,Dosage,2.5,model,y,,eduvaris
4101,26177937,127,129,Units,μg,model,y,,eduvaris
4102,26177937,130,133,Intervention Frequency,BID,model,y,,eduvaris
4103,26177937,359,366,Intervention Duration,3 weeks,model,y,,ccurtis
4104,26177937,395,397,Intervention Frequency,QD,human,y,,ccurtis
4105,26177937,415,418,Intervention Frequency,BID,human,y,,ccurtis
4106,26177937,469,476,Drug Intervention,placebo,model,n,wrong label,ccurtis
4107,26177937,518,543,Group Characteristic,moderate to severe asthma,human,n,wrong label,ccurtis
4108,26177937,596,606,Drug Intervention,olodaterol,model,y,,ccurtis
4109,26177937,660,661,Dosage,5,model,y,,ccurtis
4110,26177937,662,664,Units,μg,model,y,,ccurtis
4111,26177937,666,667,Dosage,5,human,y,,ccurtis
4112,26177937,666,670,Dosage,5 μg,model,n,too much,ccurtis
4113,26177937,668,670,Units,μg,human,y,,ccurtis
4114,26177937,709,711,Dosage,10,model,y,,ccurtis
4115,26177937,712,714,Units,μg,model,y,,ccurtis
4116,26177937,716,718,Dosage,10,human,y,,ccurtis
4117,26177937,716,721,Dosage,10 μg,model,n,too much,ccurtis
4118,26177937,719,721,Units,μg,human,y,,ccurtis
4119,26177937,1134,1141,Group Name,placebo,model,y,,ccurtis
4120,26177937,1156,1190,Outcome (Study Endpoint),adjusted mean treatment difference,human,n,too much,ccurtis
4121,26177937,1170,1190,Outcome (Study Endpoint),treatment difference,model,y,,ccurtis
4122,26177937,1198,1205,Group Name,placebo,model,y,,ccurtis
4123,26177937,1222,1232,Drug Intervention,olodaterol,model,y,,ccurtis
4124,26177937,1233,1239,Dosage,2.5 μg,model,n,too much,ccurtis
4125,26177937,1233,1243,Group Name,2.5 μg BID,human,n,too much,ccurtis
4126,26177937,1240,1243,Intervention Frequency,BID,model,y,,ccurtis
4127,26177937,1275,1280,Quantitative Measurement,0.152,human,n,too little,ccurtis
4128,26177937,1275,1287,Quantitative Measurement,"0.152, 0.229",model,y,,ccurtis
4129,26177937,1282,1287,Quantitative Measurement,0.229,human,n,too little,ccurtis
4130,26177937,1319,1324,Quantitative Measurement,0.111,human,n,too little,ccurtis
4131,26177937,1319,1331,Quantitative Measurement,"0.111, 0.189",model,y,,ccurtis
4132,26177937,1326,1331,Quantitative Measurement,0.189,human,n,too little,ccurtis
4133,26177937,1364,1369,Quantitative Measurement,0.190,human,n,too little,ccurtis
4134,26177937,1364,1376,Quantitative Measurement,"0.190, 0.266",model,y,,ccurtis
4135,26177937,1371,1376,Quantitative Measurement,0.266,human,n,too little,ccurtis
4136,26177937,1412,1417,Quantitative Measurement,0.170,human,n,too little,ccurtis
4137,26177937,1412,1424,Quantitative Measurement,"0.170, 0.247",model,y,,ccurtis
4138,26177937,1419,1424,Quantitative Measurement,0.247,human,n,,ccurtis
4139,26177937,1489,1499,Drug Intervention,Olodaterol,model,y,,ccurtis
4140,26177937,1500,1504,Group Name,5 μg,model,n,too much,ccurtis
4141,26177937,1505,1507,Group Name,QD,model,n,wrong label,ccurtis
4142,26177937,1577,1587,Drug Intervention,olodaterol,model,y,,ccurtis
4143,26177937,1588,1594,Dosage,2.5 μg,model,n,too much,ccurtis
4144,26177937,1595,1598,Intervention Frequency,BID,model,y,,ccurtis
4145,26177937,1681,1691,Drug Intervention,olodaterol,model,y,,ccurtis
4146,26249301,43,51,Group Characteristic,children,human,y,,stan
4147,26249301,57,97,Disease/Condition of Interest,attention deficit hyperactivity disorder,human,y,,stan
4148,26249301,737,748,Type of Quant. Measure,odds ratios,human,y,,stan
4149,26249301,802,819,Outcome (Study Endpoint),rates of injuries,human,n,too much,stan
4150,26249301,824,845,Outcome (Study Endpoint),emergency ward visits,human,y,,stan
4151,26249301,943,951,Group Name,controls,model,y,,stan
4152,26249301,992,999,Outcome (Study Endpoint),sustain,model,n,too little,stan
4153,26249301,992,1008,Outcome (Study Endpoint),sustain injuries,human,n,too much,stan
4154,26249301,1000,1008,Outcome (Study Endpoint),injuries,model,y,,stan
4155,26249301,1033,1040,Group Name,without,model,n,too little,stan
4156,26249301,1050,1056,Outcome (Study Endpoint),age 10,model,n,wrong label,stan
4157,26249301,1107,1119,Outcome (Study Endpoint),age 12 years,model,n,wrong label,stan
4158,26249301,1156,1161,Group Characteristic,age 5,human,y,,stan
4159,26249301,1179,1201,Outcome (Study Endpoint),prevalence of injuries,model,n,too much,stan
4160,26249301,1193,1201,Outcome (Study Endpoint),injuries,human,y,,stan
4161,26249301,1233,1240,Group Name,treated,model,y,,stan
4162,26249301,1272,1275,Quantitative Measurement,19%,human,y,,stan
4163,26249301,1279,1282,Quantitative Measurement,14%,human,y,,stan
4164,26249301,1320,1322,Quantitative Measurement,17,model,n,too little,stan
4165,26249301,1320,1323,Quantitative Measurement,17%,human,y,,stan
4166,26249301,1327,1338,Group Name,non-treated,model,y,,stan
4167,26249301,1430,1452,Outcome (Study Endpoint),prevalence of injuries,model,n,too much,stan
4168,26249301,1460,1462,Group Characteristic,10,human,n,too little or too much based on context,stan
4169,26249301,1514,1520,Group Characteristic,age 12,human,y,,stan
4170,26249301,1731,1747,Outcome (Study Endpoint),risk of injuries,human,n,too much,stan
4171,26249301,1816,1832,Outcome (Study Endpoint),risk of injuries,human,n,too little,stan
4172,26249301,1842,1844,Quantitative Measurement,43,model,n,too little,stan
4173,26249301,1842,1845,Quantitative Measurement,43%,human,y,,stan
4174,26249301,1881,1884,Quantitative Measurement,45%,human,y,,stan
4175,26331791,20,31,Drug Intervention,venlafaxine,model,y,,cjackson
4176,26331791,69,78,Disease/Condition of Interest,psoriasis,model,y,,cjackson
4177,26331791,89,98,Disease/Condition of Interest,Psoriasis,model,y,,cjackson
4178,26331791,316,327,Drug Intervention,Venlafaxine,model,y,,cjackson
4179,26331791,611,620,Group Characteristic,Psoriasis,model,n,wrong label,cjackson
4180,26331791,643,650,Group Characteristic,healthy,model,y,,cjackson
4181,26331791,733,734,Sample Size,1,model,y,,cjackson
4182,26331791,774,785,Drug Intervention,racemic VLX,model,y,,cjackson
4183,26331791,934,960,Outcome (Study Endpoint),IL-6 plasma concentrations,model,y,,cjackson
4184,26331791,939,960,Outcome (Study Endpoint),plasma concentrations,human,n,too little,cjackson
4185,26331791,980,984,Quantitative Measurement,12.9,human,y,,cjackson
4186,26331791,1002,1007,Units,pg/mL,model,y,,cjackson
4187,26331791,1040,1043,Quantitative Measurement,0.4,model,y,,cjackson
4188,26331791,1047,1051,Quantitative Measurement,29.3,human,y,,cjackson
4189,26331791,1052,1057,Units,pg/mL,model,y,,cjackson
4190,26331791,1069,1074,Units,pg/mL,model,y,,cjackson
4191,26596670,0,30,Drug Intervention,Chemotherapy plus lenalidomide,human,n,too much,hcho
4192,26596670,18,30,Drug Intervention,lenalidomide,model,y,,hcho
4193,26596670,38,64,Non-Pharmaceutical Intervention,autologous transplantation,human,y,,hcho
4194,26596670,63,66,Quantitative Measurement,11%,model,y,,eduvaris
4195,26596670,68,76,Group Characteristic,patients,human,n,not needed,eduvaris
4196,26596670,78,90,Drug Intervention,lenalidomide,model,y,,hcho
4197,26596670,78,106,Drug Intervention,lenalidomide plus prednisone,human,n,too much,hcho
4198,26596670,86,98,Drug Intervention,lenalidomide,model,y,,eduvaris
4199,26596670,86,114,Drug Intervention,lenalidomide plus prednisone,human,n,multiple entities,eduvaris
4200,26596670,96,106,Drug Intervention,prednisone,model,y,,hcho
4201,26596670,104,114,Drug Intervention,prednisone,model,y,,eduvaris
4202,26596670,117,126,Drug Intervention,melphalan,human,y,,ccurtis
4203,26596670,127,129,Quantitative Measurement,9%,model,y,,eduvaris
4204,26596670,141,153,Drug Intervention,lenalidomide,human,y,,eduvaris
4205,26596670,141,159,Group Name,lenalidomide alone,model,n,wrong label,eduvaris
4206,26596670,143,151,Group Characteristic,patients,human,n,wrong label,hcho
4207,26596670,144,174,Drug Intervention,chemotherapy plus lenalidomide,human,n,too much,ccurtis
4208,26596670,166,174,Group Characteristic,patients,human,n,not needed,eduvaris
4209,26596670,207,212,Sample Size,three,human,n,wrong label,eduvaris
4210,26596670,214,226,Drug Intervention,lenalidomide,model,y,,ccurtis
4211,26596670,214,242,Drug Intervention,lenalidomide plus prednisone,human,n,too much,ccurtis
4212,26596670,217,226,Dosage,High-dose,human,n,wrong label,hcho
4213,26596670,218,228,Side Effects,infections,model,y,,eduvaris
4214,26596670,227,236,Drug Intervention,melphalan,human,y,,hcho
4215,26596670,285,288,Sample Size,one,human,n,wrong label,eduvaris
4216,26596670,293,304,Follow-up period,52·0 months,human,y,,ccurtis
4217,26596670,314,333,Group Characteristic,transplant-eligible,model,y,,hcho
4218,26596670,322,347,Outcome (Study Endpoint),Progression-free survival,model,y,,ccurtis
4219,26596670,322,399,Outcome (Study Endpoint),Progression-free survival during consolidation was significantly shorter with,human,n,too much,ccurtis
4220,26596670,323,524,Outcome (Study Endpoint),"Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide",human,n,too much,eduvaris
4221,26596670,373,386,Outcome (Study Endpoint),significantly,model,n,not needed,ccurtis
4222,26596670,400,430,Drug Intervention,chemotherapy plus lenalidomide,human,n,too much,ccurtis
4223,26596670,417,426,Dosage,high-dose,human,n,wrong label,hcho
4224,26596670,437,453,Disease/Condition of Interest,multiple myeloma,model,y,,eduvaris
4225,26596670,442,446,Drug Intervention,ASCT,human,y,,hcho
4226,26596670,445,454,Dosage,high-dose,human,n,not needed,ccurtis
4227,26596670,454,466,Drug Intervention,chemotherapy,human,y,,hcho
4228,26596670,455,464,Drug Intervention,melphalan,human,y,,ccurtis
4229,26596670,495,501,Type of Quant. Measure,95% CI,model,y,,ccurtis
4230,26596670,557,561,Group Name,plus,human,n,wrong label,hcho
4231,26596670,618,643,Outcome (Study Endpoint),Progression-free survival,model,y,,ccurtis
4232,26596670,618,658,Outcome (Study Endpoint),Progression-free survival did not differ,human,n,too much,ccurtis
4233,26596670,711,714,Quantitative Measurement,95%,human,n,wrong label,ccurtis
4234,26596670,711,717,Type of Quant. Measure,95% CI,model,y,,ccurtis
4235,26596670,728,747,Group Characteristic,transplant-eligible,model,y,,hcho
4236,26596670,728,756,Group Characteristic,transplant-eligible patients,human,n,too much or multiple entities based on context,hcho
4237,26596670,743,755,Drug Intervention,lenalidomide,model,y,,ccurtis
4238,26596670,743,771,Drug Intervention,lenalidomide plus prednisone,human,n,too much,ccurtis
4239,26596670,761,771,Drug Intervention,prednisone,model,y,,ccurtis
4240,26596670,762,810,Group Characteristic,newly diagnosed myeloma aged 65 years or younger,human,n,multiple entities,hcho
4241,26596670,786,810,Group Characteristic,aged 65 years or younger,model,y,,hcho
4242,26596670,812,820,Group Characteristic,Patients,human,n,too little,hcho
4243,26596670,833,839,Type of Quant. Measure,95% CI,model,y,,ccurtis
4244,26596670,859,872,Intervention Duration,28-day cycles,human,n,too much,hcho
4245,26596670,897,906,Intervention Frequency,days 1-21,model,n,wrong label,hcho
4246,26596670,913,925,Drug Intervention,chemotherapy,human,y,,ccurtis
4247,26596670,931,943,Drug Intervention,lenalidomide,human,y,,ccurtis
4248,26596670,934,955,Intervention Frequency,"days 1, 8, 15, and 22",model,n,wrong label,hcho
4249,26596670,964,973,Drug Intervention,melphalan,human,y,,ccurtis
4250,26596670,1007,1021,Side Effects,haematological,model,y,,ccurtis
4251,26596670,1027,1030,Quantitative Measurement,26%,model,y,,ccurtis
4252,26596670,1030,1067,Non-Pharmaceutical Intervention,granulocyte colony-stimulating factor,human,n,wrong label,hcho
4253,26596670,1035,1038,Sample Size,129,human,y,,ccurtis
4254,26596670,1056,1059,Quantitative Measurement,84%,model,y,,ccurtis
4255,26596670,1064,1067,Sample Size,127,human,y,,ccurtis
4256,26596670,1079,1095,Side Effects,gastrointestinal,model,y,,ccurtis
4257,26596670,1102,1104,Quantitative Measurement,5%,model,y,,ccurtis
4258,26596670,1113,1116,Quantitative Measurement,20%,model,y,,ccurtis
4259,26596670,1124,1133,Side Effects,infection,model,y,,ccurtis
4260,26596670,1135,1144,Quantitative Measurement,seven [5%,human,n,too much,ccurtis
4261,26596670,1142,1144,Quantitative Measurement,5%,model,y,,ccurtis
4262,26596670,1153,1156,Quantitative Measurement,19%,model,y,,ccurtis
4263,26596670,1160,1174,Side Effects,Haematological,model,y,,ccurtis
4264,26596670,1203,1233,Drug Intervention,chemotherapy plus lenalidomide,human,n,too much,hcho
4265,26596670,1220,1222,Quantitative Measurement,2%,model,y,,ccurtis
4266,26596670,1221,1233,Drug Intervention,lenalidomide,model,y,,hcho
4267,26596670,1242,1254,Drug Intervention,chemotherapy,human,y,,ccurtis
4268,26596670,1260,1272,Drug Intervention,lenalidomide,human,y,,ccurtis
4269,26596670,1267,1270,Dosage,300,human,y,,hcho
4270,26596670,1267,1278,Dosage,300 mg/m(2),model,n,multiple entities,hcho
4271,26596670,1271,1278,Units,mg/m(2),human,y,,hcho
4272,26596670,1280,1297,Intervention Frequency,"days 1, 8, and 15",model,n,wrong label,hcho
4273,26596670,1309,1318,Drug Intervention,melphalan,human,y,,ccurtis
4274,26596670,1322,1343,Intervention Frequency,"days 1, 8, 15, and 22",model,n,wrong label,hcho
4275,26596670,1329,1370,Side Effects,Non-haematological serious adverse events,model,y,,ccurtis
4276,26596670,1371,1380,Intervention Frequency,days 1-21,model,n,wrong label,hcho
4277,26596670,1392,1395,Quantitative Measurement,10%,model,y,,ccurtis
4278,26596670,1415,1427,Drug Intervention,chemotherapy,human,y,,ccurtis
4279,26596670,1422,1425,Dosage,200,human,y,,hcho
4280,26596670,1422,1433,Dosage,200 mg/m(2),model,n,multiple entities,hcho
4281,26596670,1426,1433,Units,mg/m(2),human,y,,hcho
4282,26596670,1433,1445,Drug Intervention,lenalidomide,human,y,,ccurtis
4283,26596670,1480,1489,Drug Intervention,melphalan,human,y,,ccurtis
4284,26596670,1514,1523,Intervention Frequency,days 1-21,model,n,wrong label,hcho
4285,26596670,1617,1628,Side Effects,neutropenia,model,y,,ccurtis
4286,26596670,1636,1638,Quantitative Measurement,8%,model,y,,ccurtis
4287,26596670,1643,1646,Sample Size,117,human,y,,ccurtis
4288,26596670,1665,1693,Drug Intervention,lenalidomide plus prednisone,human,n,too much,ccurtis
4289,26596670,1701,1704,Quantitative Measurement,13%,model,y,,ccurtis
4290,26596670,1723,1735,Drug Intervention,lenalidomide,human,y,,ccurtis
4291,26596670,1744,1753,Side Effects,infection,model,y,,ccurtis
4292,26596670,1762,1764,Quantitative Measurement,8%,model,y,,ccurtis
4293,26596670,1775,1777,Quantitative Measurement,5%,model,y,,ccurtis
4294,26596670,1785,1804,Side Effects,systemic toxicities,model,y,,ccurtis
4295,26596670,1813,1815,Quantitative Measurement,6%,model,y,,ccurtis
4296,26596670,1820,1823,Sample Size,two,human,n,wrong label,ccurtis
4297,26596670,1825,1827,Quantitative Measurement,2%,model,y,,ccurtis
4298,26596670,1865,1872,Group Characteristic,patient,human,n,wrong label,hcho
4299,26627879,94,102,Drug Intervention,Apixaban,human,y,,stan
4300,26627879,133,151,Disease/Condition of Interest,Pulmonary Embolism,model,y,,stan
4301,26627879,156,176,Disease/Condition of Interest,Deep-Vein Thrombosis,model,y,,stan
4302,26627879,223,231,Drug Intervention,Apixaban,human,y,,stan
4303,26627879,262,280,Disease/Condition of Interest,Pulmonary Embolism,model,y,,stan
4304,26627879,345,353,Drug Intervention,apixaban,human,y,,stan
4305,26627879,373,383,Drug Intervention,enoxaparin,human,n,wrong label,stan
4306,26627879,384,392,Drug Intervention,warfarin,human,n,wrong label,stan
4307,26627879,572,580,Drug Intervention,apixaban,human,y,,stan
4308,26627879,588,598,Drug Intervention,enoxaparin,human,n,wrong label,stan
4309,26627879,599,607,Drug Intervention,warfarin,human,n,wrong label,stan
4310,26627879,661,665,Sample Size,5365,model,y,,stan
4311,26627879,699,707,Drug Intervention,apixaban,human,y,,stan
4312,26627879,726,736,Drug Intervention,enoxaparin,human,n,wrong label,stan
4313,26627879,737,745,Drug Intervention,warfarin,human,n,wrong label,stan
4314,26627879,1214,1226,Group Characteristic,hospitalized,human,y,,stan
4315,26627879,1214,1240,Outcome (Study Endpoint),hospitalized at least once,model,n,wrong label,stan
4316,26627879,1227,1229,Group Characteristic,at,human,n,too little,stan
4317,26627879,1230,1235,Group Characteristic,least,human,n,too little,stan
4318,26627879,1236,1240,Group Characteristic,once,human,n,too little,stan
4319,26627879,1420,1432,Type of Quant. Measure,hazard ratio,model,y,,stan
4320,26627879,1433,1438,Quantitative Measurement,0.804,model,y,,stan
4321,26627879,1470,1526,Outcome (Study Endpoint),All-cause hospitalization rates within the first 30 days,model,n,too much,stan
4322,26627879,1470,1548,Outcome (Study Endpoint),All-cause hospitalization rates within the first 30 days after the index event,human,n,too much,stan
4323,26627879,1577,1585,Group Name,apixaban,human,n,,stan
4324,26627879,1590,1600,Group Name,enoxaparin,human,n,wrong label,stan
4325,26627879,1601,1609,Group Name,warfarin,human,n,wrong label,stan
4326,26627879,1632,1644,Type of Quant. Measure,hazard ratio,model,y,,stan
4327,26627879,1645,1650,Quantitative Measurement,0.676,model,y,,stan
4328,26627879,1704,1716,Outcome (Study Endpoint),average per-,model,n,too little,stan
4329,26627879,1704,1762,Outcome (Study Endpoint),average per-patient estimated mean length of hospital stay,human,n,multiple entities,stan
4330,26627879,1785,1793,Drug Intervention,apixaban,human,y,,stan
4331,26627879,1799,1809,Drug Intervention,enoxaparin,human,n,wrong label,stan
4332,26627879,1810,1818,Drug Intervention,warfarin,human,n,wrong label,stan
4333,26627879,1990,1998,Group Characteristic,patients,human,y,,stan
4334,26627879,1999,2003,Group Characteristic,with,human,n,too little,stan
4335,26627879,2004,2009,Group Characteristic,acute,human,n,too little,stan
4336,26627879,2010,2016,Group Characteristic,venous,human,n,too little,stan
4337,26627879,2017,2032,Group Characteristic,thromboembolism,human,n,too little,stan
4338,26763986,72,88,Disease/Condition of Interest,Hodgkin lymphoma,model,y,,cjackson
4339,26763986,410,419,Group Characteristic,untreated,model,y,,cjackson
4340,26763986,420,422,Group Characteristic,HL,model,n,wrong label,cjackson
4341,26763986,433,461,Group Characteristic,aged between 65 and 80 years,model,y,,cjackson
4342,26763986,446,461,Group Characteristic,65 and 80 years,human,n,too little,cjackson
4343,26763986,743,747,Group Name,ABVD,human,n,not needed,cjackson
4344,26763986,761,770,Drug Intervention,bleomycin,model,y,,cjackson
4345,26763986,772,783,Drug Intervention,vinblastine,model,y,,cjackson
4346,26763986,980,989,Follow-up period,76 months,model,y,,cjackson
4347,26763986,1029,1050,Type of Quant. Measure,adjusted Hazard ratio,model,y,,cjackson
4348,26763986,1052,1054,Type of Quant. Measure,HR,human,y,,cjackson
4349,26763986,1146,1148,Outcome (Study Endpoint),OS,model,y,,cjackson
4350,26763986,1174,1185,Type of Quant. Measure,adjusted HR,model,y,,cjackson
4351,26763986,1183,1185,Type of Quant. Measure,HR,human,y,,cjackson
4352,26763986,1229,1235,Group Name,VEPEMB,model,n,not needed,cjackson
4353,26763986,1248,1252,Group Name,ABVD,model,n,not needed,cjackson
4354,26763986,1254,1289,Outcome (Study Endpoint),Overall treatment-related mortality,model,n,too much,cjackson
4355,26763986,1262,1289,Outcome (Study Endpoint),treatment-related mortality,human,y,,cjackson
4356,26765458,730,793,Group Characteristic,received coprescription of statins and CCBs that inhibit CYP3A4,human,n,wrong label,hcho
4357,26765458,795,805,Drug Intervention,amlodipine,model,y,,hcho
4358,26765458,807,816,Drug Intervention,diltiazem,model,y,,hcho
4359,26765458,818,840,Drug Intervention,felodipine nicardipine,model,y,,hcho
4360,26765458,842,852,Drug Intervention,nifedipine,model,y,,hcho
4361,26765458,858,867,Drug Intervention,verapamil,model,y,,hcho
4362,26765458,1217,1219,Follow-up period,90,human,n,too little,hcho
4363,26765458,1217,1224,Follow-up period,90 days,model,y,,hcho
4364,26765458,1628,1632,Outcome (Study Endpoint),risk,model,n,too little,hcho
4365,26765458,1628,1655,Outcome (Study Endpoint),risk of acute kidney injury,human,y,,hcho
4366,26765458,1636,1655,Outcome (Study Endpoint),acute kidney injury,model,n,too little,hcho
4367,26765458,1678,1680,Type of Quant. Measure,OR,model,y,,hcho
4368,27185164,0,7,Group Name,FP/FORM,human,y,,eduvaris
4369,27185164,2,9,Study Duration,12-week,human,y,,ccurtis
4370,27185164,90,96,Group Name,FP/SAL,human,y,,eduvaris
4371,27185164,163,171,Group Characteristic,children,model,y,,eduvaris
4372,27185164,172,187,Group Characteristic,aged 4-12 years,model,y,,eduvaris
4373,27185164,275,285,Drug Intervention,formoterol,model,y,,ccurtis
4374,27185164,275,294,Drug Intervention,formoterol fumarate,human,y,,ccurtis
4375,27185164,428,436,Group Characteristic,children,human,y,,ccurtis
4376,27185164,538,553,Group Characteristic,aged 4-12 years,model,n,too much,ccurtis
4377,27185164,543,553,Group Characteristic,4-12 years,human,y,,ccurtis
4378,27185164,712,719,Group Name,FP/FORM,human,n,wrong label,ccurtis
4379,27185164,721,724,Dosage,100,model,y,,ccurtis
4380,27185164,721,727,Dosage,100/10,human,n,too much,ccurtis
4381,27185164,725,727,Dosage,10,model,y,,ccurtis
4382,27185164,742,748,Group Name,FP/SAL,human,n,wrong label,ccurtis
4383,27185164,750,753,Dosage,100,model,y,,ccurtis
4384,27185164,750,756,Dosage,100/50,human,n,too much,ccurtis
4385,27185164,754,756,Dosage,50,model,y,,ccurtis
4386,27185164,844,851,Intervention Duration,24-week,human,n,wrong label,ccurtis
4387,27185164,873,880,Group Name,FP/FORM,human,n,wrong label,ccurtis
4388,27185164,1239,1242,Sample Size,210,human,n,wrong label,ccurtis
4389,27185164,1288,1291,Sample Size,208,model,n,wrong label,ccurtis
4390,27185164,1304,1307,Sample Size,205,human,y,,ccurtis
4391,27185164,1352,1364,Outcome (Study Endpoint),Predose FEV1,human,y,,ccurtis
4392,27185164,1352,1374,Outcome (Study Endpoint),Predose FEV1 increased,model,n,too much,ccurtis
4393,27185164,1397,1404,Group Name,FP/FORM,human,n,wrong label,ccurtis
4394,27185164,1454,1460,Group Name,FP/SAL,human,n,wrong label,ccurtis
4395,27185164,1492,1499,Group Name,FP/FORM,human,n,wrong label,ccurtis
4396,27185164,1519,1525,Group Name,FP/SAL,human,n,wrong label,ccurtis
4397,27185164,1527,1571,Type of Quant. Measure,least squares (LS) mean treatment difference,model,y,,ccurtis
4398,27185164,1573,1579,Quantitative Measurement,-0.031,model,y,,ccurtis
4399,27185164,1844,1851,Group Name,FP/FORM,human,n,wrong label,ccurtis
4400,27185164,1903,1910,Group Name,FP/FORM,human,n,wrong label,ccurtis
4401,27298379,80,89,Disease/Condition of Interest,cirrhosis,human,y,wrong label,stan
4402,27298379,185,210,Disease/Condition of Interest,large oesophageal varices,model,y,,stan
4403,27298379,313,323,Group Characteristic,cirrhotics,model,y,,stan
4404,27298379,329,354,Group Characteristic,small oesophageal varices,model,y,,stan
4405,27298379,416,423,Group Name,placebo,model,y,,stan
4406,27298379,464,466,Follow-up period,24,model,n,too little,stan
4407,27298379,464,473,Follow-up period,24 months,human,y,,stan
4408,27298379,1025,1032,Group Name,placebo,model,y,,stan
4409,27298379,1063,1067,Type of Quant. Measure,mean,human,y,,stan
4410,27298379,1063,1108,Outcome (Study Endpoint),mean time of non-progression to large varices,model,n,multiple entities,stan
4411,27298379,1068,1108,Outcome (Study Endpoint),time of non-progression to large varices,human,n,too much,stan
4412,27298379,1251,1268,Outcome (Study Endpoint),reduction of HVPG,model,n,too much,stan
4413,27298379,1264,1268,Outcome (Study Endpoint),HVPG,human,y,,stan
4414,27541383,183,210,Group Characteristic,diabetic painful neuropathy,human,n,wrong label,cjackson
4415,27541383,212,215,Disease/Condition of Interest,DPN,model,y,,cjackson
4416,27541383,520,544,Drug Intervention,tricyclic antidepressant,model,y,,cjackson
4417,27541383,546,553,Drug Intervention,opioids,model,y,,cjackson
4418,27541383,555,565,Drug Intervention,duloxetine,model,y,,cjackson
4419,27541383,567,577,Drug Intervention,gabapentin,model,y,,cjackson
4420,27541383,579,589,Drug Intervention,pregabalin,model,y,,cjackson
4421,27541383,594,603,Drug Intervention,lidocaine,model,y,,cjackson
4422,27541383,838,842,Group Name,mono,human,n,not needed,cjackson
4423,27541383,838,858,Group Name,mono-pharmacotherapy,model,y,,cjackson
4424,27541383,879,890,Group Name,combination,human,n,not needed,cjackson
4425,27541383,879,906,Group Name,combination pharmacotherapy,model,y,,cjackson
4426,27541383,1256,1274,Outcome (Study Endpoint),total cost of care,model,n,too much,cjackson
4427,27624700,32,34,Type of Quant. Measure,HR,model,y,,ccurtis
4428,27624700,86,115,Disease/Condition of Interest,diffuse large B-cell lymphoma,model,y,,hcho
4429,27624700,157,186,Disease/Condition of Interest,diffuse large B-cell lymphoma,model,y,,hcho
4430,27624700,173,175,Type of Quant. Measure,HR,model,y,,ccurtis
4431,27624700,184,190,Type of Quant. Measure,95% CI,model,y,,ccurtis
4432,27624700,188,193,Disease/Condition of Interest,DLBCL,model,y,,hcho
4433,27624700,233,235,Type of Quant. Measure,HR,model,y,,ccurtis
4434,27624700,244,250,Type of Quant. Measure,95% CI,model,y,,ccurtis
4435,27624700,290,292,Type of Quant. Measure,HR,model,y,,ccurtis
4436,27624700,301,307,Type of Quant. Measure,95% CI,model,y,,ccurtis
4437,27624700,339,344,Group Characteristic,DLBCL,model,n,wrong label,hcho
4438,27624700,365,367,Type of Quant. Measure,HR,model,y,,ccurtis
4439,27624700,376,382,Type of Quant. Measure,95% CI,model,y,,ccurtis
4440,27624700,386,395,Drug Intervention,rituximab,model,y,,hcho
4441,27624700,468,484,Outcome (Study Endpoint),Bone involvement,model,y,,ccurtis
4442,27624700,486,488,Type of Quant. Measure,HR,model,y,,ccurtis
4443,27624700,493,514,Group Characteristic,newly diagnosed DLBCL,model,n,wrong label,hcho
4444,27624700,497,503,Type of Quant. Measure,95% CI,model,y,,ccurtis
4445,27624700,542,544,Type of Quant. Measure,HR,model,y,,ccurtis
4446,27624700,554,560,Type of Quant. Measure,95% CI,model,y,,ccurtis
4447,27624700,578,595,Outcome (Study Endpoint),renal involvement,model,y,,ccurtis
4448,27624700,597,599,Type of Quant. Measure,HR,model,y,,ccurtis
4449,27624700,609,615,Type of Quant. Measure,95% CI,model,y,,ccurtis
4450,27624700,809,825,Drug Intervention,cyclophosphamide,model,y,,hcho
4451,27624700,827,838,Drug Intervention,doxorubicin,model,y,,hcho
4452,27624700,840,851,Drug Intervention,vincristine,model,y,,hcho
4453,27624700,1004,1029,Group Characteristic,high risk for CNS relapse,human,y,,hcho
4454,27624700,1005,1010,Disease/Condition of Interest,DLBCL,model,y,,ccurtis
4455,27624700,1382,1384,Quantitative Measurement,25,human,y,,hcho
4456,27624700,1570,1574,Group Name,CHOP,human,n,too little,hcho
4457,27624700,1570,1580,Group Name,CHOP group,model,y,,hcho
4458,27624700,1593,1599,Group Name,R-CHOP,human,n,too little,hcho
4459,27624700,1593,1605,Group Name,R-CHOP group,model,y,,hcho
4460,27809351,135,142,Group Name,placebo,human,n,too little,eduvaris
4461,27809351,308,317,Drug Intervention,memantine,human,y,,eduvaris
4462,27809351,384,393,Sample Size,Sixty-six,model,n,not needed,eduvaris
4463,27809351,428,446,Group Characteristic,moderate-to-severe,model,y,,eduvaris
4464,27809351,428,472,Group Characteristic,moderate-to-severe major depressive disorder,human,n,multiple entities,eduvaris
4465,27809351,447,472,Disease/Condition of Interest,major depressive disorder,model,y,,eduvaris
4466,27809351,665,667,Units,mg,model,y,,eduvaris
4467,27809351,665,671,Units,mg/day,human,n,multiple entities,eduvaris
4468,27809351,668,671,Intervention Frequency,day,model,y,,eduvaris
4469,27809351,678,688,Non-Study Drug,sertraline,human,y,wrong label,eduvaris
4470,27809351,694,696,Units,mg,model,y,,eduvaris
4471,27809351,694,700,Units,mg/day,human,n,multiple entities,eduvaris
4472,27809351,697,700,Intervention Frequency,day,model,y,,eduvaris
4473,27809351,718,728,Drug Intervention,sertraline,model,n,wrong label,eduvaris
4474,27809351,734,736,Units,mg,model,y,,eduvaris
4475,27809351,734,740,Units,mg/day,human,n,multiple entities,eduvaris
4476,27809351,737,740,Intervention Frequency,day,model,y,,eduvaris
4477,27809351,1064,1074,Outcome (Study Endpoint),HDRS score,model,y,,eduvaris
4478,27809351,1076,1092,Type of Quant. Measure,"F (2·09, 125·67)",human,n,multiple entities,eduvaris
4479,27809351,1135,1146,Outcome (Study Endpoint),improvement,human,n,not needed,eduvaris
4480,27809351,1300,1309,Group Name,memantine,human,n,wrong label,eduvaris
4481,27809351,1356,1388,Outcome (Study Endpoint),more rapid response to treatment,model,n,too much,eduvaris
4482,27809351,1361,1388,Outcome (Study Endpoint),rapid response to treatment,human,n,too much,eduvaris
4483,27809351,1607,1621,Group Name,placebo groups,human,y,,eduvaris
4484,27809351,1634,1643,Type of Quant. Measure,Cohen's d,human,y,,eduvaris
4485,27831828,156,162,Disease/Condition of Interest,asthma,model,y,,stan
4486,27831828,263,273,Group Characteristic,caregivers,human,y,,stan
4487,27831828,277,285,Group Characteristic,children,human,n,wrong label,stan
4488,27831828,668,676,Group Characteristic,children,human,n,,stan
4489,27831828,695,712,Group Characteristic,mean = 10.6 ± 2.9,model,n,wrong label,stan
4490,27831828,715,725,Group Characteristic,56.6% male,human,n,wrong label,stan
4491,27831828,727,742,Group Characteristic,70.6% Caucasian,human,n,wrong label,stan
4492,27831828,778,780,Group Name,MD,model,n,wrong label,stan
4493,27831828,833,850,Outcome (Study Endpoint),mean total PACQLQ,human,n,multiple entities,stan
4494,27831828,838,850,Outcome (Study Endpoint),total PACQLQ,model,y,,stan
4495,27831828,899,900,Type of Quant. Measure,F,model,y,,stan
4496,27831828,922,953,Outcome (Study Endpoint),Total scores at the first visit,human,y,,stan
4497,27831828,1098,1104,Outcome (Study Endpoint),PACQLQ,model,n,too little,stan
4498,27831828,1098,1123,Outcome (Study Endpoint),PACQLQ emotional function,human,y,,stan
4499,27831828,1105,1123,Outcome (Study Endpoint),emotional function,model,n,too little,stan
4500,27831828,1125,1126,Type of Quant. Measure,F,model,y,,stan
4501,27831828,1304,1305,Type of Quant. Measure,r,model,y,,stan
4502,27831828,1330,1363,Outcome (Study Endpoint),fewer days/month of albuterol use,model,n,too much,stan
4503,27831828,1336,1363,Outcome (Study Endpoint),days/month of albuterol use,human,y,,stan
4504,27831828,1365,1366,Type of Quant. Measure,r,model,y,,stan
4505,27831828,1408,1409,Type of Quant. Measure,r,model,y,,stan
4506,27904973,60,86,Drug Intervention,CYP3A4-metabolized statins,human,y,,cjackson
4507,27904973,107,141,Disease/Condition of Interest,percutaneous coronary intervention,model,y,,cjackson
4508,27904973,224,235,Drug Intervention,clopidogrel,human,y,,cjackson
4509,27904973,327,340,Drug Intervention,clopidogrel's,human,n,not needed,cjackson
4510,27904973,424,449,Drug Intervention,CYP3A4-metabolized statin,human,y,,cjackson
4511,27904973,540,574,Non-Pharmaceutical Intervention,percutaneous coronary intervention,human,n,wrong label,cjackson
4512,27904973,738,763,Drug Intervention,CYP3A4-metabolized statin,human,y,too little,cjackson
4513,27904973,1125,1135,Outcome (Study Endpoint),PRU values,human,y,,cjackson
4514,27904973,1154,1161,Group Name,group A,human,y,,cjackson
4515,27904973,1166,1175,Outcome (Study Endpoint),decreased,model,n,not needed,cjackson
4516,27904973,1193,1200,Group Name,group B,human,y,,cjackson
4517,27904973,1295,1321,Group Characteristic,high PRU value at baseline,human,y,,cjackson
4518,27904973,1584,1610,Drug Intervention,CYP3A4-metabolized statins,human,y,,cjackson
4519,27904973,1657,1668,Drug Intervention,clopidogrel,human,y,,cjackson
4520,27904973,1732,1745,Drug Intervention,clopidogrel's,human,n,not needed,cjackson
4521,28122793,64,68,Intervention Administration,oral,human,y,,hcho
4522,28122793,69,82,Drug Intervention,antiplatelets,human,y,,hcho
4523,28122793,230,234,Intervention Administration,oral,human,y,,hcho
4524,28122793,230,247,Drug Intervention,oral antiplatelet,model,n,multiple entities,hcho
4525,28122793,235,247,Drug Intervention,antiplatelet,human,y,,hcho
4526,28122793,271,279,Follow-up period,one-year,model,y,,hcho
4527,28122793,311,334,Disease/Condition of Interest,acute coronary syndrome,human,y,,hcho
4528,28122793,336,339,Disease/Condition of Interest,ACS,model,y,,hcho
4529,28122793,481,491,Group Characteristic,discharged,model,n,too little,hcho
4530,28122793,481,531,Group Characteristic,discharged from a hospital in Belgium after an ACS,human,y,,hcho
4531,28122793,528,531,Group Characteristic,ACS,model,n,too little,hcho
4532,28122793,532,567,Group Characteristic,between 1 July 2012 and 1 June 2013,model,n,too little,hcho
4533,28122793,540,567,Study Years,1 July 2012 and 1 June 2013,human,n,wrong label,hcho
4534,28122793,659,662,Sample Size,671,model,y,,hcho
4535,28122793,871,887,Outcome (Study Endpoint),still using OAPs,model,y,,hcho
4536,28122793,925,927,Quantitative Measurement,92,model,y,,hcho
4537,28122793,929,931,Quantitative Measurement,89,model,y,,hcho
4538,28122793,933,935,Quantitative Measurement,83,model,y,,hcho
4539,28122793,941,944,Quantitative Measurement,73%,model,y,,hcho
4540,28122793,1013,1022,Drug Intervention,prasugrel,model,y,,hcho
4541,28122793,1026,1036,Drug Intervention,ticagrelor,model,y,,hcho
4542,28122793,1074,1116,Outcome (Study Endpoint),ST-segment elevation myocardial infarction,human,n,wrong label,hcho
4543,28122793,1118,1123,Group Characteristic,STEMI,model,y,,hcho
4544,28122793,1152,1161,Group Characteristic,non-STEMI,model,y,,hcho
4545,28122793,1285,1308,Outcome (Study Endpoint),mean treatment duration,human,n,multiple entities,hcho
4546,28122793,1313,1327,Quantitative Measurement,197.0 ± 125.18,model,y,,hcho
4547,28122793,1328,1332,Units,days,model,y,,hcho
4548,28355356,11,21,Drug Intervention,tacrolimus,model,y,,ccurtis
4549,28355356,142,145,Drug Intervention,TAC,model,y,,ccurtis
4550,28355356,203,236,Disease/Condition of Interest,idiopathic membranous nephropathy,model,y,,ccurtis
4551,28355356,238,241,Disease/Condition of Interest,IMN,model,y,,ccurtis
4552,28355356,270,287,Group Characteristic,biopsy-proven IMN,human,n,too much,ccurtis
4553,28355356,374,377,Drug Intervention,TAC,model,y,,ccurtis
4554,28355356,446,451,Intervention Frequency,daily,model,y,,ccurtis
4555,28355356,470,473,Drug Intervention,CYC,model,y,,ccurtis
4556,28355356,644,647,Outcome (Study Endpoint),1st,human,n,wrong label,ccurtis
4557,28355356,657,661,Quantitative Measurement,19.7,human,n,too little,ccurtis
4558,28355356,657,662,Quantitative Measurement,19.7%,model,y,,ccurtis
4559,28355356,661,662,Units,%,human,n,too little,ccurtis
4560,28355356,672,675,Outcome (Study Endpoint),2nd,human,n,wrong label,ccurtis
4561,28355356,685,689,Quantitative Measurement,38.5,human,n,too little,ccurtis
4562,28355356,685,690,Quantitative Measurement,38.5%,model,y,,ccurtis
4563,28355356,689,690,Units,%,human,n,too little,ccurtis
4564,28355356,700,703,Outcome (Study Endpoint),3rd,human,n,wrong label,ccurtis
4565,28355356,713,717,Quantitative Measurement,59.0,human,n,too little,ccurtis
4566,28355356,713,718,Quantitative Measurement,59.0%,model,y,,ccurtis
4567,28355356,717,718,Units,%,human,n,too little,ccurtis
4568,28355356,752,791,Outcome (Study Endpoint),daily urinary protein and serum albumin,human,n,too much,ccurtis
4569,28355356,799,802,Group Name,TAC,model,y,,ccurtis
4570,28355356,856,859,Group Name,CYC,model,y,,ccurtis
4571,28355356,944,983,Outcome (Study Endpoint),daily urinary protein and serum albumin,human,n,too much,ccurtis
4572,28355356,1066,1078,Outcome (Study Endpoint),relapse rate,human,y,,ccurtis
4573,28355356,1117,1121,Quantitative Measurement,12.0,human,n,too little,ccurtis
4574,28355356,1117,1122,Quantitative Measurement,12.0%,model,y,,ccurtis
4575,28355356,1121,1122,Units,%,human,n,too little,ccurtis
4576,28528780,268,299,Group Characteristic,nonvalvular atrial fibrillation,human,n,wrong label,eduvaris
4577,28528780,301,305,Disease/Condition of Interest,NVAF,model,y,,eduvaris
4578,28528780,390,398,Drug Intervention,apixaban,human,y,,eduvaris
4579,28528780,403,406,Drug Intervention,VKA,human,y,,eduvaris
4580,28528780,410,430,Group Characteristic,German NVAF patients,human,n,not needed,eduvaris
4581,28528780,532,547,Group Characteristic,newly-initiated,model,n,not needed,eduvaris
4582,28528780,551,559,Drug Intervention,apixaban,human,y,,eduvaris
4583,28528780,574,600,Study Years,January 2013 to March 2015,model,n,not needed,eduvaris
4584,28528780,980,988,Drug Intervention,Apixaban,human,y,,eduvaris
4585,28528780,993,996,Drug Intervention,VKA,human,y,,eduvaris
4586,28528780,1322,1330,Group Name,apixaban,human,n,wrong label,eduvaris
4587,28528780,1339,1342,Group Name,VKA,human,n,wrong label,eduvaris
4588,28528780,1407,1413,Outcome (Study Endpoint),Hazard,model,n,not needed,eduvaris
4589,28528780,1407,1439,Outcome (Study Endpoint),Hazard of the composite endpoint,human,n,wrong label,eduvaris
4590,28528780,1463,1471,Group Name,apixaban,human,n,wrong label,eduvaris
4591,28528780,1476,1479,Group Name,VKA,human,n,wrong label,eduvaris
4592,28528780,1514,1530,Outcome (Study Endpoint),Ischaemic stroke,model,n,too little,eduvaris
4593,28528780,1514,1537,Outcome (Study Endpoint),Ischaemic stroke and MI,human,y,,eduvaris
4594,28528780,1535,1537,Outcome (Study Endpoint),MI,model,n,too little,eduvaris
4595,28528780,1614,1622,Group Name,apixaban,human,n,wrong label,eduvaris
4596,28528780,1627,1630,Group Name,VKA,human,n,wrong label,eduvaris
4597,28528780,1766,1774,Drug Intervention,Apixaban,human,y,,eduvaris
4598,28528780,1779,1782,Drug Intervention,VKA,human,y,,eduvaris
4599,28528780,2014,2022,Drug Intervention,apixaban,human,y,,eduvaris
4600,28528780,2065,2073,Drug Intervention,apixaban,human,y,,eduvaris
4601,28606123,17,27,Disease/Condition of Interest,restenosis,model,y,,stan
4602,28606123,34,56,Non-Pharmaceutical Intervention,coronary artery bypass,model,y,,stan
4603,28606123,454,458,Drug Intervention,t-PA,model,y,,stan
4604,28606123,472,484,Group Name,conventional,model,n,wrong label,stan
4605,28606123,935,957,Outcome (Study Endpoint),mean stenosis severity,model,n,multiple entities,stan
4606,28606123,935,986,Outcome (Study Endpoint),mean stenosis severity of the saphenous vein grafts,human,n,multiple entities,stan
4607,28606123,1004,1014,Group Name,t-PA group,model,y,,stan
4608,28606123,1033,1051,Group Name,conventional group,model,y,,stan
4609,28606123,1168,1180,Outcome (Study Endpoint),patency rate,model,y,,stan
4610,28606123,1168,1194,Outcome (Study Endpoint),patency rate of the grafts,human,n,multiple entities,stan
4611,28929323,22,37,Disease/Condition of Interest,antidepressants,model,n,not needed,cjackson
4612,28929323,53,63,Disease/Condition of Interest,non-cancer,model,n,wrong label,cjackson
4613,28929323,566,587,Group Characteristic,diagnosed with cancer,model,n,too little,cjackson
4614,28929323,576,587,Group Characteristic,with cancer,human,n,too little,cjackson
4615,28929323,588,613,Group Characteristic,within the past 12 months,human,n,wrong label,cjackson
4616,28929323,599,613,Group Characteristic,past 12 months,model,n,wrong label,cjackson
4617,28929323,698,724,Group Characteristic,chronic disease conditions,human,y,,cjackson
4618,28929323,1033,1044,Outcome (Study Endpoint),Mirtazapine,human,y,wrong label,cjackson
4619,28929323,1117,1127,Outcome (Study Endpoint),duloxetine,human,y,wrong label,cjackson
4620,28929323,1140,1154,Outcome (Study Endpoint),Desvenlafaxine,human,y,wrong label,cjackson
4621,28929323,1160,1162,Quantitative Measurement,15,human,y,,cjackson
4622,28929323,1234,1245,Drug Intervention,mirtazapine,model,n,wrong label,cjackson
4623,28929323,1408,1410,Quantitative Measurement,23,human,y,,cjackson
4624,28929323,1463,1465,Quantitative Measurement,18,human,y,,cjackson
4625,28929323,1475,1501,Outcome (Study Endpoint),prescribed other medicines,human,y,,cjackson
4626,29336432,160,175,Group Characteristic,Crohn's disease,model,y,,hcho
4627,29336432,177,179,Group Characteristic,CD,model,y,,hcho
4628,29336432,185,203,Group Characteristic,ulcerative colitis,model,y,,hcho
4629,29336432,205,207,Group Characteristic,UC,model,y,,hcho
4630,29336432,213,240,Disease/Condition of Interest,inflammatory bowel diseases,human,y,,hcho
4631,29336432,242,245,Disease/Condition of Interest,IBD,human,y,,hcho
4632,29336432,413,421,Drug Intervention,anti-TNF,human,y,,hcho
4633,29336432,432,435,Disease/Condition of Interest,IBD,human,y,,hcho
4634,29336432,486,521,Group Characteristic,Medicaid and Medicare beneficiaries,model,y,,hcho
4635,29336432,527,539,Study Years,2001 to 2013,model,y,,hcho
4636,29336432,545,548,Disease/Condition of Interest,IBD,human,y,,hcho
4637,29336432,651,667,Drug Intervention,anti-TNF therapy,human,n,,hcho
4638,29336432,879,903,Type of Quant. Measure,95% confidence intervals,human,y,,hcho
4639,29336432,939,954,Group Name,corticosteroids,human,n,wrong label,hcho
4640,29336432,976,978,Group Characteristic,CD,model,y,,hcho
4641,29336432,1018,1032,Group Name,corticosteroid,human,n,wrong label,hcho
4642,29336432,1056,1064,Group Name,anti-TNF,human,n,wrong label,hcho
4643,29336432,1092,1094,Group Characteristic,UC,model,y,,hcho
4644,29336432,1142,1144,Group Name,CS,human,n,wrong label,hcho
4645,29336432,1159,1167,Group Name,anti-TNF,human,n,wrong label,hcho
4646,29336432,1270,1278,Group Name,anti-TNF,human,n,wrong label,hcho
4647,29336432,1291,1293,Group Name,CD,human,n,wrong label,hcho
4648,29336432,1295,1298,Quantitative Measurement,21.,model,n,too little,hcho
4649,29336432,1295,1299,Quantitative Measurement,21.4,human,y,,hcho
4650,29336432,1304,1308,Quantitative Measurement,30.1,human,y,,hcho
4651,29336432,1336,1340,Quantitative Measurement,0.78,human,y,,hcho
4652,29336432,1336,1341,Quantitative Measurement,"0.78,",model,n,too much,hcho
4653,29336432,1365,1367,Group Name,UC,human,n,wrong label,hcho
4654,29336432,1369,1371,Quantitative Measurement,23,model,n,too little,hcho
4655,29336432,1369,1373,Quantitative Measurement,23.0,human,y,,hcho
4656,29336432,1378,1382,Quantitative Measurement,30.9,human,y,,hcho
4657,29336432,1410,1414,Quantitative Measurement,0.87,human,y,,hcho
4658,29336432,1410,1415,Quantitative Measurement,"0.87,",model,n,too much,hcho
4659,29336432,1438,1440,Group Name,CD,human,n,wrong label,hcho
4660,29336432,1449,1457,Group Name,anti-TNF,human,n,wrong label,hcho
4661,29336432,1506,1541,Outcome (Study Endpoint),major adverse cardiovascular events,model,y,,hcho
4662,29336432,1543,1545,Type of Quant. Measure,OR,model,y,,hcho
4663,29336432,1546,1551,Quantitative Measurement,"0.68,",model,y,,hcho
4664,29336432,1552,1561,Quantitative Measurement,0.55-0.85,model,y,,hcho
4665,29336432,1567,1579,Outcome (Study Endpoint),hip fracture,model,y,,hcho
4666,29336432,1581,1583,Type of Quant. Measure,OR,model,y,,hcho
4667,29336432,1584,1589,Quantitative Measurement,"0.54,",model,y,,hcho
4668,29336432,1590,1599,Quantitative Measurement,0.34-0.83,model,y,,hcho
4669,29394348,0,12,Drug Intervention,Rosuvastatin,human,y,,ccurtis
4670,29394348,67,84,Disease/Condition of Interest,venous thrombosis,model,y,,ccurtis
4671,29394348,159,176,Disease/Condition of Interest,venous thrombosis,human,y,,ccurtis
4672,29394348,178,180,Disease/Condition of Interest,VT,human,y,,ccurtis
4673,29394348,348,356,Group Characteristic,prior VT,human,n,too much,ccurtis
4674,29394348,445,449,Intervention Frequency,/day,human,n,too much,ccurtis
4675,29394348,446,449,Intervention Frequency,day,model,y,,ccurtis
4676,29394348,735,743,Group Characteristic,58 years,model,y,,ccurtis
4677,29394348,772,785,Group Characteristic,unprovoked VT,model,n,not needed,ccurtis
4678,29394348,980,985,Outcome (Study Endpoint),FVIII,model,y,,ccurtis
4679,29394348,999,1006,Outcome (Study Endpoint),FVIII:C,human,n,too much,ccurtis
4680,29394348,1220,1257,Outcome (Study Endpoint),adjusted difference in FVIII:C change,human,n,too much,ccurtis
4681,29394348,1229,1257,Outcome (Study Endpoint),difference in FVIII:C change,model,y,,ccurtis
4682,29394348,1404,1416,Drug Intervention,rosuvastatin,human,y,,ccurtis
4683,29394348,1519,1531,Drug Intervention,Rosuvastatin,human,y,,ccurtis
4684,29394348,1532,1534,Dosage,20,human,y,,ccurtis
4685,29394348,1535,1537,Units,mg,human,y,,ccurtis
4686,29394348,1537,1541,Intervention Frequency,/day,human,n,too much,ccurtis
4687,29622587,158,189,Disease/Condition of Interest,nonvalvular atrial fibrillation,model,y,,stan
4688,29622587,211,217,Group Characteristic,Asians,model,y,,eduvaris
4689,29622587,308,316,Drug Intervention,apixaban,model,y,,stan
4690,29622587,391,399,Drug Intervention,warfarin,model,y,,stan
4691,29622587,429,460,Group Characteristic,nonvalvular atrial fibrillation,model,n,wrong label,eduvaris
4692,29622587,544,577,Study Years,"June 1, 2012 to December 31, 2016",model,y,,eduvaris
4693,29622587,783,785,Statistical Significance,95,model,n,wrong label,eduvaris
4694,29622587,783,807,Type of Quant. Measure,95% confidence intervals,human,y,,eduvaris
4695,29622587,819,827,Drug Intervention,apixaban,model,y,,eduvaris
4696,29622587,829,839,Drug Intervention,dabigatran,model,y,,eduvaris
4697,29622587,845,856,Drug Intervention,rivaroxaban,model,y,,eduvaris
4698,29622587,862,870,Drug Intervention,warfarin,model,y,,eduvaris
4699,29622587,912,917,Outcome (Study Endpoint),IS/SE,human,y,,eduvaris
4700,29622587,920,924,Quantitative Measurement,0.55,human,y,,eduvaris
4701,29622587,938,942,Quantitative Measurement,0.82,human,y,,eduvaris
4702,29622587,960,964,Quantitative Measurement,0.81,human,y,,eduvaris
4703,29622587,994,998,Quantitative Measurement,0.41,human,y,,eduvaris
4704,29622587,1012,1016,Quantitative Measurement,0.65,human,y,,eduvaris
4705,29622587,1034,1038,Quantitative Measurement,0.58,human,y,,eduvaris
4706,29622587,1077,1079,Quantitative Measurement,0.,model,n,too little,eduvaris
4707,29622587,1077,1081,Quantitative Measurement,0.58,human,y,,eduvaris
4708,29622587,1117,1119,Quantitative Measurement,0.,model,n,too little,eduvaris
4709,29622587,1117,1121,Quantitative Measurement,0.57,human,y,,eduvaris
4710,29622587,1219,1227,Drug Intervention,apixaban,model,y,,eduvaris
4711,29622587,1229,1232,Dosage,2.5,human,y,,eduvaris
4712,29622587,1229,1235,Dosage,2.5 mg,model,n,multiple entities,eduvaris
4713,29622587,1233,1235,Units,mg,human,y,,eduvaris
4714,29622587,1250,1260,Drug Intervention,dabigatran,model,y,,eduvaris
4715,29622587,1262,1265,Dosage,110,human,y,,eduvaris
4716,29622587,1262,1268,Dosage,110 mg,model,n,multiple entities,eduvaris
4717,29622587,1266,1268,Units,mg,human,y,,eduvaris
4718,29622587,1287,1298,Drug Intervention,rivaroxaban,model,y,,eduvaris
4719,29622587,1300,1305,Dosage,10-15,human,y,,eduvaris
4720,29622587,1300,1308,Dosage,10-15 mg,model,n,multiple entities,eduvaris
4721,29622587,1306,1308,Units,mg,human,y,,eduvaris
4722,29622587,1537,1548,Outcome (Study Endpoint),lower risks,human,n,not needed,eduvaris
4723,29622587,1552,1557,Outcome (Study Endpoint),IS/SE,human,y,,eduvaris
4724,29622587,1559,1563,Quantitative Measurement,0.45,human,y,,eduvaris
4725,29622587,1578,1592,Outcome (Study Endpoint),major bleeding,human,y,,eduvaris
4726,29622587,1617,1626,Outcome (Study Endpoint),mortality,human,y,,eduvaris
4727,29622587,1651,1659,Drug Intervention,warfarin,model,y,,eduvaris
4728,30129417,26,30,Intervention Administration,Oral,human,y,,cjackson
4729,30129417,35,42,Intervention Administration,Topical,human,y,,cjackson
4730,30129417,480,484,Intervention Administration,oral,human,y,,cjackson
4731,30129417,489,496,Intervention Administration,topical,human,y,,cjackson
4732,30129417,649,661,Drug Intervention,azithromycin,model,n,wrong label,cjackson
4733,30129417,707,723,Drug Intervention,benzoyl peroxide,model,n,wrong label,cjackson
4734,30129417,724,727,Intervention Administration,gel,model,n,not needed,cjackson
4735,30129417,729,730,Dosage,5,model,n,not needed,cjackson
4736,30129417,730,731,Units,%,model,n,not needed,cjackson
4737,30129417,811,815,Intervention Administration,oral,human,y,,cjackson
4738,30129417,816,827,Drug Intervention,simvastatin,human,y,,cjackson
4739,30129417,832,846,Drug Intervention,blank solution,human,n,not needed,cjackson
4740,30129417,886,887,Dosage,1,human,n,not needed,cjackson
4741,30129417,886,888,Dosage,1%,model,n,not needed,cjackson
4742,30129417,889,896,Intervention Administration,topical,human,y,,cjackson
4743,30129417,910,914,Intervention Administration,oral,human,y,,cjackson
4744,30129417,1147,1158,Drug Intervention,simvastatin,human,y,,cjackson
4745,30129417,1248,1262,Group Name,placebo groups,human,y,,cjackson
4746,30129417,1315,1326,Outcome (Study Endpoint),efficacious,human,y,,cjackson
4747,30129417,1344,1357,Group Name,placebo group,human,y,,cjackson
4748,30129417,1375,1379,Intervention Administration,Oral,human,y,,cjackson
4749,30129417,1384,1391,Intervention Administration,topical,human,y,,cjackson
4750,30129417,1392,1403,Drug Intervention,simvastatin,human,y,,cjackson
4751,30129417,1508,1512,Intervention Administration,oral,human,y,,cjackson
4752,30129417,1517,1524,Intervention Administration,topical,human,y,,cjackson
4753,30129417,1760,1771,Drug Intervention,simvastatin,human,y,,cjackson
4754,30308586,0,9,Drug Intervention,Prasugrel,human,y,,hcho
4755,30308586,75,117,Disease/Condition of Interest,ST-segment elevation myocardial infarction,model,y,,hcho
4756,30308586,96,117,Disease/Condition of Interest,myocardial infarction,human,n,too little,hcho
4757,30308586,419,461,Disease/Condition of Interest,ST-segment elevation myocardial infarction,model,y,,hcho
4758,30308586,463,468,Disease/Condition of Interest,STEMI,model,y,,hcho
4759,30308586,1059,1066,Quantitative Measurement,134-214,model,y,,hcho
4760,30308586,1080,1087,Quantitative Measurement,128-210,model,y,,hcho
4761,30308586,1223,1232,Quantitative Measurement,0.16-1.09,model,y,,hcho
4762,30308586,1244,1253,Quantitative Measurement,0.32-2.30,model,y,,hcho
4763,30308586,1272,1276,Type of Quant. Measure,mean,human,y,,hcho
4764,30308586,1272,1281,Outcome (Study Endpoint),mean area,model,n,multiple entities,hcho
4765,30308586,1277,1281,Outcome (Study Endpoint),area,human,y,,hcho
4766,30308586,1373,1384,Group Name,clopidogrel,model,n,too little,hcho
4767,30308586,1398,1407,Quantitative Measurement,0.01-0.05,model,y,,hcho
4768,30308586,1419,1428,Quantitative Measurement,0.01-0.10,model,y,,hcho
4769,30308586,1452,1461,Quantitative Measurement,0.27-0.75,model,y,,hcho
4770,30308586,1473,1482,Quantitative Measurement,0.34-1.23,model,y,,hcho
4771,30346533,32,53,Group Characteristic,major lung resections,human,n,wrong label,ccurtis
4772,30346533,80,100,Drug Intervention,Acetylsalicylic acid,model,y,,ccurtis
4773,30346533,283,290,Drug Intervention,aspirin,human,y,,ccurtis
4774,30346533,510,517,Drug Intervention,aspirin,human,y,,ccurtis
4775,30346533,519,530,Group Name,group ASA-0,model,y,,ccurtis
4776,30346533,525,530,Group Name,ASA-0,human,n,too little,ccurtis
4777,30346533,545,556,Group Name,group ASA-1,model,y,,ccurtis
4778,30346533,551,556,Group Name,ASA-1,human,n,too little,ccurtis
4779,30346533,596,621,Non-Pharmaceutical Intervention,anatomical lung resection,human,y,,ccurtis
4780,30346533,1310,1316,Group Name,ASA-0M,human,y,,ccurtis
4781,30346533,1350,1352,Type of Quant. Measure,SD,human,y,,ccurtis
4782,30346533,1354,1362,Quantitative Measurement,± 364.87,model,y,,ccurtis
4783,30346533,1356,1362,Quantitative Measurement,364.87,human,n,too little,ccurtis
4784,30346533,1364,1370,Group Name,ASA-1M,human,y,,ccurtis
4785,30346533,1383,1385,Type of Quant. Measure,SD,human,y,,ccurtis
4786,30346533,1386,1394,Quantitative Measurement,± 323.84,model,y,,ccurtis
4787,30346533,1388,1394,Quantitative Measurement,323.84,human,n,too little,ccurtis
4788,30346533,1464,1470,Group Name,ASA-0M,human,y,,ccurtis
4789,30346533,1485,1487,Type of Quant. Measure,SD,human,y,,ccurtis
4790,30346533,1488,1496,Quantitative Measurement,± 816.69,model,y,,ccurtis
4791,30346533,1490,1496,Quantitative Measurement,816.69,human,n,too little,ccurtis
4792,30346533,1498,1504,Group Name,ASA-1M,human,y,,ccurtis
4793,30346533,1519,1521,Type of Quant. Measure,SD,human,y,,ccurtis
4794,30346533,1522,1530,Quantitative Measurement,± 682.12,model,y,,ccurtis
4795,30346533,1524,1530,Quantitative Measurement,682.12,human,n,too little,ccurtis
4796,30346533,1554,1557,Quantitative Measurement,104,model,n,wrong label,ccurtis
4797,30346533,1616,1618,Quantitative Measurement,71,model,n,wrong label,ccurtis
4798,30346533,1619,1627,Units,patients,model,n,not needed,ccurtis
4799,30346533,1660,1678,Outcome (Study Endpoint),blood transfusions,human,n,wrong label,ccurtis
4800,30346533,1688,1690,Sample Size,33,human,y,wrong label,ccurtis
4801,30346533,1691,1699,Units,patients,model,n,not needed,ccurtis
4802,30346533,1707,1712,Group Name,ASA-1,human,y,,ccurtis
4803,30346533,1731,1749,Outcome (Study Endpoint),blood transfusions,human,n,wrong label,ccurtis
4804,30346533,1766,1792,Outcome (Study Endpoint),indication for reoperation,model,y,,ccurtis
4805,30346533,1781,1808,Outcome (Study Endpoint),reoperation due to bleeding,human,n,too much,ccurtis
4806,30346533,1810,1815,Group Name,ASA-1,human,y,,ccurtis
4807,30346533,1821,1826,Group Name,ASA-0,human,y,,ccurtis
4808,30346533,1916,1943,Outcome (Study Endpoint),postoperative complications,human,y,,ccurtis
4809,30346533,1951,1956,Group Name,ASA-1,human,y,,ccurtis
4810,30346533,1964,1974,Type of Quant. Measure,risk ratio,model,y,,ccurtis
4811,30346533,1976,1978,Type of Quant. Measure,RR,human,y,,ccurtis
4812,30346533,2008,2036,Outcome (Study Endpoint),cardiovascular complications,model,y,,ccurtis
4813,30346533,2008,2047,Outcome (Study Endpoint),cardiovascular complications nor deaths,human,n,too much,ccurtis
4814,30346533,2041,2047,Outcome (Study Endpoint),deaths,model,y,,ccurtis
4815,30354702,83,98,Group Characteristic,euthyroid women,human,y,,stan
4816,30354702,380,389,Group Characteristic,euthyroid,model,n,too little,stan
4817,30354702,380,424,Group Characteristic,euthyroid women with Hashimoto's thyroiditis,human,y,,stan
4818,30354702,390,395,Group Characteristic,women,model,n,too little,stan
4819,30354702,401,424,Group Characteristic,Hashimoto's thyroiditis,model,n,wrong label,stan
4820,30354702,501,503,Dosage,40,model,y,,stan
4821,30354702,501,506,Dosage,40 mg,human,n,multiple entities,stan
4822,30354702,504,506,Units,mg,model,y,,stan
4823,30354702,559,575,Drug Intervention,selenomethionine,model,n,wrong label,stan
4824,30354702,577,580,Dosage,200,model,y,,stan
4825,30354702,577,583,Dosage,200 µg,human,n,multiple entities,stan
4826,30354702,581,583,Units,µg,model,y,,stan
4827,30354702,1051,1092,Outcome (Study Endpoint),Selenometionine decreased titers of TPOAb,human,n,too much,stan
4828,30354702,1077,1083,Outcome (Study Endpoint),titers,model,n,too little,stan
4829,30354702,1099,1108,Quantitative Measurement,843 ± 228,model,y,,stan
4830,30354702,1112,1121,Quantitative Measurement,562 ± 189,model,y,,stan
4831,30354702,1122,1126,Units,U/mL,model,y,,stan
4832,30354702,1143,1152,Quantitative Measurement,795 ± 286,model,y,,stan
4833,30354702,1156,1165,Quantitative Measurement,501 ± 216,model,y,,stan
4834,30354702,1166,1170,Units,U/mL,model,y,,stan
4835,30354702,1175,1195,Group Name,atorvastatin-treated,model,y,,stan
4836,30354702,1188,1195,Group Characteristic,treated,human,n,wrong label,stan
4837,30354702,1196,1201,Group Characteristic,women,human,y,,stan
4838,30354702,1236,1245,Quantitative Measurement,892 ± 247,model,y,,stan
4839,30354702,1249,1258,Quantitative Measurement,705 ± 205,model,y,,stan
4840,30354702,1259,1263,Units,U/mL,model,y,,stan
4841,30354702,1269,1273,Outcome (Study Endpoint),TgAb,model,y,,stan
4842,30354702,1280,1289,Quantitative Measurement,810 ± 301,model,y,,stan
4843,30354702,1293,1302,Quantitative Measurement,645 ± 224,model,y,,stan
4844,30354702,1303,1307,Units,U/mL,model,y,,stan
4845,30354702,1312,1324,Group Characteristic,statin-naive,human,n,wrong label,stan
4846,30354702,1325,1330,Group Characteristic,women,human,y,,stan
4847,30388256,27,57,Drug Intervention,Nonsteroidal Anti-Inflammatory,human,y,,cjackson
4848,30388256,27,63,Drug Intervention,Nonsteroidal Anti-Inflammatory Drugs,model,n,too little,cjackson
4849,30388256,130,137,Drug Intervention,aspirin,model,y,,cjackson
4850,30388256,142,178,Drug Intervention,nonsteroidal anti-inflammatory drugs,model,y,,cjackson
4851,30388256,243,260,Disease/Condition of Interest,colorectal cancer,model,y,,cjackson
4852,30388256,262,265,Disease/Condition of Interest,CRC,model,y,,cjackson
4853,30388256,282,285,Disease/Condition of Interest,CRC,model,y,,cjackson
4854,30388256,433,455,Group Characteristic,first diagnosis of CRC,model,n,wrong label,cjackson
4855,30388256,465,472,Group Characteristic,healthy,model,y,,cjackson
4856,30388256,473,481,Group Name,controls,model,y,,cjackson
4857,30388256,848,854,Drug Intervention,NSAIDs,model,y,,cjackson
4858,30388256,866,873,Drug Intervention,aspirin,model,y,,cjackson
4859,30388256,987,1004,Type of Quant. Measure,odds ratios (ORs),human,n,too much,cjackson
4860,30388256,1094,1100,Drug Intervention,NSAIDs,model,y,,cjackson
4861,30388256,1131,1139,Outcome (Study Endpoint),CRC risk,model,y,,cjackson
4862,30388256,1155,1158,Outcome (Study Endpoint),MSS,human,n,wrong label,cjackson
4863,30388256,1160,1162,Type of Quant. Measure,OR,model,y,,cjackson
4864,30388256,1195,1199,Outcome (Study Endpoint),BRAF,human,n,wrong label,cjackson
4865,30388256,1195,1208,Group Characteristic,BRAF wildtype,model,y,,cjackson
4866,30388256,1210,1212,Type of Quant. Measure,OR,model,y,,cjackson
4867,30388256,1248,1252,Outcome (Study Endpoint),KRAS,human,n,wrong label,cjackson
4868,30388256,1248,1261,Group Characteristic,KRAS wildtype,model,y,,cjackson
4869,30388256,1263,1265,Type of Quant. Measure,OR,model,y,,cjackson
4870,30388256,1489,1501,Group Characteristic,MSI-high CRC,model,n,too much,cjackson
4871,30388256,1518,1524,Drug Intervention,NSAIDs,model,y,,cjackson
4872,30388256,1592,1596,Outcome (Study Endpoint),BRAF,human,n,wrong label,cjackson
4873,30388256,1600,1604,Outcome (Study Endpoint),KRAS,human,n,wrong label,cjackson
4874,30388256,1616,1618,Type of Quant. Measure,OR,model,y,,cjackson
4875,30388256,1627,1630,Type of Quant. Measure,95%,model,n,too little,cjackson
4876,30388256,1636,1646,Statistical Significance,0.18 to 0.,model,n,wrong label,cjackson
4877,30388256,1663,1668,Outcome (Study Endpoint),KRAS-,model,n,wrong label,cjackson
4878,30388256,1672,1693,Group Characteristic,BRAF-mutated MSI-high,model,y,,cjackson
4879,30388256,1740,1747,Drug Intervention,aspirin,model,y,,cjackson
4880,30388256,1854,1860,Drug Intervention,NSAIDs,model,y,,cjackson
4881,30388256,1865,1872,Drug Intervention,aspirin,model,y,,cjackson
4882,30388256,1889,1895,Drug Intervention,NSAIDs,model,y,,cjackson
4883,30388256,1900,1907,Drug Intervention,aspirin,model,y,,cjackson
4884,30407457,19,28,Group Characteristic,pediatric,human,y,,hcho
4885,30407457,43,49,Group Characteristic,cancer,model,n,wrong label,hcho
4886,30407457,51,56,Disease/Condition of Interest,fever,model,y,,hcho
4887,30407457,62,73,Disease/Condition of Interest,neutropenia,model,y,,hcho
4888,30407457,175,186,Disease/Condition of Interest,neutropenia,model,y,,hcho
4889,30407457,371,379,Group Characteristic,children,model,y,,hcho
4890,30407457,385,391,Disease/Condition of Interest,cancer,human,y,,hcho
4891,30407457,417,419,Disease/Condition of Interest,FN,model,y,,hcho
4892,30407457,426,466,Group Characteristic,low risk of invasive bacterial infection,human,y,,hcho
4893,30407457,540,548,Group Characteristic,Children,model,y,,hcho
4894,30407457,643,652,Group Name,inpatient,model,n,wrong label,hcho
4895,30407457,688,700,Drug Intervention,piperacillin,human,y,,hcho
4896,30407457,688,711,Drug Intervention,piperacillin/tazobactam,model,n,too much,hcho
4897,30407457,701,711,Drug Intervention,tazobactam,human,y,,hcho
4898,30407457,717,729,Group Name,experimental,model,n,too little,hcho
4899,30407457,717,735,Group Name,experimental group,human,y,,hcho
4900,30407457,740,755,Group Name,early discharge,model,n,wrong label,hcho
4901,30407457,779,781,Intervention Duration,48,model,n,too little,hcho
4902,30407457,779,783,Intervention Duration,48 h,human,y,,hcho
4903,30407457,787,789,Intervention Administration,IV,human,y,,hcho
4904,30407457,847,863,Outcome (Study Endpoint),fever resolution,model,y,,hcho
4905,30407457,865,877,Outcome (Study Endpoint),readmissions,model,y,,hcho
4906,30407457,883,892,Outcome (Study Endpoint),mortality,model,y,,hcho
4907,30407457,894,900,Sample Size,Eighty,model,y,,hcho
4908,30407457,941,981,Group Characteristic,median age was 6 years old (2.6-11 years,model,y,,hcho
4909,30407457,1244,1255,Drug Intervention,amoxicillin,human,y,,hcho
4910,30407457,1244,1267,Drug Intervention,amoxicillin/clavulanate,model,n,too much,hcho
4911,30407457,1256,1267,Drug Intervention,clavulanate,human,y,,hcho
4912,30407457,1313,1352,Side Effects,relapse of fever with tumor progression,model,y,,hcho
4913,30407457,1374,1383,Side Effects,epistaxis,model,y,,hcho
4914,30407457,1426,1441,Group Name,early discharge,model,n,wrong label,hcho
4915,30407457,1426,1447,Group Name,early discharge group,human,y,,hcho
4916,30407457,1463,1488,Group Name,inpatient treatment group,human,y,,hcho
4917,30610806,0,7,Drug Intervention,Aspirin,model,y,,ccurtis
4918,30610806,67,74,Group Characteristic,Chinese,model,y,,ccurtis
4919,30610806,67,78,Group Characteristic,Chinese men,human,n,too much,ccurtis
4920,30610806,75,78,Group Characteristic,men,model,y,,ccurtis
4921,30610806,162,177,Disease/Condition of Interest,prostate cancer,model,y,,ccurtis
4922,30610806,258,319,Group Characteristic,underwent radical prostatectomy for localized prostate cancer,human,n,too much,ccurtis
4923,30610806,672,685,Group Name,aspirin group,model,y,,ccurtis
4924,30610806,734,741,Outcome (Study Endpoint),5 years,model,n,wrong label,ccurtis
4925,30610806,803,820,Group Characteristic,high-risk disease,model,y,,ccurtis
4926,30610806,826,835,Outcome (Study Endpoint),FFBF rate,model,y,,ccurtis
4927,31088848,14,39,Drug Intervention,High-Dose Glucocorticoids,human,y,,eduvaris
4928,31088848,94,111,Disease/Condition of Interest,Thyroid Disorders,human,y,,eduvaris
4929,31088848,113,130,Disease/Condition of Interest,Thyroid disorders,human,y,,eduvaris
4930,31088848,170,199,Disease/Condition of Interest,immune-related adverse events,human,n,not needed,eduvaris
4931,31088848,303,327,Drug Intervention,High-dose glucocorticoid,human,y,,eduvaris
4932,31088848,329,332,Drug Intervention,HDG,human,y,,eduvaris
4933,31088848,507,524,Disease/Condition of Interest,thyroid disorders,human,y,,eduvaris
4934,31088848,562,607,Group Characteristic,with or without ICI-related thyroid disorders,human,n,not needed,eduvaris
4935,31088848,694,698,Group Name,with,model,n,not needed,eduvaris
4936,31088848,703,724,Group Name,without HDG treatment,model,n,not needed,eduvaris
4937,31088848,780,783,Group Name,HDG,human,n,wrong label,eduvaris
4938,31088848,788,794,Drug Intervention,no HDG,human,n,too little,eduvaris
4939,31088848,818,824,Outcome (Study Endpoint),median,model,n,wrong label,eduvaris
4940,31088848,818,851,Outcome (Study Endpoint),median duration of thyrotoxicosis,human,n,multiple entities,eduvaris
4941,31088848,825,851,Outcome (Study Endpoint),duration of thyrotoxicosis,model,y,,eduvaris
4942,31088848,864,868,Quantitative Measurement,7-85,model,y,,eduvaris
4943,31088848,885,891,Quantitative Measurement,14-273,model,y,,eduvaris
4944,31088848,984,990,Quantitative Measurement,14-169,model,y,,eduvaris
4945,31088848,1012,1018,Quantitative Measurement,14-315,model,y,,eduvaris
4946,31088848,1081,1087,Quantitative Measurement,21-190,model,y,,eduvaris
4947,31088848,1104,1110,Quantitative Measurement,14-489,model,y,,eduvaris
4948,31088848,1126,1166,Outcome (Study Endpoint),median maintenance dose of levothyroxine,human,n,multiple entities,eduvaris
4949,31088848,1133,1149,Outcome (Study Endpoint),maintenance dose,model,n,too little,eduvaris
4950,31088848,1153,1166,Drug Intervention,levothyroxine,model,n,too little,eduvaris
4951,31088848,1189,1194,Units,μg/kg,model,n,too little,eduvaris
4952,31088848,1189,1198,Units,μg/kg/day,human,y,,eduvaris
4953,31088848,1195,1198,Intervention Frequency,day,model,n,too little,eduvaris
4954,31088848,1225,1230,Units,μg/kg,model,n,too little,eduvaris
4955,31088848,1225,1234,Units,μg/kg/day,human,y,,eduvaris
4956,31088848,1231,1234,Intervention Frequency,day,model,n,too little,eduvaris
4957,31088848,1280,1287,Quantitative Measurement,0.3-5.2,model,y,,eduvaris
4958,31088848,1311,1318,Quantitative Measurement,0.5-4.5,model,y,,eduvaris
4959,31088848,1320,1325,Units,mIU/L,human,y,,eduvaris
4960,31088848,1495,1498,Statistical Significance,<i>,model,n,too little,eduvaris
4961,31088848,1495,1510,Statistical Significance,<i>P</i> = 0.05,human,y,,eduvaris
4962,31088848,1498,1510,Statistical Significance,P</i> = 0.05,model,n,too little,eduvaris
4963,31195244,272,289,Disease/Condition of Interest,bipolar disorders,model,y,,stan
4964,31195244,296,303,Group Characteristic,Smokers,human,y,,stan
4965,31195244,449,477,Drug Intervention,nicotine replacement therapy,human,y,,stan
4966,31195244,479,481,Non-Pharmaceutical Intervention,NR,model,n,wrong label,stan
4967,31195244,479,482,Drug Intervention,NRT,human,y,,stan
4968,31195244,488,495,Drug Intervention,placebo,human,n,wrong label,stan
4969,31195244,515,521,Intervention Frequency,weekly,human,y,,stan
4970,31195244,522,532,Non-Pharmaceutical Intervention,counseling,human,y,,stan
4971,31195244,707,717,Group Name,BD smokers,human,y,,stan
4972,31195244,763,774,Group Name,varenicline,model,n,wrong label,stan
4973,31195244,871,892,Outcome (Study Endpoint),ORs for Weeks 9-12 CA,human,n,wrong label,stan
4974,31195244,975,984,Quantitative Measurement,0.68-9.95,model,y,,stan
4975,31195244,1004,1013,Quantitative Measurement,0.31-5.37,model,y,,stan
4976,31195244,1027,1036,Quantitative Measurement,0.14-3.74,model,y,,stan
4977,31445345,28,34,Study Duration,6-week,model,y,,cjackson
4978,31445345,169,181,Drug Intervention,escitalopram,model,y,,cjackson
4979,31445345,421,433,Drug Intervention,escitalopram,human,y,,cjackson
4980,31445345,444,446,Units,mg,model,y,,cjackson
4981,31445345,497,500,Disease/Condition of Interest,MDD,model,y,,cjackson
4982,31445345,555,557,Sample Size,98,model,n,not needed,cjackson
4983,31445345,602,603,Intervention Duration,4,model,n,too little,cjackson
4984,31445345,602,609,Intervention Duration,4 weeks,human,y,,cjackson
4985,31445345,664,671,Intervention Frequency,per day,model,n,too much,cjackson
4986,31445345,668,671,Intervention Frequency,day,human,y,,cjackson
4987,31445345,829,836,Intervention Frequency,per day,model,n,too much,cjackson
4988,31445345,833,836,Intervention Frequency,day,human,y,,cjackson
4989,31445345,861,868,Intervention Frequency,per day,model,n,too much,cjackson
4990,31445345,865,868,Intervention Frequency,day,human,y,,cjackson
4991,31445345,1089,1091,Sample Size,44,human,n,not needed,cjackson
4992,31445345,1093,1096,Quantitative Measurement,88%,model,n,not needed,cjackson
4993,31445345,1309,1312,Quantitative Measurement,1.2,model,y,,cjackson
4994,31445345,1321,1344,Group Name,placebo dose-escalation,model,y,,cjackson
4995,31445345,1356,1359,Quantitative Measurement,1.2,model,y,,cjackson
4996,31445345,1368,1396,Group Name,escitalopram dose-escalation,model,y,,cjackson
4997,31445345,1675,1685,Units,mg per day,model,n,too much,cjackson
4998,31445345,1784,1786,Units,mg,model,y,,cjackson
4999,31508883,0,14,Drug Intervention,Benzodiazepine,human,y,,hcho
5000,31508883,84,100,Disease/Condition of Interest,Neuropathic Pain,model,y,,hcho
5001,31508883,158,172,Drug Intervention,benzodiazepine,human,y,,hcho
5002,31508883,376,390,Drug Intervention,benzodiazepine,human,y,,hcho
5003,31508883,444,458,Drug Intervention,benzodiazepine,human,y,,hcho
5004,31508883,645,658,Study Years,1997 and 2014,model,n,wrong label,hcho
5005,31508883,669,673,Sample Size,1117,model,y,,hcho
5006,31508883,889,905,Outcome (Study Endpoint),device explanted,model,n,wrong label,hcho
5007,31508883,924,954,Outcome (Study Endpoint),unsuccessful trial stimulation,model,n,wrong label,hcho
5008,31508883,1049,1061,Drug Intervention,Diazepam use,model,n,too much,hcho
5009,31508883,1087,1113,Outcome (Study Endpoint),odds for explanting of SCS,model,y,,hcho
5010,31508883,1127,1133,Type of Quant. Measure,95% Cl,model,y,,hcho
5011,31508883,1135,1142,Quantitative Measurement,1.0-5.4,model,y,,hcho
5012,31508883,1154,1164,Drug Intervention,clonazepam,human,y,,hcho
5013,31508883,1154,1168,Drug Intervention,clonazepam use,model,n,too much,hcho
5014,31508883,1211,1217,Type of Quant. Measure,95% CI,model,y,,hcho
5015,31508883,1217,1218,Statistical Significance,:,model,n,wrong label,hcho
5016,31508883,1219,1227,Quantitative Measurement,1.5-18.9,model,y,,hcho
5017,31508883,1289,1303,Drug Intervention,benzodiazepine,human,y,,hcho
5018,32643426,213,222,Drug Intervention,tirofiban,model,y,,eduvaris
5019,32643426,286,288,Intervention Administration,IV,model,y,,ccurtis
5020,32643426,290,299,Drug Intervention,tirofiban,model,y,,ccurtis
5021,32643426,401,440,Disease/Condition of Interest,acutely ruptured intracranial aneurysms,model,y,,ccurtis
5022,32643426,456,458,Intervention Administration,IV,model,y,,ccurtis
5023,32643426,459,468,Drug Intervention,tirofiban,model,y,,ccurtis
5024,32643426,709,746,Group Characteristic,did not receive an antiplatelet agent,model,y,,ccurtis
5025,32643426,755,778,Study Years,June 2013 and June 2019,human,n,wrong label,ccurtis
5026,32643426,792,823,Group Characteristic,treated for a ruptured aneurysm,human,y,,ccurtis
5027,32643426,830,845,Group Characteristic,required an EVD,human,y,,ccurtis
5028,32643426,898,920,Group Characteristic,stent-assisted coiling,human,y,,ccurtis
5029,32643426,982,986,Group Name,DAPT,model,y,,ccurtis
5030,32643426,1225,1243,Group Name,antiplatelet group,model,y,,ccurtis
5031,32643426,1265,1278,Group Name,control group,model,y,,ccurtis
5032,32643426,1409,1431,Outcome (Study Endpoint),EVD-related hemorrhage,model,y,,ccurtis
5033,32643426,1409,1450,Outcome (Study Endpoint),EVD-related hemorrhage after IV tirofiban,human,n,too much,ccurtis
5034,32643426,1441,1450,Drug Intervention,tirofiban,model,y,,ccurtis
5035,32643426,1497,1519,Outcome (Study Endpoint),EVD-related hemorrhage,model,y,,ccurtis
5036,32643426,1645,1661,Statistical Significance,<i>p</i> = 0.124,model,y,,ccurtis
5037,32643426,1737,1769,Outcome (Study Endpoint),increased EVD-related hemorrhage,model,n,too much,ccurtis
5038,32643426,1857,1863,Quantitative Measurement,29.63%,model,y,,ccurtis
5039,32643426,1925,1931,Quantitative Measurement,15.79%,model,y,,ccurtis
5040,32649216,0,7,Intervention Administration,Inhaled,human,y,,stan
5041,32649216,128,135,Intervention Administration,inhaled,model,y,,stan
5042,32649216,136,151,Drug Intervention,corticosteroids,model,y,,stan
5043,32649216,153,156,Drug Intervention,ICS,model,y,,stan
5044,32649216,250,253,Disease/Condition of Interest,IPD,human,y,,stan
5045,32649216,929,952,Group Characteristic,prescriptions dispensed,human,n,not needed,stan
5046,32649216,960,962,Group Characteristic,60,human,n,not needed,stan
5047,32649216,966,977,Group Characteristic,61-365 days,human,n,not needed,stan
5048,32649216,1404,1418,Outcome (Study Endpoint),Current use of,model,n,not needed,stan
5049,32649216,1437,1449,Outcome (Study Endpoint),risk for IPD,model,y,,stan
5050,32649216,1454,1472,Outcome (Study Endpoint),IPD with pneumonia,model,y,,stan
5051,32649216,1599,1643,Outcome (Study Endpoint),current use of ICS and IPD without pneumonia,model,y,,stan
5052,32649216,1804,1816,Outcome (Study Endpoint),odds for IPD,model,y,,stan
5053,32652935,68,73,Group Name,CAE-B,human,n,too little,ccurtis
5054,32652935,98,103,Group Name,CAE-B,human,n,too little,ccurtis
5055,32652935,113,136,Disease/Condition of Interest,Coronary artery ectasia,model,y,,hcho
5056,32652935,113,142,Disease/Condition of Interest,Coronary artery ectasia (CAE),human,n,too much,hcho
5057,32652935,122,127,Group Name,CAE-C,human,n,too little,ccurtis
5058,32652935,138,141,Disease/Condition of Interest,CAE,model,y,,hcho
5059,32652935,228,234,Outcome (Study Endpoint),hs-CRP,model,y,,ccurtis
5060,32652935,239,243,Outcome (Study Endpoint),IL-6,model,y,,ccurtis
5061,32652935,258,263,Group Name,CAE-A,human,n,too little,ccurtis
5062,32652935,282,287,Group Name,CAE-B,human,n,too little,ccurtis
5063,32652935,310,313,Disease/Condition of Interest,CAE,human,y,,hcho
5064,32652935,327,332,Group Name,CAE-B,human,n,too little,ccurtis
5065,32652935,351,356,Group Name,CAE-C,human,n,too little,ccurtis
5066,32652935,396,408,Drug Intervention,rosuvastatin,human,y,,ccurtis
5067,32652935,563,571,Group Characteristic,with CAE,human,n,wrong label,hcho
5068,32652935,568,571,Disease/Condition of Interest,CAE,model,y,,hcho
5069,32652935,572,683,Group Characteristic,"treated at the Department of Cardiology, Shanghai East Hospital, Ji'an Campus and the Baoshan People's Hospital",human,y,,hcho
5070,32652935,690,722,Study Years,"January 1, 2015 to July 30, 2019",model,n,wrong label,hcho
5071,32652935,1056,1063,Group Name,control,model,n,too little,hcho
5072,32652935,1056,1074,Group Name,control (NC) group,human,y,,hcho
5073,32652935,1065,1067,Group Name,NC,model,n,too little,hcho
5074,32652935,1164,1166,Dosage,10,model,y,,hcho
5075,32652935,1164,1169,Dosage,10 mg,human,n,multiple entities,hcho
5076,32652935,1167,1169,Units,mg,model,y,,hcho
5077,32652935,1171,1173,Intervention Frequency,QN,model,y,,hcho
5078,32652935,1296,1303,Follow-up period,6-month,model,y,,hcho
5079,32652935,1319,1321,Group Name,NC,model,n,too little,hcho
5080,32652935,1319,1327,Group Name,NC group,human,y,,hcho
5081,32652935,1378,1390,Drug Intervention,rosuvastatin,human,n,wrong label,hcho
5082,32652935,1426,1463,Outcome (Study Endpoint),"inflammatory markers, hs-CRP and IL-6",human,n,too much,hcho
5083,32652935,1448,1454,Outcome (Study Endpoint),hs-CRP,model,y,,hcho
5084,32652935,1459,1463,Outcome (Study Endpoint),IL-6,model,y,,hcho
5085,32652935,1567,1573,Outcome (Study Endpoint),hs-CRP,model,y,,hcho
5086,32652935,1578,1582,Outcome (Study Endpoint),Il-6,model,y,,hcho
5087,32652935,1726,1728,Type of Quant. Measure,OR,model,y,,hcho
5088,32652935,1731,1736,Quantitative Measurement,1.782,model,y,,hcho
5089,32652935,1738,1744,Type of Quant. Measure,95% CI,model,y,,hcho
5090,32652935,1746,1757,Quantitative Measurement,1.124-2.014,model,y,,hcho
5091,32652935,1774,1777,Outcome (Study Endpoint),IL-,model,n,too little,hcho
5092,32652935,1780,1782,Type of Quant. Measure,OR,model,y,,hcho
5093,32652935,1785,1790,Quantitative Measurement,1.584,model,y,,hcho
5094,32652935,1792,1798,Type of Quant. Measure,95% CI,model,y,,hcho
5095,32652935,1800,1811,Quantitative Measurement,1.112-1.986,model,y,,hcho
5096,32847676,0,19,Drug Intervention,Aromatase inhibitor,human,y,,eduvaris
5097,32847676,98,118,Drug Intervention,Aromatase inhibitors,model,y,,eduvaris
5098,32847676,363,367,Group Characteristic,with,human,n,not needed,eduvaris
5099,32847676,714,719,Group Characteristic,women,model,y,,eduvaris
5100,32847676,772,774,Quantitative Measurement,6%,human,n,too little,eduvaris
5101,32847676,806,808,Quantitative Measurement,4%,human,n,too little,eduvaris
5102,32847676,825,830,Quantitative Measurement,71.9%,human,n,not needed,eduvaris
5103,32847676,873,878,Quantitative Measurement,54.1%,model,n,not needed,eduvaris
5104,32847676,1163,1167,Quantitative Measurement,14.7,model,y,,eduvaris
5105,32847676,1322,1324,Type of Quant. Measure,OR,model,y,,eduvaris
5106,32847676,1365,1367,Type of Quant. Measure,OR,model,y,,eduvaris
5107,32847676,1443,1450,Outcome (Study Endpoint),disease,model,n,too little,eduvaris
5108,32847676,1464,1469,Quantitative Measurement,87.9%,human,y,,eduvaris
5109,33009489,54,83,Disease/Condition of Interest,metastatic castrate-resistant,model,n,not needed,stan
5110,33009489,559,570,Drug Intervention,abiraterone,model,y,,stan
5111,33009489,588,591,Group Name,AAP,model,n,wrong label,stan
5112,33009489,596,608,Drug Intervention,enzalutamide,model,y,,stan
5113,33009489,781,792,Drug Intervention,abiraterone,model,y,,stan
5114,33009489,796,808,Drug Intervention,enzalutamide,model,y,,stan
5115,33009489,826,845,Group Characteristic,median age 68 years,human,y,,stan
5116,33009489,826,852,Group Characteristic,median age 68 years [51-82,model,n,multiple entities,stan
5117,33009489,847,852,Group Characteristic,51-82,human,n,wrong label,stan
5118,33009489,885,889,Dosage,1000,human,y,,stan
5119,33009489,885,892,Dosage,1000 mg,model,n,multiple entities,stan
5120,33009489,890,892,Units,mg,human,y,,stan
5121,33009489,913,915,Dosage,10,human,y,,stan
5122,33009489,913,918,Dosage,10 mg,model,n,multiple entities,stan
5123,33009489,916,918,Units,mg,human,y,,stan
5124,33009489,954,957,Dosage,160,human,y,,stan
5125,33009489,954,960,Dosage,160 mg,model,n,multiple entities,stan
5126,33009489,958,960,Units,mg,human,y,,stan
5127,33009489,1004,1012,Group Name,training,model,y,,stan
5128,33009489,1026,1030,Group Name,test,model,y,,stan
5129,33009489,1248,1264,Outcome (Study Endpoint),overall survival,human,y,,stan
5130,33009489,1467,1474,Type of Quant. Measure,c-index,model,y,,stan
5131,33009489,1651,1654,Group Characteristic,low,model,n,too little,stan
5132,33009489,1701,1710,Outcome (Study Endpoint),median OS,model,n,multiple entities,stan
5133,33009489,1708,1710,Outcome (Study Endpoint),OS,human,y,,stan
5134,33009489,1731,1733,Quantitative Measurement,18,model,y,,stan
5135,33009489,1734,1740,Units,months,model,n,wrong label,stan
5136,33009489,1829,1854,Outcome (Study Endpoint),progression-free survival,model,y,,stan
5137,33009489,1885,1895,Outcome (Study Endpoint),median PFS,model,n,multiple entities,stan
5138,33009489,1892,1895,Outcome (Study Endpoint),PFS,human,y,,stan
5139,33009489,1916,1924,Group Characteristic,low-risk,human,y,,stan
5140,33009489,1928,1937,Group Characteristic,high-risk,human,y,,stan
5141,33009489,1999,2001,Type of Quant. Measure,HR,model,y,,stan
5142,33222712,127,135,Group Characteristic,Children,human,y,,hcho
5143,33222712,510,534,Disease/Condition of Interest,congenital heart disease,human,y,,hcho
5144,33222712,539,553,Disease/Condition of Interest,cardiomyopathy,human,y,,hcho
5145,33222712,608,622,Disease/Condition of Interest,cardiomyopathy,human,y,,hcho
5146,33222712,1007,1028,Group Characteristic,experienced mortality,human,y,,hcho
5147,33222712,1019,1028,Outcome (Study Endpoint),mortality,model,n,wrong label,hcho
5148,33222712,1053,1074,Group Name,experienced mortality,human,n,wrong label,hcho
5149,33222712,1167,1169,Type of Quant. Measure,OR,model,y,,hcho
5150,33222712,1262,1268,Type of Quant. Measure,95% CI,human,y,wrong label,hcho
5151,33222712,1329,1335,Type of Quant. Measure,95% CI,human,y,wrong label,hcho
5152,33222712,1544,1553,Drug Intervention,Diuretics,model,y,,hcho
5153,33222712,1565,1605,Drug Intervention,angiotensin-converting enzyme inhibitors,model,y,,hcho
5154,33242419,10,13,Sample Size,136,model,y,,eduvaris
5155,33242419,70,77,Disease/Condition of Interest,fatigue,human,y,,ccurtis
5156,33242419,116,135,Outcome (Study Endpoint),mean values of MFIS,human,n,multiple entities,eduvaris
5157,33242419,268,275,Drug Intervention,placebo,human,y,,eduvaris
5158,33242419,272,290,Disease/Condition of Interest,multiple sclerosis,human,n,wrong label,ccurtis
5159,33242419,387,389,Statistical Significance,p=,model,n,too little,eduvaris
5160,33242419,387,393,Statistical Significance,p=0·20,human,y,,eduvaris
5161,33242419,491,498,Drug Intervention,placebo,human,y,,eduvaris
5162,33242419,504,507,Quantitative Measurement,31%,human,y,,eduvaris
5163,33242419,571,585,Outcome (Study Endpoint),adverse events,human,y,,eduvaris
5164,33242419,846,877,Side Effects,multiple sclerosis exacerbation,human,n,too little,eduvaris
5165,33242419,846,906,Side Effects,multiple sclerosis exacerbation requiring hospital admission,model,y,,eduvaris
5166,33242419,970,983,Intervention Duration,up to 6 weeks,human,n,too much,ccurtis
5167,33242419,976,983,Intervention Duration,6 weeks,model,y,,ccurtis
5168,33242419,996,1003,Drug Intervention,placebo,human,y,,eduvaris
5169,33242419,1565,1569,Outcome (Study Endpoint),MFIS,model,y,,ccurtis
5170,33242419,1800,1829,Intervention Duration,"Oct 4, 2017, and Feb 27, 2019",human,n,,ccurtis
5171,33242419,1962,1965,Quantitative Measurement,25%,model,y,,ccurtis
5172,33242419,1983,2043,Group Name,"amantadine, placebo, modafinil, and methylphenidate sequence",human,n,wrong label,ccurtis
5173,33242419,2045,2047,Sample Size,34,human,y,wrong label,ccurtis
5174,33242419,2049,2052,Quantitative Measurement,24%,model,y,,ccurtis
5175,33242419,2070,2130,Group Name,"placebo, methylphenidate, amantadine, and modafinil sequence",human,n,wrong label,ccurtis
5176,33242419,2132,2134,Sample Size,35,human,y,wrong label,ccurtis
5177,33242419,2136,2139,Quantitative Measurement,25%,model,y,,ccurtis
5178,33242419,2157,2217,Group Name,"modafinil, amantadine, methylphenidate, and placebo sequence",human,n,wrong label,ccurtis
5179,33242419,2223,2225,Sample Size,37,human,y,wrong label,ccurtis
5180,33242419,2248,2308,Group Name,"methylphenidate, modafinil, placebo, and amantadine sequence",human,n,wrong label,ccurtis
5181,33242982,24,36,Drug Intervention,Atorvastatin,model,y,,stan
5182,33242982,96,108,Disease/Condition of Interest,Dyslipidemia,model,y,,stan
5183,33242982,536,544,Group Characteristic,children,model,y,,stan
5184,33242982,550,562,Disease/Condition of Interest,dyslipidemia,human,y,,stan
5185,33242982,629,683,Group Characteristic,low-density lipoprotein cholesterol [LDL-C] ≥190 mg/dL,human,n,multiple entities,stan
5186,33242982,731,748,Group Characteristic,LDL-C ≤ 130 mg/dL,human,n,multiple entities,stan
5187,33242982,753,786,Group Characteristic,"lipoprotein (a), Lp(a), ≤30 mg/dL",human,n,multiple entities,stan
5188,33242982,988,993,Group Characteristic,Males,model,y,,stan
5189,33242982,1018,1030,Outcome (Study Endpoint),greater cIMT,human,n,too much,stan
5190,33242982,1026,1030,Outcome (Study Endpoint),cIMT,model,y,,stan
5191,33242982,1148,1164,Outcome (Study Endpoint),decrease in cIMT,human,n,too much,stan
5192,33242982,1160,1164,Outcome (Study Endpoint),cIMT,model,y,,stan
5193,33242982,1228,1240,Drug Intervention,atorvastatin,model,y,,stan
5194,33242982,1278,1291,Outcome (Study Endpoint),lipid profile,human,y,,stan
5195,33242982,1339,1351,Outcome (Study Endpoint),thinner cIMT,human,n,too much,stan
5196,33509804,40,48,Disease/Condition of Interest,Adenomas,human,n,,cjackson
5197,33509804,52,65,Group Characteristic,Patients with,model,n,not needed,cjackson
5198,33509804,66,96,Group Characteristic,Familial Adenomatous Polyposis,human,n,wrong label,cjackson
5199,33509804,505,522,Group Characteristic,patients with FAP,model,n,not needed,cjackson
5200,33509804,536,539,Group Characteristic,FAP,model,n,wrong label,cjackson
5201,33509804,600,607,Group Name,placebo,human,y,wrong label,cjackson
5202,33509804,864,971,Outcome (Study Endpoint),No significant differences were determined in the percentage change of colorectal and duodenal polyp number,human,n,too much,cjackson
5203,33509804,935,971,Outcome (Study Endpoint),colorectal and duodenal polyp number,model,y,,cjackson
5204,33509804,1096,1184,Outcome (Study Endpoint),no significant differences in the percentage change of colorectal or duodenal polyp size,human,n,too much,cjackson
5205,33509804,1392,1549,Outcome (Study Endpoint),Colon polyps removed from the metformin-treated patients showed significantly lower mTOR signal (p-S6) expression than those from patients in the placebo arm,human,n,too much,cjackson
5206,33509804,1538,1545,Group Name,placebo,model,y,,cjackson
5207,33509804,1597,1599,Units,mg,human,y,,cjackson
5208,33509804,1609,1611,Units,mg,human,y,,cjackson
5209,33509804,1933,1940,Group Name,placebo,human,y,,cjackson
5210,33566107,4,8,Type of Quant. Measure,mean,human,y,,ccurtis
5211,33566107,10,12,Type of Quant. Measure,SD,human,y,,ccurtis
5212,33566107,28,32,Quantitative Measurement,6.57,human,y,,ccurtis
5213,33566107,34,38,Quantitative Measurement,2.22,human,y,,ccurtis
5214,33566107,40,45,Units,mIU/L,human,y,,ccurtis
5215,33566107,54,64,Disease/Condition of Interest,Depressive,human,n,too little,hcho
5216,33566107,54,73,Disease/Condition of Interest,Depressive Symptoms,model,y,,hcho
5217,33566107,91,95,Quantitative Measurement,3.83,human,y,,ccurtis
5218,33566107,95,121,Disease/Condition of Interest,Subclinical Hypothyroidism,model,n,wrong label,hcho
5219,33566107,97,101,Quantitative Measurement,2.29,human,y,,ccurtis
5220,33566107,103,108,Units,mIU/L,human,y,,ccurtis
5221,33566107,116,129,Group Name,levothyroxine,model,n,wrong label,ccurtis
5222,33566107,116,135,Group Name,levothyroxine group,human,y,,ccurtis
5223,33566107,144,151,Group Name,placebo,model,y,,ccurtis
5224,33566107,144,157,Group Name,placebo group,human,y,,ccurtis
5225,33566107,177,181,Quantitative Measurement,6.55,human,y,,ccurtis
5226,33566107,183,187,Quantitative Measurement,2.04,human,y,,ccurtis
5227,33566107,198,202,Quantitative Measurement,5.91,human,y,,ccurtis
5228,33566107,204,208,Quantitative Measurement,2.66,human,y,,ccurtis
5229,33566107,210,215,Units,mIU/L,human,y,,ccurtis
5230,33566107,280,293,Group Name,levothyroxine,model,n,wrong label,ccurtis
5231,33566107,323,336,Group Name,placebo group,model,y,,ccurtis
5232,33566107,352,358,Outcome (Study Endpoint),GDS-15,human,n,too little,ccurtis
5233,33566107,352,364,Outcome (Study Endpoint),GDS-15 score,model,y,,ccurtis
5234,33566107,390,403,Drug Intervention,levothyroxine,model,y,,hcho
5235,33566107,460,493,Outcome (Study Endpoint),adjusted between-group difference,human,n,,ccurtis
5236,33566107,618,638,Group Characteristic,GDS-15 of at least 2,model,y,,ccurtis
5237,33566107,812,815,Sample Size,278,model,y,,ccurtis
5238,33566107,939,961,Group Characteristic,aged 65 years or older,model,y,,hcho
5239,33566107,941,969,Type of Quant. Measure,standardized mean difference,model,n,too much,ccurtis
5240,33566107,944,961,Group Characteristic,65 years or older,human,n,too little,hcho
5241,33566107,979,985,Type of Quant. Measure,95% CI,model,y,,ccurtis
5242,33566107,1385,1388,Sample Size,472,model,y,,hcho
5243,33566107,1530,1537,Group Name,placebo,model,y,,hcho
5244,33566107,1587,1625,Study Years,"December 1, 2019, to September 1, 2020",model,y,,hcho
5245,33566107,1677,1702,Outcome (Study Endpoint),Depressive symptom scores,model,y,,hcho
5246,33566107,1709,1718,Follow-up period,12 months,human,y,,hcho
5247,33566107,1937,1954,Group Characteristic,"mean [SD] age, 74",model,n,too little,hcho
5248,33566107,1972,1981,Group Characteristic,239 women,model,y,,hcho
5249,33685298,46,83,Disease/Condition of Interest,postoperative pulmonary complications,model,y,,eduvaris
5250,33685298,153,166,Drug Intervention,gabapentinoid,human,y,,eduvaris
5251,33685298,200,237,Disease/Condition of Interest,postoperative pulmonary complications,model,y,,eduvaris
5252,33685298,447,485,Group Characteristic,underwent elective gynecologic surgery,model,y,,eduvaris
5253,33685298,447,503,Group Characteristic,underwent elective gynecologic surgery from 2015 to 2018,human,n,too much,eduvaris
5254,33685298,491,503,Study Years,2015 to 2018,model,n,not needed,eduvaris
5255,33685298,508,516,Group Characteristic,received,model,n,not needed,eduvaris
5256,33685298,508,570,Group Characteristic,received either gabapentin or pregabalin on the day of surgery,human,n,not needed,eduvaris
5257,33685298,524,534,Drug Intervention,gabapentin,model,y,,eduvaris
5258,33685298,538,548,Drug Intervention,pregabalin,model,y,,eduvaris
5259,33685298,636,655,Outcome (Study Endpoint),respiratory failure,human,n,not needed,eduvaris
5260,33685298,657,666,Outcome (Study Endpoint),pneumonia,human,n,not needed,eduvaris
5261,33685298,668,680,Outcome (Study Endpoint),reintubation,human,n,not needed,eduvaris
5262,33685298,682,697,Outcome (Study Endpoint),pulmonary edema,human,n,not needed,eduvaris
5263,33685298,703,715,Outcome (Study Endpoint),non-invasive,human,n,not needed,eduvaris
5264,33685298,719,739,Outcome (Study Endpoint),invasive ventilation,human,n,not needed,eduvaris
5265,33685298,769,778,Outcome (Study Endpoint),mortality,human,n,not needed,eduvaris
5266,33685298,780,809,Outcome (Study Endpoint),intensive care unit admission,human,n,not needed,eduvaris
5267,33685298,811,821,Outcome (Study Endpoint),mechanical,human,n,not needed,eduvaris
5268,33685298,825,849,Outcome (Study Endpoint),non-invasive ventilation,human,y,,eduvaris
5269,33685298,851,874,Outcome (Study Endpoint),hospital length of stay,human,n,not needed,eduvaris
5270,33685298,876,903,Outcome (Study Endpoint),re-admission within 30 days,human,n,not needed,eduvaris
5271,33685298,905,923,Outcome (Study Endpoint),opioid consumption,human,n,not needed,eduvaris
5272,33685298,928,942,Outcome (Study Endpoint),antiemetic use,human,n,not needed,eduvaris
5273,33685298,1040,1054,Drug Intervention,gabapentinoids,human,y,,eduvaris
5274,33685298,1157,1163,Sample Size,"19,121",model,y,,eduvaris
5275,33685298,1165,1166,Quantitative Measurement,7,model,n,not needed,eduvaris
5276,33685298,1197,1222,Outcome (Study Endpoint),Gabapentinoid utilization,human,n,multiple entities,eduvaris
5277,33685298,1211,1222,Outcome (Study Endpoint),utilization,model,y,,eduvaris
5278,33685298,1394,1396,Type of Quant. Measure,OR,model,y,,eduvaris
5279,33685298,1450,1458,Type of Quant. Measure,% change,model,y,,eduvaris
5280,33685298,1484,1506,Outcome (Study Endpoint),daily antiemetic doses,human,n,too little,eduvaris
5281,33685298,1484,1524,Outcome (Study Endpoint),daily antiemetic doses on day of surgery,model,y,,eduvaris
5282,33685298,1526,1541,Type of Quant. Measure,mean difference,model,y,,eduvaris
5283,33685298,1543,1545,Type of Quant. Measure,MD,model,y,,eduvaris
5284,33685298,1575,1587,Outcome (Study Endpoint),subsequently,model,y,,eduvaris
5285,33685298,1589,1591,Type of Quant. Measure,MD,model,y,,eduvaris
5286,33685298,1621,1641,Outcome (Study Endpoint),higher daily average,model,n,not needed,eduvaris
5287,33685298,1628,1641,Type of Quant. Measure,daily average,human,n,not needed,eduvaris
5288,33685298,1643,1645,Type of Quant. Measure,MD,model,y,,eduvaris
5289,33685298,1646,1650,Quantitative Measurement,4.59,model,y,,eduvaris
5290,33685298,1651,1653,Units,mg,model,y,,eduvaris
5291,33685298,1677,1682,Type of Quant. Measure,total,human,n,wrong label,eduvaris
5292,33685298,1684,1686,Type of Quant. Measure,MD,model,y,,eduvaris
5293,33685298,1687,1691,Quantitative Measurement,8.74,model,y,,eduvaris
5294,33685298,1692,1694,Units,mg,model,y,,eduvaris
5295,33685298,1715,1746,Outcome (Study Endpoint),parenteral morphine equivalents,model,y,,eduvaris
5296,33685298,1748,1761,Drug Intervention,Gabapentinoid,human,y,,eduvaris
5297,33725664,37,49,Group Characteristic,TKA patients,human,y,,stan
5298,33725664,145,148,Non-Pharmaceutical Intervention,TKA,model,y,,stan
5299,33725664,296,299,Non-Pharmaceutical Intervention,TKA,model,y,,stan
5300,33725664,313,327,Group Characteristic,undergoing TKA,model,y,,stan
5301,33725664,324,327,Group Characteristic,TKA,human,n,wrong label,stan
5302,33725664,485,502,Non-Study Drug,spinal anesthetic,human,y,,stan
5303,33725664,1025,1029,Group Name,POD1,human,y,wrong label,stan
5304,33725664,1042,1051,Outcome (Study Endpoint),daily MED,model,n,wrong label,stan
5305,33725664,1048,1051,Outcome (Study Endpoint),MED,human,y,,stan
5306,33725664,1065,1070,Type of Quant. Measure,range,human,y,,stan
5307,33725664,1071,1076,Quantitative Measurement,0-110,human,y,,stan
5308,33725664,1079,1083,Group Name,POD2,human,y,wrong label,stan
5309,33725664,1111,1116,Outcome (Study Endpoint),POD 3,model,n,wrong label,stan
5310,33725664,1117,1129,Outcome (Study Endpoint),daily usages,model,n,too little or too much based on context,stan
5311,33725664,1145,1150,Type of Quant. Measure,range,human,y,,stan
5312,33725664,1236,1253,Outcome (Study Endpoint),off all narcotics,model,y,,stan
5313,33725664,1269,1278,Follow-up period,week four,human,y,,stan
5314,33725664,1284,1303,Outcome (Study Endpoint),average daily usage,human,y,,stan
5315,33725664,1337,1354,Outcome (Study Endpoint),off all narcotics,human,y,,stan
5316,33725664,1359,1366,Follow-up period,8 weeks,human,y,,stan
5317,33725664,1454,1460,Follow-up period,6 week,human,y,,stan
5318,33725664,1484,1491,Follow-up period,3-month,human,y,,stan
5319,33725664,1505,1511,Quantitative Measurement,72-100,human,y,,stan
5320,33764413,85,89,Group Characteristic,gout,human,n,wrong label,cjackson
5321,33764413,222,224,Group Name,RD,model,n,not needed,cjackson
5322,33764413,232,236,Intervention Frequency,/day,human,n,too much,cjackson
5323,33764413,233,236,Intervention Frequency,day,model,y,,cjackson
5324,33764413,261,265,Intervention Frequency,/day,human,n,too much,cjackson
5325,33764413,262,265,Intervention Frequency,day,model,y,,cjackson
5326,33764413,281,285,Disease/Condition of Interest,gout,human,n,too little,cjackson
5327,33764413,380,393,Group Characteristic,gout patients,model,n,not needed,cjackson
5328,33764413,423,434,Drug Intervention,allopurinol,model,n,wrong label,cjackson
5329,33764413,438,448,Drug Intervention,febuxostat,model,n,wrong label,cjackson
5330,33764413,470,480,Drug Intervention,colchicine,model,y,,cjackson
5331,33764413,514,515,Follow-up period,3,human,n,too little,cjackson
5332,33764413,514,522,Follow-up period,3 months,model,y,,cjackson
5333,33764413,516,522,Units,months,human,n,wrong label,cjackson
5334,33764413,944,946,Group Name,LD,model,n,not needed,cjackson
5335,33764413,997,999,Group Name,RD,model,n,not needed,cjackson
5336,33764413,1186,1206,Outcome (Study Endpoint),events of gout flare,human,y,,cjackson
5337,33764413,1196,1206,Outcome (Study Endpoint),gout flare,model,n,too little,cjackson
5338,33764413,1275,1280,Quantitative Measurement,14.3%,model,y,,cjackson
5339,33764413,1284,1289,Quantitative Measurement,11.3%,model,y,,cjackson
5340,33764413,1291,1301,Type of Quant. Measure,odds ratio,model,y,,cjackson
5341,33764413,1303,1305,Type of Quant. Measure,OR,model,y,,cjackson
5342,33764413,1308,1313,Quantitative Measurement,1.309,model,y,,cjackson
5343,33764413,1323,1335,Quantitative Measurement,"0.668, 2.566",model,y,,cjackson
5344,33764413,1352,1357,Quantitative Measurement,15.3%,model,y,,cjackson
5345,33764413,1361,1366,Quantitative Measurement,10.0%,model,y,,cjackson
5346,33764413,1372,1377,Quantitative Measurement,1.623,model,y,,cjackson
5347,33764413,1387,1399,Quantitative Measurement,"0.765, 3.443",model,y,,cjackson
5348,33764413,1512,1516,Quantitative Measurement,8.2%,model,y,,cjackson
5349,33764413,1520,1525,Quantitative Measurement,17.9%,model,y,,cjackson
5350,33764413,1546,1558,Quantitative Measurement,"0.217, 0.777",model,y,,cjackson
5351,33764413,1574,1578,Quantitative Measurement,8.4%,model,y,,cjackson
5352,33764413,1582,1587,Quantitative Measurement,17.2%,model,y,,cjackson
5353,33764413,1600,1606,Type of Quant. Measure,95% CI,human,y,,cjackson
5354,33764413,1608,1620,Quantitative Measurement,"0.223, 0.878",model,y,,cjackson
5355,33849926,182,233,Disease/Condition of Interest,immune checkpoint inhibitor (ICI)-induced nephritis,human,y,,hcho
5356,33849926,485,489,Dosage,/day,human,n,too much,hcho
5357,33849926,486,489,Intervention Frequency,day,model,y,,hcho
5358,33849926,505,518,Dosage,tapered to 10,human,y,,hcho
5359,33849926,516,518,Dosage,10,model,n,too little,hcho
5360,33849926,553,566,Group Name,control group,human,y,,hcho
5361,33849926,583,587,Dosage,/day,human,n,too much,hcho
5362,33849926,584,587,Intervention Frequency,day,model,y,,hcho
5363,33849926,621,637,Group Name,standard of care,model,n,wrong label,hcho
5364,33849926,846,848,Follow-up period,30,human,y,,hcho
5365,33849926,850,852,Follow-up period,60,human,y,,hcho
5366,33849926,857,859,Follow-up period,90,human,y,,hcho
5367,33849926,860,864,Follow-up period,days,human,n,wrong label,hcho
5368,33849926,910,918,Sample Size,Thirteen,model,y,,hcho
5369,33849926,910,927,Sample Size,Thirteen patients,human,n,too much,hcho
5370,33849926,937,963,Group Name,rapid corticosteroid taper,human,n,wrong label,hcho
5371,33849926,968,970,Sample Size,14,model,y,,hcho
5372,33849926,968,979,Sample Size,14 patients,human,n,too much,hcho
5373,33849926,989,1005,Group Name,standard of care,human,n,wrong label,hcho
5374,33849926,1065,1150,Outcome (Study Endpoint),median time to ≤10 mg/day prednisone was 20 days (IQR 15-25) in the rapid-taper group,human,n,too much,hcho
5375,33849926,1072,1101,Outcome (Study Endpoint),time to ≤10 mg/day prednisone,model,y,,hcho
5376,33849926,1106,1108,Quantitative Measurement,20,model,y,,hcho
5377,33849926,1109,1113,Units,days,model,y,,hcho
5378,33849926,1115,1118,Type of Quant. Measure,IQR,model,y,,hcho
5379,33849926,1119,1124,Quantitative Measurement,15-25,model,y,,hcho
5380,33849926,1133,1144,Group Name,rapid-taper,model,n,wrong label,hcho
5381,33849926,1165,1167,Quantitative Measurement,38,model,y,,hcho
5382,33849926,1168,1172,Units,days,model,y,,hcho
5383,33849926,1174,1177,Type of Quant. Measure,IQR,model,y,,hcho
5384,33849926,1178,1183,Quantitative Measurement,30-58,model,y,,hcho
5385,33849926,1192,1208,Group Name,standard-of-care,model,n,wrong label,hcho
5386,33849926,1374,1377,Quantitative Measurement,85%,model,y,,hcho
5387,33849926,1412,1415,Quantitative Measurement,46%,model,y,,hcho
5388,33849926,1424,1440,Group Name,standard of care,model,n,wrong label,hcho
5389,33849926,1446,1454,Outcome (Study Endpoint),Exposure,model,n,too little,hcho
5390,33849926,1446,1629,Outcome (Study Endpoint),"Exposure to other nephritis-causing medications (proton pump inhibitor or trimethoprim-sulfamethoxazole) during the corticosteroid taper was more common in the standard of care group,",human,n,not needed,hcho
5391,33849926,1633,1636,Quantitative Measurement,64%,model,y,,hcho
5392,33849926,1638,1663,Outcome (Study Endpoint),"versus rapid-taper group,",human,n,wrong label,hcho
5393,33849926,1667,1670,Quantitative Measurement,15%,model,y,,hcho
5394,33849926,1671,1735,Outcome (Study Endpoint),", and was associated with longer time to renal recovery, 20 days",human,n,too much,hcho
5395,33849926,1704,1726,Outcome (Study Endpoint),time to renal recovery,model,y,,hcho
5396,33849926,1728,1730,Quantitative Measurement,20,model,y,,hcho
5397,33849926,1731,1735,Units,days,model,y,,hcho
5398,33849926,1737,1740,Type of Quant. Measure,IQR,model,y,,hcho
5399,33849926,1741,1747,Quantitative Measurement,14-101,model,y,,hcho
5400,33849926,1756,1758,Quantitative Measurement,13,model,y,,hcho
5401,33849926,1759,1763,Units,days,model,y,,hcho
5402,33849926,1765,1768,Type of Quant. Measure,IQR,model,y,,hcho
5403,33849926,1769,1773,Quantitative Measurement,7-34,model,y,,hcho
5404,33849926,1842,1845,Quantitative Measurement,56%,model,y,,hcho
5405,33849926,1902,1905,Quantitative Measurement,13%,model,y,,hcho
5406,33957371,85,90,Group Characteristic,adult,model,y,,ccurtis
5407,33957371,222,242,Disease/Condition of Interest,tumor lysis syndrome,model,y,,ccurtis
5408,33957371,348,351,Dosage,0.2,model,y,,ccurtis
5409,33957371,352,357,Units,mg/kg,model,y,,ccurtis
5410,33957371,358,361,Intervention Frequency,day,model,y,,ccurtis
5411,33957371,372,378,Intervention Duration,5 days,model,y,,ccurtis
5412,33957371,754,768,Group Characteristic,acute leukemia,model,y,,ccurtis
5413,33957371,853,856,Dosage,1.5,model,y,,ccurtis
5414,33957371,853,859,Dosage,1.5 mg,human,n,too much,ccurtis
5415,33957371,857,859,Units,mg,model,y,,ccurtis
5416,33957371,871,872,Dosage,3,model,y,,ccurtis
5417,33957371,871,875,Dosage,3 mg,human,n,too much,ccurtis
5418,33957371,873,875,Units,mg,model,y,,ccurtis
5419,33957371,947,950,Dosage,300,model,y,,ccurtis
5420,33957371,947,953,Dosage,300 mg,human,n,too much,ccurtis
5421,33957371,951,953,Units,mg,model,y,,ccurtis
5422,33957371,963,971,Intervention Duration,days 1-6,human,y,,ccurtis
5423,33957371,1011,1013,Sample Size,14,human,y,,ccurtis
5424,33957371,1024,1026,Sample Size,10,human,y,,ccurtis
5425,33957371,1134,1135,Sample Size,3,model,n,,ccurtis
5426,33957371,1180,1208,Group Characteristic,acute promyelocytic leukemia,model,n,too much,ccurtis
5427,33957371,1238,1241,Quantitative Measurement,9.8,model,y,,ccurtis
5428,33957371,1242,1247,Units,mg/dL,model,y,,ccurtis
5429,33957371,1249,1261,Quantitative Measurement,Eighty-three,human,n,too little,ccurtis
5430,33957371,1249,1269,Quantitative Measurement,Eighty-three percent,model,y,,ccurtis
5431,33957371,1290,1335,Outcome (Study Endpoint),achieved UA < 7.5 mg/dL by 24 h after therapy,human,n,,ccurtis
5432,33957371,1299,1313,Outcome (Study Endpoint),UA < 7.5 mg/dL,model,n,,ccurtis
5433,33957371,1360,1365,Group Name,Arm A,human,y,,ccurtis
5434,33957371,1377,1382,Group Name,Arm B,human,y,,ccurtis
5435,33957371,1393,1403,Outcome (Study Endpoint),additional,model,n,,ccurtis
5436,33957371,1413,1424,Drug Intervention,rasburicase,model,y,,ccurtis
5437,33957371,1440,1445,Quantitative Measurement,23/24,human,y,,ccurtis
5438,33957371,1454,1502,Outcome (Study Endpoint),achieved UA goals after 1-2 doses of rasburicase,human,n,,ccurtis
5439,33957371,1491,1502,Drug Intervention,rasburicase,model,y,,ccurtis
5440,33957371,1671,1673,Units,mg,model,y,,ccurtis
5441,33957371,1695,1706,Drug Intervention,allopurinol,model,n,wrong label,ccurtis
5442,33957371,1751,1753,Quantitative Measurement,83,model,n,too little,ccurtis
5443,33957371,1756,1769,Outcome (Study Endpoint),response rate,model,y,,ccurtis
5444,34279598,239,260,Disease/Condition of Interest,myocardial infarction,model,y,,eduvaris
5445,34279598,435,446,Disease/Condition of Interest,LV thrombus,human,n,wrong label,eduvaris
5446,34279598,617,641,Group Characteristic,1-14 days after acute MI,model,n,not needed,eduvaris
5447,34279598,633,641,Group Characteristic,acute MI,human,y,,eduvaris
5448,34279598,735,743,Drug Intervention,warfarin,model,y,,eduvaris
5449,34279598,763,771,Drug Intervention,apixaban,model,y,,eduvaris
5450,34279598,822,833,Outcome (Study Endpoint),LV thrombus,human,n,not needed,eduvaris
5451,34279598,834,842,Follow-up period,3 months,human,y,,eduvaris
5452,34279598,904,918,Outcome (Study Endpoint),major bleeding,human,y,,eduvaris
5453,34279598,920,926,Outcome (Study Endpoint),stroke,human,y,,eduvaris
5454,34279598,949,967,Outcome (Study Endpoint),re-hospitalization,human,y,,eduvaris
5455,34279598,973,992,Outcome (Study Endpoint),all-cause mortality,human,y,,eduvaris
5456,34279598,999,1015,Outcome (Study Endpoint),LV thrombus size,model,n,,eduvaris
5457,34279598,1033,1037,Quantitative Measurement,18.5,model,y,,eduvaris
5458,34279598,1038,1040,Units,mm,model,y,,eduvaris
5459,34279598,1048,1050,Units,mm,model,y,,eduvaris
5460,34279598,1058,1066,Group Name,warfarin,human,n,wrong label,eduvaris
5461,34279598,1058,1072,Group Name,warfarin group,model,y,,eduvaris
5462,34279598,1077,1081,Quantitative Measurement,19.9,model,y,,eduvaris
5463,34279598,1082,1084,Units,mm,model,y,,eduvaris
5464,34279598,1092,1094,Units,mm,model,y,,eduvaris
5465,34279598,1102,1110,Group Name,apixaban,human,n,wrong label,eduvaris
5466,34279598,1102,1116,Group Name,apixaban group,model,y,,eduvaris
5467,34279598,1118,1124,Statistical Significance,P = NS,model,y,,eduvaris
5468,34279598,1157,1165,Follow-up period,3 months,model,y,,eduvaris
5469,34279598,1261,1265,Outcome (Study Endpoint),died,model,y,,eduvaris
5470,34279598,1305,1307,Sample Size,15,human,y,,eduvaris
5471,34279598,1308,1316,Units,patients,human,n,not needed,eduvaris
5472,34279598,1352,1354,Sample Size,17,human,y,,eduvaris
5473,34279598,1355,1363,Units,patients,human,n,not needed,eduvaris
5474,34279598,1387,1393,Statistical Significance,P = NS,model,y,,eduvaris
5475,34279598,1430,1433,Quantitative Measurement,Two,human,y,,eduvaris
5476,34279598,1447,1461,Outcome (Study Endpoint),major bleeding,model,y,,eduvaris
5477,34279598,1567,1573,Side Effects,stroke,model,n,wrong label,eduvaris
5478,34279598,1600,1603,Quantitative Measurement,one,human,y,,eduvaris
5479,34279598,1604,1609,Side Effects,death,model,n,not needed,eduvaris
5480,34915723,0,15,Disease/Condition of Interest,Ischemic Events,human,y,,stan
5481,34915723,51,85,Group Characteristic,Percutaneous Coronary Intervention,human,n,wrong label,stan
5482,34915723,102,136,Outcome (Study Endpoint),moderate or severe bleeding events,human,y,,cjackson
5483,34915723,107,110,Drug Intervention,Can,model,n,too little,stan
5484,34915723,107,116,Drug Intervention,Cangrelor,human,y,,stan
5485,34915723,168,193,Outcome (Study Endpoint),no significant difference,model,n,not needed,cjackson
5486,34915723,199,208,Group Name,cangrelor,human,n,wrong label,cjackson
5487,34915723,223,234,Group Name,clopidogrel,human,n,wrong label,cjackson
5488,34915723,267,286,Type of Quant. Measure,adjusted odds ratio,model,y,,cjackson
5489,34915723,276,286,Type of Quant. Measure,odds ratio,human,n,too little,cjackson
5490,34915723,314,327,Statistical Significance,<i>P</i>=0.62,model,n,too much,cjackson
5491,34915723,317,327,Statistical Significance,P</i>=0.62,human,y,,cjackson
5492,34915723,521,530,Drug Intervention,cangrelor,human,y,,cjackson
5493,34915723,590,635,Group Characteristic,undergoing percutaneous coronary intervention,human,y,,stan
5494,34915723,713,722,Drug Intervention,cangrelor,human,y,,stan
5495,34915723,801,806,Outcome (Study Endpoint),death,model,y,,stan
5496,34915723,808,829,Outcome (Study Endpoint),myocardial infarction,model,y,,stan
5497,34915723,831,864,Outcome (Study Endpoint),ischemia-driven revascularization,model,y,,stan
5498,34915723,869,885,Outcome (Study Endpoint),stent thrombosis,model,y,,stan
5499,34915723,1449,1476,Outcome (Study Endpoint),primary composite end point,human,y,,stan
5500,34915723,1542,1548,Type of Quant. Measure,95% CI,model,y,,stan
5501,34915723,1550,1559,Quantitative Measurement,0.64-0.90,model,y,wrong label,stan
5502,34915723,1637,1642,Outcome (Study Endpoint),death,human,y,,stan
5503,34915723,1637,1782,Outcome (Study Endpoint),"death, Society of Coronary Angiography and Intervention myocardial infarction, ischemia-driven revascularization, or Academic Research Consortium",model,n,too much,stan
5504,34915723,1850,1856,Type of Quant. Measure,95% CI,model,y,,stan
5505,34915723,1942,1969,Outcome (Study Endpoint),primary composite end point,human,y,,stan
5506,34915723,2007,2013,Type of Quant. Measure,95% CI,model,y,,stan
5507,34915723,2027,2040,Statistical Significance,<i>P</i>=0.53,model,n,not needed,stan
5508,34915723,2030,2040,Statistical Significance,P</i>=0.53,human,y,,stan
5509,35040887,52,67,Group Name,P2Y12 inhibitor,model,n,too little,ccurtis
5510,35040887,106,116,Group Name,usual care,model,n,too little,ccurtis
5511,35040887,113,121,Disease/Condition of Interest,COVID-19,human,y,,hcho
5512,35040887,151,157,Type of Quant. Measure,95% CI,human,y,,ccurtis
5513,35040887,484,502,Group Characteristic,non-critically ill,model,y,,hcho
5514,35040887,659,661,Follow-up period,90,model,n,too little,hcho
5515,35040887,659,665,Follow-up period,90-day,human,y,,hcho
5516,35040887,830,840,Group Name,usual care,model,n,wrong label,hcho
5517,35040887,930,940,Drug Intervention,Ticagrelor,model,y,,hcho
5518,35040887,1650,1681,Group Characteristic,"mean age, 52.7 [SD, 13.5] years",model,y,,hcho
5519,35040887,1683,1688,Group Characteristic,41.5%,model,n,too little,hcho
5520,35040887,1689,1694,Group Characteristic,women,model,n,too little,hcho
5521,35040887,1797,1812,Group Name,P2Y12 inhibitor,model,n,too little,hcho
5522,35040887,1797,1818,Group Name,P2Y12 inhibitor group,human,y,,hcho
5523,35040887,1820,1830,Drug Intervention,ticagrelor,model,y,,hcho
5524,35040887,1843,1846,Quantitative Measurement,63%,model,y,,hcho
5525,35040887,1878,1881,Quantitative Measurement,37%,model,y,,hcho
5526,35040887,1980,1995,Group Name,P2Y12 inhibitor,model,n,too little,hcho
5527,36206137,140,167,Disease/Condition of Interest,Acute Myocardial Infarction,model,n,too much,eduvaris
5528,36206137,234,244,Drug Intervention,ticagrelor,model,y,,stan
5529,36206137,282,303,Disease/Condition of Interest,myocardial infarction,model,y,,eduvaris
5530,36206137,305,307,Disease/Condition of Interest,MI,model,y,,eduvaris
5531,36206137,1206,1211,Sample Size,4 553,model,y,,eduvaris
5532,36206137,1208,1211,Sample Size,553,human,n,too little,eduvaris
5533,36206137,1222,1247,Drug Intervention,Dual antiplatelet therapy,model,n,not needed,eduvaris
5534,36206137,1277,1279,Quantitative Measurement,94,model,n,too little,eduvaris
5535,36206137,1326,1330,Quantitative Measurement,52 %,model,y,,eduvaris
5536,36206137,1346,1352,Quantitative Measurement,42.2 %,model,y,,eduvaris
5537,36206137,1371,1373,Sample Size,11,model,n,wrong label,eduvaris
5538,36206137,1384,1389,Quantitative Measurement,0.2 %,model,y,,eduvaris
5539,36206137,1392,1402,Drug Intervention,Ticagrelor,model,y,,eduvaris
5540,36206137,1497,1502,Group Name,STEMI,model,y,,eduvaris
5541,36206137,1512,1518,Group Name,NSTEMI,model,y,,eduvaris
5542,36206137,1520,1524,Quantitative Measurement,45 %,model,y,,eduvaris
5543,36206137,1529,1533,Quantitative Measurement,33 %,model,y,,eduvaris
5544,36206137,1549,1559,Statistical Significance,p&lt;0.001,model,y,,eduvaris
5545,36206137,1562,1573,Drug Intervention,clopidogrel,model,y,,eduvaris
5546,36206137,1653,1657,Quantitative Measurement,59 %,model,y,,eduvaris
5547,36206137,1662,1666,Quantitative Measurement,50 %,model,y,,eduvaris
5548,36206137,1716,1746,Outcome (Study Endpoint),MI and a high risk of bleeding,human,n,multiple entities,eduvaris
5549,36206137,1748,1759,Drug Intervention,clopidogrel,model,y,,eduvaris
5550,36206137,1824,1834,Drug Intervention,Ticagrelor,model,y,,eduvaris
5551,36206137,1899,1928,Outcome (Study Endpoint),MI and a low risk of bleeding,human,n,multiple entities,eduvaris
5552,36206137,1980,2012,Outcome (Study Endpoint),STEMI and a low risk of bleeding,human,n,multiple entities,eduvaris
5553,36206137,2014,2024,Drug Intervention,ticagrelor,model,y,,eduvaris
5554,36206137,2072,2083,Drug Intervention,clopidogrel,model,y,,eduvaris
5555,36206137,2085,2087,Quantitative Measurement,56,human,n,too little,eduvaris
5556,36206137,2085,2089,Quantitative Measurement,56 %,model,y,,eduvaris
5557,36206137,2094,2096,Quantitative Measurement,44,human,n,too little,eduvaris
5558,36206137,2094,2098,Quantitative Measurement,44 %,model,y,,eduvaris
5559,36206137,2129,2162,Outcome (Study Endpoint),NSTEMI and a low risk of bleeding,human,n,multiple entities,eduvaris
5560,36206137,2164,2175,Drug Intervention,clopidogrel,model,y,,eduvaris
5561,36206137,2226,2228,Quantitative Measurement,53,human,n,too little,eduvaris
5562,36206137,2226,2230,Quantitative Measurement,53 %,model,y,,eduvaris
5563,36206137,2235,2237,Quantitative Measurement,47,human,n,too little,eduvaris
5564,36206137,2235,2239,Quantitative Measurement,47 %,model,y,,eduvaris
5565,36206137,2288,2292,Quantitative Measurement,94 %,model,y,,eduvaris
